{"0050cb5ead95958706cd183ab1115e70c6a626ba": [["No differences in static lung function were found between the two groups.", [["lung", "ANATOMY", 25, 29], ["lung", "ORGAN", 25, 29], ["static lung function", "TEST", 18, 38], ["differences", "OBSERVATION_MODIFIER", 3, 14], ["lung", "ANATOMY", 25, 29], ["function", "OBSERVATION", 30, 38]]], ["Overall, pulmonary abnormalities and/or significant ongoing respiratory symptoms were detected in nearly a third of ALL survivors treated without HSCT.", [["pulmonary", "ANATOMY", 9, 18], ["respiratory", "ANATOMY", 60, 71], ["ALL", "ANATOMY", 116, 119], ["pulmonary abnormalities", "DISEASE", 9, 32], ["ALL", "DISEASE", 116, 119], ["pulmonary", "ORGAN", 9, 18], ["ALL", "CANCER", 116, 119], ["pulmonary abnormalities", "PROBLEM", 9, 32], ["significant ongoing respiratory symptoms", "PROBLEM", 40, 80], ["HSCT", "TREATMENT", 146, 150], ["pulmonary", "ANATOMY", 9, 18], ["abnormalities", "OBSERVATION", 19, 32], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["ongoing", "OBSERVATION_MODIFIER", 52, 59], ["respiratory symptoms", "OBSERVATION", 60, 80]]], ["Larger, prospective studies are warranted to evaluate the etiology and clinical significance of these findings. follow-up studies have found respiratory-related deaths to be second only to subsequent malignancy, and pulmonary abnormalities have been detected in up to 81% of survivors before the age of 50 years.", [["respiratory", "ANATOMY", 141, 152], ["pulmonary", "ANATOMY", 216, 225], ["deaths", "DISEASE", 161, 167], ["malignancy", "DISEASE", 200, 210], ["pulmonary abnormalities", "DISEASE", 216, 239], ["malignancy", "CANCER", 200, 210], ["pulmonary", "ORGAN", 216, 225], ["prospective studies", "TEST", 8, 27], ["follow-up studies", "TEST", 112, 129], ["subsequent malignancy", "PROBLEM", 189, 210], ["pulmonary abnormalities", "PROBLEM", 216, 239], ["malignancy", "OBSERVATION", 200, 210], ["pulmonary", "ANATOMY", 216, 225], ["abnormalities", "OBSERVATION", 226, 239]]], ["Of all childhood cancers, acute lymphoblastic leukemia (ALL) is the most common and carries an excellent prognosis with a 10-year survival exceeding 90%.", [["childhood cancers", "ANATOMY", 7, 24], ["acute lymphoblastic leukemia", "ANATOMY", 26, 54], ["ALL", "ANATOMY", 56, 59], ["cancers", "DISEASE", 17, 24], ["acute lymphoblastic leukemia", "DISEASE", 26, 54], ["ALL", "DISEASE", 56, 59], ["childhood cancers", "CANCER", 7, 24], ["acute lymphoblastic leukemia", "CANCER", 26, 54], ["ALL", "CANCER", 56, 59], ["all childhood cancers", "PROBLEM", 3, 24], ["acute lymphoblastic leukemia", "PROBLEM", 26, 54], ["all", "OBSERVATION_MODIFIER", 3, 6], ["childhood", "OBSERVATION_MODIFIER", 7, 16], ["cancers", "OBSERVATION", 17, 24], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["lymphoblastic leukemia", "OBSERVATION", 32, 54], ["excellent", "OBSERVATION_MODIFIER", 95, 104]]], ["3 In an era of rising cure rates, late pulmonary effects will become increasingly important for a growing population of survivors.", [["pulmonary", "ANATOMY", 39, 48], ["pulmonary", "ORGAN", 39, 48], ["rising cure rates", "TREATMENT", 15, 32], ["late pulmonary effects", "PROBLEM", 34, 56], ["pulmonary", "ANATOMY", 39, 48]]], ["4 Historically, research has focused on identifying pulmonary-toxic therapies, such as radiation and hematopoietic stem cell transplant (HSCT), to inform risk-based pulmonary follow-up.", [["pulmonary", "ANATOMY", 52, 61], ["hematopoietic stem cell", "ANATOMY", 101, 124], ["pulmonary", "ANATOMY", 165, 174], ["pulmonary", "ORGAN", 52, 61], ["hematopoietic stem cell", "CELL", 101, 124], ["pulmonary", "ORGAN", 165, 174], ["pulmonary-toxic therapies", "TREATMENT", 52, 77], ["radiation", "TREATMENT", 87, 96], ["hematopoietic stem cell transplant", "TREATMENT", 101, 135], ["pulmonary", "ANATOMY", 52, 61], ["toxic therapies", "OBSERVATION", 62, 77], ["hematopoietic stem cell transplant", "OBSERVATION", 101, 135], ["pulmonary", "ANATOMY", 165, 174]]], ["[4] [5] [6] However, respiratory infections are also a significant cause of pulmonary morbidity during treatment.", [["respiratory", "ANATOMY", 21, 32], ["pulmonary", "ANATOMY", 76, 85], ["respiratory infections", "DISEASE", 21, 43], ["pulmonary", "ORGAN", 76, 85], ["respiratory infections", "PROBLEM", 21, 43], ["pulmonary morbidity", "PROBLEM", 76, 95], ["treatment", "TREATMENT", 103, 112], ["respiratory", "ANATOMY", 21, 32], ["infections", "OBSERVATION", 33, 43], ["pulmonary", "ANATOMY", 76, 85], ["morbidity", "OBSERVATION", 86, 95]]], ["7 In particular, recent studies using polymerase chain reaction (PCR) diagnostics have found respiratory viral infections (RVI) cause up to 57% of febrile episodes, and that children undergoing chemotherapy are at risk of more severe RVIs with a prolonged clinical course and higher viral loads.", [["respiratory viral infections", "DISEASE", 93, 121], ["RVI", "DISEASE", 123, 126], ["febrile", "DISEASE", 147, 154], ["RVIs", "DISEASE", 234, 238], ["children", "ORGANISM", 174, 182], ["children", "SPECIES", 174, 182], ["recent studies", "TEST", 17, 31], ["polymerase chain reaction", "PROBLEM", 38, 63], ["PCR) diagnostics", "TEST", 65, 81], ["respiratory viral infections", "PROBLEM", 93, 121], ["febrile episodes", "PROBLEM", 147, 163], ["chemotherapy", "TREATMENT", 194, 206], ["more severe RVIs", "PROBLEM", 222, 238], ["higher viral loads", "PROBLEM", 276, 294], ["respiratory", "ANATOMY", 93, 104], ["viral infections", "OBSERVATION", 105, 121], ["viral loads", "OBSERVATION", 283, 294]]], ["[7] [8] [9] [10] [11] In general population-based studies, respiratory syncytial virus (RSV) and rhinovirus (HRV) bronchiolitis during infancy have been associated with subsequent wheeze and obstructive defects.", [["respiratory syncytial virus (RSV) and rhinovirus (HRV) bronchiolitis", "DISEASE", 59, 127], ["wheeze", "DISEASE", 180, 186], ["obstructive defects", "DISEASE", 191, 210], ["[7] [8] [9] [10] [11", "SIMPLE_CHEMICAL", 0, 20], ["respiratory syncytial virus", "ORGANISM", 59, 86], ["RSV", "ORGANISM", 88, 91], ["rhinovirus", "ORGANISM", 97, 107], ["respiratory syncytial virus", "SPECIES", 59, 86], ["RSV", "SPECIES", 88, 91], ["HRV", "SPECIES", 109, 112], ["general population", "TEST", 25, 43], ["based studies", "TEST", 44, 57], ["respiratory syncytial virus (RSV)", "PROBLEM", 59, 92], ["rhinovirus (HRV) bronchiolitis", "PROBLEM", 97, 127], ["subsequent wheeze", "PROBLEM", 169, 186], ["obstructive defects", "PROBLEM", 191, 210], ["respiratory", "ANATOMY", 59, 70], ["syncytial virus", "OBSERVATION", 71, 86], ["bronchiolitis", "OBSERVATION", 114, 127], ["wheeze", "OBSERVATION", 180, 186], ["obstructive defects", "OBSERVATION", 191, 210]]], ["12, 13 RVIs have also been shown to precipitate late airflow decline 14 and alloimmune lung syndromes 15 in transplant recipients.", [["lung", "ANATOMY", 87, 91], ["alloimmune lung syndromes", "DISEASE", 76, 101], ["lung", "ORGAN", 87, 91], ["recipients", "ORGANISM", 119, 129], ["late airflow decline", "PROBLEM", 48, 68], ["alloimmune lung syndromes", "PROBLEM", 76, 101], ["transplant recipients", "TREATMENT", 108, 129], ["airflow", "OBSERVATION", 53, 60], ["lung", "ANATOMY", 87, 91], ["syndromes", "OBSERVATION", 92, 101]]], ["However, the long-term pulmonary sequelae of these RVIs in children undergoing chemotherapy alone have not been investigated.", [["pulmonary", "ANATOMY", 23, 32], ["RVIs", "DISEASE", 51, 55], ["pulmonary", "ORGAN", 23, 32], ["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["chemotherapy", "TREATMENT", 79, 91], ["long-term", "OBSERVATION_MODIFIER", 13, 22], ["pulmonary", "ANATOMY", 23, 32], ["sequelae", "OBSERVATION", 33, 41]]], ["Currently, the Children's Oncology Group (COG) 16 have not prescribed recommendations for long-term pulmonary function screening for this cohort.", [["pulmonary", "ANATOMY", 100, 109], ["pulmonary", "ORGAN", 100, 109], ["Children", "SPECIES", 15, 23], ["long-term pulmonary function screening", "TREATMENT", 90, 128], ["pulmonary", "ANATOMY", 100, 109]]]], "7ba43b027d5621418b5c740c96a748c4721a6824": [["IntroductionInfection with Mycobacterium tuberculosis currently affects nearly one-third of the world's population [1] .", [["IntroductionInfection", "DISEASE", 0, 21], ["Mycobacterium tuberculosis", "DISEASE", 27, 53], ["Mycobacterium tuberculosis", "ORGANISM", 27, 53], ["Mycobacterium tuberculosis", "SPECIES", 27, 53], ["Mycobacterium tuberculosis", "SPECIES", 27, 53], ["IntroductionInfection", "TREATMENT", 0, 21], ["Mycobacterium tuberculosis", "PROBLEM", 27, 53], ["Mycobacterium tuberculosis", "OBSERVATION", 27, 53]]], ["Highly contagious pulmonary tuberculosis (PTB) can masquerade as communityacquired pneumonia (CAP) and escape initial diagnosis by emergency room (ER) physicians, thereby increasing the risk of nosocomial infection and further transmission to the general population [1] [2] [3] [4] [5] .", [["pulmonary", "ANATOMY", 18, 27], ["contagious pulmonary tuberculosis", "DISEASE", 7, 40], ["PTB", "DISEASE", 42, 45], ["pneumonia", "DISEASE", 83, 92], ["CAP", "DISEASE", 94, 97], ["infection", "DISEASE", 205, 214], ["[1] [2] [3] [4] [5]", "CHEMICAL", 266, 285], ["pulmonary", "ORGAN", 18, 27], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 266, 285], ["Highly contagious pulmonary tuberculosis (PTB)", "PROBLEM", 0, 46], ["communityacquired pneumonia", "PROBLEM", 65, 92], ["nosocomial infection", "PROBLEM", 194, 214], ["contagious", "OBSERVATION_MODIFIER", 7, 17], ["pulmonary", "ANATOMY", 18, 27], ["tuberculosis", "OBSERVATION", 28, 40], ["pneumonia", "OBSERVATION", 83, 92], ["nosocomial", "OBSERVATION_MODIFIER", 194, 204], ["infection", "OBSERVATION", 205, 214]]], ["Current screening methods recommended by the Centers for Disease Control and Prevention (CDC) involve respiratory isolation (RI) of suspected PTB patients until 3 sputum samples obtained over 48 h are negative [6] .", [["respiratory", "ANATOMY", 102, 113], ["sputum samples", "ANATOMY", 163, 177], ["PTB", "DISEASE", 142, 145], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["Current screening methods", "TEST", 0, 25], ["Disease Control", "TREATMENT", 57, 72], ["respiratory isolation", "TREATMENT", 102, 123], ["sputum samples", "TEST", 163, 177]]], ["This expanded RI policy for all patients suspected of PTB in the United States led to the proper isolation of over 95% of PTB upon admission; however, it also resulted in an 8-fold overuse of the isolation room, and eventually led to an insufficient number of isolation rooms [7] .", [["PTB", "DISEASE", 54, 57], ["PTB", "DISEASE", 122, 125], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["PTB", "PROBLEM", 54, 57], ["PTB", "OBSERVATION", 54, 57]]], ["Under the threatening of acute lung disease such as the severe acute respiratory syndrome (SARS) virus and the new H1N1 influenza nowadays, a 3-day isolation policy for waiting times for smear results for all patients merely suspected of active PTB, may prove too burdensome for most hospitals [8, 9] .", [["lung", "ANATOMY", 31, 35], ["acute lung disease", "DISEASE", 25, 43], ["acute respiratory syndrome (SARS) virus", "DISEASE", 63, 102], ["influenza", "DISEASE", 120, 129], ["PTB", "DISEASE", 245, 248], ["lung", "ORGAN", 31, 35], ["patients", "ORGANISM", 209, 217], ["H1N1 influenza", "SPECIES", 115, 129], ["patients", "SPECIES", 209, 217], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 56, 102], ["acute lung disease", "PROBLEM", 25, 43], ["the severe acute respiratory syndrome", "PROBLEM", 52, 89], ["SARS) virus", "PROBLEM", 91, 102], ["the new H1N1 influenza", "PROBLEM", 107, 129], ["smear", "TEST", 187, 192], ["active PTB", "PROBLEM", 238, 248], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["lung", "ANATOMY", 31, 35], ["disease", "OBSERVATION", 36, 43], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory syndrome", "OBSERVATION", 69, 89], ["new", "OBSERVATION_MODIFIER", 111, 114], ["H1N1", "OBSERVATION", 115, 119], ["active", "OBSERVATION_MODIFIER", 238, 244], ["PTB", "OBSERVATION", 245, 248]]], ["Furthermore, an isolation policy based solely upon negative sputum samples may not adequately account for the truly positive sputums missed due to low organism loads [10] .", [["sputum samples", "ANATOMY", 60, 74], ["sputums", "ANATOMY", 125, 132], ["sputums", "DISEASE", 125, 132], ["sputum samples", "TEST", 60, 74], ["the truly positive sputums", "PROBLEM", 106, 132], ["low organism loads", "PROBLEM", 147, 165]]], ["Therefore, more effective diagnostic tests and/or criteria for differentiating those patients at highest risk of active PTB are desperately needed.IntroductionHigh-resolution computed tomography (HRCT) has been shown to be more effective in the differential diagnosis of acute parenchymal lung disease than chest radiographs (CXR) [11] .", [["parenchymal lung", "ANATOMY", 277, 293], ["PTB", "DISEASE", 120, 123], ["parenchymal lung disease", "DISEASE", 277, 301], ["patients", "ORGANISM", 85, 93], ["lung", "ORGAN", 289, 293], ["patients", "SPECIES", 85, 93], ["diagnostic tests", "TEST", 26, 42], ["active PTB", "PROBLEM", 113, 123], ["acute parenchymal lung disease", "PROBLEM", 271, 301], ["chest radiographs", "TEST", 307, 324], ["CXR", "TEST", 326, 329], ["active", "OBSERVATION_MODIFIER", 113, 119], ["PTB", "OBSERVATION", 120, 123], ["more effective", "OBSERVATION_MODIFIER", 223, 237], ["acute", "OBSERVATION_MODIFIER", 271, 276], ["parenchymal", "ANATOMY_MODIFIER", 277, 288], ["lung", "ANATOMY", 289, 293], ["disease", "OBSERVATION", 294, 301], ["chest", "ANATOMY", 307, 312]]], ["HRCT can indicate findings suggestive of pneumonia almost 5 days earlier than CXR [12] .", [["pneumonia", "DISEASE", 41, 50], ["HRCT", "TEST", 0, 4], ["pneumonia", "PROBLEM", 41, 50], ["CXR", "TEST", 78, 81], ["suggestive of", "UNCERTAINTY", 27, 40], ["pneumonia", "OBSERVATION", 41, 50]]], ["More recently, Ito et al., used HRCT to differentiate bacterial CAP from non-bacterial CAP [11] .", [["HRCT", "TEST", 32, 36], ["bacterial CAP", "PROBLEM", 54, 67], ["non-bacterial CAP", "PROBLEM", 73, 90], ["bacterial CAP", "OBSERVATION", 54, 67], ["non-bacterial CAP", "OBSERVATION", 73, 90]]], ["Although several prediction models for the diagnosis of active PTB have been proposed in recent years [13] [14] [15] , none have specifically focused on the diagnosis of smear-positive active PTB with HRCT.IntroductionThe objective of this study is to investigate a proposed triage protocol using HRCT to initiate RI for patients with AFB smear positive PTB in the ER before the sputum smear results are known, with the ultimate intention of reducing the spatial and financial burden to hospitals, while minimizing any additional risk to patients and healthcare workers.PatientsFrom July 2005 through March 2008, a retrospective study was performed on all 19990 patients evaluated in the ER of PingTung Christian Hospital, a 706-bed teaching hospital in PingTung, Taiwan, to identify those with pulmonary symptoms.", [["sputum", "ANATOMY", 379, 385], ["pulmonary", "ANATOMY", 795, 804], ["PTB", "DISEASE", 63, 66], ["PTB", "DISEASE", 192, 195], ["PTB", "DISEASE", 354, 357], ["pulmonary symptoms", "DISEASE", 795, 813], ["PTB", "GENE_OR_GENE_PRODUCT", 63, 66], ["patients", "ORGANISM", 321, 329], ["ER", "GENE_OR_GENE_PRODUCT", 365, 367], ["patients", "ORGANISM", 538, 546], ["Patients", "ORGANISM", 570, 578], ["patients", "ORGANISM", 662, 670], ["pulmonary", "ORGAN", 795, 804], ["PTB", "PROTEIN", 63, 66], ["ER", "PROTEIN", 365, 367], ["patients", "SPECIES", 321, 329], ["patients", "SPECIES", 538, 546], ["Patients", "SPECIES", 570, 578], ["patients", "SPECIES", 662, 670], ["active PTB", "PROBLEM", 56, 66], ["smear", "TEST", 170, 175], ["HRCT", "TEST", 201, 205], ["this study", "TEST", 235, 245], ["a proposed triage protocol", "TEST", 264, 290], ["HRCT", "TEST", 297, 301], ["AFB smear", "TEST", 335, 344], ["the sputum smear", "TEST", 375, 391], ["a retrospective study", "TEST", 613, 634], ["pulmonary symptoms", "PROBLEM", 795, 813], ["active", "OBSERVATION_MODIFIER", 56, 62], ["PTB", "OBSERVATION", 63, 66], ["positive", "OBSERVATION_MODIFIER", 176, 184], ["active", "OBSERVATION_MODIFIER", 185, 191], ["PTB", "OBSERVATION", 192, 195], ["pulmonary", "ANATOMY", 795, 804]]], ["Initial inclusion criteria were presence of infiltrate on CXR and symptoms suggestive of a CAP.", [["CAP", "DISEASE", 91, 94], ["infiltrate", "PROBLEM", 44, 54], ["CXR", "TEST", 58, 61], ["symptoms", "PROBLEM", 66, 74], ["a CAP", "PROBLEM", 89, 94], ["infiltrate", "OBSERVATION", 44, 54], ["suggestive of", "UNCERTAINTY", 75, 88], ["CAP", "OBSERVATION_MODIFIER", 91, 94]]], ["CAP was defined as the presence of an acute illness of 21 days or less duration with (1) one or more symptoms such as fever >38.5, confusion, sweating aches, etc., (2) at least two or more of new or increasing cough, sputum production, shortness of breath, wheeze, new focal or diffuse signs on physical examinations, (3) CXR consistent with infection and which was neither pre-existing nor of other known cause and (4) treatment with antibiotics for pneumonia by the pulmonologists or infection clinicians [16] .", [["sputum", "ANATOMY", 217, 223], ["CAP", "DISEASE", 0, 3], ["fever", "DISEASE", 118, 123], ["confusion", "DISEASE", 131, 140], ["sweating aches", "DISEASE", 142, 156], ["cough", "DISEASE", 210, 215], ["shortness of breath", "DISEASE", 236, 255], ["wheeze", "DISEASE", 257, 263], ["infection", "DISEASE", 342, 351], ["pneumonia", "DISEASE", 451, 460], ["infection", "DISEASE", 486, 495], ["an acute illness", "PROBLEM", 35, 51], ["more symptoms", "PROBLEM", 96, 109], ["fever", "PROBLEM", 118, 123], ["confusion", "PROBLEM", 131, 140], ["sweating aches", "PROBLEM", 142, 156], ["new or increasing cough", "PROBLEM", 192, 215], ["sputum production", "PROBLEM", 217, 234], ["shortness of breath", "PROBLEM", 236, 255], ["wheeze", "PROBLEM", 257, 263], ["new focal or diffuse signs", "PROBLEM", 265, 291], ["physical examinations", "TEST", 295, 316], ["CXR", "TEST", 322, 325], ["infection", "PROBLEM", 342, 351], ["antibiotics", "TREATMENT", 435, 446], ["pneumonia", "PROBLEM", 451, 460], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["illness", "OBSERVATION", 44, 51], ["new", "OBSERVATION_MODIFIER", 192, 195], ["increasing", "OBSERVATION_MODIFIER", 199, 209], ["cough", "OBSERVATION", 210, 215], ["new", "OBSERVATION_MODIFIER", 265, 268], ["focal", "OBSERVATION_MODIFIER", 269, 274], ["diffuse", "OBSERVATION_MODIFIER", 278, 285], ["consistent with", "UNCERTAINTY", 326, 341], ["infection", "OBSERVATION", 342, 351]]], ["Patients were treated by the ER physician, followed by either a pulmonologist or infectious disease specialist.", [["infectious disease", "DISEASE", 81, 99], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["There were 1719 patients with pulmonary infiltrates, and 1300 were selected for further analysis after excluding 419 patients refused to participate in the study or were lost to follow-up.PatientsThe majority of these 1300 patients were also excluded from the study for various reasons: HIV infection (n = 5); hospitalization within 7 days of ER presentation (n = 125); no HRCT study (n = 750); presence of tumors (n = 25); presence of an underlying disease (collagen vascular disease) or co-infection (n = 16); those not requiring hospitalization (n = 196) who isolated at home if symptom and sign were mild and anti-TB drugs were tolerated [17] .", [["pulmonary", "ANATOMY", 30, 39], ["tumors", "ANATOMY", 407, 413], ["vascular", "ANATOMY", 468, 476], ["HIV infection", "DISEASE", 287, 300], ["tumors", "DISEASE", 407, 413], ["collagen vascular disease", "DISEASE", 459, 484], ["co-infection", "DISEASE", 489, 501], ["patients", "ORGANISM", 16, 24], ["pulmonary", "ORGAN", 30, 39], ["patients", "ORGANISM", 117, 125], ["Patients", "ORGANISM", 188, 196], ["patients", "ORGANISM", 223, 231], ["HIV", "ORGANISM", 287, 290], ["ER", "GENE_OR_GENE_PRODUCT", 343, 345], ["tumors", "CANCER", 407, 413], ["collagen", "GENE_OR_GENE_PRODUCT", 459, 467], ["vascular", "MULTI-TISSUE_STRUCTURE", 468, 476], ["ER", "PROTEIN", 343, 345], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 117, 125], ["Patients", "SPECIES", 188, 196], ["patients", "SPECIES", 223, 231], ["HIV", "SPECIES", 287, 290], ["HIV", "SPECIES", 287, 290], ["pulmonary infiltrates", "PROBLEM", 30, 51], ["further analysis", "TEST", 80, 96], ["the study", "TEST", 152, 161], ["the study", "TEST", 256, 265], ["HIV infection", "PROBLEM", 287, 300], ["HRCT study", "TEST", 373, 383], ["tumors", "PROBLEM", 407, 413], ["an underlying disease", "PROBLEM", 436, 457], ["collagen vascular disease)", "PROBLEM", 459, 485], ["co-infection", "PROBLEM", 489, 501], ["symptom", "PROBLEM", 582, 589], ["anti-TB drugs", "TREATMENT", 613, 626], ["pulmonary", "ANATOMY", 30, 39], ["infiltrates", "OBSERVATION", 40, 51], ["infection", "OBSERVATION", 291, 300], ["tumors", "OBSERVATION", 407, 413], ["disease", "OBSERVATION", 450, 457], ["vascular", "ANATOMY", 468, 476], ["disease", "OBSERVATION", 477, 484]]], ["The remaining 183 patients suspected of CAP or PTB received an HRCT study for enrollment into this study.Microbiology evaluationRegular sampling included at least 3 sputum specimens, 2 or more blood cultures, and paired serologic specimens (at admission and within the 4th and 8th week thereafter).", [["sputum specimens", "ANATOMY", 165, 181], ["blood cultures", "ANATOMY", 193, 207], ["specimens", "ANATOMY", 230, 239], ["CAP", "DISEASE", 40, 43], ["PTB", "DISEASE", 47, 50], ["patients", "ORGANISM", 18, 26], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["patients", "SPECIES", 18, 26], ["CAP", "PROBLEM", 40, 43], ["PTB", "PROBLEM", 47, 50], ["an HRCT study", "TEST", 60, 73], ["this study", "TEST", 94, 104], ["Microbiology evaluationRegular sampling", "TEST", 105, 144], ["sputum specimens", "TEST", 165, 181], ["blood cultures", "TEST", 193, 207], ["paired serologic specimens", "TEST", 213, 239]]], ["Additional diagnostic techniques utilized included pleural puncture, transbronchial aspirates, flexible bronchoscopy with a protected specimen brush, and urine samples for Legionella species antigen [16] .Microbiology evaluationSputum samples were gram stained.", [["pleural", "ANATOMY", 51, 58], ["transbronchial aspirates", "ANATOMY", 69, 93], ["specimen brush", "ANATOMY", 134, 148], ["urine samples", "ANATOMY", 154, 167], ["samples", "ANATOMY", 235, 242], ["pleural puncture", "MULTI-TISSUE_STRUCTURE", 51, 67], ["transbronchial aspirates", "MULTI-TISSUE_STRUCTURE", 69, 93], ["urine samples", "ORGANISM_SUBSTANCE", 154, 167], ["diagnostic techniques", "TEST", 11, 32], ["pleural puncture", "TEST", 51, 67], ["transbronchial aspirates", "TEST", 69, 93], ["flexible bronchoscopy", "TEST", 95, 116], ["a protected specimen brush", "TEST", 122, 148], ["urine samples", "TEST", 154, 167], ["Legionella species antigen", "TEST", 172, 198], ["Microbiology evaluationSputum samples", "TEST", 205, 242], ["pleural", "ANATOMY", 51, 58], ["transbronchial", "ANATOMY", 69, 83]]], ["Sputum appropriate for analysis and originating from the lower respiratory tract was defined as containing at least 25 granulocytes and less than 10 epithelial cells per low-power field.", [["Sputum", "ANATOMY", 0, 6], ["lower respiratory tract", "ANATOMY", 57, 80], ["granulocytes", "ANATOMY", 119, 131], ["epithelial cells", "ANATOMY", 149, 165], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["lower respiratory", "ORGANISM_SUBDIVISION", 57, 74], ["tract", "ORGANISM_SUBDIVISION", 75, 80], ["granulocytes", "CELL", 119, 131], ["epithelial cells", "CELL", 149, 165], ["granulocytes", "CELL_TYPE", 119, 131], ["epithelial cells", "CELL_TYPE", 149, 165], ["Sputum", "TEST", 0, 6], ["analysis", "TEST", 23, 31], ["the lower respiratory tract", "PROBLEM", 53, 80], ["granulocytes", "TEST", 119, 131], ["epithelial cells", "TEST", 149, 165], ["lower", "ANATOMY_MODIFIER", 57, 62], ["respiratory tract", "ANATOMY", 63, 80], ["low", "OBSERVATION_MODIFIER", 170, 173]]], ["Validated sputum samples, blood culture samples, pleural fluid, and protected specimen brush samples were plated on sheep blood agar.", [["sputum samples", "ANATOMY", 10, 24], ["blood culture samples", "ANATOMY", 26, 47], ["pleural fluid", "ANATOMY", 49, 62], ["specimen brush samples", "ANATOMY", 78, 100], ["blood", "ANATOMY", 122, 127], ["sputum samples", "ORGANISM_SUBSTANCE", 10, 24], ["blood culture samples", "ORGANISM_SUBSTANCE", 26, 47], ["pleural fluid", "ORGANISM_SUBSTANCE", 49, 62], ["specimen brush samples", "ORGANISM_SUBSTANCE", 78, 100], ["sheep", "ORGANISM", 116, 121], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["sheep", "SPECIES", 116, 121], ["sheep", "SPECIES", 116, 121], ["Validated sputum samples", "TEST", 0, 24], ["blood culture samples", "TEST", 26, 47], ["pleural fluid", "TEST", 49, 62], ["protected specimen brush samples", "TEST", 68, 100], ["sheep blood agar", "TEST", 116, 132], ["pleural", "ANATOMY", 49, 56], ["fluid", "OBSERVATION", 57, 62]]], ["Microorganism identification was performed according to standard protocols [16] .Confirmation of PTBThe 183 patients were assigned to groups according to sputum and culture results.", [["sputum", "ANATOMY", 154, 160], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["Microorganism identification", "TEST", 0, 28], ["sputum", "TEST", 154, 160], ["culture", "TEST", 165, 172]]], ["Those with AFB sputum smear positive, active PTB (n = 84) included patients with at least one positive sputum smear and a positive culture for Mycobacterium tuberculosis (Group 1-G1).", [["sputum", "ANATOMY", 103, 109], ["PTB", "DISEASE", 45, 48], ["Mycobacterium tuberculosis", "DISEASE", 143, 169], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Mycobacterium tuberculosis", "SPECIES", 143, 169], ["Mycobacterium tuberculosis", "SPECIES", 143, 169], ["AFB sputum smear", "TEST", 11, 27], ["active PTB", "PROBLEM", 38, 48], ["one positive sputum smear", "PROBLEM", 90, 115], ["a positive culture", "TEST", 120, 138], ["Mycobacterium tuberculosis", "PROBLEM", 143, 169], ["active", "OBSERVATION_MODIFIER", 38, 44], ["positive", "OBSERVATION_MODIFIER", 94, 102], ["sputum", "OBSERVATION", 103, 109], ["Mycobacterium tuberculosis", "OBSERVATION", 143, 169]]], ["The remaining 99 patients had negative sputum smears and culture of Mycobacterium tuberculosis (Group 2-G2).Confirmation of PTBG2 was subdivided into 3 additional groups.", [["sputum", "ANATOMY", 39, 45], ["Mycobacterium tuberculosis", "DISEASE", 68, 94], ["patients", "ORGANISM", 17, 25], ["Mycobacterium tuberculosis", "ORGANISM", 68, 94], ["PTBG2", "GENE_OR_GENE_PRODUCT", 124, 129], ["PTBG2", "DNA", 124, 129], ["patients", "SPECIES", 17, 25], ["Mycobacterium tuberculosis", "SPECIES", 68, 94], ["Mycobacterium tuberculosis", "SPECIES", 68, 94], ["sputum smears", "TEST", 39, 52], ["culture", "TEST", 57, 64], ["Mycobacterium tuberculosis", "PROBLEM", 68, 94], ["PTBG2", "TREATMENT", 124, 129], ["Mycobacterium tuberculosis", "OBSERVATION", 68, 94]]], ["Group 2a included 40 patients who were AFB-smear negative with active PTB based upon at least three negative sputum smears and a positive culture [18] .", [["sputum", "ANATOMY", 109, 115], ["PTB", "DISEASE", 70, 73], ["AFB", "CHEMICAL", 39, 42], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["AFB", "TEST", 39, 42], ["smear", "TEST", 43, 48], ["active PTB", "PROBLEM", 63, 73], ["sputum smears", "TEST", 109, 122], ["a positive culture", "TEST", 127, 145]]], ["Group 2b included 27 patients with inactive PTB based upon findings of residual fibrotic changes on CXR, absence of disease progression on CXR at recruitment when compared to 6 months previously or on follow-up, and absence of AFB in sputum or bronchial washings on the smears and cultures [18] .", [["sputum", "ANATOMY", 234, 240], ["bronchial", "ANATOMY", 244, 253], ["smears", "ANATOMY", 270, 276], ["PTB", "DISEASE", 44, 47], ["AFB", "CHEMICAL", 227, 230], ["patients", "ORGANISM", 21, 29], ["sputum", "ORGANISM_SUBSTANCE", 234, 240], ["patients", "SPECIES", 21, 29], ["inactive PTB", "PROBLEM", 35, 47], ["residual fibrotic changes", "PROBLEM", 71, 96], ["CXR", "TEST", 100, 103], ["disease progression", "PROBLEM", 116, 135], ["CXR", "TEST", 139, 142], ["AFB in sputum", "PROBLEM", 227, 240], ["bronchial washings", "TEST", 244, 262], ["the smears", "TEST", 266, 276], ["cultures", "TEST", 281, 289], ["residual", "OBSERVATION_MODIFIER", 71, 79], ["fibrotic", "OBSERVATION", 80, 88], ["disease", "OBSERVATION", 116, 123], ["sputum", "OBSERVATION", 234, 240], ["bronchial", "ANATOMY", 244, 253], ["washings", "OBSERVATION", 254, 262]]], ["Group 2c included 32 patients without evidence of PTB and definite pathogens was identified when (1) an isolate such as Pneumococcus pneumoniae, Klebsiella pneumonia, or Hemophilus influenzae was cultured from the blood or pleural effusion, (2) atypical pneumonia or bacterial pneumonia, such as Legionella pneumophila or Mycoplasma pneumoniae caused a 4-fold rise in antibody titers in serological testing, or (3) lung biopsy or wedge section proved the presence of herpes simplex virus, Actinomycosis, or Aspergillosis [16, 19, 20] .Criteria for recommendation of HRCTPatients with following characteristics were recommended to process HRCT: age > 65, complicated CAP, interstitial lung disease, or tumor was suspected.HRCT morphology descriptionThe HRCT morphology patterns of PTB are described in Figs.", [["blood", "ANATOMY", 214, 219], ["pleural effusion", "ANATOMY", 223, 239], ["lung", "ANATOMY", 415, 419], ["interstitial lung", "ANATOMY", 671, 688], ["tumor", "ANATOMY", 701, 706], ["PTB", "DISEASE", 50, 53], ["Pneumococcus pneumoniae", "DISEASE", 120, 143], ["Klebsiella pneumonia", "DISEASE", 145, 165], ["Hemophilus influenzae", "DISEASE", 170, 191], ["pleural effusion", "DISEASE", 223, 239], ["pneumonia", "DISEASE", 254, 263], ["bacterial pneumonia", "DISEASE", 267, 286], ["Legionella pneumophila", "DISEASE", 296, 318], ["Mycoplasma pneumoniae", "DISEASE", 322, 343], ["herpes simplex virus", "DISEASE", 467, 487], ["Actinomycosis", "DISEASE", 489, 502], ["CAP", "DISEASE", 666, 669], ["interstitial lung disease", "DISEASE", 671, 696], ["tumor", "DISEASE", 701, 706], ["PTB", "DISEASE", 780, 783], ["patients", "ORGANISM", 21, 29], ["Pneumococcus pneumoniae", "ORGANISM", 120, 143], ["Klebsiella pneumonia", "ORGANISM", 145, 165], ["Hemophilus influenzae", "ORGANISM", 170, 191], ["blood", "ORGANISM_SUBSTANCE", 214, 219], ["pleural effusion", "PATHOLOGICAL_FORMATION", 223, 239], ["Legionella pneumophila", "ORGANISM", 296, 318], ["Mycoplasma pneumoniae", "ORGANISM", 322, 343], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 415, 426], ["herpes simplex virus", "ORGANISM", 467, 487], ["lung", "ORGAN", 684, 688], ["tumor", "CANCER", 701, 706], ["PTB", "GENE_OR_GENE_PRODUCT", 780, 783], ["PTB", "PROTEIN", 780, 783], ["patients", "SPECIES", 21, 29], ["Pneumococcus pneumoniae", "SPECIES", 120, 143], ["Klebsiella pneumonia", "SPECIES", 145, 165], ["Hemophilus influenzae", "SPECIES", 170, 191], ["Legionella pneumophila", "SPECIES", 296, 318], ["Mycoplasma pneumoniae", "SPECIES", 322, 343], ["herpes simplex virus", "SPECIES", 467, 487], ["Pneumococcus pneumoniae", "SPECIES", 120, 143], ["Klebsiella pneumonia", "SPECIES", 145, 165], ["Hemophilus influenzae", "SPECIES", 170, 191], ["Legionella pneumophila", "SPECIES", 296, 318], ["Mycoplasma pneumoniae", "SPECIES", 322, 343], ["herpes simplex virus", "SPECIES", 467, 487], ["PTB", "PROBLEM", 50, 53], ["definite pathogens", "PROBLEM", 58, 76], ["an isolate", "TEST", 101, 111], ["Pneumococcus pneumoniae", "PROBLEM", 120, 143], ["Klebsiella pneumonia", "PROBLEM", 145, 165], ["Hemophilus influenzae", "PROBLEM", 170, 191], ["the blood or pleural effusion", "PROBLEM", 210, 239], ["atypical pneumonia", "PROBLEM", 245, 263], ["bacterial pneumonia", "PROBLEM", 267, 286], ["Legionella pneumophila", "PROBLEM", 296, 318], ["Mycoplasma pneumoniae", "PROBLEM", 322, 343], ["a 4-fold rise in antibody titers", "PROBLEM", 351, 383], ["serological testing", "TEST", 387, 406], ["lung biopsy", "TEST", 415, 426], ["wedge section", "TEST", 430, 443], ["herpes simplex virus", "PROBLEM", 467, 487], ["Actinomycosis", "PROBLEM", 489, 502], ["Aspergillosis", "PROBLEM", 507, 520], ["HRCT", "TEST", 638, 642], ["complicated CAP", "PROBLEM", 654, 669], ["interstitial lung disease", "PROBLEM", 671, 696], ["tumor", "PROBLEM", 701, 706], ["HRCT morphology", "TEST", 721, 736], ["PTB", "PROBLEM", 780, 783], ["without evidence of", "UNCERTAINTY", 30, 49], ["PTB", "OBSERVATION", 50, 53], ["Klebsiella", "OBSERVATION_MODIFIER", 145, 155], ["pneumonia", "OBSERVATION", 156, 165], ["blood", "ANATOMY", 214, 219], ["pleural", "ANATOMY", 223, 230], ["effusion", "OBSERVATION", 231, 239], ["atypical", "OBSERVATION_MODIFIER", 245, 253], ["pneumonia", "OBSERVATION", 254, 263], ["bacterial", "OBSERVATION_MODIFIER", 267, 276], ["pneumonia", "OBSERVATION", 277, 286], ["Mycoplasma pneumoniae", "OBSERVATION", 322, 343], ["4-fold", "OBSERVATION_MODIFIER", 353, 359], ["rise", "OBSERVATION_MODIFIER", 360, 364], ["lung", "ANATOMY", 415, 419], ["biopsy", "OBSERVATION", 420, 426], ["herpes simplex virus", "OBSERVATION", 467, 487], ["Aspergillosis", "OBSERVATION", 507, 520], ["CAP", "OBSERVATION_MODIFIER", 666, 669], ["interstitial", "ANATOMY_MODIFIER", 671, 683], ["lung", "ANATOMY", 684, 688], ["disease", "OBSERVATION", 689, 696], ["tumor", "OBSERVATION", 701, 706], ["PTB", "OBSERVATION", 780, 783]]], ["1 and 2 [21] [22] [23] .HRCT imaging evaluationChest CT scans without contrast media (0.625 mm collimation, 100-120 kV, 250 mA s), table speed of 57.5 mm/s and a rotation time of 0.75 s, pitch of 1.07) using a 64-MDCT scanner (Brilliance, Philips Medical Systems, Cleveland, OH, USA) were performed on 183 patients.", [["2 [21] [22] [23]", "SIMPLE_CHEMICAL", 6, 22], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 306, 314], ["HRCT imaging evaluation", "TEST", 24, 47], ["Chest CT scans", "TEST", 47, 61], ["table speed", "TEST", 131, 142], ["a rotation time", "TEST", 160, 175], ["pitch", "TEST", 187, 192], ["Chest", "ANATOMY", 47, 52]]], ["Images were acquired during a single breath-hold 5-8 s long, making respiratory motion artifacts very uncommon.", [["respiratory", "ANATOMY", 68, 79], ["Images", "TEST", 0, 6], ["respiratory motion", "OBSERVATION", 68, 86]]], ["The images were reconstructed with a 1-mm slice thickness in the axial plane (no gap) and in the coronal plane (5-mm apart) using a high spatial-frequency algorithm, and then sent to PACS for review.", [["slice", "ANATOMY", 42, 47], ["The images", "TEST", 0, 10]]], ["All thin-section MDCT images were displayed on a monitor at the pulmonary window level setting (level, \u2212600 HU; width, 1200 HU).Reading criteriaThe HRCT scans were evaluated by two radiologists and a chest physician.", [["pulmonary", "ANATOMY", 64, 73], ["chest", "ANATOMY", 200, 205], ["pulmonary", "ORGAN", 64, 73], ["All thin-section MDCT images", "TEST", 0, 28], ["a monitor", "TEST", 47, 56], ["The HRCT scans", "TEST", 144, 158], ["pulmonary", "ANATOMY", 64, 73], ["1200 HU", "OBSERVATION_MODIFIER", 119, 126], ["chest", "ANATOMY", 200, 205]]], ["Each specialist had more than 15 years of experience reading thoracic radiology studies and was unaware of the sputum smear and clinical examination results.", [["sputum", "ANATOMY", 111, 117], ["reading thoracic radiology studies", "TEST", 53, 87], ["the sputum smear", "TEST", 107, 123], ["clinical examination", "TEST", 128, 148], ["thoracic", "ANATOMY", 61, 69]]], ["The HRCT scans were assessed for the presence and distribution of parenchyma abnormalities.", [["parenchyma", "ANATOMY", 66, 76], ["parenchyma abnormalities", "DISEASE", 66, 90], ["parenchyma", "TISSUE", 66, 76], ["The HRCT scans", "TEST", 0, 14], ["parenchyma abnormalities", "PROBLEM", 66, 90], ["parenchyma", "ANATOMY_MODIFIER", 66, 76], ["abnormalities", "OBSERVATION", 77, 90]]], ["Location of lung involvement was reported as one or more of 18 designated segments in the lungs.Statistical analysesStatistical analyses were performed using SPSS 15.0 statistics software (SPSS Inc, Chicago, IL, USA).", [["lung", "ANATOMY", 12, 16], ["lungs", "ANATOMY", 90, 95], ["lung", "ORGAN", 12, 16], ["lungs", "ORGAN", 90, 95], ["Statistical analysesStatistical analyses", "TEST", 96, 136], ["SPSS", "TEST", 158, 162], ["statistics software", "TEST", 168, 187], ["lung", "ANATOMY", 12, 16], ["involvement", "OBSERVATION", 17, 28], ["segments", "ANATOMY_MODIFIER", 74, 82], ["lungs", "ANATOMY", 90, 95]]], ["Data is presented as mean \u00b1 standard deviation (SD) for continuous data, such as age, lag time of TB smear, and lag time of TB culture.", [["TB", "DISEASE", 124, 126], ["continuous data", "TEST", 56, 71], ["TB smear", "TEST", 98, 106], ["TB culture", "TEST", 124, 134]]], ["Two-sample t-test is used to compare the difference between groups for continuous data.", [["Two-sample t-test", "TEST", 0, 17], ["continuous data", "TEST", 71, 86]]], ["Pearson's chi-square test or Fisher's exact test was used to compare the difference in distribution of the categorical data between groups.", [["Pearson's chi-square test", "TEST", 0, 25], ["Fisher's exact test", "TEST", 29, 48]]], ["Furthermore, a multiple logistic regression model was performed to indicate the predictors of the subjects with smear-positive, active PTB.", [["PTB", "DISEASE", 135, 138], ["a multiple logistic regression model", "TEST", 13, 49], ["smear", "TEST", 112, 117], ["active PTB", "PROBLEM", 128, 138], ["active", "OBSERVATION_MODIFIER", 128, 134], ["PTB", "OBSERVATION", 135, 138]]], ["The estimated beta (\u02c7) with standard error (Std.", [["beta (\u02c7)", "PROTEIN", 14, 22]]], ["Err.) and odds ratio (OR) with 95% confidence interval (D) Histologic specimen (biopsies of the right upper lobe via video-assisted thoracoscopy, H&E stain, 40\u00d7) photomicrograph shows more concentrated granulomas at the center of the nodule clusters and granulomatous inflammation with peribroncho-arterial distribution (C, white arrow) and a small granulomata (C, white arrowhead) at the periphery of the large nodules.", [["specimen", "ANATOMY", 70, 78], ["biopsies", "ANATOMY", 80, 88], ["right upper lobe", "ANATOMY", 96, 112], ["granulomas", "ANATOMY", 202, 212], ["nodule clusters", "ANATOMY", 234, 249], ["granulomatous", "ANATOMY", 254, 267], ["arterial", "ANATOMY", 298, 306], ["granulomata", "ANATOMY", 349, 360], ["nodules", "ANATOMY", 412, 419], ["granulomas", "DISEASE", 202, 212], ["inflammation", "DISEASE", 268, 280], ["granulomata", "DISEASE", 349, 360], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 102, 112], ["granulomas", "PATHOLOGICAL_FORMATION", 202, 212], ["nodule clusters", "PATHOLOGICAL_FORMATION", 234, 249], ["arterial", "MULTI-TISSUE_STRUCTURE", 298, 306], ["nodules", "CANCER", 412, 419], ["Histologic specimen", "TEST", 59, 78], ["biopsies of the right upper lobe", "TEST", 80, 112], ["video-assisted thoracoscopy", "TEST", 117, 144], ["H&E stain", "TEST", 146, 155], ["photomicrograph", "TEST", 162, 177], ["more concentrated granulomas", "PROBLEM", 184, 212], ["the nodule clusters", "PROBLEM", 230, 249], ["granulomatous inflammation", "PROBLEM", 254, 280], ["peribroncho-arterial distribution (C, white arrow)", "PROBLEM", 286, 336], ["a small granulomata (C, white arrowhead)", "PROBLEM", 341, 381], ["the large nodules", "PROBLEM", 402, 419], ["right upper lobe", "ANATOMY", 96, 112], ["more", "OBSERVATION_MODIFIER", 184, 188], ["concentrated", "OBSERVATION_MODIFIER", 189, 201], ["granulomas", "OBSERVATION", 202, 212], ["nodule", "OBSERVATION", 234, 240], ["granulomatous", "OBSERVATION_MODIFIER", 254, 267], ["inflammation", "OBSERVATION", 268, 280], ["arterial", "ANATOMY", 298, 306], ["distribution", "OBSERVATION_MODIFIER", 307, 319], ["small", "OBSERVATION_MODIFIER", 343, 348], ["granulomata", "OBSERVATION", 349, 360], ["periphery", "ANATOMY_MODIFIER", 389, 398], ["large", "OBSERVATION_MODIFIER", 406, 411], ["nodules", "OBSERVATION", 412, 419]]], ["(E) Histologic specimen (biopsies of the right upper lobe via video-assisted thoracoscopy, H&E stain, 40\u00d7) photomicrograph shows large tuberculous nodules (C, white arrow) produced by numerous small nodules and a small granulomata (C, white arrowhead) at the periphery of the large nodules.", [["specimen", "ANATOMY", 15, 23], ["biopsies", "ANATOMY", 25, 33], ["right upper lobe", "ANATOMY", 41, 57], ["tuberculous nodules", "ANATOMY", 135, 154], ["nodules", "ANATOMY", 199, 206], ["granulomata", "ANATOMY", 219, 230], ["nodules", "ANATOMY", 282, 289], ["granulomata", "DISEASE", 219, 230], ["biopsies", "CANCER", 25, 33], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 47, 57], ["tuberculous nodules", "PATHOLOGICAL_FORMATION", 135, 154], ["nodules", "CANCER", 199, 206], ["nodules", "CANCER", 282, 289], ["Histologic specimen (biopsies of the right upper lobe", "TEST", 4, 57], ["video-assisted thoracoscopy", "TEST", 62, 89], ["H&E stain", "TEST", 91, 100], ["photomicrograph", "TEST", 107, 122], ["large tuberculous nodules (C, white arrow)", "PROBLEM", 129, 171], ["numerous small nodules", "PROBLEM", 184, 206], ["a small granulomata (C, white arrowhead)", "PROBLEM", 211, 251], ["the large nodules", "PROBLEM", 272, 289], ["right upper lobe", "ANATOMY", 41, 57], ["large", "OBSERVATION_MODIFIER", 129, 134], ["tuberculous", "OBSERVATION_MODIFIER", 135, 146], ["nodules", "OBSERVATION", 147, 154], ["numerous", "OBSERVATION_MODIFIER", 184, 192], ["small", "OBSERVATION_MODIFIER", 193, 198], ["nodules", "OBSERVATION", 199, 206], ["small", "OBSERVATION_MODIFIER", 213, 218], ["granulomata", "OBSERVATION", 219, 230], ["periphery", "ANATOMY_MODIFIER", 259, 268], ["large", "OBSERVATION_MODIFIER", 276, 281], ["nodules", "OBSERVATION", 282, 289]]], ["Peripheral low attenuation spots on HRCT correspond to spaces between partially coalescent small nodules (C = clusters of nodules; B = bronchus; A = artery).Statistical analyses(CI) are presented from the multivariate logistic regression model in Table 4 .", [["nodules", "ANATOMY", 97, 104], ["nodules", "ANATOMY", 122, 129], ["B = bronchus", "ANATOMY", 131, 143], ["artery", "ANATOMY", 149, 155], ["nodules", "PATHOLOGICAL_FORMATION", 97, 104], ["bronchus", "MULTI-TISSUE_STRUCTURE", 135, 143], ["artery", "MULTI-TISSUE_STRUCTURE", 149, 155], ["Peripheral low attenuation spots", "PROBLEM", 0, 32], ["HRCT", "TEST", 36, 40], ["spaces", "PROBLEM", 55, 61], ["partially coalescent small nodules (C = clusters of nodules", "PROBLEM", 70, 129], ["low attenuation", "OBSERVATION_MODIFIER", 11, 26], ["spots", "OBSERVATION", 27, 32], ["partially", "OBSERVATION_MODIFIER", 70, 79], ["coalescent", "OBSERVATION_MODIFIER", 80, 90], ["small", "OBSERVATION_MODIFIER", 91, 96], ["nodules", "OBSERVATION", 97, 104], ["nodules", "OBSERVATION", 122, 129], ["bronchus", "ANATOMY", 135, 143], ["artery", "ANATOMY", 149, 155]]], ["In addition, a relative score is given by using the estimate\u010f as a base according to the study of Kanaya et al. [14] .", [["the study", "TEST", 85, 94]]], ["The relative score is given as 1, 2, or 3 if the relative ratio is <1.5, >1.5, and >2.5.", [["The relative score", "TEST", 0, 18], ["the relative ratio", "TEST", 45, 63]]], ["The area under the receiver operating characteristic (ROC) curve is shown to indicate the best cut-off point (Fig. 3) .", [["ROC) curve", "TEST", 54, 64]]], ["All statistical analyses are considered significant at p < 0.05.EthicsAll participants in this study gave written consent after being fully informed.", [["participants", "SPECIES", 74, 86], ["All statistical analyses", "TEST", 0, 24]]], ["This study was approved by the Ethics Review Board of our institution.ResultsA total of 183 subjects receiving HRCT analysis are included for evaluation.", [["This study", "TEST", 0, 10], ["HRCT analysis", "TEST", 111, 124], ["evaluation", "TEST", 142, 152]]], ["The subjects are classified as Group 1 AFB sputum smear positive, active PTB (n = 84) and Group 2 sputum smear negative pulmonary infection patients (n = 99).", [["pulmonary", "ANATOMY", 120, 129], ["PTB", "DISEASE", 73, 76], ["pulmonary infection", "DISEASE", 120, 139], ["pulmonary", "ORGAN", 120, 129], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["Group 1 AFB sputum smear", "TEST", 31, 55], ["active PTB", "PROBLEM", 66, 76], ["Group 2 sputum smear", "TEST", 90, 110], ["pulmonary infection", "PROBLEM", 120, 139], ["negative", "UNCERTAINTY", 111, 119], ["pulmonary", "ANATOMY", 120, 129], ["infection", "OBSERVATION", 130, 139]]], ["Table 1 presents the demographic data, and methods of confirmation of smear-positive PTB and non-AFB smear-positive pulmonary infection for all the patients by group and subgroup.", [["pulmonary", "ANATOMY", 116, 125], ["PTB", "DISEASE", 85, 88], ["pulmonary infection", "DISEASE", 116, 135], ["pulmonary", "ORGAN", 116, 125], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["the demographic data", "TEST", 17, 37], ["smear", "TEST", 70, 75], ["positive PTB", "PROBLEM", 76, 88], ["non-AFB smear", "TEST", 93, 106], ["positive pulmonary infection", "PROBLEM", 107, 135], ["positive", "OBSERVATION_MODIFIER", 107, 115], ["pulmonary", "ANATOMY", 116, 125], ["infection", "OBSERVATION", 126, 135]]], ["There was no significant age difference between the groups.", [["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["age", "OBSERVATION_MODIFIER", 25, 28], ["difference", "OBSERVATION", 29, 39]]], ["Co-morbid conditions such as anemia, diabetes, alcoholism, chronic steroid use, uremia, and hypoalbuminemia were noted in the 183 studied patients; however, only the presence of anemia proved to be a statistically significant finding among those with AFB sputum positive, active PTB (Group 1).", [["sputum", "ANATOMY", 255, 261], ["anemia", "DISEASE", 29, 35], ["diabetes", "DISEASE", 37, 45], ["alcoholism", "DISEASE", 47, 57], ["steroid", "CHEMICAL", 67, 74], ["uremia", "DISEASE", 80, 86], ["hypoalbuminemia", "DISEASE", 92, 107], ["anemia", "DISEASE", 178, 184], ["PTB", "DISEASE", 279, 282], ["steroid", "CHEMICAL", 67, 74], ["AFB", "CHEMICAL", 251, 254], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["Co-morbid conditions", "PROBLEM", 0, 20], ["anemia", "PROBLEM", 29, 35], ["diabetes", "PROBLEM", 37, 45], ["alcoholism", "PROBLEM", 47, 57], ["chronic steroid use", "PROBLEM", 59, 78], ["uremia", "PROBLEM", 80, 86], ["hypoalbuminemia", "PROBLEM", 92, 107], ["anemia", "PROBLEM", 178, 184], ["AFB sputum", "TEST", 251, 261], ["anemia", "OBSERVATION", 29, 35], ["diabetes", "OBSERVATION", 37, 45], ["alcoholism", "OBSERVATION", 47, 57], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["steroid use", "OBSERVATION", 67, 78], ["uremia", "OBSERVATION", 80, 86], ["hypoalbuminemia", "OBSERVATION", 92, 107], ["anemia", "OBSERVATION", 178, 184]]], ["A history of previous PTB was a significant finding among those with negative sputum smears.", [["sputum", "ANATOMY", 78, 84], ["PTB", "DISEASE", 22, 25], ["previous PTB", "PROBLEM", 13, 25], ["sputum smears", "TEST", 78, 91], ["PTB", "OBSERVATION", 22, 25]]], ["Group 1 generated spontaneous sputum for examination (p < 0.001), while a greater percentage of Group 2 patients required bronchoscopy for sputum examination (p < 0.001).ResultsHRCT was performed on all 183 patients within 24 h of presentation in the ER, and the results are described in Table 2 .", [["sputum", "ANATOMY", 30, 36], ["sputum", "ANATOMY", 139, 145], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 207, 215], ["ER", "GENE_OR_GENE_PRODUCT", 251, 253], ["ER", "PROTEIN", 251, 253], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 207, 215], ["examination", "TEST", 41, 52], ["bronchoscopy", "TEST", 122, 134], ["sputum examination", "TEST", 139, 157], ["ResultsHRCT", "TEST", 170, 181]]], ["HRCT patterns like ground glass opacity, consolidation, bronchial wall thickening, clusters of nodules, paratracheal adenopathy, interlobular septal thickening, and cavitations were more frequent in G1 (p < 0.05).", [["bronchial wall", "ANATOMY", 56, 70], ["nodules", "ANATOMY", 95, 102], ["paratracheal adenopathy", "ANATOMY", 104, 127], ["interlobular septal", "ANATOMY", 129, 148], ["adenopathy", "DISEASE", 117, 127], ["cavitations", "DISEASE", 165, 176], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 56, 70], ["nodules", "PATHOLOGICAL_FORMATION", 95, 102], ["interlobular septal", "MULTI-TISSUE_STRUCTURE", 129, 148], ["HRCT patterns", "TEST", 0, 13], ["ground glass opacity", "PROBLEM", 19, 39], ["consolidation", "PROBLEM", 41, 54], ["bronchial wall thickening", "PROBLEM", 56, 81], ["nodules", "PROBLEM", 95, 102], ["paratracheal adenopathy", "PROBLEM", 104, 127], ["interlobular septal thickening", "PROBLEM", 129, 159], ["cavitations", "PROBLEM", 165, 176], ["ground glass opacity", "OBSERVATION", 19, 39], ["consolidation", "OBSERVATION", 41, 54], ["bronchial", "ANATOMY", 56, 65], ["wall", "ANATOMY_MODIFIER", 66, 70], ["thickening", "OBSERVATION", 71, 81], ["clusters", "OBSERVATION_MODIFIER", 83, 91], ["nodules", "OBSERVATION", 95, 102], ["paratracheal", "ANATOMY", 104, 116], ["adenopathy", "OBSERVATION", 117, 127], ["interlobular", "ANATOMY_MODIFIER", 129, 141], ["septal", "ANATOMY_MODIFIER", 142, 148], ["thickening", "OBSERVATION", 149, 159], ["cavitations", "OBSERVATION_MODIFIER", 165, 176]]], ["Meanwhile, HRCT patterns of calcification and fibrosis were more frequent in G2 (all p < 0.05).", [["calcification", "DISEASE", 28, 41], ["fibrosis", "DISEASE", 46, 54], ["calcification", "PROBLEM", 28, 41], ["fibrosis", "PROBLEM", 46, 54], ["calcification", "OBSERVATION", 28, 41], ["fibrosis", "OBSERVATION", 46, 54]]], ["There were no statistically significant differences in centrilobular nodules and tree-in-bud between G1 and G2 (p = 0.156 and p = 0.781, respectively).ResultsThe anatomic distribution and numbers of lung segments/subsegments with consolidation, cavitations, and clusters of nodules are described in Table 3 .", [["centrilobular nodules", "ANATOMY", 55, 76], ["bud", "ANATOMY", 89, 92], ["lung", "ANATOMY", 199, 203], ["subsegments", "ANATOMY", 213, 224], ["nodules", "ANATOMY", 274, 281], ["cavitations", "DISEASE", 245, 256], ["centrilobular nodules", "PATHOLOGICAL_FORMATION", 55, 76], ["lung segments", "MULTI-TISSUE_STRUCTURE", 199, 212], ["nodules", "CANCER", 274, 281], ["centrilobular nodules", "PROBLEM", 55, 76], ["tree", "TEST", 81, 85], ["p", "TEST", 126, 127], ["numbers of lung segments/subsegments", "PROBLEM", 188, 224], ["consolidation", "PROBLEM", 230, 243], ["cavitations", "PROBLEM", 245, 256], ["nodules", "PROBLEM", 274, 281], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["differences", "OBSERVATION_MODIFIER", 40, 51], ["centrilobular", "OBSERVATION_MODIFIER", 55, 68], ["nodules", "OBSERVATION", 69, 76], ["tree", "OBSERVATION_MODIFIER", 81, 85], ["bud", "ANATOMY_MODIFIER", 89, 92], ["anatomic distribution", "OBSERVATION", 162, 183], ["numbers", "OBSERVATION_MODIFIER", 188, 195], ["lung", "ANATOMY", 199, 203], ["segments", "ANATOMY_MODIFIER", 204, 212], ["consolidation", "OBSERVATION", 230, 243], ["cavitations", "OBSERVATION_MODIFIER", 245, 256], ["clusters", "OBSERVATION_MODIFIER", 262, 270], ["nodules", "OBSERVATION", 274, 281]]], ["Consolidation involving an apex segment (s1), posterior segment of the right upper lobe (s2), or apicoposterior segment of the left upper lobe (s1 + s2); consolidation involving the superior segment of the right or left lower lobe (s6); cavitation in the apex segment (s1), posterior segment of the right upper lobe (s2), or apico-posterior segment of the left upper lobe (s1 + s2); number of cavitation >1, number of consolidations >2; number of clusters of nodules >3 were more frequent in G1 (all p < 0.05).ResultsIn the multivariate analysis, consolidations in the apex segment (s1), posterior segment of the right upper lobe (s2), or apico-posterior segment of the left upper lobe (s1 + s2) (p = 0.010); consolidation of the superior segment of either lower lobe (s6)Table 3Anatomic distribution of involved segments/sub-segments and the number of segments with consolidation, cavitation, and clusters of nodules (N = 183). (p < 0.001); cavitations (p = 0.033); clusters of nodules (p < 0.001) not related to the number and location were independently significant factors that were predictive for G1.", [["apex segment", "ANATOMY", 27, 39], ["posterior segment", "ANATOMY", 46, 63], ["right upper lobe", "ANATOMY", 71, 87], ["apicoposterior segment", "ANATOMY", 97, 119], ["left upper lobe", "ANATOMY", 127, 142], ["superior segment", "ANATOMY", 182, 198], ["right", "ANATOMY", 206, 211], ["left lower lobe", "ANATOMY", 215, 230], ["apex segment", "ANATOMY", 255, 267], ["posterior segment", "ANATOMY", 274, 291], ["right upper lobe", "ANATOMY", 299, 315], ["left upper lobe", "ANATOMY", 356, 371], ["nodules", "ANATOMY", 459, 466], ["apex segment", "ANATOMY", 569, 581], ["posterior segment", "ANATOMY", 588, 605], ["right upper lobe", "ANATOMY", 613, 629], ["left upper lobe", "ANATOMY", 670, 685], ["superior segment", "ANATOMY", 730, 746], ["lower lobe", "ANATOMY", 757, 767], ["nodules", "ANATOMY", 910, 917], ["nodules", "ANATOMY", 979, 986], ["cavitation", "DISEASE", 882, 892], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 77, 87], ["upper lobe", "CANCER", 132, 142], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 220, 230], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 305, 315], ["upper lobe", "ORGAN", 361, 371], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 619, 629], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 675, 685], ["nodules", "PATHOLOGICAL_FORMATION", 910, 917], ["nodules", "PATHOLOGICAL_FORMATION", 979, 986], ["s1", "DNA", 687, 689], ["Consolidation", "PROBLEM", 0, 13], ["consolidation", "PROBLEM", 154, 167], ["cavitation in the apex segment (s1), posterior segment of the right upper lobe (s2), or apico-posterior segment of the left upper lobe", "PROBLEM", 237, 371], ["cavitation", "PROBLEM", 393, 403], ["consolidations", "PROBLEM", 418, 432], ["nodules", "PROBLEM", 459, 466], ["the multivariate analysis", "TEST", 520, 545], ["consolidations in the apex segment (s1), posterior segment of the right upper lobe (s2), or apico-posterior segment of the left upper lobe", "PROBLEM", 547, 685], ["consolidation of the superior segment of either lower lobe", "PROBLEM", 709, 767], ["consolidation", "PROBLEM", 867, 880], ["cavitation", "PROBLEM", 882, 892], ["nodules", "PROBLEM", 910, 917], ["cavitations", "PROBLEM", 942, 953], ["nodules", "PROBLEM", 979, 986], ["G1", "PROBLEM", 1102, 1104], ["apex", "ANATOMY_MODIFIER", 27, 31], ["segment", "ANATOMY_MODIFIER", 32, 39], ["posterior", "ANATOMY_MODIFIER", 46, 55], ["segment", "ANATOMY_MODIFIER", 56, 63], ["right upper lobe", "ANATOMY", 71, 87], ["s2", "ANATOMY_MODIFIER", 89, 91], ["apicoposterior", "ANATOMY_MODIFIER", 97, 111], ["segment", "ANATOMY_MODIFIER", 112, 119], ["left upper lobe", "ANATOMY", 127, 142], ["s1", "ANATOMY_MODIFIER", 144, 146], ["s2", "ANATOMY_MODIFIER", 149, 151], ["consolidation", "OBSERVATION", 154, 167], ["superior", "ANATOMY_MODIFIER", 182, 190], ["segment", "ANATOMY_MODIFIER", 191, 198], ["right", "ANATOMY_MODIFIER", 206, 211], ["left lower lobe", "ANATOMY", 215, 230], ["cavitation", "OBSERVATION_MODIFIER", 237, 247], ["apex", "ANATOMY_MODIFIER", 255, 259], ["segment", "ANATOMY_MODIFIER", 260, 267], ["posterior", "ANATOMY_MODIFIER", 274, 283], ["segment", "ANATOMY_MODIFIER", 284, 291], ["right upper lobe", "ANATOMY", 299, 315], ["s2", "ANATOMY_MODIFIER", 317, 319], ["apico", "ANATOMY_MODIFIER", 325, 330], ["posterior", "ANATOMY_MODIFIER", 331, 340], ["segment", "ANATOMY_MODIFIER", 341, 348], ["left upper lobe", "ANATOMY", 356, 371], ["s1", "ANATOMY_MODIFIER", 373, 375], ["s2", "ANATOMY_MODIFIER", 378, 380], ["number", "OBSERVATION_MODIFIER", 383, 389], ["cavitation", "OBSERVATION_MODIFIER", 393, 403], ["number", "OBSERVATION_MODIFIER", 408, 414], ["consolidations", "OBSERVATION", 418, 432], ["clusters", "OBSERVATION_MODIFIER", 447, 455], ["nodules", "OBSERVATION", 459, 466], ["consolidations", "OBSERVATION", 547, 561], ["apex", "ANATOMY_MODIFIER", 569, 573], ["segment", "ANATOMY_MODIFIER", 574, 581], ["posterior", "ANATOMY_MODIFIER", 588, 597], ["segment", "ANATOMY_MODIFIER", 598, 605], ["right upper lobe", "ANATOMY", 613, 629], ["s2", "ANATOMY_MODIFIER", 631, 633], ["apico", "ANATOMY_MODIFIER", 639, 644], ["posterior", "ANATOMY_MODIFIER", 645, 654], ["segment", "ANATOMY_MODIFIER", 655, 662], ["left upper lobe", "ANATOMY", 670, 685], ["s1", "ANATOMY_MODIFIER", 687, 689], ["s2", "ANATOMY_MODIFIER", 692, 694], ["consolidation", "OBSERVATION", 709, 722], ["superior", "ANATOMY_MODIFIER", 730, 738], ["segment", "ANATOMY_MODIFIER", 739, 746], ["lower lobe", "ANATOMY", 757, 767], ["segments", "ANATOMY_MODIFIER", 813, 821], ["sub-", "ANATOMY_MODIFIER", 822, 826], ["segments", "ANATOMY_MODIFIER", 826, 834], ["number", "OBSERVATION_MODIFIER", 843, 849], ["segments", "ANATOMY_MODIFIER", 853, 861], ["consolidation", "OBSERVATION", 867, 880], ["cavitation", "OBSERVATION_MODIFIER", 882, 892], ["clusters", "OBSERVATION_MODIFIER", 898, 906], ["nodules", "OBSERVATION", 910, 917], ["cavitations", "OBSERVATION_MODIFIER", 942, 953], ["nodules", "OBSERVATION", 979, 986]]], ["Only the centrilobular nodules had an independently negative predictive value for G1 (p = 0.011) ( Table 4 ).Table 3Using the five independent variables that were associated with G1, a prediction score was generated to help differentiate between G1 and G2.", [["centrilobular nodules", "ANATOMY", 9, 30], ["centrilobular nodules", "CANCER", 9, 30], ["the centrilobular nodules", "PROBLEM", 5, 30], ["a prediction score", "TEST", 183, 201], ["centrilobular", "OBSERVATION_MODIFIER", 9, 22], ["nodules", "OBSERVATION", 23, 30]]], ["The ROC curve analysis is shown in Fig. 3 .", [["The ROC curve analysis", "TEST", 0, 22]]], ["The area under the curve is 0.96 \u00b1 0.014 for our prediction model.", [["our prediction model", "TEST", 45, 65]]], ["With an ideal cutoff point score of 3, the specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) are 90.9%, 96.4%, 90.0%, and 96.8%, respectively.DiscussionThe clusters of nodules represent the peri-bronchovascular nodules, which were significant findings in G1.", [["nodules", "ANATOMY", 213, 220], ["peri-bronchovascular nodules", "ANATOMY", 235, 263], ["nodules", "CANCER", 213, 220], ["peri-bronchovascular nodules", "CANCER", 235, 263], ["an ideal cutoff point score", "TEST", 5, 32], ["PPV", "TEST", 96, 99], ["NPV", "TEST", 133, 136], ["nodules", "PROBLEM", 213, 220], ["the peri-bronchovascular nodules", "PROBLEM", 231, 263], ["clusters", "OBSERVATION_MODIFIER", 201, 209], ["nodules", "OBSERVATION", 213, 220], ["peri-bronchovascular", "ANATOMY", 235, 255], ["nodules", "OBSERVATION", 256, 263], ["significant", "OBSERVATION_MODIFIER", 276, 287]]], ["Poey et al. and Heo et al. found similar results among patients with active PTB [24, 25] .", [["PTB", "DISEASE", 76, 79], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["active PTB", "PROBLEM", 69, 79]]], ["In our study, no clusters of nodules were identified in the G2c patients, which is comparable to the Tanaka et al. study which revealed no Abbreviations: s1 = apical segment; s2 = posterior segment right upper lobe; s1 + s2 = apico-posterior segment left upper lobe; s6 = superior segment of right or left lower lobe.", [["nodules", "ANATOMY", 29, 36], ["right upper lobe", "ANATOMY", 198, 214], ["left upper lobe", "ANATOMY", 250, 265], ["superior segment", "ANATOMY", 272, 288], ["right", "ANATOMY", 292, 297], ["left lower lobe", "ANATOMY", 301, 316], ["nodules", "CANCER", 29, 36], ["patients", "ORGANISM", 64, 72], ["upper lobe", "CANCER", 255, 265], ["superior segment", "MULTI-TISSUE_STRUCTURE", 272, 288], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 306, 316], ["patients", "SPECIES", 64, 72], ["our study", "TEST", 3, 12], ["nodules", "PROBLEM", 29, 36], ["study", "TEST", 115, 120], ["s1 = apical segment; s2 = posterior segment right upper lobe", "PROBLEM", 154, 214], ["posterior segment left upper lobe", "PROBLEM", 232, 265], ["no", "UNCERTAINTY", 14, 16], ["clusters", "OBSERVATION_MODIFIER", 17, 25], ["nodules", "OBSERVATION", 29, 36], ["no", "UNCERTAINTY", 136, 138], ["s1", "ANATOMY_MODIFIER", 154, 156], ["apical", "ANATOMY_MODIFIER", 159, 165], ["segment", "ANATOMY_MODIFIER", 166, 173], ["s2", "ANATOMY_MODIFIER", 175, 177], ["posterior", "ANATOMY_MODIFIER", 180, 189], ["segment", "ANATOMY_MODIFIER", 190, 197], ["right upper lobe", "ANATOMY", 198, 214], ["s1", "ANATOMY_MODIFIER", 216, 218], ["s2", "ANATOMY_MODIFIER", 221, 223], ["apico", "ANATOMY_MODIFIER", 226, 231], ["posterior", "ANATOMY_MODIFIER", 232, 241], ["segment", "ANATOMY_MODIFIER", 242, 249], ["left upper lobe", "ANATOMY", 250, 265], ["s6", "ANATOMY_MODIFIER", 267, 269], ["superior", "ANATOMY_MODIFIER", 272, 280], ["segment", "ANATOMY_MODIFIER", 281, 288], ["right", "ANATOMY_MODIFIER", 292, 297], ["left lower lobe", "ANATOMY", 301, 316]]], ["Weighting score is observed according the ratio of each estimated \u02c7 using the estimated \u02c7 1.72 of cavitation as for the base.", [["Weighting score", "TEST", 0, 15], ["cavitation", "PROBLEM", 98, 108], ["cavitation", "OBSERVATION", 98, 108], ["base", "ANATOMY_MODIFIER", 120, 124]]], ["The relative score is given 1 as the ratio <1.5, 2 as ratio > 1.5, and 3 as ratio > 2.5.", [["The relative score", "TEST", 0, 18], ["the ratio", "TEST", 33, 42], ["ratio", "TEST", 54, 59], ["ratio", "TEST", 76, 81]]], ["Since the effect of centrilobular nodules is negative with a ratio < 1.5, then the relative score is set as for \u22121. * p-Value < 0.05. nodules on HRCT examination of CAP patients (no active PTB cases) [26] .", [["centrilobular nodules", "ANATOMY", 20, 41], ["nodules", "ANATOMY", 134, 141], ["CAP", "DISEASE", 165, 168], ["PTB", "DISEASE", 189, 192], ["centrilobular nodules", "CANCER", 20, 41], ["nodules", "PATHOLOGICAL_FORMATION", 134, 141], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["centrilobular nodules", "PROBLEM", 20, 41], ["a ratio", "TEST", 59, 66], ["p-Value", "TEST", 118, 125], ["nodules", "PROBLEM", 134, 141], ["HRCT examination", "TEST", 145, 161], ["CAP patients", "TEST", 165, 177], ["active PTB cases", "PROBLEM", 182, 198], ["centrilobular", "OBSERVATION_MODIFIER", 20, 33], ["nodules", "OBSERVATION", 34, 41], ["negative", "OBSERVATION", 45, 53], ["CAP", "OBSERVATION_MODIFIER", 165, 168], ["no", "UNCERTAINTY", 179, 181], ["active", "OBSERVATION_MODIFIER", 182, 188]]], ["Physicians in the ER play a crucial role in the identification of potential PTB patients.", [["PTB", "DISEASE", 76, 79], ["ER", "GENE_OR_GENE_PRODUCT", 18, 20], ["patients", "ORGANISM", 80, 88], ["ER", "PROTEIN", 18, 20], ["patients", "SPECIES", 80, 88]]], ["Hsieh et al. revealed that a high proportion of hospitalized, active PTB cases are often admitted through the ERwith an initial diagnosis of CAP, which further delays RI and increases the risk of nosocomial infection [4, 27] .", [["PTB", "DISEASE", 69, 72], ["CAP", "DISEASE", 141, 144], ["infection", "DISEASE", 207, 216], ["active PTB cases", "PROBLEM", 62, 78], ["CAP", "PROBLEM", 141, 144], ["further delays RI", "PROBLEM", 152, 169], ["nosocomial infection", "PROBLEM", 196, 216], ["high", "OBSERVATION_MODIFIER", 29, 33], ["active", "OBSERVATION_MODIFIER", 62, 68], ["PTB", "OBSERVATION", 69, 72], ["CAP", "OBSERVATION", 141, 144], ["nosocomial", "OBSERVATION_MODIFIER", 196, 206], ["infection", "OBSERVATION", 207, 216]]], ["Furthermore, 34% of active PTB cases had atypical CXR presentations, and only 37.7% with sputum from spontaneous cough [4] .", [["sputum", "ANATOMY", 89, 95], ["PTB", "DISEASE", 27, 30], ["cough", "DISEASE", 113, 118], ["active PTB cases", "PROBLEM", 20, 36], ["CXR presentations", "TEST", 50, 67], ["sputum", "TEST", 89, 95], ["spontaneous cough", "PROBLEM", 101, 118], ["cough", "OBSERVATION", 113, 118]]], ["Steen reported 31 of 212 (15%) smear-positive PTB patients also had one or more negative initial sputum smears [28] .", [["sputum", "ANATOMY", 97, 103], ["PTB", "DISEASE", 46, 49], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["Steen", "TEST", 0, 5], ["smear", "TEST", 31, 36], ["sputum smears", "TEST", 97, 110]]], ["The diverse clinical presentation of ER patients with PTB, as well as the limited number of isolation rooms available (especially during influenza outbreaks), not only complicates triage, but also makes development and implementation of effective triage screening criteria crucial to the success of PTB management [29, 30] .DiscussionWhile reducing the number of isolated patients who have a low likelihood of active PTB may reduce hospital costs, it is important not to misdiagnose patients who have smear-positive PTB.", [["PTB", "DISEASE", 54, 57], ["PTB", "DISEASE", 299, 302], ["PTB", "DISEASE", 417, 420], ["PTB", "DISEASE", 516, 519], ["ER", "GENE_OR_GENE_PRODUCT", 37, 39], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 372, 380], ["patients", "ORGANISM", 483, 491], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 372, 380], ["patients", "SPECIES", 483, 491], ["PTB", "PROBLEM", 54, 57], ["PTB management", "TREATMENT", 299, 313], ["active PTB", "PROBLEM", 410, 420], ["smear", "TEST", 501, 506], ["positive PTB", "PROBLEM", 507, 519], ["diverse", "OBSERVATION_MODIFIER", 4, 11], ["active", "OBSERVATION_MODIFIER", 410, 416], ["PTB", "OBSERVATION", 417, 420], ["positive PTB", "OBSERVATION", 507, 519]]], ["The subsequent costs associated with late treatment and contact investigation could actually offset the original savings [31] .", [["late treatment", "TREATMENT", 37, 51], ["contact investigation", "TEST", 56, 77]]], ["During flu season, influenza is one of the leading causes of ER visits, and the availability of isolation rooms is essential [30] .", [["influenza", "DISEASE", 19, 28], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["influenza", "PROBLEM", 19, 28]]], ["With this in mind, we created a G1 prediction score based on 5 key HRCT findings: (1) consolidation involving the apex segment of either lung (s1), posterior segment of the right upper lobe (s2), or apico-posterior segment of the left upper lobe (s1 + s2); (2) consolidation involving the superior segment of the right or left lower lobe (s6); (3) presence of a cavitary lesion; (4) presence of clusters of nodules; (5) absence of centrilobular nodules.", [["apex segment", "ANATOMY", 114, 126], ["lung", "ANATOMY", 137, 141], ["posterior segment", "ANATOMY", 148, 165], ["right upper lobe", "ANATOMY", 173, 189], ["left upper lobe", "ANATOMY", 230, 245], ["superior segment", "ANATOMY", 289, 305], ["right", "ANATOMY", 313, 318], ["left lower lobe", "ANATOMY", 322, 337], ["s6", "ANATOMY", 339, 341], ["cavitary lesion", "ANATOMY", 362, 377], ["nodules", "ANATOMY", 407, 414], ["centrilobular nodules", "ANATOMY", 431, 452], ["lung", "ORGAN", 137, 141], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 179, 189], ["upper lobe", "ORGAN", 235, 245], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 327, 337], ["cavitary lesion", "PATHOLOGICAL_FORMATION", 362, 377], ["nodules", "CANCER", 407, 414], ["centrilobular nodules", "CANCER", 431, 452], ["a G1 prediction score", "TEST", 30, 51], ["consolidation", "PROBLEM", 86, 99], ["(2) consolidation", "PROBLEM", 257, 274], ["a cavitary lesion", "PROBLEM", 360, 377], ["clusters of nodules", "PROBLEM", 395, 414], ["centrilobular nodules", "PROBLEM", 431, 452], ["consolidation", "OBSERVATION", 86, 99], ["apex", "ANATOMY_MODIFIER", 114, 118], ["segment", "ANATOMY_MODIFIER", 119, 126], ["lung", "ANATOMY", 137, 141], ["posterior", "ANATOMY_MODIFIER", 148, 157], ["segment", "ANATOMY_MODIFIER", 158, 165], ["right upper lobe", "ANATOMY", 173, 189], ["s2", "ANATOMY_MODIFIER", 191, 193], ["apico", "ANATOMY_MODIFIER", 199, 204], ["posterior", "ANATOMY_MODIFIER", 205, 214], ["segment", "ANATOMY_MODIFIER", 215, 222], ["left upper lobe", "ANATOMY", 230, 245], ["s1", "ANATOMY_MODIFIER", 247, 249], ["s2", "ANATOMY_MODIFIER", 252, 254], ["consolidation", "OBSERVATION", 261, 274], ["superior", "ANATOMY_MODIFIER", 289, 297], ["segment", "ANATOMY_MODIFIER", 298, 305], ["right", "ANATOMY_MODIFIER", 313, 318], ["left lower lobe", "ANATOMY", 322, 337], ["cavitary", "OBSERVATION_MODIFIER", 362, 370], ["lesion", "OBSERVATION", 371, 377], ["clusters", "OBSERVATION_MODIFIER", 395, 403], ["nodules", "OBSERVATION", 407, 414], ["centrilobular", "OBSERVATION_MODIFIER", 431, 444], ["nodules", "OBSERVATION", 445, 452]]], ["The ROC curve (Fig. 3) identified a score of 3 points as the cut-off.", [["The ROC curve", "TEST", 0, 13]]], ["At this point, the sensitivity hits 96.4%, and the NPV approaches 96.8%.", [["the sensitivity hits", "TEST", 15, 35], ["the NPV approaches", "TEST", 47, 65]]], ["An ideal test would have both 100% sensitivity to avoid missing any patients with active disease and 100% NPV to assure negative results truly represented diseasefree status.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["An ideal test", "TEST", 0, 13], ["active disease", "PROBLEM", 82, 96]]], ["This is extremely important in public health situations that deal with highly infectious diseases like AFB sputum positive, active PTB.DiscussionCampos et al. evaluated the efficacy of a single first-sputum nucleic acid amplification (NAA) test to rapidly and accurately identify the subset of patients with suspected TB who require isolation [10] .", [["sputum", "ANATOMY", 107, 113], ["PTB", "DISEASE", 131, 134], ["nucleic acid", "CHEMICAL", 207, 219], ["NAA", "CHEMICAL", 235, 238], ["TB", "DISEASE", 318, 320], ["NAA", "SIMPLE_CHEMICAL", 235, 238], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 294, 302], ["highly infectious diseases", "PROBLEM", 71, 97], ["AFB sputum", "TEST", 103, 113], ["active PTB", "PROBLEM", 124, 134], ["a single first-sputum nucleic acid amplification", "TREATMENT", 185, 233], ["NAA) test", "TEST", 235, 244], ["TB", "PROBLEM", 318, 320], ["infectious", "OBSERVATION", 78, 88], ["active", "OBSERVATION_MODIFIER", 124, 130], ["PTB", "OBSERVATION", 131, 134]]], ["Compared to serial sputum smear analysis currently endorsed by the CDC, first sputum NAA demonstrated an 87% sensitivity and 99% NPV in this study.", [["sputum", "ANATOMY", 78, 84], ["NAA", "CHEMICAL", 85, 88], ["NAA", "CHEMICAL", 85, 88], ["serial sputum smear analysis", "TEST", 12, 40], ["first sputum NAA", "TEST", 72, 88], ["NPV", "TEST", 129, 132], ["this study", "TEST", 136, 146]]], ["The future of diagnostic testing may soon include the use of first sputum NAA, but current guidelines are still in effect.", [["NAA", "CHEMICAL", 74, 77], ["NAA", "CHEMICAL", 74, 77], ["diagnostic testing", "TEST", 14, 32], ["first sputum NAA", "PROBLEM", 61, 77], ["current guidelines", "TREATMENT", 83, 101]]], ["Furthermore, if sputum was not available from spontaneous cough or specimens of bronchoscope, the NAA test was not feasible.", [["sputum", "ANATOMY", 16, 22], ["specimens", "ANATOMY", 67, 76], ["cough", "DISEASE", 58, 63], ["NAA", "CHEMICAL", 98, 101], ["NAA", "CHEMICAL", 98, 101], ["sputum", "ORGANISM_SUBSTANCE", 16, 22], ["sputum", "TEST", 16, 22], ["spontaneous cough", "PROBLEM", 46, 63], ["bronchoscope", "TEST", 80, 92], ["the NAA test", "TEST", 94, 106]]], ["Our study demonstrates the effective use of HRCT to predict smear-positive, active PTB cases in advance of the serial sputum results or patients without spontaneous sputum, thereby decreasing the transmission rate and opening up isolation rooms needed for other communicable diseases, such as influenza and SARS.LimitationsWe limited our scope to the reliability and reproducibility of the five variables predictive of PTB.", [["sputum", "ANATOMY", 118, 124], ["sputum", "ANATOMY", 165, 171], ["PTB", "DISEASE", 83, 86], ["communicable diseases", "DISEASE", 262, 283], ["influenza", "DISEASE", 293, 302], ["SARS", "DISEASE", 307, 311], ["PTB", "DISEASE", 419, 422], ["patients", "ORGANISM", 136, 144], ["PTB", "PROTEIN", 419, 422], ["patients", "SPECIES", 136, 144], ["Our study", "TEST", 0, 9], ["HRCT", "TEST", 44, 48], ["smear", "TEST", 60, 65], ["active PTB cases", "PROBLEM", 76, 92], ["the serial sputum results", "TEST", 107, 132], ["spontaneous sputum", "PROBLEM", 153, 171], ["the transmission rate", "TEST", 192, 213], ["opening up isolation rooms", "TREATMENT", 218, 244], ["other communicable diseases", "PROBLEM", 256, 283], ["influenza", "PROBLEM", 293, 302], ["SARS", "PROBLEM", 307, 311], ["the reliability", "TEST", 347, 362], ["PTB", "PROBLEM", 419, 422], ["sputum", "OBSERVATION", 165, 171], ["PTB", "OBSERVATION", 419, 422]]], ["The demographic and clinical characteristics of patients with PTB may differ in other geographic areas, so the model needs to be validated in other settings before it can be implemented in clinical practice.", [["PTB", "DISEASE", 62, 65], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["PTB", "PROBLEM", 62, 65], ["PTB", "OBSERVATION", 62, 65]]], ["Although HRCT is widely available today, some countries may not have access to HRCT technology.", [["HRCT", "TEST", 9, 13], ["HRCT technology", "TEST", 79, 94]]], ["Reader experience is another limitation also.ConclusionThe smear-positive, active PTB prediction model based upon five characteristic HRCT findings may ease the burden of RI in areas where availability and financial resources are limited.", [["PTB", "PROTEIN", 82, 85], ["The smear", "TEST", 55, 64], ["active PTB prediction model", "PROBLEM", 75, 102]]]], "64c9f7e68f526e733f706bdee1c9861c5fc71aa6": [["INTRODUCTION 27Many viruses including alpha-and gammaherpesviruses, influenza A virus, and SARS 28 coronavirus induce widespread mRNA decay through the use of virally encoded endonucleases 29INTRODUCTION 27(1-5).", [["influenza A virus", "DISEASE", 68, 85], ["SARS", "DISEASE", 91, 95], ["alpha", "GENE_OR_GENE_PRODUCT", 38, 43], ["gammaherpesviruses", "GENE_OR_GENE_PRODUCT", 48, 66], ["influenza A virus", "ORGANISM", 68, 85], ["SARS 28 coronavirus", "ORGANISM", 91, 110], ["virally encoded endonucleases", "PROTEIN", 159, 188], ["influenza A virus", "SPECIES", 68, 85], ["SARS 28 coronavirus", "SPECIES", 91, 110], ["influenza A virus", "SPECIES", 68, 85], ["SARS 28 coronavirus", "SPECIES", 91, 110], ["Many viruses", "PROBLEM", 15, 27], ["alpha", "TEST", 38, 43], ["gammaherpesviruses", "PROBLEM", 48, 66], ["influenza A virus", "PROBLEM", 68, 85], ["SARS", "PROBLEM", 91, 95], ["coronavirus", "PROBLEM", 99, 110], ["widespread mRNA decay", "PROBLEM", 118, 139], ["virally encoded endonucleases", "TREATMENT", 159, 188], ["viruses", "OBSERVATION", 20, 27], ["gammaherpesviruses", "ANATOMY", 48, 66]]], ["This process, known as \"host shutoff\", allows viruses to rapidly restrict gene expression in 30 order to dampen immune responses and provide access to the host's resources for viral 31 replication (2,6,7).", [["the host's resources", "TREATMENT", 151, 171], ["viral 31 replication", "TREATMENT", 176, 196]]], ["One well-studied viral endonuclease is the SOX protein encoded by Kaposi's 32 sarcoma-associated herpesvirus (KSHV).", [["Kaposi's 32 sarcoma", "DISEASE", 66, 85], ["SOX", "GENE_OR_GENE_PRODUCT", 43, 46], ["Kaposi's 32 sarcoma-associated herpesvirus", "ORGANISM", 66, 108], ["KSHV", "ORGANISM", 110, 114], ["viral endonuclease", "PROTEIN", 17, 35], ["SOX protein", "PROTEIN", 43, 54], ["sarcoma-associated herpesvirus", "SPECIES", 78, 108], ["KSHV", "SPECIES", 110, 114], ["the SOX protein", "TEST", 39, 54], ["Kaposi's 32 sarcoma", "PROBLEM", 66, 85], ["herpesvirus", "PROBLEM", 97, 108], ["sarcoma", "OBSERVATION", 78, 85]]], ["SOX is conserved throughout the herpesvirus family, 33 but only gammaherpesviral SOX homologs display ribonuclease activity in cells (8) (9) (10) and 34 studies indicate that SOX activity is important for the in-vivo viral lifecycle (11,12).", [["cells", "ANATOMY", 127, 132], ["SOX", "GENE_OR_GENE_PRODUCT", 0, 3], ["herpesvirus", "ORGANISM", 32, 43], ["SOX", "GENE_OR_GENE_PRODUCT", 81, 84], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 102, 114], ["cells", "CELL", 127, 132], ["SOX", "GENE_OR_GENE_PRODUCT", 175, 178], ["SOX", "PROTEIN", 0, 3], ["gammaherpesviral SOX homologs", "PROTEIN", 64, 93], ["ribonuclease", "PROTEIN", 102, 114], ["SOX", "PROTEIN", 175, 178], ["ribonuclease activity in cells", "PROBLEM", 102, 132], ["34 studies", "TEST", 150, 160], ["SOX activity", "PROBLEM", 175, 187], ["ribonuclease activity", "OBSERVATION", 102, 123]]], ["Although SOX 35 targets a degenerate RNA motif present on most mRNA (13-15), multiple studies have shown 36 that some transcripts robustly escape SOX-induced decay (16-21).", [["SOX 35", "GENE_OR_GENE_PRODUCT", 9, 15], ["SOX", "GENE_OR_GENE_PRODUCT", 146, 149], ["SOX 35", "PROTEIN", 9, 15], ["degenerate RNA motif", "RNA", 26, 46], ["mRNA", "RNA", 63, 67], ["SOX", "PROTEIN", 146, 149], ["a degenerate RNA motif", "PROBLEM", 24, 46], ["multiple studies", "TEST", 77, 93]]], ["These include lack of a targeting motif, indirect transcriptional effects, and active 39 evasion of ribonucleolytic cleavage (16,20-24).", [["a targeting motif", "TREATMENT", 22, 39], ["ribonucleolytic cleavage", "PROBLEM", 100, 124]]], ["This latter phenotype, termed \"dominant 40 escape\", is particularly notable as it involves a specific RNA element whose presence in the 3' 41 UTR of an mRNA protects against SOX cleavage, regardless of whether the RNA contains a 42 targeting motif (19-21).", [["3' 41 UTR", "CELLULAR_COMPONENT", 136, 145], ["SOX", "GENE_OR_GENE_PRODUCT", 174, 177], ["RNA element", "DNA", 102, 113], ["3' 41 UTR", "DNA", 136, 145], ["mRNA", "RNA", 152, 156], ["SOX", "PROTEIN", 174, 177], ["42 targeting motif", "DNA", 229, 247], ["an mRNA protects", "TREATMENT", 149, 165], ["SOX cleavage", "TREATMENT", 174, 186], ["the RNA", "PROBLEM", 210, 217], ["dominant", "OBSERVATION_MODIFIER", 31, 39], ["40 escape", "OBSERVATION_MODIFIER", 40, 49]]], ["This protective RNA element was termed SRE (for SOX Resistance 43 Element), but we recently showed that the SRE is also effective against a broad range of viral 44 endonucleases.", [["SRE", "GENE_OR_GENE_PRODUCT", 39, 42], ["SOX", "GENE_OR_GENE_PRODUCT", 48, 51], ["protective RNA element", "DNA", 5, 27], ["SRE", "DNA", 39, 42], ["SOX", "PROTEIN", 48, 51], ["SRE", "DNA", 108, 111], ["viral 44 endonucleases", "PROTEIN", 155, 177], ["This protective RNA element", "PROBLEM", 0, 27], ["SOX Resistance", "TEST", 48, 62], ["the SRE", "PROBLEM", 104, 111], ["viral 44 endonucleases", "PROBLEM", 155, 177], ["RNA element", "OBSERVATION", 16, 27]]], ["Perhaps more surprisingly, the SRE is unable to restrict endonucleolytic 45 cleavage originating from a cellular endonuclease, making it the first identified viral-specific 46 ribonuclease escape element (19) .", [["cellular", "ANATOMY", 104, 112], ["cellular", "CELL", 104, 112], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 176, 188], ["SRE", "DNA", 31, 34], ["cellular endonuclease", "PROTEIN", 104, 125], ["46 ribonuclease escape element", "DNA", 173, 203], ["endonucleolytic 45 cleavage", "PROBLEM", 57, 84], ["a cellular endonuclease", "PROBLEM", 102, 125], ["cellular endonuclease", "OBSERVATION", 104, 125]]], ["We showed that this broad-acting RNA element is not 47 characterized by a defined sequence motif (19) rendering it difficult to identify new escaping 48 transcripts by traditional sequence search.", [["broad-acting RNA element", "DNA", 20, 44], ["48 transcripts", "RNA", 150, 164], ["this broad-acting RNA element", "PROBLEM", 15, 44], ["a defined sequence motif", "TEST", 72, 96], ["traditional sequence search", "TEST", 168, 195], ["broad", "OBSERVATION_MODIFIER", 20, 25], ["RNA element", "OBSERVATION", 33, 44]]], ["Consequently, the host vs. viral endonuclease 49 dichotomy to only defining characteristic of this novel type of RNA element.", [["RNA element", "DNA", 113, 124], ["viral endonuclease", "TREATMENT", 27, 45], ["RNA element", "PROBLEM", 113, 124], ["RNA element", "OBSERVATION", 113, 124]]], ["50INTRODUCTION 27Little is currently known about these types of RNA elements; how widespread they may 51 be in the genome and how they may contribute to the overall viral-host arms race for the control 52 of resources.", [["RNA elements", "DNA", 64, 76], ["RNA elements", "PROBLEM", 64, 76], ["RNA elements", "OBSERVATION", 64, 76]]], ["To date, only two SRE-bearing dominant escapees are known: the host 53 interleukin-6 (IL-6) (18,20,21) and the growth arrest and DNA damage-inducible 45 beta 54 (GADD45B) (19) transcripts.", [["interleukin-6", "GENE_OR_GENE_PRODUCT", 71, 84], ["IL-6", "GENE_OR_GENE_PRODUCT", 86, 90], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["damage-inducible 45 beta 54", "GENE_OR_GENE_PRODUCT", 133, 160], ["GADD45B) (19)", "GENE_OR_GENE_PRODUCT", 162, 175], ["SRE", "DNA", 18, 21], ["inducible 45 beta 54 (GADD45B) (19) transcripts", "RNA", 140, 187], ["interleukin", "TEST", 71, 82], ["IL", "TEST", 86, 88], ["the growth arrest", "PROBLEM", 107, 124], ["DNA damage", "PROBLEM", 129, 139], ["growth arrest", "OBSERVATION", 111, 124]]], ["Both the IL-6 and GADD45B SREs were mapped to their 3'UTR 55INTRODUCTION 27and were shown to protect against an array of viral -but not host -RNAses.", [["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["GADD45B", "GENE_OR_GENE_PRODUCT", 18, 25], ["IL-6 and GADD45B SREs", "DNA", 9, 30], ["3'UTR 55INTRODUCTION 27and", "DNA", 52, 78], ["GADD45B SREs", "TREATMENT", 18, 30], ["viral", "PROBLEM", 121, 126], ["viral", "OBSERVATION", 121, 126]]], ["Furthermore, while 56 little sequence homology was detected among these SREs, we showed that they share 57 similarity in their secondary structure; reinforcing the idea the SRE may function as a platform to 58 recruit a protective protein complex as previously observed (19-21).", [["SRE", "GENE_OR_GENE_PRODUCT", 173, 176], ["SREs", "DNA", 72, 76], ["SRE", "DNA", 173, 176], ["protective protein complex", "PROTEIN", 220, 246], ["a protective protein complex", "PROBLEM", 218, 246]]], ["Functionally, while the 59 beneficial role of IL-6 for KSHV during infection is well documented (25-33), the role of 60 GADD45B is still unclear.", [["infection", "DISEASE", 67, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 46, 50], ["KSHV", "ORGANISM", 55, 59], ["GADD45B", "GENE_OR_GENE_PRODUCT", 120, 127], ["IL-6", "PROTEIN", 46, 50], ["60 GADD45B", "PROTEIN", 117, 127], ["KSHV", "SPECIES", 55, 59], ["IL", "TREATMENT", 46, 48], ["KSHV during infection", "PROBLEM", 55, 76]]], ["In fact, GADD45B is repressed during KSHV latency (34) and 61 GADD45B known pro-apoptotic roles may indicate that this transcript escapes to participate in 62 an anti-viral response to host shutoff.", [["GADD45B", "GENE_OR_GENE_PRODUCT", 9, 16], ["KSHV", "ORGANISM", 37, 41], ["GADD45B", "GENE_OR_GENE_PRODUCT", 62, 69], ["GADD45B", "PROTEIN", 9, 16], ["KSHV", "SPECIES", 37, 41], ["KSHV latency", "TEST", 37, 49], ["this transcript escapes", "PROBLEM", 114, 137], ["host shutoff", "TREATMENT", 185, 197]]], ["63INTRODUCTION 27Here, taking advantage of the ability of the SRE element to block decay from a diverse 64 set of viral endonucleases, we sought to identify novel escaping mRNAs containing SRE or 65 SRE-like elements in the transcriptome.", [["SRE", "GENE_OR_GENE_PRODUCT", 189, 192], ["SRE element", "DNA", 62, 73], ["viral endonucleases", "PROTEIN", 114, 133], ["mRNAs", "RNA", 172, 177], ["SRE", "DNA", 189, 192], ["65 SRE-like elements", "DNA", 196, 216], ["block decay", "PROBLEM", 77, 88], ["viral endonucleases", "TREATMENT", 114, 133], ["novel escaping mRNAs containing SRE", "PROBLEM", 157, 192]]], ["Using comparative RNA-seq, we uncovered a cluster of 66 75 host mRNAs that escape degradation from four herpesviral endonucleases.", [["66 75 host mRNAs", "RNA", 53, 69], ["herpesviral endonucleases", "PROTEIN", 104, 129], ["escape degradation", "PROBLEM", 75, 93], ["four herpesviral endonucleases", "TREATMENT", 99, 129], ["herpesviral endonucleases", "OBSERVATION", 104, 129]]], ["Similarly to the 67 previously identified SRE-bearing transcripts, these transcripts were spared from a range of viral 68 -but not host -endonucleases, further supporting that our approach successfully identified 69 Simplex 1 (HSV-1) vhs or an empty vector control were generated using Thy1.1-based cell 97 sorting as described before (45).", [["cell", "ANATOMY", 299, 303], ["SRE", "GENE_OR_GENE_PRODUCT", 42, 45], ["69 Simplex 1", "ORGANISM", 213, 225], ["HSV-1", "ORGANISM", 227, 232], ["vhs", "GENE_OR_GENE_PRODUCT", 234, 237], ["cell 97", "CELL", 299, 306], ["SRE-bearing transcripts", "RNA", 42, 65], ["viral 68", "DNA", 113, 121], ["Thy1.1", "CELL_LINE", 286, 292], ["HSV-1", "SPECIES", 227, 232], ["viral", "TEST", 113, 118], ["Simplex", "TEST", 216, 223], ["HSV", "TEST", 227, 230], ["vhs", "TEST", 234, 237], ["an empty vector control", "TREATMENT", 241, 264], ["empty vector", "OBSERVATION", 244, 256]]], ["Total RNA was extracted, polyA enriched and cDNA were 98 generated. cDNA libraries were sequenced with a 100-base single-end read on an Illumina 99INTRODUCTION 27HiSeq4000.", [["cDNA libraries", "DNA", 68, 82], ["100-base single-end", "DNA", 105, 124], ["Illumina 99INTRODUCTION 27HiSeq4000", "DNA", 136, 171], ["Total RNA", "TEST", 0, 9], ["polyA enriched and cDNA", "TEST", 25, 48], ["cDNA libraries", "TREATMENT", 68, 82]]], ["Resulting reads were aligned to the human genome (hg38) using Bowtie, replicates 100 were merged using CuffCompare and significant expression fold change between mock and 101 each of the endonuclease conditions were assessed by CuffDiff (Figure 1, Figure S1 & Table 102 S1).", [["human", "ORGANISM", 36, 41], ["human genome", "DNA", 36, 48], ["hg38", "DNA", 50, 54], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["CuffCompare", "TREATMENT", 103, 114], ["significant expression fold change", "PROBLEM", 119, 153], ["the endonuclease conditions", "TREATMENT", 183, 210], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["expression fold", "OBSERVATION", 131, 146]]], ["The reproducibility between replicate experiments was high ( Fig. 1A-D) , which is in line 103 with previous reports showing that these endonucleases target transcripts in a 104 selective/sequence-specific manner as previously observed (13).", [["these endonucleases", "PROBLEM", 130, 149]]], ["As expected, a number of 105 transcripts were significantly affected upon expression of the various herpesviral endonucleases 106 ( Fig. S1) : we observed that between 55-60% of total mRNA were degraded, with muSOX being 107 the most effective of the endonucleases tested here (Fig. S1 ).", [["105 transcripts", "RNA", 25, 40], ["herpesviral endonucleases 106", "PROTEIN", 100, 129], ["total mRNA", "RNA", 178, 188], ["endonucleases", "PROTEIN", 251, 264], ["the various herpesviral endonucleases", "PROBLEM", 88, 125], ["total mRNA", "TEST", 178, 188], ["muSOX", "TEST", 209, 214], ["the endonucleases", "TEST", 247, 264]]], ["Gene Ontology (GO) analysis on the transcripts 109 spared from degradation revealed that they encode proteins that have a wide array of functions, 110 ranging from ion binding to RNA binding (Fig S2) .", [["transcripts 109", "DNA", 35, 50], ["the transcripts", "TEST", 31, 46]]], ["111INTRODUCTION 27To identify transcripts that escape degradation from all 4 endonucleases, we performed 112 hierarchical clustering on the transcript expression data.", [["escape degradation", "PROBLEM", 47, 65], ["all 4 endonucleases", "TREATMENT", 71, 90]]], ["A cluster encompassing 75 transcripts ( We next set out to investigate further this cluster of common escapees.", [["A cluster encompassing 75 transcripts", "PROBLEM", 0, 37], ["common escapees", "PROBLEM", 95, 110]]], ["The RNA-seq hits 121 identified by hierarchical clustering were ranked by confidence (reproducibility among 122 experimental replicates and escaped all endonucleases in all replicates).", [["RNA-seq hits 121", "DNA", 4, 20], ["The RNA", "TEST", 0, 7], ["seq hits", "TEST", 8, 16], ["all endonucleases", "TREATMENT", 148, 165]]], ["To confirm the RNA-123 seq data, we first examined whether the top 10% (Table S2) cycle upon doxycycline treatment (46,47).", [["doxycycline", "CHEMICAL", 93, 104], ["doxycycline", "CHEMICAL", 93, 104], ["doxycycline", "SIMPLE_CHEMICAL", 93, 104], ["the RNA", "TEST", 11, 18], ["doxycycline treatment", "TREATMENT", 93, 114]]], ["As opposed to the housekeeping gene GAPDH that is 128 naturally susceptible to host shutoff, we observed that the mRNA levels of these candidate 129 SRE-bearing mRNAs remained unchanged in reactivated iSLK.219 cells as measured by RT-130 qPCR ( Fig. 2A) confirming that these transcripts are resistant to host shutoff in lytically infected 131 cells.", [["219 cells", "ANATOMY", 206, 215], ["cells", "ANATOMY", 344, 349], ["GAPDH", "GENE_OR_GENE_PRODUCT", 36, 41], ["SRE", "GENE_OR_GENE_PRODUCT", 149, 152], ["iSLK", "GENE_OR_GENE_PRODUCT", 201, 205], ["219 cells", "CELL", 206, 215], ["131 cells", "CELL", 340, 349], ["housekeeping gene", "DNA", 18, 35], ["GAPDH", "DNA", 36, 41], ["129 SRE-bearing mRNAs", "RNA", 145, 166], ["iSLK", "PROTEIN", 201, 205], ["219 cells", "CELL_LINE", 206, 215], ["lytically infected 131 cells", "CELL_LINE", 321, 349], ["host shutoff", "TREATMENT", 79, 91], ["the mRNA levels", "TEST", 110, 125], ["these candidate", "TEST", 129, 144], ["RT", "TEST", 231, 233], ["these transcripts", "PROBLEM", 270, 287], ["host shutoff", "TREATMENT", 305, 317], ["unchanged", "OBSERVATION_MODIFIER", 176, 185]]], ["Additionally, we recently showed that SRE-containing transcripts are resistant to 132 endonucleases beyond the herpesvirus family (19).", [["SRE", "GENE_OR_GENE_PRODUCT", 38, 41], ["herpesvirus", "ORGANISM", 111, 122], ["SRE", "DNA", 38, 41], ["132 endonucleases", "PROTEIN", 82, 99], ["SRE", "PROBLEM", 38, 41]]], ["We next tested the ability of these novel 133 escapees to evade the heterologous host shutoff from the influenza A virus endonuclease (IAV; 134 PA-X).", [["influenza A virus", "ORGANISM", 103, 120], ["PA-X", "GENE_OR_GENE_PRODUCT", 144, 148], ["influenza A virus", "SPECIES", 103, 120], ["influenza A virus", "SPECIES", 103, 120], ["the heterologous host shutoff", "PROBLEM", 64, 93], ["the influenza A virus endonuclease", "TREATMENT", 99, 133]]], ["As shown in Figure 2B , contrary to GAPDH, the candidate transcripts were resistant to 135 all endonucleases tested, including PA-X.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 36, 41], ["PA-X.", "GENE_OR_GENE_PRODUCT", 127, 132], ["GAPDH", "PROTEIN", 36, 41], ["GAPDH", "PROBLEM", 36, 41], ["all endonucleases", "TEST", 91, 108], ["PA", "TEST", 127, 129]]], ["Finally, one characteristic of SRE-containing mRNAs 136 is that they are still susceptible to cleavage by cellular endonucleases (19).", [["cellular", "ANATOMY", 106, 114], ["SRE", "GENE_OR_GENE_PRODUCT", 31, 34], ["cellular", "CELL", 106, 114], ["SRE", "DNA", 31, 34], ["mRNAs 136", "RNA", 46, 55], ["cellular endonucleases", "PROTEIN", 106, 128], ["SRE", "TEST", 31, 34], ["cellular endonucleases", "TEST", 106, 128], ["cellular endonucleases", "OBSERVATION", 106, 128]]], ["To test whether this 137 was also the case for our novel candidate SRE-bearing transcripts, we monitored cleavage 138 upon expression of the nsp1 protein from SARS coronavirus.", [["SARS coronavirus", "DISEASE", 159, 175], ["SRE", "GENE_OR_GENE_PRODUCT", 67, 70], ["nsp1", "GENE_OR_GENE_PRODUCT", 141, 145], ["SARS coronavirus", "ORGANISM", 159, 175], ["SRE", "DNA", 67, 70], ["nsp1 protein", "PROTEIN", 141, 153], ["SARS coronavirus", "SPECIES", 159, 175], ["the nsp1 protein", "PROBLEM", 137, 153], ["SARS coronavirus", "PROBLEM", 159, 175]]], ["Nsp1 is not a nuclease but rather 139 activates mRNA cleavage by an as yet unknown cellular endonuclease via a mechanism 140 reminiscent of no-go decay (48,49).", [["cellular", "ANATOMY", 83, 91], ["Nsp1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 83, 91], ["Nsp1", "PROTEIN", 0, 4], ["nuclease", "PROTEIN", 14, 22], ["cellular endonuclease", "PROTEIN", 83, 104], ["Nsp1", "PROBLEM", 0, 4], ["a nuclease", "PROBLEM", 12, 22], ["mRNA cleavage", "PROBLEM", 48, 61]]], ["Nsp1 thus allows us to induce RNA decay using a viral 141 trigger but carried out by a cellular endonuclease.", [["cellular", "ANATOMY", 87, 95], ["Nsp1", "CHEMICAL", 0, 4], ["Nsp1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 87, 95], ["Nsp1", "PROTEIN", 0, 4], ["cellular endonuclease", "PROTEIN", 87, 108], ["Nsp1", "PROBLEM", 0, 4], ["RNA decay", "PROBLEM", 30, 39], ["a viral 141 trigger", "PROBLEM", 46, 65], ["a cellular endonuclease", "PROBLEM", 85, 108], ["cellular endonuclease", "OBSERVATION", 87, 108]]], ["Nsp1 was transfected into 293T cells and 142 depletion of the candidate transcripts was measured by RT-qPCR.", [["293T cells", "ANATOMY", 26, 36], ["Nsp1", "GENE_OR_GENE_PRODUCT", 0, 4], ["293T cells", "CELL", 26, 36], ["Nsp1", "PROTEIN", 0, 4], ["293T cells", "CELL_LINE", 26, 36], ["Nsp1", "TEST", 0, 4], ["the candidate transcripts", "TREATMENT", 58, 83], ["293T cells", "OBSERVATION", 26, 36]]], ["Similar to what we observed 143 before, the candidate escapee mRNAs were not protected in nsp1-expressing cells (Fig. 2C) .", [["cells", "ANATOMY", 106, 111], ["nsp1", "GENE_OR_GENE_PRODUCT", 90, 94], ["cells", "CELL", 106, 111], ["candidate escapee mRNAs", "RNA", 44, 67], ["nsp1-expressing cells", "CELL_LINE", 90, 111]]], ["144INTRODUCTION 27Collectively, these results suggest that the escaping mRNAs identified in our comparative RNA-145 seq dataset are broadly protected against viral but not cellular endonucleases and we predict 146 that these transcripts may contain an SRE or an SRE-like element that provides broad 147 protection.", [["cellular", "ANATOMY", 172, 180], ["cellular", "CELL", 172, 180], ["escaping mRNAs", "RNA", 63, 77], ["cellular endonucleases", "PROTEIN", 172, 194], ["SRE", "DNA", 252, 255], ["SRE-like element", "DNA", 262, 278], ["the escaping mRNAs", "PROBLEM", 59, 77], ["our comparative RNA", "TEST", 92, 111], ["viral", "PROBLEM", 158, 163], ["cellular endonucleases", "PROBLEM", 172, 194], ["an SRE", "PROBLEM", 249, 255], ["escaping mRNAs", "OBSERVATION", 63, 77]]], ["148 149The C19ORF66 mRNA 3' UTR contains an SRE 150The pool of escaping transcripts did not appear to be strongly enriched for particular 151 functions or processes when evaluated by GO-term analysis.", [["C19ORF66 mRNA 3' UTR", "DNA", 11, 31], ["SRE 150", "DNA", 44, 51], ["The C19ORF66 mRNA", "TREATMENT", 7, 24], ["an SRE", "TEST", 41, 47], ["escaping transcripts", "PROBLEM", 63, 83], ["escaping transcripts", "OBSERVATION", 63, 83]]], ["We thus proceeded to manually 152 mine the literature to identify functions that could be important during viral infection.", [["viral infection", "DISEASE", 107, 122], ["viral infection", "PROBLEM", 107, 122], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infection", "OBSERVATION", 113, 122]]], ["We were 153 drawn to C19ORF66 (also known as RyDEN, IRAV, and SVA-1), as it was reported to be an 154The C19ORF66 mRNA 3' UTR contains an SRE 150anti-viral interferon stimulated gene (ISG) in the context of multiple viral infections (40,43,44).", [["viral infections", "DISEASE", 216, 232], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 21, 29], ["SVA-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 105, 113], ["interferon stimulated gene", "GENE_OR_GENE_PRODUCT", 156, 182], ["C19ORF66", "DNA", 21, 29], ["RyDEN", "DNA", 45, 50], ["IRAV", "PROTEIN", 52, 56], ["SVA", "DNA", 62, 65], ["C19ORF66 mRNA 3' UTR", "DNA", 105, 125], ["SRE 150anti-viral interferon stimulated gene", "DNA", 138, 182], ["ISG", "DNA", 184, 187], ["SVA", "TEST", 62, 65], ["The C19ORF66 mRNA", "TREATMENT", 101, 118], ["UTR", "TEST", 122, 125], ["an SRE", "TEST", 135, 141], ["viral interferon stimulated gene", "TREATMENT", 150, 182], ["multiple viral infections", "PROBLEM", 207, 232], ["viral interferon", "OBSERVATION", 150, 166], ["multiple", "OBSERVATION_MODIFIER", 207, 215], ["viral infections", "OBSERVATION", 216, 232]]], ["155The C19ORF66 mRNA 3' UTR contains an SRE 150Furthermore, the transcript for C19ORF66 appeared in our comparative RNA-seq as the top 156 escapee in all the replicates and with all the endonucleases tested.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 7, 15], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 79, 87], ["C19ORF66 mRNA 3' UTR", "DNA", 7, 27], ["SRE 150Furthermore", "DNA", 40, 58], ["C19ORF66", "DNA", 79, 87], ["top 156 escapee", "DNA", 131, 146], ["The C19ORF66 mRNA", "TEST", 3, 20], ["UTR", "TEST", 24, 27], ["an SRE", "TEST", 37, 43], ["endonucleases", "OBSERVATION", 186, 199]]], ["We first evaluated whether 157 this transcript contained a putative SRE-like element in its 3'UTR by testing whether it could 158 protect the GFP mRNA, which is normally susceptible to viral endonuclease cleavage.", [["3'UTR", "CELLULAR_COMPONENT", 92, 97], ["GFP", "GENE_OR_GENE_PRODUCT", 142, 145], ["SRE-like element", "DNA", 68, 84], ["3'UTR", "DNA", 92, 97], ["GFP mRNA", "RNA", 142, 150], ["viral endonuclease", "PROTEIN", 185, 203], ["a putative SRE", "PROBLEM", 57, 71], ["the GFP mRNA", "PROBLEM", 138, 150], ["viral endonuclease cleavage", "TREATMENT", 185, 212], ["GFP mRNA", "OBSERVATION", 142, 150]]], ["We fused 159 the C19ORF66 3' UTR to GFP (C19-3'UTR) and found that it was sufficient to confer protection 160 from SOX and other viral endonucleases in transfected 293T cells (Fig. 3A) .", [["293T cells", "ANATOMY", 164, 174], ["GFP", "GENE_OR_GENE_PRODUCT", 36, 39], ["SOX", "GENE_OR_GENE_PRODUCT", 115, 118], ["293T cells", "CELL", 164, 174], ["Fig. 3A", "CELL", 176, 183], ["C19ORF66 3' UTR", "DNA", 17, 32], ["GFP (C19-3'UTR", "DNA", 36, 50], ["SOX", "PROTEIN", 115, 118], ["viral endonucleases", "PROTEIN", 129, 148], ["transfected 293T cells", "CELL_LINE", 152, 174], ["GFP", "TEST", 36, 39], ["C19", "TEST", 41, 44], ["other viral endonucleases", "PROBLEM", 123, 148], ["293T cells", "OBSERVATION", 164, 174]]], ["Thus, similar to 161 the IL-6 and GADD45B 3' UTRs, previously identified dominant escapees, C19ORF66 contains 162 an SRE-like element in its 3'UTR that is sufficient to provide protection against a range of viral 163The C19ORF66 mRNA 3' UTR contains an SRE 150endonucleases.", [["IL-6", "GENE_OR_GENE_PRODUCT", 25, 29], ["GADD45B", "GENE_OR_GENE_PRODUCT", 34, 41], ["3'UTR", "CELLULAR_COMPONENT", 141, 146], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 220, 228], ["161 the IL-6 and GADD45B 3' UTRs", "DNA", 17, 49], ["C19ORF66", "DNA", 92, 100], ["SRE-like element", "DNA", 117, 133], ["3'UTR", "DNA", 141, 146], ["C19ORF66 mRNA 3' UTR", "DNA", 220, 240], ["SRE 150endonucleases", "DNA", 253, 273], ["the IL", "TEST", 21, 27], ["dominant escapees", "PROBLEM", 73, 90], ["an SRE", "TEST", 114, 120], ["viral", "TEST", 207, 212], ["The C19ORF66 mRNA", "TREATMENT", 216, 233], ["UTR", "TEST", 237, 240], ["an SRE 150endonucleases", "TEST", 250, 273], ["dominant", "OBSERVATION_MODIFIER", 73, 81], ["escapees", "OBSERVATION_MODIFIER", 82, 90]]], ["As we previously demonstrated, there is no significant sequence conservation 164 between the 3'UTRs of these known dominant escapees.", [["3'UTRs", "DNA", 93, 99], ["significant sequence conservation", "PROBLEM", 43, 76], ["no", "UNCERTAINTY", 40, 42], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["dominant", "OBSERVATION_MODIFIER", 115, 123], ["escapees", "OBSERVATION", 124, 132]]], ["However, the highest similarities were 165 located near the second half of C19ORF66 3'UTR, and RNAfold secondary structure prediction 166 of this UTR section revealed a long stem-loop structure with a bulge in the middle, consistent 167 with previously found SRE structures (Fig. S3) .", [["C19ORF66 3'UTR", "DNA", 75, 89], ["UTR section", "DNA", 146, 157], ["SRE structures", "DNA", 259, 273], ["this UTR section", "TEST", 141, 157], ["a long stem-loop structure", "PROBLEM", 167, 193], ["a bulge in the middle", "PROBLEM", 199, 220], ["long stem", "OBSERVATION_MODIFIER", 169, 178], ["loop structure", "OBSERVATION", 179, 193], ["bulge", "OBSERVATION", 201, 206], ["middle", "ANATOMY_MODIFIER", 214, 220]]], ["168The C19ORF66 mRNA 3' UTR contains an SRE 150Because C19ORF66 expression was previously shown to be increased in the context of 169 various viral infections, we next sought to investigate its expression upon KSHV lytic reactivation 170 when host shutoff occurs. iSLK.219 cells were reactivated and total protein harvested at various 171 time points over the course of 96 hours.", [["219 cells", "ANATOMY", 269, 278], ["viral infections", "DISEASE", 142, 158], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 7, 15], ["SRE 150Because C19ORF66", "GENE_OR_GENE_PRODUCT", 40, 63], ["KSHV", "ORGANISM", 210, 214], ["219 cells", "CELL", 269, 278], ["C19ORF66 mRNA 3' UTR", "DNA", 7, 27], ["SRE 150Because", "DNA", 40, 54], ["C19ORF66", "DNA", 55, 63], ["iSLK", "PROTEIN", 264, 268], ["219 cells", "CELL_LINE", 269, 278], ["KSHV", "SPECIES", 210, 214], ["The C19ORF66 mRNA", "TEST", 3, 20], ["UTR", "TEST", 24, 27], ["an SRE", "TEST", 37, 43], ["various viral infections", "PROBLEM", 134, 158], ["KSHV lytic reactivation", "PROBLEM", 210, 233], ["iSLK", "PROBLEM", 264, 268], ["total protein harvested", "TREATMENT", 300, 323], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["viral", "OBSERVATION_MODIFIER", 142, 147], ["infections", "OBSERVATION", 148, 158]]], ["C19ORF66 expression was increased upon KSHV lytic 172 reactivation and continued to accumulate over time (Fig. 3B) .", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 0, 8], ["KSHV", "ORGANISM", 39, 43], ["C19ORF66", "PROTEIN", 0, 8], ["KSHV", "SPECIES", 39, 43], ["KSHV lytic 172 reactivation", "PROBLEM", 39, 66], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["KSHV", "OBSERVATION_MODIFIER", 39, 43], ["lytic", "OBSERVATION_MODIFIER", 44, 49]]], ["Various other proteins were also 173 previously shown to change subcellular localization in response to host shutoff (45), so we 174 proceeded to monitor C19ORF66 expression and did not find differential shuttling upon KSHV 175 lytic reactivation (Fig. 3C) .", [["subcellular", "ANATOMY", 64, 75], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 154, 162], ["KSHV", "ORGANISM", 219, 223], ["C19ORF66", "PROTEIN", 154, 162], ["KSHV", "SPECIES", 219, 223], ["Various other proteins", "TEST", 0, 22], ["subcellular localization", "TEST", 64, 88]]], ["Thus, C19ORF66 escapes SOX degradation by encoding an SRE-176 like element on its 3' UTR that allows it to escape host shutoff and accumulate in lytically 177 infected cells.", [["cells", "ANATOMY", 168, 173], ["C19ORF66", "CHEMICAL", 6, 14], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 6, 14], ["SOX", "GENE_OR_GENE_PRODUCT", 23, 26], ["SRE-176", "GENE_OR_GENE_PRODUCT", 54, 61], ["3' UTR", "CELLULAR_COMPONENT", 82, 88], ["cells", "CELL", 168, 173], ["C19ORF66", "PROTEIN", 6, 14], ["SOX", "PROTEIN", 23, 26], ["SRE-176 like element", "DNA", 54, 74], ["3' UTR", "DNA", 82, 88], ["lytically 177 infected cells", "CELL_LINE", 145, 173], ["an SRE", "TEST", 51, 57], ["its 3' UTR", "TREATMENT", 78, 88], ["infected cells", "OBSERVATION", 159, 173]]], ["PAN promoter (Fig. 4A) . siRNA-mediated depletion of C19ORF66 in iSLK.219 cells during 187 latency and at 48h and 72h post-reactivation was efficient, reducing expression levels by 94.6%, 188 97% and 97.8%, respectively (Fig. 4B) .", [["219 cells", "ANATOMY", 70, 79], ["PAN", "CHEMICAL", 0, 3], ["PAN", "GENE_OR_GENE_PRODUCT", 0, 3], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 53, 61], ["iSLK", "GENE_OR_GENE_PRODUCT", 65, 69], ["219 cells", "CELL", 70, 79], ["PAN promoter", "DNA", 0, 12], ["C19ORF66", "PROTEIN", 53, 61], ["iSLK", "PROTEIN", 65, 69], ["siRNA", "TEST", 25, 30], ["latency", "TEST", 91, 98], ["reactivation", "PROBLEM", 123, 135], ["expression levels", "TEST", 160, 177]]], ["72h hours post-reactivation, GFP and RFP positive cells 189The C19ORF66 mRNA 3' UTR contains an SRE 150were analyzed by fluorescence microscopy in siRNA C19ORF66-treated cells (or siRNA 190 Control).", [["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 170, 175], ["C19ORF66", "CHEMICAL", 153, 161], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["RFP", "GENE_OR_GENE_PRODUCT", 37, 40], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 63, 71], ["C19ORF66", "SIMPLE_CHEMICAL", 153, 161], ["cells", "CELL", 170, 175], ["RFP", "PROTEIN", 37, 40], ["C19ORF66 mRNA 3' UTR", "DNA", 63, 83], ["SRE 150", "DNA", 96, 103], ["siRNA C19ORF66-treated cells", "CELL_LINE", 147, 175], ["reactivation", "PROBLEM", 15, 27], ["GFP", "TEST", 29, 32], ["RFP positive cells", "TEST", 37, 55], ["The C19ORF66 mRNA", "TEST", 59, 76], ["UTR", "TEST", 80, 83], ["an SRE", "TEST", 93, 99], ["fluorescence microscopy", "TEST", 120, 143], ["siRNA", "TEST", 147, 152]]], ["C19ORF66 depletion resulted in a marked increase in the number of RFP positive 191 cells (Fig. 4C) .", [["RFP positive 191 cells", "ANATOMY", 66, 88], ["C19ORF66", "CHEMICAL", 0, 8], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 0, 8], ["RFP", "GENE_OR_GENE_PRODUCT", 66, 69], ["C19ORF66", "PROTEIN", 0, 8], ["RFP positive 191 cells", "CELL_LINE", 66, 88], ["C19ORF66 depletion", "PROBLEM", 0, 18], ["a marked increase", "PROBLEM", 31, 48], ["marked", "OBSERVATION_MODIFIER", 33, 39], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["191 cells", "OBSERVATION", 79, 88]]], ["Conversely, overexpression of C19ORF66 in these cells (Fig. 4D) resulted in 192 almost no RFP detection (Fig. 4C) .", [["cells", "ANATOMY", 48, 53], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 30, 38], ["cells", "CELL", 48, 53], ["RFP", "GENE_OR_GENE_PRODUCT", 90, 93], ["C19ORF66", "PROTEIN", 30, 38], ["RFP", "PROTEIN", 90, 93], ["RFP detection", "TEST", 90, 103], ["RFP", "OBSERVATION", 90, 93]]], ["Taken together, these results suggest that C19ORF66 193 expression negatively regulates the progression of KSHV life cycle.", [["C19ORF66", "CHEMICAL", 43, 51], ["C19ORF66 193", "GENE_OR_GENE_PRODUCT", 43, 55], ["KSHV", "ORGANISM", 107, 111], ["C19ORF66 193", "PROTEIN", 43, 55], ["KSHV", "SPECIES", 107, 111], ["KSHV life cycle", "TREATMENT", 107, 122], ["progression", "OBSERVATION_MODIFIER", 92, 103]]], ["194The C19ORF66 mRNA 3' UTR contains an SRE 150We next hypothesized that the reactivation defect due to C19ORF66 expression may 195 lead to restriction of the formation of viral particles.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 7, 15], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 104, 112], ["C19ORF66 mRNA 3' UTR", "DNA", 7, 27], ["SRE 150We", "DNA", 40, 49], ["C19ORF66", "DNA", 104, 112], ["The C19ORF66 mRNA", "TEST", 3, 20], ["UTR", "TEST", 24, 27], ["an SRE", "TEST", 37, 43], ["the reactivation defect", "PROBLEM", 73, 96], ["viral particles", "PROBLEM", 172, 187], ["reactivation defect", "OBSERVATION", 77, 96], ["viral particles", "OBSERVATION", 172, 187]]], ["To test this, we performed a supernatant 196 transfer assay (Fig. 5A) . iSLK.219 cells were treated with siRNA C19ORF66 (or control siRNA) 197The C19ORF66 mRNA 3' UTR contains an SRE 150and reactivated for 72h.", [["219 cells", "ANATOMY", 77, 86], ["219 cells", "CELL", 77, 86], ["C19ORF66", "SIMPLE_CHEMICAL", 111, 119], ["iSLK", "PROTEIN", 72, 76], ["C19ORF66 mRNA 3' UTR", "DNA", 146, 166], ["SRE 150", "DNA", 179, 186], ["iSLK", "PROBLEM", 72, 76], ["siRNA C19ORF66", "TREATMENT", 105, 119], ["The C19ORF66 mRNA", "TREATMENT", 142, 159], ["UTR", "TEST", 163, 166], ["an SRE", "TEST", 176, 182]]], ["Supernatants containing GFP expressing KSHV virions were collected 198 and used to spinfect 293T cells (Fig. 5B) .", [["Supernatants", "ANATOMY", 0, 12], ["293T cells", "ANATOMY", 92, 102], ["GFP", "GENE_OR_GENE_PRODUCT", 24, 27], ["KSHV", "ORGANISM", 39, 43], ["293T cells", "CELL", 92, 102], ["Fig. 5B", "CELL", 104, 111], ["GFP", "PROTEIN", 24, 27], ["spinfect 293T cells", "CELL_LINE", 83, 102], ["KSHV", "SPECIES", 39, 43], ["KSHV virions", "TEST", 39, 51], ["KSHV virions", "OBSERVATION", 39, 51]]], ["24h later, we observed a higher number of GFP KSHV life cycle, we next assessed whether C19ORF66 also affects viral gene expression.", [["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 88, 96], ["C19ORF66", "PROTEIN", 88, 96], ["viral gene expression", "OBSERVATION", 110, 131]]], ["202The C19ORF66 mRNA 3' UTR contains an SRE 150Using RT-qPCR, we quantified the expression of several KSHV viral genes.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 7, 15], ["KSHV", "ORGANISM", 102, 106], ["C19ORF66 mRNA 3' UTR", "DNA", 7, 27], ["KSHV viral genes", "DNA", 102, 118], ["KSHV", "SPECIES", 102, 106], ["The C19ORF66 mRNA", "TEST", 3, 20], ["UTR", "TEST", 24, 27], ["an SRE", "TEST", 37, 43], ["several KSHV viral genes", "PROBLEM", 94, 118], ["several", "OBSERVATION_MODIFIER", 94, 101], ["KSHV viral genes", "OBSERVATION", 102, 118]]], ["Viral gene 203 expression in KSHV unfolds as a cascade with the \"early\" (E) genes expressed right after lytic 204 reactivation, followed by \"delayed early\" (DE) genes and finally, after viral replication, the \"late\" 205 (L) genes.", [["KSHV", "ORGANISM", 29, 33], ["Viral gene 203", "DNA", 0, 14], ["early\" (E) genes", "DNA", 65, 81], ["delayed early\" (DE) genes", "DNA", 141, 166], ["205 (L) genes", "DNA", 216, 229], ["KSHV", "SPECIES", 29, 33], ["lytic 204 reactivation", "PROBLEM", 104, 126], ["viral replication", "PROBLEM", 186, 203], ["203 expression", "OBSERVATION_MODIFIER", 11, 25], ["right", "ANATOMY_MODIFIER", 92, 97], ["lytic", "OBSERVATION_MODIFIER", 104, 109]]], ["We harvested timepoints from 0 to 72h after iSLK.219 reactivation and measured 206 RNA levels of genes representative of each gene class upon knock-down of C19ORF66.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 156, 164], ["C19ORF66", "PROTEIN", 156, 164], ["reactivation", "PROBLEM", 53, 65], ["RNA levels", "TEST", 83, 93]]], ["We 207 observed a shift in viral gene expression with early and delayed early viral genes -but not with 208 the late gene -which were expressed earlier and at higher levels in the C19ORF66 knocked 209 down cells as measured by RT-qPCR (Fig. 5C-E) .", [["cells", "ANATOMY", 206, 211], ["cells", "CELL", 206, 211], ["early and delayed early viral genes", "DNA", 54, 89], ["208 the late gene", "DNA", 104, 121], ["C19ORF66 knocked 209 down cells", "CELL_LINE", 180, 211], ["a shift in viral gene expression", "PROBLEM", 16, 48], ["delayed early viral genes", "PROBLEM", 64, 89], ["RT", "TEST", 227, 229], ["viral gene expression", "OBSERVATION", 27, 48], ["viral genes", "OBSERVATION", 78, 89]]], ["Taken together, these results suggest that 210 reveal that a cluster of 75 host transcripts can systematically escape viral-induced 227 endonucleolytic cleavage.", [["75 host transcripts", "RNA", 72, 91], ["endonucleolytic cleavage", "TREATMENT", 136, 160]]], ["We hypothesize that these may contain similar RNA escape elements 228 as the one we previously characterized in IL-6 and GADD45B and therefore could be important 229 regulators of the viral-host interplay.", [["IL-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["GADD45B", "GENE_OR_GENE_PRODUCT", 121, 128], ["RNA escape elements 228", "DNA", 46, 69], ["IL", "PROTEIN", 112, 114], ["GADD45B", "PROTEIN", 121, 128], ["similar RNA escape elements", "PROBLEM", 38, 65], ["GADD45B", "TREATMENT", 121, 128], ["similar", "OBSERVATION_MODIFIER", 38, 45], ["RNA escape", "OBSERVATION", 46, 56]]], ["IL-6 and GADD45B escape elements (referred to as SRE 230 and G-SRE respectively) were shown to adopt a specific secondary structure that we 231 hypothesized to be crucial in recruiting host protein to the 3'UTR of these escaping transcripts 232The C19ORF66 mRNA 3' UTR contains an SRE 150(19).", [["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["GADD45B", "GENE_OR_GENE_PRODUCT", 9, 16], ["SRE 230", "GENE_OR_GENE_PRODUCT", 49, 56], ["G-SRE", "GENE_OR_GENE_PRODUCT", 61, 66], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 248, 256], ["IL-6 and GADD45B escape elements", "DNA", 0, 32], ["SRE 230", "DNA", 49, 56], ["G", "DNA", 61, 62], ["SRE", "DNA", 63, 66], ["3'UTR", "DNA", 205, 210], ["C19ORF66 mRNA 3' UTR", "DNA", 248, 268], ["SRE 150(19)", "DNA", 281, 292], ["IL", "TEST", 0, 2], ["GADD45B escape elements", "PROBLEM", 9, 32], ["SRE", "TEST", 49, 52], ["The C19ORF66 mRNA", "TEST", 244, 261], ["UTR", "TEST", 265, 268], ["an SRE", "TEST", 278, 284], ["escape elements", "OBSERVATION", 17, 32]]], ["This RNA-protein protective complex appears to be composed of core proteins as well as 233 accessory proteins that may be transcript-dependent.", [["RNA-protein protective complex", "PROTEIN", 5, 35], ["core proteins", "PROTEIN", 62, 75], ["233 accessory proteins", "PROTEIN", 87, 109], ["This RNA", "TEST", 0, 8], ["protein protective complex", "PROBLEM", 9, 35], ["core proteins", "PROBLEM", 62, 75], ["accessory proteins", "PROBLEM", 91, 109], ["protective complex", "OBSERVATION_MODIFIER", 17, 35], ["may be", "UNCERTAINTY", 115, 121], ["dependent", "OBSERVATION_MODIFIER", 133, 142]]], ["One future goal is thus to expand our 234 knowledge of the known escapees by exploring the RNA-protein complexes on these newly 235 identified escaping transcripts with the hope of understanding the protein pre-requisite to 236 forming a protective complex.", [["RNA-protein complexes", "PROTEIN", 91, 112], ["protective complex", "PROTEIN", 238, 256], ["the known escapees", "PROBLEM", 55, 73], ["the RNA-protein complexes", "PROBLEM", 87, 112]]], ["More globally, determining whether such RNA elements impact 237 RNA fate in uninfected cells will also be key in deciphering their role.", [["cells", "ANATOMY", 87, 92], ["cells", "CELL", 87, 92], ["RNA elements", "DNA", 40, 52], ["uninfected cells", "CELL_TYPE", 76, 92], ["such RNA elements impact 237 RNA fate in uninfected cells", "PROBLEM", 35, 92]]], ["To date, no such RNA 238 elements have been found in viral genes, suggesting that this could be a cell specific 239 mechanism that has evolved in response to viral infection.", [["cell", "ANATOMY", 98, 102], ["viral infection", "DISEASE", 158, 173], ["cell", "CELL", 98, 102], ["RNA 238 elements", "DNA", 17, 33], ["viral genes", "DNA", 53, 64], ["such RNA 238 elements", "PROBLEM", 12, 33], ["viral infection", "PROBLEM", 158, 173], ["viral genes", "OBSERVATION", 53, 64], ["viral", "OBSERVATION_MODIFIER", 158, 163], ["infection", "OBSERVATION", 164, 173]]], ["240The C19ORF66 mRNA 3' UTR contains an SRE 150No common functions were enriched in the pool of escaping transcripts, rendering it 241 difficult to make any definite conclusion on whether these mRNAs escape degradation to benefit 242 the host or the virus.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 7, 15], ["C19ORF66 mRNA 3' UTR", "DNA", 7, 27], ["SRE 150", "DNA", 40, 47], ["mRNAs", "RNA", 194, 199], ["The C19ORF66 mRNA", "TEST", 3, 20], ["UTR", "TEST", 24, 27], ["an SRE", "TEST", 37, 43], ["common functions", "PROBLEM", 50, 66], ["these mRNAs escape degradation", "PROBLEM", 188, 218], ["the virus", "PROBLEM", 246, 255], ["escaping transcripts", "OBSERVATION", 96, 116]]], ["Instead, we hypothesize that these spared mRNAs may have both pro and 243The C19ORF66 mRNA 3' UTR contains an SRE 150anti-viral functions.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 77, 85], ["spared mRNAs", "RNA", 35, 47], ["C19ORF66 mRNA 3' UTR", "DNA", 77, 97], ["SRE 150anti", "DNA", 110, 121], ["The C19ORF66 mRNA", "TEST", 73, 90], ["UTR", "TEST", 94, 97], ["an SRE", "TEST", 107, 113], ["viral functions", "OBSERVATION", 122, 137]]], ["Furthermore, because of the large diversity of hosts infected by members of 244 the herpesviridae, it would be interesting to investigate whether the orthologs of the escaping 245 transcripts in other species also contain these RNA escape elements.", [["245 transcripts", "RNA", 176, 191], ["RNA escape elements", "DNA", 228, 247], ["the escaping 245 transcripts in other species", "PROBLEM", 163, 208], ["large", "OBSERVATION_MODIFIER", 28, 33], ["diversity", "OBSERVATION_MODIFIER", 34, 43], ["hosts infected", "OBSERVATION", 47, 61], ["RNA escape elements", "OBSERVATION", 228, 247]]], ["246The C19ORF66 mRNA 3' UTR contains an SRE 150Here, we also characterized the top escaping transcript in our screen, C19ORF66.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 7, 15], ["C19ORF66 mRNA 3' UTR", "DNA", 7, 27], ["SRE 150", "DNA", 40, 47], ["C19ORF66", "DNA", 118, 126], ["The C19ORF66 mRNA", "TEST", 3, 20], ["UTR", "TEST", 24, 27], ["an SRE", "TEST", 37, 43], ["top", "OBSERVATION_MODIFIER", 79, 82], ["escaping transcript", "OBSERVATION", 83, 102]]], ["Finally, none of the 3 known SREs (in IL-6, GADD45B, and now in C19ORF66) share 282 significant sequence similarity, although they do all share similar predicted secondary 283 structures.", [["IL-6", "GENE_OR_GENE_PRODUCT", 38, 42], ["GADD45B", "GENE_OR_GENE_PRODUCT", 44, 51], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 64, 72], ["SREs", "DNA", 29, 33], ["IL", "PROTEIN", 38, 40], ["GADD45B", "DNA", 44, 51], ["C19ORF66", "DNA", 64, 72], ["the 3 known SREs", "PROBLEM", 17, 33], ["IL", "TEST", 38, 40], ["GADD45B", "TEST", 44, 51]]], ["Thus, as predicted before, these RNA elements may function as scaffolds for 284 recruiting a protective protein complex.", [["RNA elements", "DNA", 33, 45], ["protective protein complex", "PROTEIN", 93, 119], ["a protective protein complex", "TREATMENT", 91, 119]]], ["Therefore, by manipulating the sequence of these RNA 285 escape elements but maintaining the structure, these nuclease escape elements could be 286 Plasmids.", [["RNA 285 escape elements", "DNA", 49, 72], ["nuclease escape elements", "DNA", 110, 134], ["these nuclease escape elements", "PROBLEM", 104, 134]]], ["The C19ORF66 3'UTR was obtained as G-blocks from IDT and cloned into a 312 pcDNA3.1 plasmid downstream of the GFP coding sequence.", [["C19ORF66 3", "GENE_OR_GENE_PRODUCT", 4, 14], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 75, 83], ["GFP", "GENE_OR_GENE_PRODUCT", 110, 113], ["C19ORF66 3'UTR", "DNA", 4, 18], ["G-blocks", "DNA", 35, 43], ["IDT", "DNA", 49, 52], ["312 pcDNA3.1 plasmid", "DNA", 71, 91], ["GFP coding sequence", "DNA", 110, 129], ["G-blocks from IDT", "TREATMENT", 35, 52]]], ["The C19ORF66 coding region 313 was obtained as a G-block from IDT and cloned in a pcDNA4 Nter-3xFlag vector.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 4, 12], ["C19ORF66 coding region 313", "DNA", 4, 30], ["G-block", "DNA", 49, 56], ["IDT", "DNA", 62, 65], ["pcDNA4 Nter-3xFlag vector", "DNA", 82, 107], ["a G-block from IDT", "TREATMENT", 47, 65], ["a pcDNA4 Nter-3xFlag vector", "TREATMENT", 80, 107]]], ["All cloning 314 step were performed using in-fusion cloning (Clonetech-takara) and were verified by 315 sequencing.", [["in-fusion cloning", "TREATMENT", 42, 59]]], ["316 317 RT-qPCR.", [["RT", "TEST", 8, 10]]], ["Total RNA was harvested using Trizol following the manufacture's protocol. cDNAs 318 were synthesized from 1 \u00b5g of total RNA using AMV reverse transcriptase (Promega), and used 319 directly for quantitative PCR (qPCR) analysis with the SYBR green qPCR kit (Bio-Rad).", [["AMV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 131, 156], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 257, 264], ["cDNAs 318", "DNA", 75, 84], ["total RNA", "RNA", 115, 124], ["AMV reverse transcriptase", "PROTEIN", 131, 156], ["Total RNA", "TREATMENT", 0, 9], ["Trizol", "TREATMENT", 30, 36], ["the manufacture's protocol", "TREATMENT", 47, 73], ["cDNAs", "TEST", 75, 80], ["total RNA", "TREATMENT", 115, 124], ["AMV reverse transcriptase", "TREATMENT", 131, 156], ["quantitative PCR", "TEST", 194, 210], ["analysis", "TEST", 218, 226], ["the SYBR", "TEST", 232, 240], ["harvested", "OBSERVATION", 14, 23]]], ["Signals 320 obtained by qPCR were normalized to 18S.", [["18S", "DNA", 48, 51], ["qPCR", "TEST", 24, 28]]], ["Supernatant transfer assay was used as a proxy for virion production and performed as 581 described in A. Infection of 293T cells was monitored by imaging GFP on a fluorescent 582 microscope.", [["Supernatant", "ANATOMY", 0, 11], ["293T cells", "ANATOMY", 119, 129], ["293T cells", "CELL", 119, 129], ["GFP", "GENE_OR_GENE_PRODUCT", 155, 158], ["293T cells", "CELL_LINE", 119, 129]]], ["(C-E) Total RNA was extracted from iSLK.219 cells treated with siRNAs targeting 583 C19ORF66 (or control non-target siRNAs) for 48h and reactivated for the indicated times.", [["219 cells", "ANATOMY", 40, 49], ["C-E", "GENE_OR_GENE_PRODUCT", 1, 4], ["219 cells", "CELL", 40, 49], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 84, 92], ["iSLK", "PROTEIN", 35, 39], ["583 C19ORF66", "DNA", 80, 92], ["Total RNA", "PROBLEM", 6, 15], ["iSLK", "PROBLEM", 35, 39], ["siRNAs", "TREATMENT", 63, 69]]], ["RNA 584The C19ORF66 mRNA 3' UTR contains an SRE 150was then subjected to RT-qPCR to quantify expression of the indicated viral genes. for C19ORF66 3'UTR with other known SRE transcripts: IL-6 and GADD45B.", [["C19ORF66", "GENE_OR_GENE_PRODUCT", 11, 19], ["IL-6", "GENE_OR_GENE_PRODUCT", 187, 191], ["GADD45B", "GENE_OR_GENE_PRODUCT", 196, 203], ["C19ORF66 mRNA 3' UTR", "DNA", 11, 31], ["SRE 150was", "DNA", 44, 54], ["viral genes", "DNA", 121, 132], ["C19ORF66 3'UTR", "DNA", 138, 152], ["SRE transcripts", "RNA", 170, 185], ["IL-6", "PROTEIN", 187, 191], ["GADD45B", "PROTEIN", 196, 203], ["RNA", "TEST", 0, 3], ["The C19ORF66 mRNA", "TEST", 7, 24], ["UTR", "TEST", 28, 31], ["an SRE", "TEST", 41, 47], ["RT-qPCR", "TEST", 73, 80], ["viral genes", "PROBLEM", 121, 132], ["GADD45B", "TREATMENT", 196, 203], ["viral genes", "OBSERVATION", 121, 132]]]], "PMC7340024": [], "PMC7183833": [["INTRODUCTIONAfter the outbreak of the novel coronavirus in December of last year in China, the virus has spread widely in countries such as South Korea, Italy, and Iran.", [["coronavirus", "DISEASE", 44, 55], ["the virus", "PROBLEM", 91, 100], ["virus", "OBSERVATION", 95, 100], ["spread", "OBSERVATION_MODIFIER", 105, 111], ["widely", "OBSERVATION_MODIFIER", 112, 118]]], ["Increasing numbers of researchers fear that the virus will become a worldwide pandemic, which will cause fatal consequences.", [["the virus", "PROBLEM", 44, 53], ["fatal consequences", "PROBLEM", 105, 123]]], ["The most common signs and symptoms of the 2019 novel coronavirus (COVID-19; temporarily termed as 2019-nCoV) at onset are fever, a dry cough, shortness of breath, myalgia or fatigue, and dyspnea.", [["coronavirus", "DISEASE", 53, 64], ["fever", "DISEASE", 122, 127], ["dry cough", "DISEASE", 131, 140], ["shortness of breath", "DISEASE", 142, 161], ["myalgia", "DISEASE", 163, 170], ["fatigue", "DISEASE", 174, 181], ["dyspnea", "DISEASE", 187, 194], ["coronavirus", "ORGANISM", 53, 64], ["coronavirus", "SPECIES", 53, 64], ["symptoms", "PROBLEM", 26, 34], ["COVID", "TEST", 66, 71], ["fever", "PROBLEM", 122, 127], ["a dry cough", "PROBLEM", 129, 140], ["shortness of breath", "PROBLEM", 142, 161], ["myalgia", "PROBLEM", 163, 170], ["fatigue", "PROBLEM", 174, 181], ["dyspnea", "PROBLEM", 187, 194], ["fever", "OBSERVATION", 122, 127], ["myalgia", "OBSERVATION", 163, 170], ["fatigue", "OBSERVATION", 174, 181]]], ["Owing to the complexity of COVID-19, some patients may present with atypical manifestations such as hemoptysis or atypical CT findings, and this presents a substantial challenge for the control of the epidemic situation.CASE REPORTA 57-year-old man, without history of respiratory disease, presented to the emergency department with a 3-hour history of hemoptysis in Hunan, China.", [["respiratory", "ANATOMY", 269, 280], ["hemoptysis", "DISEASE", 100, 110], ["respiratory disease", "DISEASE", 269, 288], ["hemoptysis", "DISEASE", 353, 363], ["patients", "ORGANISM", 42, 50], ["man", "ORGANISM", 245, 248], ["patients", "SPECIES", 42, 50], ["man", "SPECIES", 245, 248], ["COVID", "TEST", 27, 32], ["atypical manifestations", "PROBLEM", 68, 91], ["hemoptysis", "PROBLEM", 100, 110], ["atypical CT findings", "PROBLEM", 114, 134], ["a substantial challenge", "TREATMENT", 154, 177], ["respiratory disease", "PROBLEM", 269, 288], ["hemoptysis", "PROBLEM", 353, 363], ["hemoptysis", "OBSERVATION", 100, 110], ["respiratory", "ANATOMY", 269, 280], ["disease", "OBSERVATION", 281, 288], ["hemoptysis", "OBSERVATION", 353, 363]]], ["No supportive results were found in laboratory tests upon admission.", [["laboratory tests", "TEST", 36, 52]]], ["A unenhanced CT scan of the chest showed a localized area of ground-glass opacity (GGO) in the apicoposterior segment of the left upper lobe (Fig. 1).", [["chest", "ANATOMY", 28, 33], ["area", "ANATOMY", 53, 57], ["apicoposterior segment", "ANATOMY", 95, 117], ["left upper lobe", "ANATOMY", 125, 140], ["GGO", "DISEASE", 83, 86], ["chest", "ORGAN", 28, 33], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 130, 140], ["A unenhanced CT scan of the chest", "TEST", 0, 33], ["ground-glass opacity", "PROBLEM", 61, 81], ["chest", "ANATOMY", 28, 33], ["localized", "OBSERVATION_MODIFIER", 43, 52], ["area", "OBSERVATION_MODIFIER", 53, 57], ["ground-glass opacity", "OBSERVATION", 61, 81], ["GGO", "OBSERVATION_MODIFIER", 83, 86], ["apicoposterior", "ANATOMY_MODIFIER", 95, 109], ["segment", "ANATOMY_MODIFIER", 110, 117], ["left upper lobe", "ANATOMY", 125, 140]]], ["This patient was admitted to the hospital with a suspicion of pulmonary infection or tuberculosis.", [["pulmonary", "ANATOMY", 62, 71], ["pulmonary infection", "DISEASE", 62, 81], ["tuberculosis", "DISEASE", 85, 97], ["patient", "ORGANISM", 5, 12], ["pulmonary", "ORGAN", 62, 71], ["patient", "SPECIES", 5, 12], ["pulmonary infection", "PROBLEM", 62, 81], ["tuberculosis", "PROBLEM", 85, 97], ["suspicion of", "UNCERTAINTY", 49, 61], ["pulmonary", "ANATOMY", 62, 71], ["infection", "OBSERVATION", 72, 81], ["tuberculosis", "OBSERVATION", 85, 97]]], ["Three days after admission, a small amount of pleural effusion was seen.", [["pleural effusion", "ANATOMY", 46, 62], ["pleural effusion", "DISEASE", 46, 62], ["pleural", "PATHOLOGICAL_FORMATION", 46, 53], ["a small amount of pleural effusion", "PROBLEM", 28, 62], ["small", "OBSERVATION_MODIFIER", 30, 35], ["amount", "OBSERVATION_MODIFIER", 36, 42], ["pleural", "ANATOMY", 46, 53], ["effusion", "OBSERVATION", 54, 62]]], ["No affirmative results were found in the drainage of pleural effusion.", [["pleural effusion", "ANATOMY", 53, 69], ["pleural effusion", "DISEASE", 53, 69], ["pleural effusion", "PATHOLOGICAL_FORMATION", 53, 69], ["the drainage", "TREATMENT", 37, 49], ["pleural effusion", "PROBLEM", 53, 69], ["drainage", "OBSERVATION_MODIFIER", 41, 49], ["pleural", "ANATOMY", 53, 60], ["effusion", "OBSERVATION", 61, 69]]], ["Hemoptysis was unable to be controlled after symptomatic treatments including hemostasis and anti-infection therapy.", [["Hemoptysis", "DISEASE", 0, 10], ["Hemoptysis", "PROBLEM", 0, 10], ["symptomatic treatments", "TREATMENT", 45, 67], ["hemostasis", "TREATMENT", 78, 88], ["anti-infection therapy", "TREATMENT", 93, 115]]], ["Eight days later, a follow-up chest CT scan showed that the GGO in the left upper lobe had evolved into consolidation (Fig. 2).", [["left upper lobe", "ANATOMY", 71, 86], ["GGO", "DISEASE", 60, 63], ["upper lobe", "ORGAN", 76, 86], ["a follow-up chest CT scan", "TEST", 18, 43], ["the GGO in the left upper lobe", "PROBLEM", 56, 86], ["consolidation", "PROBLEM", 104, 117], ["chest", "ANATOMY", 30, 35], ["GGO", "OBSERVATION", 60, 63], ["left upper lobe", "ANATOMY", 71, 86], ["consolidation", "OBSERVATION", 104, 117]]], ["The GGO appeared on the superior segment of the left lower lobe.", [["superior segment", "ANATOMY", 24, 40], ["left lower lobe", "ANATOMY", 48, 63], ["GGO", "DISEASE", 4, 7], ["GGO", "CANCER", 4, 7], ["superior segment", "MULTI-TISSUE_STRUCTURE", 24, 40], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 53, 63], ["GGO", "OBSERVATION", 4, 7], ["superior", "ANATOMY_MODIFIER", 24, 32], ["segment", "ANATOMY_MODIFIER", 33, 40], ["left lower lobe", "ANATOMY", 48, 63]]], ["Bleeding was confirmed in the apicoposterior segment of the left upper lobe by using a fiber bronchoscope on the 10th day after admission.", [["apicoposterior segment", "ANATOMY", 30, 52], ["left upper lobe", "ANATOMY", 60, 75], ["Bleeding", "DISEASE", 0, 8], ["upper lobe", "ORGAN", 65, 75], ["Bleeding", "PROBLEM", 0, 8], ["a fiber bronchoscope", "TREATMENT", 85, 105], ["apicoposterior", "ANATOMY_MODIFIER", 30, 44], ["segment", "ANATOMY_MODIFIER", 45, 52], ["left upper lobe", "ANATOMY", 60, 75], ["fiber bronchoscope", "OBSERVATION", 87, 105]]], ["Fever occurred on the 11th day and the patient reached their highest body temperature of 39\u2103.", [["body", "ANATOMY", 69, 73], ["Fever", "DISEASE", 0, 5], ["patient", "ORGANISM", 39, 46], ["body", "ORGANISM_SUBDIVISION", 69, 73], ["patient", "SPECIES", 39, 46], ["Fever", "PROBLEM", 0, 5]]], ["Dyspnea was present on 14th day and gradually increased.", [["Dyspnea", "DISEASE", 0, 7], ["Dyspnea", "PROBLEM", 0, 7], ["increased", "OBSERVATION_MODIFIER", 46, 55]]], ["On day 18 post admission, the GGOs and consolidation in the medial aspect of the left upper lobe decreased, while diffuse GGO and consolidation increased in the remaining areas of the lungs.", [["medial aspect", "ANATOMY", 60, 73], ["left upper lobe", "ANATOMY", 81, 96], ["lungs", "ANATOMY", 184, 189], ["GGO", "DISEASE", 122, 125], ["medial aspect", "MULTI-TISSUE_STRUCTURE", 60, 73], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 86, 96], ["lungs", "ORGAN", 184, 189], ["the GGOs", "PROBLEM", 26, 34], ["consolidation", "PROBLEM", 39, 52], ["diffuse GGO", "PROBLEM", 114, 125], ["consolidation", "PROBLEM", 130, 143], ["consolidation", "OBSERVATION", 39, 52], ["medial", "ANATOMY_MODIFIER", 60, 66], ["left upper lobe", "ANATOMY", 81, 96], ["decreased", "OBSERVATION_MODIFIER", 97, 106], ["diffuse", "OBSERVATION_MODIFIER", 114, 121], ["GGO", "OBSERVATION", 122, 125], ["consolidation", "OBSERVATION", 130, 143], ["increased", "OBSERVATION_MODIFIER", 144, 153], ["remaining", "OBSERVATION_MODIFIER", 161, 170], ["areas", "OBSERVATION_MODIFIER", 171, 176], ["lungs", "ANATOMY", 184, 189]]], ["The patient showed diffuse haziness in both lungs, batwing appearance, crazy-paving appearance, and the air-bronchogram sign.", [["lungs", "ANATOMY", 44, 49], ["patient", "ORGANISM", 4, 11], ["lungs", "ORGAN", 44, 49], ["patient", "SPECIES", 4, 11], ["diffuse haziness in both lungs", "PROBLEM", 19, 49], ["the air-bronchogram sign", "TEST", 100, 124], ["diffuse", "OBSERVATION_MODIFIER", 19, 26], ["haziness", "OBSERVATION", 27, 35], ["both", "ANATOMY_MODIFIER", 39, 43], ["lungs", "ANATOMY", 44, 49], ["crazy", "OBSERVATION_MODIFIER", 71, 76], ["paving", "OBSERVATION_MODIFIER", 77, 83]]], ["GGO was also distributed along the peripheral or subpleural regions (Fig. 3).", [["subpleural regions", "ANATOMY", 49, 67], ["peripheral", "TISSUE", 35, 45], ["subpleural regions", "MULTI-TISSUE_STRUCTURE", 49, 67], ["GGO", "PROBLEM", 0, 3], ["peripheral", "ANATOMY_MODIFIER", 35, 45], ["subpleural", "ANATOMY_MODIFIER", 49, 59], ["regions", "ANATOMY_MODIFIER", 60, 67]]], ["The COVID-19 infection was eventually confirmed by a real time reverse-transcription-polymerase chain-reaction assay.", [["infection", "DISEASE", 13, 22], ["COVID-19", "SPECIES", 4, 12], ["The COVID-19 infection", "PROBLEM", 0, 22], ["infection", "OBSERVATION", 13, 22]]], ["The hemoptysis gradually decreased and the dyspnea was relieved with symptomatic treatment and antiviral therapy according to the Guidelines and Management for COVID-19.", [["hemoptysis", "DISEASE", 4, 14], ["dyspnea", "DISEASE", 43, 50], ["COVID-19", "CHEMICAL", 160, 168], ["The hemoptysis", "PROBLEM", 0, 14], ["the dyspnea", "PROBLEM", 39, 50], ["symptomatic treatment", "TREATMENT", 69, 90], ["antiviral therapy", "TREATMENT", 95, 112], ["COVID", "TEST", 160, 165], ["hemoptysis", "OBSERVATION", 4, 14], ["gradually", "OBSERVATION_MODIFIER", 15, 24], ["decreased", "OBSERVATION_MODIFIER", 25, 34]]], ["A chest CT scan showed that the consolidation in both lungs were obviously absorbed; the GGO region enlarged but the GGO density decreased on day 24 (Fig. 4A, B).", [["chest", "ANATOMY", 2, 7], ["lungs", "ANATOMY", 54, 59], ["GGO region", "ANATOMY", 89, 99], ["lungs", "ORGAN", 54, 59], ["A chest CT scan", "TEST", 0, 15], ["the consolidation in both lungs", "PROBLEM", 28, 59], ["the GGO region enlarged", "PROBLEM", 85, 108], ["the GGO density", "PROBLEM", 113, 128], ["chest", "ANATOMY", 2, 7], ["consolidation", "OBSERVATION", 32, 45], ["both", "ANATOMY_MODIFIER", 49, 53], ["lungs", "ANATOMY", 54, 59], ["absorbed", "OBSERVATION_MODIFIER", 75, 83], ["GGO", "OBSERVATION_MODIFIER", 89, 92], ["region", "OBSERVATION_MODIFIER", 93, 99], ["enlarged", "OBSERVATION_MODIFIER", 100, 108], ["GGO", "OBSERVATION_MODIFIER", 117, 120], ["density", "OBSERVATION_MODIFIER", 121, 128], ["decreased", "OBSERVATION_MODIFIER", 129, 138]]], ["On day 29 post admission, GGO and a small patch of consolidation continued to be absorbed.", [["GGO", "PROBLEM", 26, 29], ["a small patch of consolidation", "PROBLEM", 34, 64], ["GGO", "OBSERVATION", 26, 29], ["small", "OBSERVATION_MODIFIER", 36, 41], ["patch", "OBSERVATION_MODIFIER", 42, 47], ["consolidation", "OBSERVATION", 51, 64]]], ["Initial GGO on the first CT scan and the initial GGO and consolidation on the second CT scan in the apicoposterior segment of the left upper lobe were obviously absorbed (Fig. 4C, D).", [["apicoposterior segment", "ANATOMY", 100, 122], ["left upper lobe", "ANATOMY", 130, 145], ["GGO", "DISEASE", 49, 52], ["upper lobe", "ORGAN", 135, 145], ["Initial GGO", "PROBLEM", 0, 11], ["the first CT scan", "TEST", 15, 32], ["the initial GGO", "PROBLEM", 37, 52], ["consolidation", "PROBLEM", 57, 70], ["the second CT scan", "TEST", 74, 92], ["GGO", "OBSERVATION", 8, 11], ["GGO", "OBSERVATION", 49, 52], ["consolidation", "OBSERVATION", 57, 70], ["apicoposterior", "ANATOMY_MODIFIER", 100, 114], ["segment", "ANATOMY_MODIFIER", 115, 122], ["left upper lobe", "ANATOMY", 130, 145], ["absorbed", "OBSERVATION_MODIFIER", 161, 169]]], ["This study was approved by the ethics board of Hunan province Hospital, and the informed consent for present study was waived.DISCUSSIONEarly diagnosis of COVID-19 infections remains an enormous challenge (12).", [["COVID-19", "CHEMICAL", 155, 163], ["infections", "DISEASE", 164, 174], ["COVID-19", "SPECIES", 155, 163], ["This study", "TEST", 0, 10], ["present study", "TEST", 101, 114], ["COVID", "TEST", 155, 160], ["19 infections", "PROBLEM", 161, 174], ["enormous", "OBSERVATION_MODIFIER", 186, 194]]], ["The most common signs and symptoms of COVID-19 infection at onset of illness have been reported to include fever, a dry cough, shortness of breath, myalgia or fatigue, and dyspnea (345).", [["COVID-19", "CHEMICAL", 38, 46], ["infection", "DISEASE", 47, 56], ["illness", "DISEASE", 69, 76], ["fever", "DISEASE", 107, 112], ["dry cough", "DISEASE", 116, 125], ["shortness of breath", "DISEASE", 127, 146], ["myalgia", "DISEASE", 148, 155], ["fatigue", "DISEASE", 159, 166], ["dyspnea", "DISEASE", 172, 179], ["symptoms", "PROBLEM", 26, 34], ["COVID-19 infection", "PROBLEM", 38, 56], ["illness", "PROBLEM", 69, 76], ["fever", "PROBLEM", 107, 112], ["a dry cough", "PROBLEM", 114, 125], ["shortness of breath", "PROBLEM", 127, 146], ["myalgia", "PROBLEM", 148, 155], ["fatigue", "PROBLEM", 159, 166], ["dyspnea", "PROBLEM", 172, 179], ["infection", "OBSERVATION", 47, 56], ["myalgia", "OBSERVATION", 148, 155]]], ["However, hemoptysis was the only clinical symptom in this patient during the first ten days of the disease course, combined with the slow progression of lung lesions.", [["lung lesions", "ANATOMY", 153, 165], ["hemoptysis", "DISEASE", 9, 19], ["lung lesions", "DISEASE", 153, 165], ["patient", "ORGANISM", 58, 65], ["lung lesions", "CANCER", 153, 165], ["patient", "SPECIES", 58, 65], ["hemoptysis", "PROBLEM", 9, 19], ["clinical symptom", "PROBLEM", 33, 49], ["the disease course", "PROBLEM", 95, 113], ["lung lesions", "PROBLEM", 153, 165], ["hemoptysis", "OBSERVATION", 9, 19], ["disease", "OBSERVATION", 99, 106], ["slow", "OBSERVATION_MODIFIER", 133, 137], ["progression", "OBSERVATION_MODIFIER", 138, 149], ["lung", "ANATOMY", 153, 157], ["lesions", "OBSERVATION", 158, 165]]], ["Hemoptysis has been rarely reported in patients with COVID-19 infections to date (36), and thus, it has not been included in the Guidelines and Management of COVID-19, constituted by the National Health Commission of China.", [["Hemoptysis", "DISEASE", 0, 10], ["infections", "DISEASE", 62, 72], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["Hemoptysis", "PROBLEM", 0, 10], ["COVID-19 infections", "PROBLEM", 53, 72], ["COVID", "TEST", 158, 163]]], ["Hence, it is difficult to diagnose COVID-19 infections especially without obvious epidemiological exposure.", [["infections", "DISEASE", 44, 54], ["COVID", "TEST", 35, 40], ["19 infections", "PROBLEM", 41, 54]]], ["After the onset of fever and dyspnea, combined with typical CT findings, the patient was rapidly diagnosed with COVID-19 pneumonia by physicians.", [["fever", "DISEASE", 19, 24], ["dyspnea", "DISEASE", 29, 36], ["pneumonia", "DISEASE", 121, 130], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["fever", "PROBLEM", 19, 24], ["dyspnea", "PROBLEM", 29, 36], ["typical CT findings", "TEST", 52, 71], ["COVID-19 pneumonia", "PROBLEM", 112, 130], ["fever", "OBSERVATION", 19, 24], ["pneumonia", "OBSERVATION", 121, 130]]], ["This case indicates the complexity of the pathogenesis of pneumonia caused by COVID-19 infection.", [["pneumonia", "DISEASE", 58, 67], ["COVID-19", "CHEMICAL", 78, 86], ["infection", "DISEASE", 87, 96], ["COVID-19", "ORGANISM", 78, 86], ["COVID-19", "SPECIES", 78, 86], ["pneumonia", "PROBLEM", 58, 67], ["COVID-19 infection", "PROBLEM", 78, 96], ["pneumonia", "OBSERVATION", 58, 67], ["infection", "OBSERVATION", 87, 96]]], ["Typical CT findings include GGO, mixed GGO, or crazy-paving patterns and consolidation of the peripheral or subpleural regions with bilateral lower lung involvements (789).", [["peripheral", "ANATOMY", 94, 104], ["subpleural regions", "ANATOMY", 108, 126], ["lower lung", "ANATOMY", 142, 152], ["GGO", "DISEASE", 28, 31], ["GGO", "DISEASE", 39, 42], ["peripheral", "TISSUE", 94, 104], ["subpleural regions", "MULTI-TISSUE_STRUCTURE", 108, 126], ["lung", "ORGAN", 148, 152], ["Typical CT findings", "TEST", 0, 19], ["GGO", "PROBLEM", 28, 31], ["mixed GGO", "PROBLEM", 33, 42], ["crazy-paving patterns", "PROBLEM", 47, 68], ["consolidation of the peripheral or subpleural regions", "PROBLEM", 73, 126], ["bilateral lower lung involvements", "PROBLEM", 132, 165], ["GGO", "OBSERVATION", 28, 31], ["mixed", "OBSERVATION_MODIFIER", 33, 38], ["GGO", "OBSERVATION", 39, 42], ["crazy", "OBSERVATION_MODIFIER", 47, 52], ["consolidation", "OBSERVATION", 73, 86], ["peripheral", "ANATOMY_MODIFIER", 94, 104], ["subpleural", "ANATOMY_MODIFIER", 108, 118], ["regions", "ANATOMY_MODIFIER", 119, 126], ["bilateral", "ANATOMY_MODIFIER", 132, 141], ["lower", "ANATOMY_MODIFIER", 142, 147], ["lung", "ANATOMY", 148, 152], ["involvements", "OBSERVATION", 153, 165]]], ["An area of localized GGO in the apicoposterior segment of the left upper lobe of this patient was not a typical CT finding of COVID-19 pneumonia.", [["GGO", "ANATOMY", 21, 24], ["apicoposterior segment", "ANATOMY", 32, 54], ["left upper lobe", "ANATOMY", 62, 77], ["GGO", "DISEASE", 21, 24], ["pneumonia", "DISEASE", 135, 144], ["GGO", "CANCER", 21, 24], ["apicoposterior segment", "MULTI-TISSUE_STRUCTURE", 32, 54], ["upper lobe", "ORGAN", 67, 77], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["localized GGO", "PROBLEM", 11, 24], ["COVID-19 pneumonia", "PROBLEM", 126, 144], ["area", "OBSERVATION_MODIFIER", 3, 7], ["localized", "OBSERVATION_MODIFIER", 11, 20], ["GGO", "OBSERVATION", 21, 24], ["apicoposterior", "ANATOMY_MODIFIER", 32, 46], ["segment", "ANATOMY_MODIFIER", 47, 54], ["left upper lobe", "ANATOMY", 62, 77], ["pneumonia", "OBSERVATION", 135, 144]]], ["It is a challenge to diagnose COVID-19 infections from GGO with a unilateral, isolated, or non-peripheral distribution with the only symptom of hemoptysis, but without epidemiological exposure.", [["infections", "DISEASE", 39, 49], ["GGO", "DISEASE", 55, 58], ["hemoptysis", "DISEASE", 144, 154], ["GGO", "CANCER", 55, 58], ["COVID", "TEST", 30, 35], ["infections", "PROBLEM", 39, 49], ["GGO", "PROBLEM", 55, 58], ["a unilateral, isolated, or non-peripheral distribution", "PROBLEM", 64, 118], ["hemoptysis", "PROBLEM", 144, 154], ["unilateral", "OBSERVATION_MODIFIER", 66, 76], ["isolated", "OBSERVATION_MODIFIER", 78, 86], ["hemoptysis", "OBSERVATION", 144, 154], ["without", "UNCERTAINTY", 160, 167]]], ["The first consideration was blood in the alveoli or an atypical manifestation of tuberculosis upon admission.", [["blood", "ANATOMY", 28, 33], ["alveoli", "ANATOMY", 41, 48], ["tuberculosis", "DISEASE", 81, 93], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["alveoli", "MULTI-TISSUE_STRUCTURE", 41, 48], ["blood in the alveoli", "PROBLEM", 28, 48], ["tuberculosis", "PROBLEM", 81, 93], ["alveoli", "ANATOMY", 41, 48], ["atypical", "OBSERVATION_MODIFIER", 55, 63], ["tuberculosis", "OBSERVATION", 81, 93]]], ["The typical manifestations of the COVID-2019 pneumonia appeared on the 18th day after admission.", [["pneumonia", "DISEASE", 45, 54], ["the COVID", "TEST", 30, 39], ["pneumonia", "PROBLEM", 45, 54], ["pneumonia", "OBSERVATION", 45, 54]]], ["The two final CT findings corresponded to the absorption stage, in which the clinical symptoms improved after adequate treatment according to the Guidelines and Management of COVID-19.", [["COVID-19", "CHEMICAL", 175, 183], ["The two final CT findings", "TEST", 0, 25], ["the absorption stage", "PROBLEM", 42, 62], ["the clinical symptoms", "PROBLEM", 73, 94], ["adequate treatment", "TREATMENT", 110, 128], ["COVID", "TEST", 175, 180], ["absorption stage", "OBSERVATION_MODIFIER", 46, 62]]], ["Moreover, initial GGO on the first and second CT scans in the apicoposterior segment of the left upper lobe was clearly absorbed, which was consistent with the gradual improvement of hemoptysis.DISCUSSIONIn summary, the present case of COVID-19 pneumonia was likely caused by a second- or third-generation transmission of the viral infection, resulting in no traceable epidemiological history.", [["apicoposterior segment", "ANATOMY", 62, 84], ["left upper lobe", "ANATOMY", 92, 107], ["hemoptysis", "DISEASE", 183, 193], ["pneumonia", "DISEASE", 245, 254], ["viral infection", "DISEASE", 326, 341], ["apicoposterior segment", "MULTI-TISSUE_STRUCTURE", 62, 84], ["upper lobe", "ORGAN", 97, 107], ["COVID-19", "ORGANISM", 236, 244], ["initial GGO", "PROBLEM", 10, 21], ["second CT scans", "TEST", 39, 54], ["hemoptysis", "PROBLEM", 183, 193], ["COVID", "TEST", 236, 241], ["pneumonia", "PROBLEM", 245, 254], ["the viral infection", "PROBLEM", 322, 341], ["GGO", "OBSERVATION", 18, 21], ["segment", "ANATOMY_MODIFIER", 77, 84], ["left upper lobe", "ANATOMY", 92, 107], ["absorbed", "OBSERVATION_MODIFIER", 120, 128], ["consistent with", "UNCERTAINTY", 140, 155], ["gradual", "OBSERVATION_MODIFIER", 160, 167], ["improvement", "OBSERVATION_MODIFIER", 168, 179], ["hemoptysis", "OBSERVATION", 183, 193], ["pneumonia", "OBSERVATION", 245, 254], ["viral infection", "OBSERVATION", 326, 341], ["no", "UNCERTAINTY", 356, 358]]], ["Moreover, owing to the complexity of the COVID-19 pneumonia pathogenesis shown in this case, the initial symptom and imaging features of COVID-19 pneumonia could also be atypical.", [["pneumonia", "DISEASE", 50, 59], ["pneumonia", "DISEASE", 146, 155], ["the COVID", "TEST", 37, 46], ["pneumonia pathogenesis", "PROBLEM", 50, 72], ["the initial symptom", "PROBLEM", 93, 112], ["imaging features", "TEST", 117, 133], ["COVID", "TEST", 137, 142], ["pneumonia", "PROBLEM", 146, 155], ["pneumonia", "OBSERVATION", 50, 59], ["pneumonia", "OBSERVATION", 146, 155], ["could also be", "UNCERTAINTY", 156, 169], ["atypical", "OBSERVATION_MODIFIER", 170, 178]]], ["Importantly, COVID-19 pneumonia may present with atypical manifestations, such as hemoptysis and focal GGO with non-peripheral distribution, on initial CT scans.", [["focal GGO", "ANATOMY", 97, 106], ["pneumonia", "DISEASE", 22, 31], ["hemoptysis", "DISEASE", 82, 92], ["COVID-19", "SPECIES", 13, 21], ["pneumonia", "PROBLEM", 22, 31], ["atypical manifestations", "PROBLEM", 49, 72], ["hemoptysis", "PROBLEM", 82, 92], ["focal GGO", "PROBLEM", 97, 106], ["non-peripheral distribution", "PROBLEM", 112, 139], ["initial CT scans", "TEST", 144, 160], ["pneumonia", "OBSERVATION", 22, 31], ["atypical", "OBSERVATION_MODIFIER", 49, 57], ["hemoptysis", "OBSERVATION", 82, 92], ["focal", "OBSERVATION_MODIFIER", 97, 102], ["GGO", "OBSERVATION", 103, 106], ["non-peripheral", "OBSERVATION_MODIFIER", 112, 126], ["distribution", "OBSERVATION_MODIFIER", 127, 139]]]], "e7c71b11eb2fa615042e74a6906544e726b3ddf0": [["Case 1On January 20 2020, a 60-year-old male patient presented with generalized myalgia for 2 weeks and intermittent fever around 38.3\u00b0C for 5 days and was admitted in our hospital ( Figure 1A , Patient 1).", [["myalgia", "DISEASE", 80, 87], ["fever", "DISEASE", 117, 122], ["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["generalized myalgia", "PROBLEM", 68, 87], ["intermittent fever", "PROBLEM", 104, 122], ["myalgia", "OBSERVATION", 80, 87]]], ["Before admission, he had accomplished a chest computed tomography (CT) scan on January 18 2020 that showed bilateral multiple ground-glass opacities (GGO), prominent on the right lower lobe ( Figure 1B, Patient 1) .", [["right lower lobe", "ANATOMY", 173, 189], ["GGO", "DISEASE", 150, 153], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 179, 189], ["Patient", "SPECIES", 203, 210], ["a chest computed tomography", "TEST", 38, 65], ["CT) scan", "TEST", 67, 75], ["bilateral multiple ground-glass opacities", "PROBLEM", 107, 148], ["chest", "ANATOMY", 40, 45], ["bilateral", "ANATOMY_MODIFIER", 107, 116], ["multiple", "OBSERVATION_MODIFIER", 117, 125], ["ground-glass opacities", "OBSERVATION", 126, 148], ["GGO", "OBSERVATION_MODIFIER", 150, 153], ["prominent", "OBSERVATION_MODIFIER", 156, 165], ["right lower lobe", "ANATOMY", 173, 189]]], ["The test of influenza virus was negative.", [["influenza virus", "ORGANISM", 12, 27], ["influenza virus", "SPECIES", 12, 27], ["The test of influenza virus", "TEST", 0, 27]]], ["Blood cell counts were: leukocyte, 3.41\u00d710 9 /L; neutrophil, 2.25\u00d710 9 /L; lymphocyte, 0.9\u00d710 9 /L; red blood cell, 3.62\u00d710 12 /L; platelet, 95\u00d710 9 /L. The hemoglobin was 125 g/L. Other clinically cured for COVID-19 and was discharged on February 3 ( Figure 1A , Patient 1).", [["Blood cell", "ANATOMY", 0, 10], ["leukocyte", "ANATOMY", 24, 33], ["neutrophil", "ANATOMY", 49, 59], ["lymphocyte", "ANATOMY", 75, 85], ["red blood cell", "ANATOMY", 100, 114], ["platelet", "ANATOMY", 131, 139], ["Blood cell", "CELL", 0, 10], ["leukocyte", "CELL", 24, 33], ["neutrophil", "CELL", 49, 59], ["lymphocyte", "CELL", 75, 85], ["red blood cell", "CELL", 100, 114], ["platelet", "CELL", 131, 139], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 157, 167], ["neutrophil", "CELL_TYPE", 49, 59], ["red blood cell", "CELL_TYPE", 100, 114], ["platelet", "CELL_TYPE", 131, 139], ["hemoglobin", "PROTEIN", 157, 167], ["Blood cell counts", "TEST", 0, 17], ["leukocyte", "TEST", 24, 33], ["neutrophil", "TEST", 49, 59], ["lymphocyte", "TEST", 75, 85], ["red blood cell", "TEST", 100, 114], ["platelet", "TEST", 131, 139], ["The hemoglobin", "TEST", 153, 167], ["COVID", "TEST", 208, 213], ["leukocyte", "ANATOMY", 24, 33]]], ["He was asked to keep isolated at home for another two more weeks before he comes for a review of his disease.", [["his disease", "PROBLEM", 97, 108]]], ["A Chest CT on April 2 shown a significant improvement of pneumonia ( Figure 1BCase 2A 47-year-old male patient attended our hospital after seven days of fever and non-productive cough on Feburary 18, 2020.", [["pneumonia", "DISEASE", 57, 66], ["fever", "DISEASE", 153, 158], ["cough", "DISEASE", 178, 183], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["A Chest CT", "TEST", 0, 10], ["pneumonia", "PROBLEM", 57, 66], ["fever", "PROBLEM", 153, 158], ["non-productive cough", "PROBLEM", 163, 183], ["Chest", "ANATOMY", 2, 7], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["improvement", "OBSERVATION_MODIFIER", 42, 53], ["pneumonia", "OBSERVATION", 57, 66], ["non-productive", "OBSERVATION_MODIFIER", 163, 177], ["cough", "OBSERVATION", 178, 183]]], ["He had a highest body temperature of 39.8\u00b0C and generalized myalgia, sore throat, cough, intermittent shortness of breath, and diarrhea.", [["body", "ANATOMY", 17, 21], ["myalgia", "DISEASE", 60, 67], ["sore throat", "DISEASE", 69, 80], ["cough", "DISEASE", 82, 87], ["intermittent shortness of breath", "DISEASE", 89, 121], ["diarrhea", "DISEASE", 127, 135], ["He", "ORGANISM", 0, 2], ["body", "ORGANISM_SUBDIVISION", 17, 21], ["a highest body temperature", "TEST", 7, 33], ["C", "PROBLEM", 42, 43], ["generalized myalgia", "PROBLEM", 48, 67], ["sore throat", "PROBLEM", 69, 80], ["cough", "PROBLEM", 82, 87], ["intermittent shortness of breath", "PROBLEM", 89, 121], ["diarrhea", "PROBLEM", 127, 135], ["generalized", "OBSERVATION_MODIFIER", 48, 59], ["myalgia", "OBSERVATION", 60, 67], ["sore throat", "ANATOMY", 69, 80], ["cough", "OBSERVATION", 82, 87], ["diarrhea", "OBSERVATION", 127, 135]]], ["He had performed chest CT scan in local hospital which revealed bilateral multiple GGO.", [["chest", "ANATOMY", 17, 22], ["GGO", "DISEASE", 83, 86], ["chest CT scan", "TEST", 17, 30], ["bilateral multiple GGO", "PROBLEM", 64, 86], ["chest", "ANATOMY", 17, 22], ["bilateral", "ANATOMY_MODIFIER", 64, 73], ["multiple", "OBSERVATION_MODIFIER", 74, 82], ["GGO", "OBSERVATION", 83, 86]]], ["The SARS-Cov-2 RNA test was positive ( Figure 1A, Patient 2) .Case 2After admission, a chest CT scan showed increased pulmonary exudative lesions on Feburary 20 ( Figure 1B, Patient 2) .", [["pulmonary exudative lesions", "ANATOMY", 118, 145], ["pulmonary exudative lesions", "DISEASE", 118, 145], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["pulmonary exudative lesions", "PATHOLOGICAL_FORMATION", 118, 145], ["Patient", "SPECIES", 50, 57], ["Patient", "SPECIES", 174, 181], ["The SARS", "TEST", 0, 8], ["Cov-2 RNA test", "TEST", 9, 23], ["a chest CT scan", "TEST", 85, 100], ["increased pulmonary exudative lesions", "PROBLEM", 108, 145], ["Feburary", "TEST", 149, 157], ["chest", "ANATOMY", 87, 92], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["pulmonary", "ANATOMY", 118, 127], ["exudative", "OBSERVATION_MODIFIER", 128, 137], ["lesions", "OBSERVATION", 138, 145]]], ["Blood cell counts were: leukocyte, 10.51\u00d710 9 /L; neutrophil, 9.09\u00d710 9 /L; lymphocyte, 0.67\u00d710 9 /L; This article is protected by copyright.", [["Blood cell", "ANATOMY", 0, 10], ["leukocyte", "ANATOMY", 24, 33], ["neutrophil", "ANATOMY", 50, 60], ["lymphocyte", "ANATOMY", 76, 86], ["Blood cell", "CELL", 0, 10], ["leukocyte", "CELL", 24, 33], ["neutrophil", "CELL", 50, 60], ["lymphocyte", "CELL", 76, 86], ["neutrophil", "CELL_TYPE", 50, 60], ["lymphocyte", "CELL_TYPE", 76, 86], ["Blood cell counts", "TEST", 0, 17], ["leukocyte", "TEST", 24, 33], ["neutrophil", "TEST", 50, 60], ["lymphocyte", "TEST", 76, 86], ["leukocyte", "ANATOMY", 24, 33]]], ["All rights reserved.Case 2Accepted Article red blood cell, 3.99\u00d710 12 /L; platelet, 302\u00d710 9 /L. The hemoglobin was 122 g/L. PCT was 0.05 ng/ml and D-dimer was 210 ng/ml.", [["red blood cell", "ANATOMY", 43, 57], ["platelet", "ANATOMY", 74, 82], ["red blood cell", "CELL", 43, 57], ["platelet", "CELL", 74, 82], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 101, 111], ["D-dimer", "GENE_OR_GENE_PRODUCT", 148, 155], ["platelet", "CELL_TYPE", 74, 82], ["hemoglobin", "PROTEIN", 101, 111], ["red blood cell", "TEST", 43, 57], ["platelet", "TEST", 74, 82], ["The hemoglobin", "TEST", 97, 111], ["PCT", "TEST", 125, 128], ["D-dimer", "TEST", 148, 155]]], ["He had no fever, cough, myalgia but still had some dyspnea after labor.", [["fever", "DISEASE", 10, 15], ["cough", "DISEASE", 17, 22], ["myalgia", "DISEASE", 24, 31], ["dyspnea", "DISEASE", 51, 58], ["fever", "PROBLEM", 10, 15], ["cough", "PROBLEM", 17, 22], ["myalgia", "PROBLEM", 24, 31], ["some dyspnea", "PROBLEM", 46, 58], ["labor", "PROBLEM", 65, 70], ["no", "UNCERTAINTY", 7, 9], ["fever", "OBSERVATION", 10, 15], ["cough", "OBSERVATION", 17, 22], ["myalgia", "OBSERVATION", 24, 31], ["dyspnea", "OBSERVATION", 51, 58]]], ["He was discharged on March 16 and was asked keep isolated at home for another two more weeks before he comes for a review of his disease.", [["his disease", "PROBLEM", 125, 136]]], ["He was recommended to pursue anti-HIV treatment after recorvery fromCOVID-19.This article is protected by copyright.", [["He", "ORGANISM", 0, 2], ["anti-HIV treatment", "TREATMENT", 29, 47], ["recorvery fromCOVID", "TEST", 54, 73]]]], "17e768b350bcdfe3aea210063a2528516f3e553c": [["COVID-19 and immigration detention in the USA: time to actOver 37 000 immigrants are currently detained by Immigration Customs Enforcement (ICE) in more than 130 facilities across the USA.", [["COVID", "TEST", 0, 5]]], ["1 As understandable fear of the coronavirus disease 2019 (COVID-19) pandemic intensifies in the USA, so too does the imminent danger ICE prisons pose not only to the vulnerable populations detained within their walls but to the nation's public health.", [["coronavirus disease", "DISEASE", 32, 51], ["the coronavirus disease", "PROBLEM", 28, 51], ["COVID", "TEST", 58, 63]]], ["Given the urgent need to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ICE should release all detained immigrants posing no threat to public safety.", [["acute respiratory syndrome coronavirus", "DISEASE", 54, 92], ["severe acute respiratory syndrome coronavirus", "SPECIES", 47, 92], ["SARS-CoV-2", "SPECIES", 96, 106], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 47, 92], ["ICE", "TREATMENT", 109, 112], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["respiratory syndrome", "OBSERVATION", 60, 80]]], ["1 Overcrowding, poor sanitation, inadequate healthcare, and difficulty containing contagious diseases are well documented in ICE's immigration detention system.", [["Overcrowding", "DISEASE", 2, 14], ["difficulty containing contagious diseases", "PROBLEM", 60, 101], ["poor", "OBSERVATION_MODIFIER", 16, 20]]], ["3,4,5 Most facilities are run by private prisons or county jails through lucrative ICE subcontracts.", [["lucrative ICE subcontracts", "TREATMENT", 73, 99]]], ["Distancing and other necessary measures to prevent SARS-CoV-2 from spreading are not possible in immigrant prisons.", [["SARS", "DISEASE", 51, 55], ["SARS-CoV", "SPECIES", 51, 59], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["not possible", "UNCERTAINTY", 81, 93]]], ["These congregate detention facilities pose a great contagion risk: already, several staff at different immigrant detention centres have tested positive for COVID-19 and detainee infections are being reported as well.", [["infections", "DISEASE", 178, 188], ["COVID", "TEST", 156, 161], ["detainee infections", "PROBLEM", 169, 188], ["infections", "OBSERVATION", 178, 188]]], ["2,7 This reflects harsh policies implemented by the US President Administration, including mandatory detention of asylum seekers and a dramatic reduction in parole.COVID-19 and immigration detention in the USA: time to actICE detention facilities are often located in small, isolated towns that employ local residents who move each day between facility and community.", [["2,7", "CHEMICAL", 0, 3], ["a dramatic reduction", "TREATMENT", 133, 153], ["COVID", "TEST", 164, 169], ["harsh", "OBSERVATION_MODIFIER", 18, 23], ["dramatic", "OBSERVATION_MODIFIER", 135, 143], ["reduction", "OBSERVATION_MODIFIER", 144, 153], ["small", "OBSERVATION_MODIFIER", 268, 273]]], ["As SARS-CoV-2 spreads, local health-care systems will be overwhelmed.", [["SARS", "PROBLEM", 3, 7]]], ["For example, within 80 miles of the 1000 bed Pine Prairie, Louisiana, detention facility, there are only eight ICU beds.COVID-19 and immigration detention in the USA: time to actMaking matters worse, thousands of inmates are transferred between centres each year.", [["COVID", "TEST", 120, 125]]], ["Arguably, it would be difficult to devise a system better suited for spreading SARS-CoV-2.COVID-19 and immigration detention in the USA: time to actMost immigrant detainees have no criminal record and immigration proceedings are civil, not criminal.", [["spreading SARS-CoV", "TEST", 69, 87]]], ["8 Immigrant detainees include asylum seekers who fled their countries because of torture, persecution, and violence.", [["violence", "DISEASE", 107, 115]]], ["For such traumatised individuals, immigration detention can cause severe psychological distress including depression and post-traumatic stress disorder.", [["psychological distress", "DISEASE", 73, 95], ["depression", "DISEASE", 106, 116], ["post-traumatic stress disorder", "DISEASE", 121, 151], ["such traumatised individuals", "PROBLEM", 4, 32], ["severe psychological distress", "PROBLEM", 66, 95], ["depression", "PROBLEM", 106, 116], ["post-traumatic stress disorder", "PROBLEM", 121, 151], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["post-traumatic stress disorder", "OBSERVATION", 121, 151]]], ["8 Continued imprisonment during this pandemic could result in even more severe harm to the mental health of immigrant detainees.COVID-19 and immigration detention in the USA: time to actMoreover, the Migration Protection Protocol (MPP) has created an enormous and potentially dangerous SARS-CoV-2 reservoir on the US-Mexican border.", [["COVID", "TEST", 128, 133], ["enormous", "OBSERVATION_MODIFIER", 251, 259], ["dangerous", "OBSERVATION_MODIFIER", 276, 285], ["SARS", "OBSERVATION", 286, 290]]], ["Last year under that policy, nearly 60 000 asylum seekersincluding women and children-were forced to remain in Mexico during the asylum application process, 9 and live in unsanitary, overcrowded, makeshift encampments with no healthcare system, and violence.COVID-19 and immigration detention in the USA: time to actICE has full authority to release detained immigrants.", [["violence", "DISEASE", 249, 257], ["women", "ORGANISM", 67, 72], ["children", "ORGANISM", 77, 85], ["women", "SPECIES", 67, 72], ["children", "SPECIES", 77, 85], ["COVID", "TEST", 258, 263]]], ["\"Unlike the Federal Bureau of Prisons, ICE has complete control over the release of individuals.", [["ICE", "TREATMENT", 39, 42]]], ["ICE is not carrying out the sentence imposed by a federal judge,\" notes one former ICE Director.", [["ICE", "TREATMENT", 0, 3]]], ["10 As the USA and the rest of the world attempt to stave off the worst pandemic in generations there can be no doubt that continuing to hold immigrant detainees in overcrowded facilities is not only cruel but dangerous.", [["no doubt", "UNCERTAINTY", 108, 116]]], ["Failure to do so endangers the tens of thousands of civil immigrant detainees and our society.", [["Failure", "PROBLEM", 0, 7]]], ["BDW declares no competing interests.", [["no", "UNCERTAINTY", 13, 15], ["competing interests", "OBSERVATION", 16, 35]]]], "732c6fa889d9614ebeb6396706520543319bfd76": [["INTRODUCTIONNurses are the leaders of patient care, advocacy, education, and advancing the science of caring.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45]]], ["1 The environment also contributes to levels of nursing burnout and job satisfaction.", [["burnout", "DISEASE", 56, 63]]], ["2 Nurses teaching in baccalaureate programs with critical care faculty or classes in academic institutions may reap the benefits of holistic education and wellness programs and transmit these benefits to emerging practitioners.", [["holistic education and wellness programs", "TREATMENT", 132, 172]]], ["Optimal outcomes are achieved in the critical care environment when the patient characteristics and nurse competencies are in synergy.", [["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79]]], ["Spanning the continuum of health, 8 patient characteristics and 8 dimensions of nursing comprise the model ( Table 1 ) and can be applied to nursing education.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43]]], ["Matching the nurses' competencies with overall patient needs promotes favorable outcomes and supports nurse well-being.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54]]], ["4 This article proposes the application of the synergy model to improve the well-being of academicians who practice and teach critical care.", [["the synergy model", "TREATMENT", 43, 60]]], ["3 During the outbreak of COVID-19, academic faculty assumed multiple roles as clinicians, academicians, student advisors, researchers, and stewards to the profession of nursing.", [["COVID", "TEST", 25, 30]]], ["Because of the diverse clinical roles and responsibilities of academic faculty, varying levels of moral distress were observed.", [["moral distress", "PROBLEM", 98, 112], ["diverse", "OBSERVATION_MODIFIER", 15, 22]]], ["Some faculty were practicing on the front line of the critical care unit and providing direct patient care, whereas other faculty were providing mental health or women's health services.", [["patient", "ORGANISM", 94, 101], ["women", "ORGANISM", 162, 167], ["patient", "SPECIES", 94, 101], ["women", "SPECIES", 162, 167], ["direct patient care", "TREATMENT", 87, 106], ["faculty", "OBSERVATION", 5, 12]]], ["All faculty continued to teach in alternative and adaptive formats and act as a positive representation of nursing to students who will be the post-COVID generation of health care providers.INTRODUCTIONApplication of the synergy model helped to identify areas of impending and active moral distress in practicing critical care academicians.", [["the synergy model", "TREATMENT", 217, 234], ["impending and active moral distress", "PROBLEM", 263, 298], ["active", "OBSERVATION_MODIFIER", 277, 283], ["moral distress", "OBSERVATION", 284, 298]]], ["The importance of a structured wellness initiative emerged to provide support for frontline practitioners in an academic environment.", [["frontline practitioners", "TREATMENT", 82, 105]]], ["She maintains professional certifications and is active in nursing, interprofessional, and educational organizations.", [["active", "OBSERVATION_MODIFIER", 49, 55]]], ["Her clinical practice enhances the academic classroom by keeping her material timely, relevant, and evidence based.Case Study: Part 1During the COVID-19 pandemic, Robin's practice unit quickly transitioned to a designated COVID unit.", [["COVID unit", "DNA", 222, 232], ["the COVID", "TEST", 140, 149], ["a designated COVID unit", "TREATMENT", 209, 232]]], ["That night, she tosses and turns as the sounds of ventilators reverberate in her ears.", [["ears", "ORGAN", 81, 85], ["ventilators", "TREATMENT", 50, 61], ["ears", "ANATOMY", 81, 85]]], ["She awakes the next morning, returning to her university email before donning her scrubs for another shift in the ICU.ESTABLISHING THE FOCUS ON THE WELL-BEING OF CRITICAL CARE NURSES Setting the Standards for Critical Care NursesFor more than 20 years, the American Association of Critical Care Nurses (AACN) has been committed to creating healthy work environments that support excellence in nursing practice.", [["her scrubs", "TREATMENT", 78, 88]]], ["5 The \"AACN Standards for Establishing and Sustaining Healthy Work Environments: A Journey to Excellence\" 5, 6 were created in response to a large body of evidence that associated unhealthy work environments with medical errors, ineffective delivery of care, and conflict and stress among health care professionals.", [["medical errors", "PROBLEM", 213, 227]]], ["5, 6 Now, more than ever, with the COVID-19 pandemic, these standards are central to the well-being of critical care nurses and those nurses without critical care nursing backgrounds who are charged with caring for patients.ESTABLISHING THE FOCUS ON THE WELL-BEING OF CRITICAL CARE NURSES Setting the Standards for Critical Care NursesStaffing is a complex process that matches nurses' competencies with the needs of patients, and there is a significant discrepancy at this time.", [["patients", "ORGANISM", 215, 223], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 417, 425], ["a significant discrepancy", "PROBLEM", 440, 465], ["significant", "OBSERVATION_MODIFIER", 442, 453], ["discrepancy", "OBSERVATION", 454, 465]]], ["6 Of particular note, the data from participants showed alarmingly high rates of verbal abuse, discrimination, sexual harassment, and physical abuse by patients, patient family members, physician colleagues, and other health care personnel, as well as administrators, directed toward the individual critical care nurses.", [["verbal abuse", "DISEASE", 81, 93], ["sexual harassment", "DISEASE", 111, 128], ["physical abuse", "DISEASE", 134, 148], ["patients", "ORGANISM", 152, 160], ["patient", "ORGANISM", 162, 169], ["participants", "SPECIES", 36, 48], ["patients", "SPECIES", 152, 160], ["patient", "SPECIES", 162, 169]]], ["Ulrich and colleagues 9 completed another survey with samples that were similar in size and representation to past surveys, and the most significant decrease was for the item \"RNs are valued and committed partners in making policy, directing and evaluating clinical care, and leading organizational operations\" (p 67).", [["samples", "TEST", 54, 61], ["size", "OBSERVATION_MODIFIER", 83, 87], ["significant", "OBSERVATION_MODIFIER", 137, 148], ["decrease", "OBSERVATION", 149, 157]]], ["Participants also reported feeling less recognized for the value they brought to their organizations, highlighting the need to create healthy work environments and to support the well-being of critical care nurses.", [["Participants", "SPECIES", 0, 12]]], ["In the most recent survey, Ulrich and colleagues 1 found some improvement from the 2013 report; however, most participants reported problems with appropriate staffing, with 6017 participants reporting an alarming number of 198,340 incidents involving threats to their physical and mental well-being.", [["participants", "SPECIES", 110, 122], ["participants", "SPECIES", 178, 190], ["improvement", "OBSERVATION_MODIFIER", 62, 73]]], ["More than half of the participants reported their intent to leave their current position within the year, making it imperative to address the health of the work environment for critical care nurses.ESTABLISHING THE FOCUS ON THE WELL-BEING OF CRITICAL CARE NURSES Setting the Standards for Critical Care NursesThe follow-up data reported the status of the health of work environments before the COVID-19 pandemic.", [["participants", "ORGANISM", 22, 34], ["participants", "SPECIES", 22, 34], ["the COVID", "TEST", 390, 399], ["pandemic", "PROBLEM", 403, 411]]], ["A significant body of evidence supports the relationship between the health of the work environment and patient outcomes and the need to prioritize the improvement of critical care nurses' work environments.", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["1 Psychological stress, especially vicarious traumatization to nurses caused by the COVID-19 pandemic, should not be ignored.", [["traumatization", "DISEASE", 45, 59], ["Psychological stress", "PROBLEM", 2, 22], ["vicarious traumatization", "PROBLEM", 35, 59], ["the COVID", "TEST", 80, 89]]], ["10 Evidence continues to emerge as strategies to reduce the mental stress of nurses caring for patients with COVID-19.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["COVID", "TEST", 109, 114]]], ["Immediately before the pandemic, it was suggested that a new type of ICU leader is needed to improve the professional well-being of critical care nurses by using an interprofessional team and a systematic approach to provide vision and improve intractable problems within the health care system.", [["a systematic approach", "TREATMENT", 192, 213], ["intractable problems within the health care system", "PROBLEM", 244, 294]]], ["15 Jackson and colleagues 13 explored the grounded theory of managing exposure to better understand nurse burnout and resilience in response to workplace adversity in critical care settings.", [["burnout", "DISEASE", 106, 113]]], ["Burnout and resilience are not separate processes but indicators of nurses responding to workplace adversity on a continuum, trying to manage workplace adversity with varying degrees of success.", [["Burnout", "DISEASE", 0, 7]]], ["This continuum includes thriving, resilience, survival, and burnout.", [["burnout", "DISEASE", 60, 67]]], ["According to this theory, managing is affected by external factors outside of the critical care nurses' control, such as organizational policies and political climate at the organization.Empowerment of Critical Care NursesThe concept of empowerment has been explored for intrapersonal and interpersonal challenges that critical care nurses face related to confronting challenges and feeling powerless.", [["organizational policies", "TREATMENT", 121, 144]]], ["16 The benefits of empowerment are extensive and include decreased levels of distress and strain, increased sense of control over situation, development and growth, and increased comfort and inner satisfaction.", [["inner", "TISSUE", 191, 196], ["decreased levels of distress", "PROBLEM", 57, 85], ["strain", "PROBLEM", 90, 96], ["increased sense of control over situation", "PROBLEM", 98, 139], ["increased comfort and inner satisfaction", "PROBLEM", 169, 209], ["growth", "OBSERVATION_MODIFIER", 157, 163]]], ["Fitzpatrick and colleagues 17, 18 were charged by the AACN to examine the relationship between AACN specialty certification and feelings of empowerment, and to examine these variables related to the participants' intent to leave their current positions.", [["participants", "SPECIES", 199, 211]]], ["20 Over the past 2 decades, higher education has undergone tremendous change that has influenced the well-being of academicians.", [["tremendous", "OBSERVATION_MODIFIER", 59, 69], ["change", "OBSERVATION", 70, 76]]], ["20 Faculty face unique demands that may not be apparent to those working outside the role.", [["may not be apparent", "UNCERTAINTY", 36, 55]]], ["The first trend is the reduction in funding and resources.", [["reduction", "OBSERVATION_MODIFIER", 23, 32]]], ["21 University expenses continue to increase, which results in a decrease in the operating budget and a decrease in available resources for faculty.", [["decrease", "OBSERVATION_MODIFIER", 64, 72], ["decrease", "OBSERVATION_MODIFIER", 103, 111]]], ["Some faculty lines might not be replaced, which may result in increased teaching workloads, increased number of students to advise, and increased committee work.", [["Some faculty lines", "TREATMENT", 0, 18], ["faculty lines", "OBSERVATION", 5, 18], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["Colleges across the United States have already suffered significant financial losses from the first 2 months of the COVID-19 pandemic.", [["significant financial losses", "PROBLEM", 56, 84], ["the COVID", "TEST", 112, 121], ["pandemic", "PROBLEM", 125, 133], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["financial losses", "OBSERVATION", 68, 84]]], ["23 Some universities have already furloughed employees, 24 and others are already facing grave concerns of permanent closure.", [["permanent closure", "TREATMENT", 107, 124], ["permanent closure", "OBSERVATION", 107, 124]]], ["New faculty often do not have training or preparation in the educator role.", [["faculty", "OBSERVATION", 4, 11]]], ["Over the years, there has been an increase in part-time and non-tenure-track appointments.", [["increase", "OBSERVATION_MODIFIER", 34, 42]]], ["28 A third trend potentially influencing the well-being of academicians involves changes in undergraduate education.", [["undergraduate education", "TREATMENT", 92, 115]]], ["Another change in education is the increase in technology in the classroom and growth in distance education.", [["change", "OBSERVATION_MODIFIER", 8, 14], ["increase", "OBSERVATION_MODIFIER", 35, 43]]], ["29 This change necessitates that faculty learn new pedagogies, teaching strategies, and learning platforms.", [["teaching strategies", "TREATMENT", 63, 82]]], ["[30] [31] [32] Faculty also report that they have obtained insufficient training and technological support.", [["insufficient training", "TREATMENT", 59, 80], ["technological support", "TREATMENT", 85, 106]]], ["Overall, general university enrollments are decreasing, which has led universities to commit to student diversity and inclusion of first-generation, low-income, nontraditional, and minority students.", [["decreasing", "OBSERVATION_MODIFIER", 44, 54]]], ["34, 35 The changing student body places additional demands and pressures on faculty as they figure out how to address student needs.", [["body", "ANATOMY", 28, 32], ["body", "ORGANISM_SUBDIVISION", 28, 32], ["pressures on faculty", "TREATMENT", 63, 83], ["pressures", "OBSERVATION_MODIFIER", 63, 72]]], ["Despite general university enrollments being down, enrollment in traditional nursing programs tend to be increasing.", [["general university enrollments", "TREATMENT", 8, 38], ["traditional nursing programs", "TREATMENT", 65, 93], ["increasing", "OBSERVATION_MODIFIER", 105, 115]]], ["Many students experience mental health issues such as depression, anxiety, and substance abuse.", [["depression", "DISEASE", 54, 64], ["anxiety", "DISEASE", 66, 73], ["substance abuse", "DISEASE", 79, 94], ["mental health issues", "PROBLEM", 25, 45], ["depression", "PROBLEM", 54, 64], ["anxiety", "PROBLEM", 66, 73]]], ["Nursing students have a tendency to be more anxious and depressed than the general college population as they adjust to their chosen profession and the rigor of their studies.", [["depressed", "DISEASE", 56, 65], ["more anxious", "PROBLEM", 39, 51], ["depressed", "PROBLEM", 56, 65], ["their studies", "TEST", 161, 174]]], ["To address this concern, faculty are expected to identify students at risk and refer students who may be in distress.", [["distress", "PROBLEM", 108, 116]]], ["These personal interactions with students can be emotionally draining for faculty who often feel unprepared to deal with mental health issues.Recent Trends in AcademiaThese trends show that higher education no longer offers the stress-free environment it once did.", [["mental health issues", "PROBLEM", 121, 141]]], ["These trends can lead to faculty experiencing decrease in quality of life, feeling overloaded and emotional exhaustion, which can ultimately influence the well-being of academicians.ACADEMICIANS WHO WORK IN THE CRITICAL CARE SETTINGWorking as a nursing faculty member and maintaining a clinical practice leads to unique challenges and stressors that can threaten well-being.", [["decrease in quality of life", "PROBLEM", 46, 73], ["feeling overloaded", "PROBLEM", 75, 93], ["emotional exhaustion", "PROBLEM", 98, 118], ["decrease", "OBSERVATION_MODIFIER", 46, 54]]], ["Hence, nursing faculty working in critical care need to be mindful of how to implement and practice wellness strategies.", [["practice wellness strategies", "TREATMENT", 91, 119]]], ["In addition, they have an obligation to teach the next generation of nurses how to properly care for themselves and their patients holistically.ACADEMICIANS WHO PRACTICE AND TEACH CRITICAL CAREIdeally, health care agencies and higher education organizations should take a systems approach to professional well-being.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130]]], ["38 The National Academy has recommended 6 strategies to promote well-being: create positive work environments, create positive learning environments, reduce administrative burden, enable technology solutions, provide support to clinicians and learners, and invest in research.", [["enable technology solutions", "TREATMENT", 180, 207]]], ["This initiative assists in threading holistic healing throughout nursing curriculum, including courses with advanced and complex concepts, such as critical care.", [["threading holistic healing", "PROBLEM", 27, 53], ["advanced and complex concepts", "TREATMENT", 108, 137]]], ["Another added benefit to integrating holistic healing concepts in the nursing curriculum is that nursing faculty have to be well versed in the concepts in order to teach them to their students.Creating the EnvironmentThe HHI has not only revised the curriculum but the committee has organized extracurricular events to promote wellness in faculty, staff, and students.", [["integrating holistic healing", "TREATMENT", 25, 53], ["versed", "TREATMENT", 129, 135], ["Environment", "OBSERVATION_MODIFIER", 206, 217]]], ["The HHI was Igniting Change important to establish at an institution with critical care courses and faculty with critical care backgrounds because nurses practicing in the intensive care unit environment tend to have higher levels of moral distress.", [["critical care courses", "TREATMENT", 74, 95], ["moral distress", "PROBLEM", 234, 248]]], ["39 The HHI convened and served as a resource for faculty throughout the course of the COVID-19 pandemic.", [["the COVID", "TEST", 82, 91], ["pandemic", "PROBLEM", 95, 103]]], ["Graduates, current students, and critical care faculty within the school of nursing openly shared anecdotal frontline stories pulling the pandemic closer to the individual level.Creating the EnvironmentIn addition to establishing a wellness committee, there are other ways to promote well-being in the academic environment.", [["Environment", "OBSERVATION_MODIFIER", 191, 202]]], ["21 Developing a personalized wellness plan with a mentor that includes daily meditation and journaling can help decrease stress and burnout.", [["burnout", "DISEASE", 132, 139], ["daily meditation", "TREATMENT", 71, 87], ["journaling", "TREATMENT", 92, 102]]], ["26 Healthy sleep habits include keeping a consistent schedule, establishing a relaxing nighttime routine, avoiding drinking caffeine or alcohol before bed, limiting daytime napping, and keeping bedrooms cool.", [["caffeine", "CHEMICAL", 124, 132], ["alcohol", "CHEMICAL", 136, 143], ["caffeine", "CHEMICAL", 124, 132], ["alcohol", "CHEMICAL", 136, 143], ["caffeine", "SIMPLE_CHEMICAL", 124, 132], ["alcohol", "SIMPLE_CHEMICAL", 136, 143], ["a relaxing nighttime routine", "TREATMENT", 76, 104], ["caffeine", "TREATMENT", 124, 132]]], ["42 In addition to establishing a regular exercise routine, consider ways to increase activity, such as taking the stairs instead of the elevator.", [["a regular exercise routine", "TREATMENT", 31, 57]]], ["A well-balanced diet can also contribute to well-being and health.Creating the EnvironmentSpecial consideration has been given by the National Academy of Medicine for clinician wellness strategies during the COVID-19 pandemic.", [["the COVID", "TEST", 204, 213], ["pandemic", "PROBLEM", 217, 225]]], ["43 Respecting differences of others in response to the current outbreak is essential; some people find comfort in speaking with others about their experiences, whereas others prefer time alone.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97]]], ["Clinicians should self-monitor their well-being for symptoms of stress or depression and seek professional help with any occurrences of symptoms.", [["depression", "DISEASE", 74, 84], ["symptoms", "PROBLEM", 52, 60], ["stress", "PROBLEM", 64, 70], ["depression", "PROBLEM", 74, 84], ["symptoms", "PROBLEM", 136, 144]]], ["Activities such as speaking with colleagues and having hobbies are associated with critical care staff having less posttraumatic work stress and burnout; venting emotion and consuming alcohol are associated with doubling in risk of reporting burnout.", [["burnout", "DISEASE", 145, 152], ["alcohol", "CHEMICAL", 184, 191], ["burnout", "DISEASE", 242, 249], ["alcohol", "CHEMICAL", 184, 191], ["alcohol", "SIMPLE_CHEMICAL", 184, 191]]], ["44 Restoring synergy for both critical care academic clinicians and emerging practitioners in the collegiate environment was a goal of the HHI.", [["the HHI", "PROBLEM", 135, 142]]], ["Using evidence-based wellness interventions integrated into the student curriculum, the HHI implemented a variety of wellness resources.", [["based wellness interventions", "TREATMENT", 15, 43]]], ["Support from the institution, along with dually beneficial programming, added to an application of the synergy model to bring together the systematic environment of the collegiate institution, critical care clinicians, and emerging critical care nurses.", [["dually beneficial programming", "TREATMENT", 41, 70], ["the synergy model", "TREATMENT", 99, 116]]], ["To be clear, this is not a modification of the synergy model 3 but an application of this theoretic framework to help those who teach and practice critical care.", [["this theoretic framework", "TREATMENT", 85, 109], ["practice critical care", "TREATMENT", 138, 160], ["clear", "OBSERVATION", 6, 11]]], ["Smaller changes in the academic setting, including music in the office and aromatherapy from diffusers in common areas, can positively affect the mood at work.Case Study: Part 2Robin takes advantage of the university's HHI and shares her experiences with fellow faculty.", [["Smaller changes", "PROBLEM", 0, 15], ["aromatherapy", "TREATMENT", 75, 87]]], ["Robin reconnects with faculty colleagues on Igniting Change virtual yoga sessions and uses humor to alleviate her stress.", [["humor", "ORGANISM_SUBSTANCE", 91, 96], ["humor", "TREATMENT", 91, 96], ["her stress", "PROBLEM", 110, 120]]], ["Finding solace in solidarity, restoration in purpose in both nursing and education, and approaching her well-being holistically helps pave the paths Robin has chosen to travel.SUMMARYCritical care nursing is subjected to especially high turnover rates, with some figures as high as 35%.", [["solidarity", "OBSERVATION", 18, 28]]], ["Ensuring the environment of those teaching, learning, and practicing within the critical care environment is imperative to individuals' overall holistic wellbeing.", [["those teaching", "TREATMENT", 28, 42]]], ["Mitigating symptoms of stress and anxiety starts at the hedonic level through programs such as the HHI.", [["anxiety", "DISEASE", 34, 41], ["Mitigating symptoms", "PROBLEM", 0, 19], ["stress", "PROBLEM", 23, 29], ["anxiety", "PROBLEM", 34, 41], ["the HHI", "PROBLEM", 95, 102], ["stress", "OBSERVATION", 23, 29]]], ["Wellness programs are not designed to eliminate sources of stress and burnout.", [["burnout", "DISEASE", 70, 77], ["stress", "PROBLEM", 59, 65], ["burnout", "PROBLEM", 70, 77]]], ["However, they acknowledge and validate individuals' need to self-explore, thereby allowing critical care academicians and students to embrace a true sense of nursing purpose and deliver optimal patient outcomes.DISCLOSUREThe authors have nothing to disclose.", [["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 194, 201]]]], "PMC7104980": [["IntroductionThe interest of scientific community to identify and characterize bioactive constituents from various plant extracts for suitable use in pharmaceutical industry or in composition of functional foods is significantly increasing.", [["extracts", "ANATOMY", 120, 128], ["extracts", "ORGANISM_SUBSTANCE", 120, 128], ["various plant extracts", "TREATMENT", 106, 128], ["significantly", "OBSERVATION_MODIFIER", 214, 227], ["increasing", "OBSERVATION_MODIFIER", 228, 238]]], ["Today, it is generally accepted that nutrition plays an important role in the prevention of different chronic diseases and decreasing the risk factors by virtue of its functional ingredients.", [["chronic diseases", "DISEASE", 102, 118], ["different chronic diseases", "PROBLEM", 92, 118], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["diseases", "OBSERVATION", 110, 118]]], ["Among the broad category of plant-derived bioactive compounds, flavonoids are found to possess multiple health benefits.", [["flavonoids", "CHEMICAL", 63, 73], ["flavonoids", "CHEMICAL", 63, 73], ["flavonoids", "SIMPLE_CHEMICAL", 63, 73], ["flavonoids", "TREATMENT", 63, 73], ["bioactive compounds", "OBSERVATION", 42, 61]]], ["These plant-based secondary metabolites are known to represent a number of structurally diverse classes of polyphenols with potential pharmacological activities, including anticancer, anti-inflammatory, antioxidant, and anti-pathogenic properties (Rajendran et al., 2014, Ravishankar et al., 2013).", [["anticancer", "ANATOMY", 172, 182], ["polyphenols", "CHEMICAL", 107, 118], ["polyphenols", "SIMPLE_CHEMICAL", 107, 118], ["anticancer", "CANCER", 172, 182], ["polyphenols", "TREATMENT", 107, 118], ["anticancer", "TREATMENT", 172, 182], ["anti-inflammatory", "TREATMENT", 184, 201], ["antioxidant", "TREATMENT", 203, 214], ["secondary metabolites", "OBSERVATION", 18, 39], ["structurally", "OBSERVATION_MODIFIER", 75, 87], ["diverse", "OBSERVATION_MODIFIER", 88, 95], ["pharmacological activities", "OBSERVATION", 134, 160]]], ["Indeed, numerous in vitro and in vivo studies have reported the ability of flavonoids to interfere in different stages of carcinogenesis like migration, invasion, metastasis, and angiogenesis (Ravishankar et al., 2013).", [["carcinogenesis", "DISEASE", 122, 136], ["metastasis", "DISEASE", 163, 173], ["flavonoids", "CHEMICAL", 75, 85], ["flavonoids", "SIMPLE_CHEMICAL", 75, 85], ["vivo studies", "TEST", 33, 45], ["flavonoids", "TREATMENT", 75, 85], ["carcinogenesis like migration", "PROBLEM", 122, 151], ["invasion", "PROBLEM", 153, 161], ["metastasis", "PROBLEM", 163, 173], ["angiogenesis", "PROBLEM", 179, 191], ["carcinogenesis", "OBSERVATION", 122, 136], ["migration", "OBSERVATION_MODIFIER", 142, 151], ["invasion", "OBSERVATION_MODIFIER", 153, 161], ["metastasis", "OBSERVATION", 163, 173]]], ["Moreover, epidemiological studies have shown that long-term and regular consumption of dietary items rich in flavonoids, such as fruits and vegetables, are associated with the lower risk of malignancy developments (Batra and Sharma, 2013, Kozlowska and Szostak-Wegierek, 2014, Tena et al., 2013).", [["fruits", "ANATOMY", 129, 135], ["vegetables", "ANATOMY", 140, 150], ["flavonoids", "CHEMICAL", 109, 119], ["malignancy", "DISEASE", 190, 200], ["flavonoids", "CHEMICAL", 109, 119], ["flavonoids", "SIMPLE_CHEMICAL", 109, 119], ["fruits", "ORGANISM_SUBDIVISION", 129, 135], ["vegetables", "ORGANISM_SUBDIVISION", 140, 150], ["epidemiological studies", "TEST", 10, 33], ["long-term", "PROBLEM", 50, 59], ["malignancy developments", "PROBLEM", 190, 213], ["long-term", "OBSERVATION_MODIFIER", 50, 59], ["malignancy", "OBSERVATION", 190, 200]]], ["The daily intake of flavonoids among humans is still greatly variable, ranging from about twenty milligrams to virtually one gram (Jaramillo-Carmona et al., 2014).", [["flavonoids", "CHEMICAL", 20, 30], ["flavonoids", "CHEMICAL", 20, 30], ["flavonoids", "SIMPLE_CHEMICAL", 20, 30], ["humans", "ORGANISM", 37, 43], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["The daily intake of flavonoids", "TREATMENT", 0, 30]]], ["Although, flavonoids are characterized by a common skeleton of diphenyl propane, they can be further subdivided into flavanols, flavonols, flavones, flavanones, isoflavones and anthocyanins based on the peculiarities in their chemical structures (Batra and Sharma, 2013, Kozlowska and Szostak-Wegierek, 2014, Sak, 2014, Tena et al., 2013).IntroductionKaempferol (KMF), a well characterized natural flavonol, is present in 80% of plant-based foods, including broccoli, kale, cabbage, leek, tomato, beans, grapes, strawberries, apples, and tea (Chen and Chen, 2013, Chen et al., 2013, Jaramillo-Carmona et al., 2014, Kim and Choi, 2013, Rajendran et al., 2014).", [["beans", "ANATOMY", 497, 502], ["grapes", "ANATOMY", 504, 510], ["strawberries", "ANATOMY", 512, 524], ["flavonoids", "CHEMICAL", 10, 20], ["diphenyl propane", "CHEMICAL", 63, 79], ["flavanols, flavonols, flavones, flavanones, isoflavones", "CHEMICAL", 117, 172], ["anthocyanins", "CHEMICAL", 177, 189], ["IntroductionKaempferol", "CHEMICAL", 339, 361], ["KMF", "CHEMICAL", 363, 366], ["flavonol", "CHEMICAL", 398, 406], ["broccoli, kale, cabbage, leek, tomato, beans, grapes, strawberries, apples, and tea", "CHEMICAL", 458, 541], ["flavonoids", "CHEMICAL", 10, 20], ["diphenyl propane", "CHEMICAL", 63, 79], ["flavanols", "CHEMICAL", 117, 126], ["flavonols", "CHEMICAL", 128, 137], ["flavones", "CHEMICAL", 139, 147], ["flavanones", "CHEMICAL", 149, 159], ["isoflavones", "CHEMICAL", 161, 172], ["anthocyanins", "CHEMICAL", 177, 189], ["IntroductionKaempferol", "CHEMICAL", 339, 361], ["KMF", "CHEMICAL", 363, 366], ["flavonol", "CHEMICAL", 398, 406], ["flavonoids", "SIMPLE_CHEMICAL", 10, 20], ["diphenyl propane", "SIMPLE_CHEMICAL", 63, 79], ["flavanols", "SIMPLE_CHEMICAL", 117, 126], ["flavonols", "SIMPLE_CHEMICAL", 128, 137], ["flavones", "SIMPLE_CHEMICAL", 139, 147], ["flavanones", "SIMPLE_CHEMICAL", 149, 159], ["isoflavones", "SIMPLE_CHEMICAL", 161, 172], ["anthocyanins", "SIMPLE_CHEMICAL", 177, 189], ["IntroductionKaempferol", "SIMPLE_CHEMICAL", 339, 361], ["KMF", "SIMPLE_CHEMICAL", 363, 366], ["flavonol", "SIMPLE_CHEMICAL", 398, 406], ["broccoli", "ORGANISM_SUBDIVISION", 458, 466], ["cabbage", "ORGANISM_SUBDIVISION", 474, 481], ["tomato", "ORGANISM_SUBDIVISION", 489, 495], ["beans", "ORGANISM_SUBDIVISION", 497, 502], ["grapes", "ORGANISM_SUBDIVISION", 504, 510], ["strawberries", "ORGANISM_SUBDIVISION", 512, 524], ["apples", "ORGANISM_SUBDIVISION", 526, 532], ["tea", "ORGANISM_SUBDIVISION", 538, 541], ["broccoli", "SPECIES", 458, 466], ["cabbage", "SPECIES", 474, 481], ["tomato", "SPECIES", 489, 495], ["beans", "SPECIES", 497, 502], ["grapes", "SPECIES", 504, 510], ["strawberries", "SPECIES", 512, 524], ["apples", "SPECIES", 526, 532], ["broccoli", "SPECIES", 458, 466], ["cabbage", "SPECIES", 474, 481], ["tomato", "SPECIES", 489, 495], ["flavonoids", "PROBLEM", 10, 20], ["diphenyl propane", "TREATMENT", 63, 79], ["flavanols", "TREATMENT", 117, 126], ["flavonols", "TREATMENT", 128, 137], ["flavones", "TREATMENT", 139, 147], ["flavanones", "TREATMENT", 149, 159], ["isoflavones", "TREATMENT", 161, 172], ["anthocyanins", "TREATMENT", 177, 189], ["flavonoids", "OBSERVATION", 10, 20], ["chemical structures", "ANATOMY", 226, 245]]], ["It has been reported that KMF has potential to significantly modulate a variety of signaling pathways that are involved in many adverse clinico-pathological conditions (Batra and Sharma, 2013, Chen and Chen, 2013, Jaramillo-Carmona et al., 2014, Kim and Choi, 2013, Rajendran et al., 2014).", [["KMF", "CHEMICAL", 26, 29], ["KMF", "CHEMICAL", 26, 29], ["KMF", "GENE_OR_GENE_PRODUCT", 26, 29], ["KMF", "PROTEIN", 26, 29]]], ["In contrast to the standard chemotherapeutic drugs utilized in cancer treatment at present, KMF showed minimal side effects evidenced in the different experiments along with its effective synergistic ability in combination with various synthetic cytotoxic drugs (Chen and Chen, 2013, Chen et al., 2013, Kim and Choi, 2013, Rajendran et al., 2014).", [["cancer", "ANATOMY", 63, 69], ["cancer", "DISEASE", 63, 69], ["KMF", "CHEMICAL", 92, 95], ["KMF", "CHEMICAL", 92, 95], ["cancer", "CANCER", 63, 69], ["KMF", "SIMPLE_CHEMICAL", 92, 95], ["the standard chemotherapeutic drugs", "TREATMENT", 15, 50], ["cancer treatment", "TREATMENT", 63, 79], ["KMF", "TEST", 92, 95], ["minimal side effects", "PROBLEM", 103, 123], ["its effective synergistic ability", "PROBLEM", 174, 207], ["cancer", "OBSERVATION", 63, 69], ["minimal", "OBSERVATION_MODIFIER", 103, 110], ["side effects", "OBSERVATION_MODIFIER", 111, 123]]], ["This review highlights the multiple molecular targets of KMF that are involved in a variety of cellular signaling pathways.", [["cellular", "ANATOMY", 95, 103], ["KMF", "GENE_OR_GENE_PRODUCT", 57, 60], ["cellular", "CELL", 95, 103], ["KMF", "PROTEIN", 57, 60], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["cellular signaling pathways", "OBSERVATION", 95, 122]]], ["In addition to this, the review also discusses synergistic studies of KMF with other known therapeutic drugs along with its pharmacokinetics and epidemiological findings.Biosynthetic preview ::: Chemistry and source of kaempferolThe biosynthetic approach of KMF is known to involve the condensation of cinnamoyl-CoA (1) and malonyl-CoA (2) in the presence of chalcone synthase, a catalytic enzyme, which results in the formation of naringenin-chalcone (3).", [["KMF", "CHEMICAL", 70, 73], ["kaempferol", "CHEMICAL", 219, 229], ["KMF", "CHEMICAL", 258, 261], ["cinnamoyl-CoA", "CHEMICAL", 302, 315], ["malonyl-CoA", "CHEMICAL", 324, 335], ["chalcone", "CHEMICAL", 359, 367], ["naringenin-chalcone", "CHEMICAL", 432, 451], ["KMF", "CHEMICAL", 70, 73], ["kaempferol", "CHEMICAL", 219, 229], ["KMF", "CHEMICAL", 258, 261], ["cinnamoyl-CoA", "CHEMICAL", 302, 315], ["malonyl-CoA", "CHEMICAL", 324, 335], ["chalcone", "CHEMICAL", 359, 367], ["naringenin-chalcone", "CHEMICAL", 432, 451], ["KMF", "SIMPLE_CHEMICAL", 70, 73], ["kaempferol", "SIMPLE_CHEMICAL", 219, 229], ["KMF", "SIMPLE_CHEMICAL", 258, 261], ["cinnamoyl-CoA (1)", "SIMPLE_CHEMICAL", 302, 319], ["malonyl-CoA (2)", "SIMPLE_CHEMICAL", 324, 339], ["chalcone synthase", "GENE_OR_GENE_PRODUCT", 359, 376], ["naringenin-chalcone (3)", "SIMPLE_CHEMICAL", 432, 455], ["chalcone synthase", "PROTEIN", 359, 376], ["catalytic enzyme", "PROTEIN", 380, 396], ["synergistic studies", "TEST", 47, 66], ["KMF", "TREATMENT", 70, 73], ["therapeutic drugs", "TREATMENT", 91, 108], ["epidemiological findings", "TEST", 145, 169], ["Chemistry", "TEST", 195, 204], ["kaempferol", "TREATMENT", 219, 229], ["chalcone synthase", "TREATMENT", 359, 376], ["a catalytic enzyme", "TEST", 378, 396], ["naringenin-chalcone", "TREATMENT", 432, 451], ["kaempferol", "OBSERVATION", 219, 229], ["CoA", "ANATOMY", 312, 315], ["CoA", "ANATOMY", 332, 335], ["chalcone synthase", "OBSERVATION", 359, 376]]], ["Chalcone has been considered as the most widely studied precursor for a variety of flavanol synthesis.", [["Chalcone", "CHEMICAL", 0, 8], ["flavanol", "CHEMICAL", 83, 91], ["Chalcone", "CHEMICAL", 0, 8], ["flavanol", "CHEMICAL", 83, 91], ["Chalcone", "SIMPLE_CHEMICAL", 0, 8], ["flavanol", "SIMPLE_CHEMICAL", 83, 91], ["Chalcone", "TREATMENT", 0, 8], ["flavanol synthesis", "TREATMENT", 83, 101], ["flavanol synthesis", "OBSERVATION", 83, 101]]], ["Further, chalcone isomerase mediates isomerisation reactions and leads to the formation of naringenin (flavanone) (4).", [["chalcone", "CHEMICAL", 9, 17], ["naringenin", "CHEMICAL", 91, 101], ["flavanone", "CHEMICAL", 103, 112], ["chalcone", "CHEMICAL", 9, 17], ["naringenin", "CHEMICAL", 91, 101], ["flavanone", "CHEMICAL", 103, 112], ["chalcone isomerase", "GENE_OR_GENE_PRODUCT", 9, 27], ["naringenin", "SIMPLE_CHEMICAL", 91, 101], ["flavanone", "SIMPLE_CHEMICAL", 103, 112], ["chalcone isomerase", "PROTEIN", 9, 27], ["chalcone isomerase mediates", "TREATMENT", 9, 36], ["isomerisation reactions", "PROBLEM", 37, 60], ["naringenin (flavanone)", "TREATMENT", 91, 113]]], ["In the next step, the hydroxylation is known to occur at C3 position of naringenin by flavanone 3-dioxygenase which leads to the synthesis of dihydrokaempferol (5).", [["naringenin", "CHEMICAL", 72, 82], ["flavanone 3-dioxygenase", "CHEMICAL", 86, 109], ["dihydrokaempferol", "CHEMICAL", 142, 159], ["naringenin", "CHEMICAL", 72, 82], ["flavanone", "CHEMICAL", 86, 95], ["dihydrokaempferol", "CHEMICAL", 142, 159], ["naringenin", "SIMPLE_CHEMICAL", 72, 82], ["flavanone 3-dioxygenase", "SIMPLE_CHEMICAL", 86, 109], ["dihydrokaempferol", "SIMPLE_CHEMICAL", 142, 159], ["the hydroxylation", "TREATMENT", 18, 35], ["flavanone", "TREATMENT", 86, 95], ["the synthesis of dihydrokaempferol", "TREATMENT", 125, 159]]], ["In the last step, flavonol synthase mediated exordium of a double bond at the C2\u2013C3 position occurs in the dihydrokaempferol skeleton which results in the formation of KMF (Devi et al., 2015) (Fig. 2).", [["flavonol", "CHEMICAL", 18, 26], ["exordium", "CHEMICAL", 45, 53], ["dihydrokaempferol", "CHEMICAL", 107, 124], ["flavonol", "CHEMICAL", 18, 26], ["C2\u2013C3", "CHEMICAL", 78, 83], ["dihydrokaempferol", "CHEMICAL", 107, 124], ["KMF", "CHEMICAL", 168, 171], ["flavonol synthase", "GENE_OR_GENE_PRODUCT", 18, 35], ["exordium", "SIMPLE_CHEMICAL", 45, 53], ["dihydrokaempferol", "SIMPLE_CHEMICAL", 107, 124], ["KMF", "SIMPLE_CHEMICAL", 168, 171], ["flavonol synthase", "PROTEIN", 18, 35], ["flavonol synthase", "TREATMENT", 18, 35], ["a double bond", "TREATMENT", 57, 70], ["double bond", "OBSERVATION", 59, 70], ["dihydrokaempferol", "ANATOMY_MODIFIER", 107, 124], ["skeleton", "ANATOMY", 125, 133]]], ["Naturally, KMF is also known to exist in conjugate forms with different sugar molecules such as rutinose, rhamnose, glucose and galactose that cause the formation of glycosidic combinations of KMF, such as astragalin (kaempferol-3-O-glucoside), kaempferol-3-beta-D-galactoside, kaempferol-3-rutinoside.", [["KMF", "CHEMICAL", 11, 14], ["rutinose", "CHEMICAL", 96, 104], ["rhamnose", "CHEMICAL", 106, 114], ["glucose", "CHEMICAL", 116, 123], ["galactose", "CHEMICAL", 128, 137], ["KMF", "CHEMICAL", 193, 196], ["astragalin", "CHEMICAL", 206, 216], ["kaempferol-3-O-glucoside", "CHEMICAL", 218, 242], ["kaempferol-3-beta-D-galactoside", "CHEMICAL", 245, 276], ["kaempferol-3-rutinoside", "CHEMICAL", 278, 301], ["sugar", "CHEMICAL", 72, 77], ["rutinose", "CHEMICAL", 96, 104], ["rhamnose", "CHEMICAL", 106, 114], ["glucose", "CHEMICAL", 116, 123], ["galactose", "CHEMICAL", 128, 137], ["KMF", "CHEMICAL", 193, 196], ["astragalin", "CHEMICAL", 206, 216], ["kaempferol-3-O-glucoside", "CHEMICAL", 218, 242], ["kaempferol-3-beta-D-galactoside", "CHEMICAL", 245, 276], ["kaempferol-3-rutinoside", "CHEMICAL", 278, 301], ["KMF", "GENE_OR_GENE_PRODUCT", 11, 14], ["rutinose", "SIMPLE_CHEMICAL", 96, 104], ["rhamnose", "SIMPLE_CHEMICAL", 106, 114], ["glucose", "SIMPLE_CHEMICAL", 116, 123], ["galactose", "SIMPLE_CHEMICAL", 128, 137], ["KMF", "SIMPLE_CHEMICAL", 193, 196], ["astragalin", "SIMPLE_CHEMICAL", 206, 216], ["kaempferol-3-O-glucoside", "SIMPLE_CHEMICAL", 218, 242], ["kaempferol-3-beta-D-galactoside", "SIMPLE_CHEMICAL", 245, 276], ["kaempferol-3-rutinoside", "SIMPLE_CHEMICAL", 278, 301], ["KMF", "PROTEIN", 11, 14], ["different sugar molecules", "PROBLEM", 62, 87], ["rutinose, rhamnose, glucose and galactose", "PROBLEM", 96, 137], ["KMF", "TREATMENT", 193, 196], ["astragalin", "TEST", 206, 216], ["kaempferol", "TEST", 218, 228], ["glucoside", "TREATMENT", 233, 242], ["kaempferol", "TREATMENT", 245, 255], ["galactoside", "TREATMENT", 265, 276], ["kaempferol", "TREATMENT", 278, 288], ["rutinoside", "TREATMENT", 291, 301]]], ["Besides these, other derivatives, such as kaempferol methyl ether, kaempferol dimethyl ether, kaempferol trimethyl ether and kaempferol sulphate have also been noted (Calderon-Montano et al., 2011, Murakami and Tanaka, 1988).Chemical synthesis ::: Chemistry and source of kaempferolChemically, KMF is synthesized by complex reaction having many steps: (a) cross aldol condensation of 2,4,6-trimethoxyacetophenone (6) and 4-methoxybenzaldehyde (7) with KOH, (b) ortho-demethylation of 2,4,6,4\u2032- tetramethoxychalcone (8) in the presence of AlCl3, (c) I2-mediated oxidative cyclization of 2-hydroxy-4,6,4\u2032-trimethoxychalcone (9), (d) methylation of 5-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one by Me2SO4 (10), (e) oxidative hydroxylation of 5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (11) catalysed by DDO, (f) BBr3 controlled catalytic demethylation of 3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (12) (Lee & Wu, 2001) (Fig.3A).Chemical synthesis ::: Chemistry and source of kaempferolAnother convenient method for KMF synthesis involves the reaction of \u03c9-benzoyloxyphloracetophenone (13), p-(acetyloxy)benzoic anhydride (14), sodium p-acetyloxybenzoate (15) in the presence of triethylamine at 160\u2013165 \u00b0C for 8 h, followed by mechanical stirring and aqueous KOH treatment that results in the formation of desired product (Ichikawa, Pamukcu, & Bryan, 1982) (Fig.3B).Cell cycle arrest and apoptosis by kaempferol ::: Therapeutic effects of kaempferolRecent in vitro and in vivo studies have shown the antiproliferative and proapoptotic activities of KMF against various types of cancers including breast (Azevedo et al., 2015, Kim et al., 2016, Liao et al., 2016), ovarian (Luo, Rankin, Li, Depriest, & Chen, 2011), lung (Kuo et al., 2015), pancreas (Zhang, Chen, Li, Chen, & Yao, 2008), esophagus (Yao et al., 2016), stomach (Song et al., 2015), colon (Cho & Park, 2013), prostate (Halimah et al., 2015), bladder (Dang et al., 2015), kidney (Song et al., 2014) and others.", [["Cell", "ANATOMY", 1389, 1393], ["cancers", "ANATOMY", 1601, 1608], ["breast", "ANATOMY", 1619, 1625], ["ovarian", "ANATOMY", 1687, 1694], ["lung", "ANATOMY", 1738, 1742], ["pancreas", "ANATOMY", 1763, 1771], ["esophagus", "ANATOMY", 1810, 1819], ["stomach", "ANATOMY", 1840, 1847], ["colon", "ANATOMY", 1869, 1874], ["prostate", "ANATOMY", 1895, 1903], ["bladder", "ANATOMY", 1928, 1935], ["kidney", "ANATOMY", 1957, 1963], ["kaempferol methyl ether", "CHEMICAL", 42, 65], ["kaempferol dimethyl ether", "CHEMICAL", 67, 92], ["kaempferol trimethyl ether", "CHEMICAL", 94, 120], ["kaempferol sulphate", "CHEMICAL", 125, 144], ["kaempferol", "CHEMICAL", 272, 282], ["KMF", "CHEMICAL", 294, 297], ["2,4,6-trimethoxyacetophenone", "CHEMICAL", 384, 412], ["4-methoxybenzaldehyde", "CHEMICAL", 421, 442], ["KOH", "CHEMICAL", 452, 455], ["ortho", "CHEMICAL", 461, 466], ["2,4,6,4\u2032- tetramethoxychalcone", "CHEMICAL", 484, 514], ["AlCl3", "CHEMICAL", 538, 543], ["I2", "CHEMICAL", 549, 551], ["2-hydroxy-4,6,4\u2032-trimethoxychalcone", "CHEMICAL", 586, 621], ["5-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one", "CHEMICAL", 646, 698], ["Me2SO4", "CHEMICAL", 702, 708], ["5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one", "CHEMICAL", 746, 792], ["DDO", "CHEMICAL", 811, 814], ["BBr3", "CHEMICAL", 820, 824], ["3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one", "CHEMICAL", 863, 919], ["kaempferol", "CHEMICAL", 998, 1008], ["KMF", "CHEMICAL", 1038, 1041], ["\u03c9-benzoyloxyphloracetophenone", "CHEMICAL", 1077, 1106], ["13), p-(acetyloxy)benzoic anhydride", "CHEMICAL", 1108, 1143], ["sodium p-acetyloxybenzoate", "CHEMICAL", 1150, 1176], ["triethylamine", "CHEMICAL", 1201, 1214], ["KOH", "CHEMICAL", 1282, 1285], ["kaempferol", "CHEMICAL", 1424, 1434], ["kaempferol", "CHEMICAL", 1462, 1472], ["KMF", "CHEMICAL", 1572, 1575], ["cancers", "DISEASE", 1601, 1608], ["kaempferol methyl ether", "CHEMICAL", 42, 65], ["kaempferol dimethyl ether", "CHEMICAL", 67, 92], ["kaempferol trimethyl ether", "CHEMICAL", 94, 120], ["kaempferol sulphate", "CHEMICAL", 125, 144], ["kaempferol", "CHEMICAL", 272, 282], ["KMF", "CHEMICAL", 294, 297], ["2,4,6-trimethoxyacetophenone", "CHEMICAL", 384, 412], ["4-methoxybenzaldehyde", "CHEMICAL", 421, 442], ["KOH", "CHEMICAL", 452, 455], ["2,4,6,4\u2032- tetramethoxychalcone", "CHEMICAL", 484, 514], ["AlCl3", "CHEMICAL", 538, 543], ["2-hydroxy-4,6,4\u2032-trimethoxychalcone", "CHEMICAL", 586, 621], ["5-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one", "CHEMICAL", 646, 698], ["Me2SO4 (10)", "CHEMICAL", 702, 713], ["5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one", "CHEMICAL", 746, 792], ["DDO", "CHEMICAL", 811, 814], ["3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one", "CHEMICAL", 863, 919], ["kaempferol", "CHEMICAL", 998, 1008], ["\u03c9-benzoyloxyphloracetophenone", "CHEMICAL", 1077, 1106], ["p-(acetyloxy)benzoic anhydride", "CHEMICAL", 1113, 1143], ["sodium p-acetyloxybenzoate", "CHEMICAL", 1150, 1176], ["triethylamine", "CHEMICAL", 1201, 1214], ["KOH", "CHEMICAL", 1282, 1285], ["kaempferol", "CHEMICAL", 1424, 1434], ["kaempferol", "CHEMICAL", 1462, 1472], ["KMF", "CHEMICAL", 1572, 1575], ["kaempferol methyl ether", "SIMPLE_CHEMICAL", 42, 65], ["kaempferol dimethyl ether", "SIMPLE_CHEMICAL", 67, 92], ["kaempferol trimethyl ether", "SIMPLE_CHEMICAL", 94, 120], ["kaempferol sulphate", "SIMPLE_CHEMICAL", 125, 144], ["kaempferol", "SIMPLE_CHEMICAL", 272, 282], ["KMF", "SIMPLE_CHEMICAL", 294, 297], ["2,4,6-trimethoxyacetophenone (6)", "SIMPLE_CHEMICAL", 384, 416], ["4-methoxybenzaldehyde (7)", "SIMPLE_CHEMICAL", 421, 446], ["KOH", "SIMPLE_CHEMICAL", 452, 455], ["(b) ortho", "SIMPLE_CHEMICAL", 457, 466], ["2,4,6,4\u2032- tetramethoxychalcone (8)", "SIMPLE_CHEMICAL", 484, 518], ["AlCl3", "SIMPLE_CHEMICAL", 538, 543], ["(c) I2", "SIMPLE_CHEMICAL", 545, 551], ["2-hydroxy-4,6,4\u2032-trimethoxychalcone (9), (d)", "SIMPLE_CHEMICAL", 586, 630], ["5-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one", "SIMPLE_CHEMICAL", 646, 698], ["Me2SO4 (10)", "SIMPLE_CHEMICAL", 702, 713], ["(e)", "SIMPLE_CHEMICAL", 715, 718], ["5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (11)", "SIMPLE_CHEMICAL", 746, 797], ["DDO", "SIMPLE_CHEMICAL", 811, 814], ["(f) BBr3", "SIMPLE_CHEMICAL", 816, 824], ["3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (12)", "SIMPLE_CHEMICAL", 863, 924], ["kaempferol", "SIMPLE_CHEMICAL", 998, 1008], ["KMF", "SIMPLE_CHEMICAL", 1038, 1041], ["\u03c9-benzoyloxyphloracetophenone (13)", "SIMPLE_CHEMICAL", 1077, 1111], ["p-(acetyloxy)benzoic anhydride", "SIMPLE_CHEMICAL", 1113, 1143], ["sodium p-acetyloxybenzoate (15)", "SIMPLE_CHEMICAL", 1150, 1181], ["triethylamine", "SIMPLE_CHEMICAL", 1201, 1214], ["Cell", "CELL", 1389, 1393], ["kaempferol", "SIMPLE_CHEMICAL", 1424, 1434], ["kaempferol", "SIMPLE_CHEMICAL", 1462, 1472], ["KMF", "SIMPLE_CHEMICAL", 1572, 1575], ["cancers", "CANCER", 1601, 1608], ["breast", "ORGANISM_SUBDIVISION", 1619, 1625], ["ovarian", "ORGAN", 1687, 1694], ["lung", "ORGAN", 1738, 1742], ["pancreas", "ORGAN", 1763, 1771], ["esophagus", "ORGAN", 1810, 1819], ["stomach", "ORGAN", 1840, 1847], ["colon", "ORGAN", 1869, 1874], ["prostate", "ORGAN", 1895, 1903], ["bladder", "ORGAN", 1928, 1935], ["kidney", "ORGAN", 1957, 1963], ["other derivatives", "TREATMENT", 15, 32], ["kaempferol methyl ether", "TREATMENT", 42, 65], ["kaempferol dimethyl ether", "TREATMENT", 67, 92], ["kaempferol trimethyl ether", "TREATMENT", 94, 120], ["kaempferol sulphate", "TREATMENT", 125, 144], ["Chemistry", "TEST", 248, 257], ["kaempferol", "TREATMENT", 272, 282], ["a) cross aldol condensation", "TREATMENT", 353, 380], ["trimethoxyacetophenone", "TREATMENT", 390, 412], ["demethylation", "TREATMENT", 467, 480], ["tetramethoxychalcone", "TREATMENT", 494, 514], ["mediated oxidative cyclization", "TREATMENT", 552, 582], ["hydroxy", "TREATMENT", 588, 595], ["trimethoxychalcone", "TREATMENT", 603, 621], ["methylation", "TREATMENT", 631, 642], ["hydroxy", "TREATMENT", 648, 655], ["methoxy", "TREATMENT", 658, 665], ["methoxyphenyl)chromen-4", "TREATMENT", 671, 694], ["oxidative hydroxylation", "TREATMENT", 719, 742], ["dimethoxy", "TREATMENT", 750, 759], ["methoxyphenyl)chromen", "TREATMENT", 765, 786], ["catalytic demethylation", "TREATMENT", 836, 859], ["hydroxy", "TEST", 865, 872], ["dimethoxy", "TREATMENT", 877, 886], ["Chemistry", "TEST", 974, 983], ["kaempferol", "TREATMENT", 998, 1008], ["KMF synthesis", "TREATMENT", 1038, 1051], ["the reaction of \u03c9-benzoyloxyphloracetophenone", "TREATMENT", 1061, 1106], ["p-(acetyloxy)benzoic anhydride", "TREATMENT", 1113, 1143], ["sodium p-acetyloxybenzoate", "TREATMENT", 1150, 1176], ["triethylamine", "TREATMENT", 1201, 1214], ["mechanical stirring", "TREATMENT", 1250, 1269], ["aqueous KOH treatment", "TREATMENT", 1274, 1295], ["Cell cycle arrest", "PROBLEM", 1389, 1406], ["kaempferol", "TREATMENT", 1462, 1472], ["vivo studies", "TEST", 1495, 1507], ["cancers", "PROBLEM", 1601, 1608], ["prostate", "PROBLEM", 1895, 1903], ["kaempferol", "OBSERVATION", 272, 282], ["kaempferol", "OBSERVATION", 998, 1008], ["cycle arrest", "OBSERVATION", 1394, 1406], ["kaempferol", "OBSERVATION", 1462, 1472], ["cancers", "OBSERVATION", 1601, 1608], ["breast", "ANATOMY", 1619, 1625], ["ovarian", "ANATOMY", 1687, 1694], ["lung", "ANATOMY", 1738, 1742], ["pancreas", "ANATOMY", 1763, 1771], ["esophagus", "ANATOMY", 1810, 1819], ["stomach", "ANATOMY", 1840, 1847], ["colon", "ANATOMY", 1869, 1874], ["prostate", "ANATOMY", 1895, 1903], ["bladder", "ANATOMY", 1928, 1935], ["kidney", "ANATOMY", 1957, 1963]]], ["Most of these studies demonstrate that the mechanism of KMF is dependent on the inhibition of proliferation of various cancer cells either via cell cycle arrest or induction of apoptosis (Kuo et al., 2015, Liao et al., 2016).", [["cancer cells", "ANATOMY", 119, 131], ["cell", "ANATOMY", 143, 147], ["KMF", "CHEMICAL", 56, 59], ["cancer", "DISEASE", 119, 125], ["KMF", "GENE_OR_GENE_PRODUCT", 56, 59], ["cancer cells", "CELL", 119, 131], ["cell", "CELL", 143, 147], ["KMF", "PROTEIN", 56, 59], ["cancer cells", "CELL_TYPE", 119, 131], ["these studies", "TEST", 8, 21], ["various cancer cells", "PROBLEM", 111, 131], ["cell cycle arrest", "TREATMENT", 143, 160], ["apoptosis", "PROBLEM", 177, 186], ["cancer cells", "OBSERVATION", 119, 131]]], ["KMF-dependent inhibition of cancer proliferation is mediated through arrest of the different phases of cell cycle (Fig. 4) and inhibition of cell cycle transition points including G0/G1 transition in esophagus squamous cell carcinoma (Yao et al., 2016) or G2/M transition in HT-29 human colon cancer cells (Cho, 2013).", [["cancer", "ANATOMY", 28, 34], ["cell", "ANATOMY", 103, 107], ["cell", "ANATOMY", 141, 145], ["esophagus squamous cell carcinoma", "ANATOMY", 200, 233], ["HT-29 human colon cancer cells", "ANATOMY", 275, 305], ["KMF", "CHEMICAL", 0, 3], ["cancer", "DISEASE", 28, 34], ["squamous cell carcinoma", "DISEASE", 210, 233], ["colon cancer", "DISEASE", 287, 299], ["KMF", "GENE_OR_GENE_PRODUCT", 0, 3], ["cancer", "CANCER", 28, 34], ["cell", "CELL", 103, 107], ["cell", "CELL", 141, 145], ["esophagus squamous cell carcinoma", "CANCER", 200, 233], ["HT-29 human colon cancer cells", "CELL", 275, 305], ["Cho", "CELL", 307, 310], ["KMF", "PROTEIN", 0, 3], ["HT-29 human colon cancer cells", "CELL_LINE", 275, 305], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 281, 286], ["KMF", "TEST", 0, 3], ["cancer proliferation", "PROBLEM", 28, 48], ["cell cycle transition points", "TREATMENT", 141, 169], ["G0/G1 transition in esophagus squamous cell carcinoma", "PROBLEM", 180, 233], ["G2/M transition", "PROBLEM", 256, 271], ["HT", "TEST", 275, 277], ["human colon cancer cells", "PROBLEM", 281, 305], ["dependent inhibition", "OBSERVATION_MODIFIER", 4, 24], ["cancer proliferation", "OBSERVATION", 28, 48], ["different phases", "OBSERVATION_MODIFIER", 83, 99], ["cell cycle", "OBSERVATION", 103, 113], ["cell cycle", "OBSERVATION", 141, 151], ["esophagus", "ANATOMY", 200, 209], ["squamous cell carcinoma", "OBSERVATION", 210, 233], ["colon", "ANATOMY", 287, 292], ["cancer", "OBSERVATION", 293, 299]]], ["KMF additionally inhibits the expression of various cyclins like cyclin D1 and cyclin E in breast cancer cells (Kim et al., 2016), cyclin B1 in gastric cancer cells and renal cell carcinoma (Song et al., 2014, Song et al., 2015) cyclin D, cyclin E and cyclin A in colon cancer cells (Cho, 2013) and cyclin-dependent kinases like CDK4 and CDK2 (Cho, 2013).", [["breast cancer cells", "ANATOMY", 91, 110], ["gastric cancer cells", "ANATOMY", 144, 164], ["renal cell carcinoma", "ANATOMY", 169, 189], ["colon cancer cells", "ANATOMY", 264, 282], ["KMF", "CHEMICAL", 0, 3], ["breast cancer", "DISEASE", 91, 104], ["gastric cancer", "DISEASE", 144, 158], ["renal cell carcinoma", "DISEASE", 169, 189], ["colon cancer", "DISEASE", 264, 276], ["KMF", "CHEMICAL", 0, 3], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["cyclins", "GENE_OR_GENE_PRODUCT", 52, 59], ["cyclin D1", "GENE_OR_GENE_PRODUCT", 65, 74], ["cyclin E", "GENE_OR_GENE_PRODUCT", 79, 87], ["breast cancer cells", "CELL", 91, 110], ["cyclin B1", "GENE_OR_GENE_PRODUCT", 131, 140], ["gastric cancer cells", "CELL", 144, 164], ["renal cell carcinoma", "CANCER", 169, 189], ["cyclin D", "GENE_OR_GENE_PRODUCT", 229, 237], ["cyclin E", "GENE_OR_GENE_PRODUCT", 239, 247], ["cyclin A", "GENE_OR_GENE_PRODUCT", 252, 260], ["colon cancer cells", "CELL", 264, 282], ["Cho", "CELL", 284, 287], ["cyclin-dependent kinases", "GENE_OR_GENE_PRODUCT", 299, 323], ["CDK4", "GENE_OR_GENE_PRODUCT", 329, 333], ["CDK2", "GENE_OR_GENE_PRODUCT", 338, 342], ["cyclins", "PROTEIN", 52, 59], ["cyclin D1", "PROTEIN", 65, 74], ["cyclin E", "PROTEIN", 79, 87], ["breast cancer cells", "CELL_TYPE", 91, 110], ["cyclin B1", "PROTEIN", 131, 140], ["gastric cancer cells", "CELL_TYPE", 144, 164], ["cyclin D", "PROTEIN", 229, 237], ["cyclin E", "PROTEIN", 239, 247], ["cyclin A", "PROTEIN", 252, 260], ["colon cancer cells", "CELL_TYPE", 264, 282], ["cyclin-dependent kinases", "PROTEIN", 299, 323], ["CDK4", "PROTEIN", 329, 333], ["CDK2", "PROTEIN", 338, 342], ["various cyclins", "PROBLEM", 44, 59], ["cyclin D1", "PROBLEM", 65, 74], ["cyclin E in breast cancer cells", "PROBLEM", 79, 110], ["cyclin B1 in gastric cancer cells", "PROBLEM", 131, 164], ["renal cell carcinoma", "PROBLEM", 169, 189], ["cyclin D", "TREATMENT", 229, 237], ["cyclin E", "TREATMENT", 239, 247], ["cyclin A in colon cancer cells", "PROBLEM", 252, 282], ["Cho", "TEST", 284, 287], ["cyclin-dependent kinases", "PROBLEM", 299, 323], ["CDK4", "PROBLEM", 329, 333], ["CDK2", "PROBLEM", 338, 342], ["breast", "ANATOMY", 91, 97], ["cancer", "OBSERVATION", 98, 104], ["gastric", "ANATOMY", 144, 151], ["cancer cells", "OBSERVATION", 152, 164], ["renal", "ANATOMY", 169, 174], ["cell carcinoma", "OBSERVATION", 175, 189], ["colon", "ANATOMY", 264, 269], ["cancer", "OBSERVATION", 270, 276]]], ["KMF treatment has also been known to up-regulate the CDK inhibitors including p21 and p27 (Fig. 4).", [["KMF", "CHEMICAL", 0, 3], ["KMF", "CHEMICAL", 0, 3], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["CDK", "GENE_OR_GENE_PRODUCT", 53, 56], ["p21", "GENE_OR_GENE_PRODUCT", 78, 81], ["p27", "GENE_OR_GENE_PRODUCT", 86, 89], ["CDK inhibitors", "PROTEIN", 53, 67], ["p21", "PROTEIN", 78, 81], ["p27 (Fig. 4", "PROTEIN", 86, 97], ["KMF treatment", "TREATMENT", 0, 13], ["the CDK inhibitors", "TREATMENT", 49, 67], ["p21", "TEST", 78, 81], ["p27", "TEST", 86, 89]]], ["Furthermore, results of these studies demonstrate that KMF-dependent arrest of G0/G1 or G2/M transition is possibly due to inhibition of epidermal growth factor receptor (EGFR) activity, hexokinase-2 expression (Yao et al., 2016), inhibition of the activity of estrogen (Kim et al., 2016) or uptake of glucose (Azevedo et al., 2015).", [["KMF", "CHEMICAL", 55, 58], ["estrogen", "CHEMICAL", 261, 269], ["glucose", "CHEMICAL", 302, 309], ["estrogen", "CHEMICAL", 261, 269], ["glucose", "CHEMICAL", 302, 309], ["KMF", "GENE_OR_GENE_PRODUCT", 55, 58], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 137, 169], ["EGFR", "GENE_OR_GENE_PRODUCT", 171, 175], ["hexokinase-2", "GENE_OR_GENE_PRODUCT", 187, 199], ["estrogen", "SIMPLE_CHEMICAL", 261, 269], ["glucose", "SIMPLE_CHEMICAL", 302, 309], ["KMF", "PROTEIN", 55, 58], ["epidermal growth factor receptor", "PROTEIN", 137, 169], ["EGFR", "PROTEIN", 171, 175], ["hexokinase", "PROTEIN", 187, 197], ["these studies", "TEST", 24, 37], ["KMF", "TEST", 55, 58], ["dependent arrest", "PROBLEM", 59, 75], ["G0/G1", "PROBLEM", 79, 84], ["G2/M transition", "PROBLEM", 88, 103], ["epidermal growth factor receptor", "PROBLEM", 137, 169], ["hexokinase", "TEST", 187, 197], ["glucose", "TEST", 302, 309], ["possibly due to", "UNCERTAINTY", 107, 122]]], ["Of note, growth factors, hormones, glucose and hexokinases are positive regulators of cell cycle.Cell cycle arrest and apoptosis by kaempferol ::: Therapeutic effects of kaempferolA large body of evidence indicates that KMF induces cancer cells apoptosis by activating the apoptosis-related signaling pathways (Fig. 5).", [["cell", "ANATOMY", 86, 90], ["Cell", "ANATOMY", 97, 101], ["cancer cells", "ANATOMY", 232, 244], ["glucose", "CHEMICAL", 35, 42], ["kaempferol", "CHEMICAL", 132, 142], ["kaempferol", "CHEMICAL", 170, 180], ["KMF", "CHEMICAL", 220, 223], ["cancer", "DISEASE", 232, 238], ["glucose", "CHEMICAL", 35, 42], ["kaempferol", "CHEMICAL", 132, 142], ["kaempferol", "CHEMICAL", 170, 180], ["KMF", "CHEMICAL", 220, 223], ["glucose", "SIMPLE_CHEMICAL", 35, 42], ["hexokinases", "GENE_OR_GENE_PRODUCT", 47, 58], ["cell", "CELL", 86, 90], ["Cell", "CELL", 97, 101], ["kaempferol", "SIMPLE_CHEMICAL", 132, 142], ["kaempferol", "SIMPLE_CHEMICAL", 170, 180], ["KMF", "SIMPLE_CHEMICAL", 220, 223], ["cancer cells", "CELL", 232, 244], ["growth factors", "PROTEIN", 9, 23], ["hexokinases", "PROTEIN", 47, 58], ["KMF", "PROTEIN", 220, 223], ["cancer cells", "CELL_TYPE", 232, 244], ["glucose", "TEST", 35, 42], ["hexokinases", "TEST", 47, 58], ["Cell cycle arrest", "PROBLEM", 97, 114], ["kaempferol", "TREATMENT", 170, 180], ["cancer cells apoptosis", "PROBLEM", 232, 254], ["the apoptosis", "TEST", 269, 282], ["cell cycle", "OBSERVATION", 86, 96], ["cycle arrest", "OBSERVATION", 102, 114], ["large", "OBSERVATION_MODIFIER", 182, 187], ["cancer cells", "OBSERVATION", 232, 244]]], ["Xu, Liu, Li, Wu, and Liu (2008) have indicated mitochondria in human cervical cancer cells (Hela cells) and HEK293 cells (embryonic kidney cells) as the source of KMF-dependent activation of intrinsic apoptotic signaling (Xu et al., 2008).", [["mitochondria", "ANATOMY", 47, 59], ["cervical cancer cells", "ANATOMY", 69, 90], ["Hela cells", "ANATOMY", 92, 102], ["HEK293 cells", "ANATOMY", 108, 120], ["embryonic kidney cells", "ANATOMY", 122, 144], ["cervical cancer", "DISEASE", 69, 84], ["mitochondria", "CELLULAR_COMPONENT", 47, 59], ["human", "ORGANISM", 63, 68], ["cervical cancer cells", "CELL", 69, 90], ["Hela cells", "CELL", 92, 102], ["HEK293 cells", "CELL", 108, 120], ["embryonic kidney cells", "CELL", 122, 144], ["KMF", "GENE_OR_GENE_PRODUCT", 163, 166], ["human cervical cancer cells", "CELL_TYPE", 63, 90], ["Hela cells", "CELL_LINE", 92, 102], ["HEK293 cells", "CELL_LINE", 108, 120], ["embryonic kidney cells", "CELL_TYPE", 122, 144], ["KMF", "PROTEIN", 163, 166], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["mitochondria in human cervical cancer cells", "PROBLEM", 47, 90], ["Hela cells", "TEST", 92, 102], ["HEK293 cells", "PROBLEM", 108, 120], ["embryonic kidney cells", "PROBLEM", 122, 144], ["KMF", "TEST", 163, 166], ["intrinsic apoptotic signaling", "PROBLEM", 191, 220], ["Li", "ANATOMY", 9, 11], ["cervical cancer", "ANATOMY", 69, 84], ["HEK293 cells", "OBSERVATION", 108, 120], ["kidney", "ANATOMY", 132, 138], ["apoptotic signaling", "OBSERVATION", 201, 220]]], ["Further, studies by Kang et al. (2009) have substantiated that KMF could cause apoptosis MCF-7 breast cancer cells with estrogen receptor (ER) by activating intrinsic apoptosis signaling pathway and by down-regulation of PLK1 expression (Kang et al., 2009).", [["MCF-7 breast cancer cells", "ANATOMY", 89, 114], ["KMF", "CHEMICAL", 63, 66], ["breast cancer", "DISEASE", 95, 108], ["estrogen", "CHEMICAL", 120, 128], ["estrogen", "CHEMICAL", 120, 128], ["KMF", "SIMPLE_CHEMICAL", 63, 66], ["MCF-7 breast cancer cells", "CELL", 89, 114], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 120, 137], ["ER", "GENE_OR_GENE_PRODUCT", 139, 141], ["PLK1", "GENE_OR_GENE_PRODUCT", 221, 225], ["KMF", "PROTEIN", 63, 66], ["breast cancer cells", "CELL_TYPE", 95, 114], ["estrogen receptor", "PROTEIN", 120, 137], ["ER", "PROTEIN", 139, 141], ["PLK1", "PROTEIN", 221, 225], ["apoptosis MCF", "PROBLEM", 79, 92], ["breast cancer cells", "PROBLEM", 95, 114], ["estrogen receptor", "TREATMENT", 120, 137], ["activating intrinsic apoptosis signaling pathway", "PROBLEM", 146, 194], ["breast", "ANATOMY", 95, 101], ["cancer", "OBSERVATION", 102, 108]]], ["Similarly, Song et al. (2015) have shown that in gastric cancer cells KMF decreases the expression level of an anti-apoptotic protein Bcl2 on the mitochondrial membrane and concomitant induction of pro-apoptotic protein Bax release from mitochondria (Song et al., 2015).", [["gastric cancer cells", "ANATOMY", 49, 69], ["mitochondrial membrane", "ANATOMY", 146, 168], ["mitochondria", "ANATOMY", 237, 249], ["gastric cancer", "DISEASE", 49, 63], ["gastric cancer cells KMF", "CELL", 49, 73], ["Bcl2", "GENE_OR_GENE_PRODUCT", 134, 138], ["mitochondrial membrane", "CELLULAR_COMPONENT", 146, 168], ["Bax", "GENE_OR_GENE_PRODUCT", 220, 223], ["mitochondria", "CELLULAR_COMPONENT", 237, 249], ["gastric cancer cells", "CELL_TYPE", 49, 69], ["anti-apoptotic protein", "PROTEIN", 111, 133], ["Bcl2", "PROTEIN", 134, 138], ["pro-apoptotic protein", "PROTEIN", 198, 219], ["Bax", "PROTEIN", 220, 223], ["gastric cancer cells", "PROBLEM", 49, 69], ["an anti-apoptotic protein Bcl2", "TREATMENT", 108, 138], ["the mitochondrial membrane", "TREATMENT", 142, 168], ["pro-apoptotic protein Bax release", "TREATMENT", 198, 231], ["gastric", "ANATOMY", 49, 56], ["cancer", "OBSERVATION", 57, 63], ["protein Bcl2", "OBSERVATION", 126, 138], ["mitochondrial membrane", "ANATOMY", 146, 168]]], ["Very recently, by utilizing a number of cancer cell lines, including human breast carcinoma (MCF-7) cells, human stomach carcinoma (SGC-7901) cells, human cervical carcinoma (Hela) cells and human lung carcinoma (A549) cells Laio et al. have attested that mitochondrial dysfunction is the major reason of KMF-dependent apoptosis induction in these cancer cells (Liao et al., 2016).", [["cancer cell lines", "ANATOMY", 40, 57], ["breast carcinoma (MCF-7) cells", "ANATOMY", 75, 105], ["stomach carcinoma", "ANATOMY", 113, 130], ["SGC-7901) cells", "ANATOMY", 132, 147], ["cervical carcinoma (Hela) cells", "ANATOMY", 155, 186], ["lung carcinoma (A549) cells", "ANATOMY", 197, 224], ["mitochondrial", "ANATOMY", 256, 269], ["cancer cells", "ANATOMY", 348, 360], ["cancer", "DISEASE", 40, 46], ["breast carcinoma", "DISEASE", 75, 91], ["stomach carcinoma", "DISEASE", 113, 130], ["cervical carcinoma", "DISEASE", 155, 173], ["lung carcinoma", "DISEASE", 197, 211], ["mitochondrial dysfunction", "DISEASE", 256, 281], ["cancer", "DISEASE", 348, 354], ["cancer cell lines", "CELL", 40, 57], ["human", "ORGANISM", 69, 74], ["breast carcinoma", "CANCER", 75, 91], ["MCF-7) cells", "CELL", 93, 105], ["human", "ORGANISM", 107, 112], ["stomach carcinoma", "CELL", 113, 130], ["SGC-7901) cells", "CELL", 132, 147], ["human", "ORGANISM", 149, 154], ["cervical carcinoma (Hela) cells", "CELL", 155, 186], ["human", "ORGANISM", 191, 196], ["lung carcinoma (A549) cells", "CELL", 197, 224], ["mitochondrial", "CELLULAR_COMPONENT", 256, 269], ["KMF", "GENE_OR_GENE_PRODUCT", 305, 308], ["cancer cells", "CELL", 348, 360], ["cancer cell lines", "CELL_LINE", 40, 57], ["human breast carcinoma (MCF-7) cells", "CELL_LINE", 69, 105], ["human stomach carcinoma (SGC-7901) cells", "CELL_LINE", 107, 147], ["human cervical carcinoma (Hela) cells", "CELL_LINE", 149, 186], ["human lung carcinoma (A549) cells", "CELL_LINE", 191, 224], ["KMF", "PROTEIN", 305, 308], ["cancer cells", "CELL_TYPE", 348, 360], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 191, 196], ["cancer cell lines", "TREATMENT", 40, 57], ["human breast carcinoma", "PROBLEM", 69, 91], ["MCF", "TEST", 93, 96], ["human stomach carcinoma", "PROBLEM", 107, 130], ["SGC", "TEST", 132, 135], ["cells", "PROBLEM", 142, 147], ["human cervical carcinoma (Hela) cells", "PROBLEM", 149, 186], ["human lung carcinoma", "PROBLEM", 191, 211], ["mitochondrial dysfunction", "PROBLEM", 256, 281], ["KMF", "PROBLEM", 305, 308], ["dependent apoptosis induction", "PROBLEM", 309, 338], ["cancer cell lines", "OBSERVATION", 40, 57], ["breast", "ANATOMY", 75, 81], ["carcinoma", "OBSERVATION", 82, 91], ["stomach", "ANATOMY", 113, 120], ["carcinoma", "OBSERVATION", 121, 130], ["cervical", "ANATOMY", 155, 163], ["carcinoma", "OBSERVATION", 164, 173], ["lung", "ANATOMY", 197, 201], ["carcinoma", "OBSERVATION", 202, 211], ["mitochondrial dysfunction", "OBSERVATION", 256, 281], ["dependent", "OBSERVATION_MODIFIER", 309, 318], ["apoptosis", "OBSERVATION", 319, 328]]], ["However, a number of other independent studies claimed that TNF cognate apoptosis-inducing ligand (TRAIL) is related to KMF-dependent apoptosis in cancer cells.", [["cancer cells", "ANATOMY", 147, 159], ["cancer", "DISEASE", 147, 153], ["TNF cognate apoptosis-inducing ligand", "GENE_OR_GENE_PRODUCT", 60, 97], ["TRAIL", "GENE_OR_GENE_PRODUCT", 99, 104], ["KMF", "GENE_OR_GENE_PRODUCT", 120, 123], ["cancer cells", "CELL", 147, 159], ["TNF cognate apoptosis-inducing ligand", "PROTEIN", 60, 97], ["TRAIL", "PROTEIN", 99, 104], ["KMF", "PROTEIN", 120, 123], ["cancer cells", "CELL_TYPE", 147, 159], ["other independent studies", "TEST", 21, 46], ["KMF", "TEST", 120, 123], ["dependent apoptosis in cancer cells", "PROBLEM", 124, 159], ["dependent", "OBSERVATION_MODIFIER", 124, 133], ["apoptosis", "OBSERVATION", 134, 143], ["cancer cells", "OBSERVATION", 147, 159]]], ["Of note, the proinflammatory cytokine TNF-\u03b1, and TRAIL are cognate to the activation of extrinsic apoptosis signaling pathway.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 38, 43], ["TRAIL", "GENE_OR_GENE_PRODUCT", 49, 54], ["proinflammatory cytokine", "PROTEIN", 13, 37], ["TNF", "PROTEIN", 38, 41], ["\u03b1", "PROTEIN", 42, 43], ["TRAIL", "PROTEIN", 49, 54], ["the proinflammatory cytokine TNF", "TEST", 9, 41], ["TRAIL", "TREATMENT", 49, 54], ["extrinsic apoptosis signaling pathway", "PROBLEM", 88, 125], ["extrinsic apoptosis", "OBSERVATION", 88, 107]]], ["For example, Yoshida et al. (2008), have shown that KMF-dependent apoptosis in colon cancer cell lines is mediated by inducing TRAIL (Yoshida et al., 2008).", [["colon cancer cell lines", "ANATOMY", 79, 102], ["colon cancer", "DISEASE", 79, 91], ["KMF", "GENE_OR_GENE_PRODUCT", 52, 55], ["colon cancer cell lines", "CELL", 79, 102], ["TRAIL", "GENE_OR_GENE_PRODUCT", 127, 132], ["KMF", "PROTEIN", 52, 55], ["colon cancer cell lines", "CELL_LINE", 79, 102], ["TRAIL", "PROTEIN", 127, 132], ["KMF", "TEST", 52, 55], ["dependent apoptosis in colon cancer cell lines", "PROBLEM", 56, 102], ["dependent", "OBSERVATION_MODIFIER", 56, 65], ["apoptosis", "OBSERVATION", 66, 75], ["colon", "ANATOMY", 79, 84], ["cancer cell lines", "OBSERVATION", 85, 102]]], ["Likewise, TRAIL-KMF, mediated apoptosis is the result of suppression of survivin in human glioma cells (Siegelin, Reuss, Habel, Herold-Mende, & von Deimling, 2008).", [["glioma cells", "ANATOMY", 90, 102], ["glioma", "DISEASE", 90, 96], ["TRAIL-KMF", "GENE_OR_GENE_PRODUCT", 10, 19], ["survivin", "GENE_OR_GENE_PRODUCT", 72, 80], ["human", "ORGANISM", 84, 89], ["glioma cells", "CELL", 90, 102], ["Siegelin", "CELL", 104, 112], ["TRAIL", "PROTEIN", 10, 15], ["KMF", "PROTEIN", 16, 19], ["survivin", "PROTEIN", 72, 80], ["human glioma cells", "CELL_TYPE", 84, 102], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["mediated apoptosis", "PROBLEM", 21, 39], ["survivin in human glioma cells", "PROBLEM", 72, 102], ["human glioma cells", "OBSERVATION", 84, 102]]], ["Besides, KMF may also affect and inhibit various pro-survival molecules, i.e. Akt, PI(3)K, ERK 1/2 in the downstream signaling pathways (Kim et al., 2016, Kuo et al., 2015).", [["KMF", "CHEMICAL", 9, 12], ["KMF", "GENE_OR_GENE_PRODUCT", 9, 12], ["Akt", "GENE_OR_GENE_PRODUCT", 78, 81], ["PI(3)K", "GENE_OR_GENE_PRODUCT", 83, 89], ["ERK 1/2", "GENE_OR_GENE_PRODUCT", 91, 98], ["KMF", "PROTEIN", 9, 12], ["pro-survival molecules", "PROTEIN", 49, 71], ["Akt", "PROTEIN", 78, 81], ["PI(3)K", "PROTEIN", 83, 89], ["ERK 1/2", "PROTEIN", 91, 98], ["various pro-survival molecules", "PROBLEM", 41, 71], ["PI", "TEST", 83, 85], ["K", "TEST", 88, 89], ["ERK", "TEST", 91, 94]]], ["KMF also suppresses cancer metastasis in osteosarcoma cells (Chen et al., 2013) and induces autophagy (programmed cell survival) in human hepatic cancer cells (Huang et al., 2013).", [["cancer", "ANATOMY", 20, 26], ["osteosarcoma cells", "ANATOMY", 41, 59], ["cell", "ANATOMY", 114, 118], ["hepatic cancer cells", "ANATOMY", 138, 158], ["KMF", "CHEMICAL", 0, 3], ["cancer metastasis", "DISEASE", 20, 37], ["osteosarcoma", "DISEASE", 41, 53], ["hepatic cancer", "DISEASE", 138, 152], ["KMF", "CHEMICAL", 0, 3], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["cancer", "CANCER", 20, 26], ["osteosarcoma cells", "CELL", 41, 59], ["cell", "CELL", 114, 118], ["human", "ORGANISM", 132, 137], ["hepatic cancer cells", "CELL", 138, 158], ["KMF", "PROTEIN", 0, 3], ["osteosarcoma cells", "CELL_TYPE", 41, 59], ["human hepatic cancer cells", "CELL_TYPE", 132, 158], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["cancer metastasis", "PROBLEM", 20, 37], ["osteosarcoma cells", "PROBLEM", 41, 59], ["autophagy (programmed cell survival", "TREATMENT", 92, 127], ["human hepatic cancer cells", "PROBLEM", 132, 158], ["suppresses", "OBSERVATION_MODIFIER", 9, 19], ["cancer", "OBSERVATION_MODIFIER", 20, 26], ["metastasis", "OBSERVATION", 27, 37], ["osteosarcoma cells", "OBSERVATION", 41, 59], ["hepatic", "ANATOMY", 138, 145], ["cancer", "OBSERVATION", 146, 152]]], ["It has been shown that carcinoma cells activate AMP-activated protein kinase-dependent autophagy as the survival response to KMF-mediated energetic impairment (Filomeni et al., 2010).", [["carcinoma cells", "ANATOMY", 23, 38], ["carcinoma", "DISEASE", 23, 32], ["AMP", "CHEMICAL", 48, 51], ["KMF", "CHEMICAL", 125, 128], ["energetic impairment", "DISEASE", 138, 158], ["AMP", "CHEMICAL", 48, 51], ["carcinoma cells", "CELL", 23, 38], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 48, 76], ["KMF", "GENE_OR_GENE_PRODUCT", 125, 128], ["carcinoma cells", "CELL_TYPE", 23, 38], ["AMP-activated protein kinase", "PROTEIN", 48, 76], ["KMF", "PROTEIN", 125, 128], ["carcinoma cells", "PROBLEM", 23, 38], ["AMP", "TEST", 48, 51], ["activated protein kinase", "TEST", 52, 76], ["dependent autophagy", "PROBLEM", 77, 96], ["KMF", "TEST", 125, 128], ["energetic impairment", "PROBLEM", 138, 158], ["carcinoma", "OBSERVATION", 23, 32]]], ["In summary, KMF decreases the number of various cancer cells through a multiprong mechanisms that include the arrest of the cell cycle, activation of proapoptotic proteins, inhibition of antiapoptotic proteins and by attenuating the phosphorylation and activity of prosurvival proteins (e.g. Akt) and activation of programmed cell survival or autophagy.Anti-angiogenesis effect of kaempferol ::: Therapeutic effects of kaempferolCancer cells exhibit high metabolic rate to fulfil their energy requirements that in turn is found to be associated with the neovascularization (angiogenesis).", [["cancer cells", "ANATOMY", 48, 60], ["cell", "ANATOMY", 124, 128], ["cell", "ANATOMY", 326, 330], ["Cancer cells", "ANATOMY", 429, 441], ["KMF", "CHEMICAL", 12, 15], ["cancer", "DISEASE", 48, 54], ["kaempferol", "CHEMICAL", 381, 391], ["kaempferol", "CHEMICAL", 419, 429], ["Cancer", "DISEASE", 429, 435], ["neovascularization", "DISEASE", 554, 572], ["KMF", "CHEMICAL", 12, 15], ["kaempferol", "CHEMICAL", 381, 391], ["kaempferol", "CHEMICAL", 419, 429], ["KMF", "SIMPLE_CHEMICAL", 12, 15], ["cancer cells", "CELL", 48, 60], ["cell", "CELL", 124, 128], ["Akt", "GENE_OR_GENE_PRODUCT", 292, 295], ["cell", "CELL", 326, 330], ["kaempferol", "SIMPLE_CHEMICAL", 381, 391], ["kaempferol", "SIMPLE_CHEMICAL", 419, 429], ["Cancer cells", "CELL", 429, 441], ["KMF", "PROTEIN", 12, 15], ["cancer cells", "CELL_TYPE", 48, 60], ["proapoptotic proteins", "PROTEIN", 150, 171], ["antiapoptotic proteins", "PROTEIN", 187, 209], ["prosurvival proteins", "PROTEIN", 265, 285], ["Akt", "PROTEIN", 292, 295], ["Cancer cells", "CELL_TYPE", 429, 441], ["KMF", "TEST", 12, 15], ["various cancer cells", "PROBLEM", 40, 60], ["a multiprong mechanisms", "PROBLEM", 69, 92], ["the arrest", "PROBLEM", 106, 116], ["the cell cycle", "TREATMENT", 120, 134], ["proapoptotic proteins", "TREATMENT", 150, 171], ["antiapoptotic proteins", "TREATMENT", 187, 209], ["attenuating the phosphorylation", "TREATMENT", 217, 248], ["prosurvival proteins", "TREATMENT", 265, 285], ["programmed cell survival", "TREATMENT", 315, 339], ["autophagy", "PROBLEM", 343, 352], ["kaempferol", "TREATMENT", 381, 391], ["kaempferol", "TREATMENT", 419, 429], ["Cancer cells", "PROBLEM", 429, 441], ["high metabolic rate", "PROBLEM", 450, 469], ["the neovascularization", "PROBLEM", 550, 572], ["cancer cells", "OBSERVATION", 48, 60], ["cell survival", "OBSERVATION", 326, 339], ["kaempferol", "OBSERVATION", 419, 429], ["high", "OBSERVATION_MODIFIER", 450, 454], ["metabolic rate", "OBSERVATION", 455, 469], ["neovascularization", "OBSERVATION", 554, 572]]], ["A number of studies have reported the involvement of a variety of transcriptional (ERK 1/2, Akt, and MAPK) and growth factors (VEGF and FGF) in the tumour microenvironment for the neovascularization (Kashyap et al., 2016, Kashyap et al., 2016, Kashyap et al., 2016, Kumar et al., 2016, Tuli et al., 2014).", [["tumour", "ANATOMY", 148, 154], ["tumour", "DISEASE", 148, 154], ["neovascularization", "DISEASE", 180, 198], ["ERK 1/2", "GENE_OR_GENE_PRODUCT", 83, 90], ["Akt", "GENE_OR_GENE_PRODUCT", 92, 95], ["MAPK", "GENE_OR_GENE_PRODUCT", 101, 105], ["growth factors", "GENE_OR_GENE_PRODUCT", 111, 125], ["VEGF", "GENE_OR_GENE_PRODUCT", 127, 131], ["FGF", "GENE_OR_GENE_PRODUCT", 136, 139], ["tumour", "CANCER", 148, 154], ["ERK 1/2", "PROTEIN", 83, 90], ["Akt", "PROTEIN", 92, 95], ["MAPK", "PROTEIN", 101, 105], ["growth factors", "PROTEIN", 111, 125], ["VEGF", "PROTEIN", 127, 131], ["FGF", "PROTEIN", 136, 139], ["ERK", "TEST", 83, 86], ["Akt", "TEST", 92, 95], ["MAPK", "TEST", 101, 105], ["growth factors", "PROBLEM", 111, 125], ["VEGF", "TEST", 127, 131], ["FGF", "TEST", 136, 139], ["the neovascularization", "PROBLEM", 176, 198], ["neovascularization", "OBSERVATION", 180, 198]]], ["These factors are being targeted as therapeutic approach for the cure of cancer in advanced stages (Fig. 6).", [["cancer", "ANATOMY", 73, 79], ["cancer", "DISEASE", 73, 79], ["cancer", "CANCER", 73, 79], ["therapeutic approach", "TREATMENT", 36, 56], ["cancer", "PROBLEM", 73, 79], ["cancer", "OBSERVATION", 73, 79]]], ["Treatment of Huh7 cell with KMF under hypoxic (low oxygen tension) condition inhibits the HIF-1\u03b1 protein through the inactivation of p44/42 MAPK pathways which could be possible ways of cancer inhibition (Mylonis, Lakka, Tsakalof, & Simos, 2010).", [["Huh7 cell", "ANATOMY", 13, 22], ["cancer", "ANATOMY", 186, 192], ["KMF", "CHEMICAL", 28, 31], ["oxygen", "CHEMICAL", 51, 57], ["cancer", "DISEASE", 186, 192], ["KMF", "CHEMICAL", 28, 31], ["oxygen", "CHEMICAL", 51, 57], ["Huh7 cell", "CELL", 13, 22], ["KMF", "SIMPLE_CHEMICAL", 28, 31], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 90, 96], ["p44/42 MAPK", "GENE_OR_GENE_PRODUCT", 133, 144], ["cancer", "CANCER", 186, 192], ["Huh7 cell", "CELL_LINE", 13, 22], ["HIF-1\u03b1 protein", "PROTEIN", 90, 104], ["p44/42 MAPK", "PROTEIN", 133, 144], ["Huh7 cell", "PROBLEM", 13, 22], ["KMF", "TEST", 28, 31], ["hypoxic (low oxygen tension) condition", "PROBLEM", 38, 76], ["the HIF", "TEST", 86, 93], ["p44/42 MAPK pathways", "TEST", 133, 153], ["cancer inhibition", "PROBLEM", 186, 203], ["Huh7 cell", "OBSERVATION", 13, 22], ["hypoxic", "OBSERVATION_MODIFIER", 38, 45], ["cancer", "OBSERVATION", 186, 192]]], ["In a study conducted by Luo et al. (2009) using human ovarian cancer cells, they suggested that KMF can inhibit angiogenesis significantly by altering the VEGF expression through both HIF dependent and independent (ESRRA) pathways (Luo et al., 2009).", [["ovarian cancer cells", "ANATOMY", 54, 74], ["ovarian cancer", "DISEASE", 54, 68], ["KMF", "CHEMICAL", 96, 99], ["KMF", "CHEMICAL", 96, 99], ["human", "ORGANISM", 48, 53], ["ovarian cancer cells", "CELL", 54, 74], ["KMF", "SIMPLE_CHEMICAL", 96, 99], ["VEGF", "GENE_OR_GENE_PRODUCT", 155, 159], ["HIF", "GENE_OR_GENE_PRODUCT", 184, 187], ["ESRRA", "GENE_OR_GENE_PRODUCT", 215, 220], ["human ovarian cancer cells", "CELL_TYPE", 48, 74], ["KMF", "PROTEIN", 96, 99], ["VEGF", "PROTEIN", 155, 159], ["HIF", "PROTEIN", 184, 187], ["ESRRA", "PROTEIN", 215, 220], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["a study", "TEST", 3, 10], ["human ovarian cancer cells", "PROBLEM", 48, 74], ["angiogenesis", "PROBLEM", 112, 124], ["ovarian", "ANATOMY", 54, 61], ["cancer", "OBSERVATION", 62, 68]]], ["In context to their previous studies Luo et al., 2012a, Luo et al., 2012b, Luo et al., 2012 further proposed a novel angio-prevention mechanism of KMF via down-regulation of ERK-NF\u03baB-cMyc-p21-VEGF signaling pathway (Luo et al., 2012a, Luo et al., 2012b, Luo et al., 2012).", [["KMF", "CHEMICAL", 147, 150], ["KMF", "GENE_OR_GENE_PRODUCT", 147, 150], ["ERK", "GENE_OR_GENE_PRODUCT", 174, 177], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 178, 182], ["cMyc", "GENE_OR_GENE_PRODUCT", 183, 187], ["p21", "GENE_OR_GENE_PRODUCT", 188, 191], ["VEGF", "GENE_OR_GENE_PRODUCT", 192, 196], ["KMF", "PROTEIN", 147, 150], ["ERK", "PROTEIN", 174, 177], ["\u03baB", "PROTEIN", 180, 182], ["cMyc", "PROTEIN", 183, 187], ["p21", "PROTEIN", 188, 191], ["VEGF", "PROTEIN", 192, 196], ["KMF", "TEST", 147, 150], ["ERK", "TEST", 174, 177], ["NF", "TEST", 178, 180], ["\u03baB", "TEST", 180, 182], ["cMyc", "TEST", 183, 187], ["cMyc", "ANATOMY", 183, 187]]], ["In in vitro (HUVECs model) and in vivo studies (zebrafish model), Liang et al. (2015) demonstrated the anti-angiogenic effect of KMF via VEGF and FGF angiogenic promoters inactivation that are further known to interact with tyrosine kinase-associated angiogenic receptors.", [["HUVECs", "ANATOMY", 13, 19], ["KMF", "CHEMICAL", 129, 132], ["tyrosine", "CHEMICAL", 224, 232], ["tyrosine", "CHEMICAL", 224, 232], ["HUVECs", "CELL", 13, 19], ["zebrafish", "ORGANISM", 48, 57], ["KMF", "SIMPLE_CHEMICAL", 129, 132], ["VEGF", "GENE_OR_GENE_PRODUCT", 137, 141], ["FGF", "GENE_OR_GENE_PRODUCT", 146, 149], ["HUVECs model", "CELL_LINE", 13, 25], ["VEGF", "PROTEIN", 137, 141], ["FGF", "PROTEIN", 146, 149], ["tyrosine kinase-associated angiogenic receptors", "PROTEIN", 224, 271], ["KMF via VEGF", "TREATMENT", 129, 141], ["FGF angiogenic promoters inactivation", "TREATMENT", 146, 183], ["tyrosine kinase", "TEST", 224, 239], ["associated angiogenic receptors", "PROBLEM", 240, 271]]], ["Fig. 6 summarizes the various above discussed molecular targets of KMF in the inhibition of cancer angiogenesis and further research is required to explore the remaining details of its mechanisms of action.Anti-metastasis effect of kaempferol ::: Therapeutic effects of kaempferolMetastasis is considered as a hallmark of uncontrolled proliferation of the tumour cells at primary site followed by the invasion to the nearby tissue and invasion to the distant organs via bloodstream.", [["cancer", "ANATOMY", 92, 98], ["tumour cells", "ANATOMY", 356, 368], ["primary site", "ANATOMY", 372, 384], ["tissue", "ANATOMY", 424, 430], ["organs", "ANATOMY", 459, 465], ["bloodstream", "ANATOMY", 470, 481], ["KMF", "CHEMICAL", 67, 70], ["cancer", "DISEASE", 92, 98], ["kaempferol", "CHEMICAL", 232, 242], ["kaempferol", "CHEMICAL", 270, 280], ["Metastasis", "DISEASE", 280, 290], ["tumour", "DISEASE", 356, 362], ["kaempferol", "CHEMICAL", 232, 242], ["kaempferol", "CHEMICAL", 270, 280], ["KMF", "GENE_OR_GENE_PRODUCT", 67, 70], ["cancer", "CANCER", 92, 98], ["kaempferol", "SIMPLE_CHEMICAL", 232, 242], ["kaempferol", "SIMPLE_CHEMICAL", 270, 280], ["tumour cells", "CELL", 356, 368], ["tissue", "TISSUE", 424, 430], ["organs", "ORGAN", 459, 465], ["KMF", "PROTEIN", 67, 70], ["tumour cells", "CELL_TYPE", 356, 368], ["cancer angiogenesis", "PROBLEM", 92, 111], ["further research", "TEST", 116, 132], ["kaempferol", "TREATMENT", 232, 242], ["kaempferol", "TREATMENT", 270, 280], ["Metastasis", "PROBLEM", 280, 290], ["uncontrolled proliferation of the tumour cells", "PROBLEM", 322, 368], ["the invasion", "PROBLEM", 397, 409], ["cancer", "OBSERVATION", 92, 98], ["kaempferol", "OBSERVATION", 232, 242], ["kaempferol", "OBSERVATION", 270, 280], ["hallmark", "OBSERVATION_MODIFIER", 310, 318], ["uncontrolled", "OBSERVATION_MODIFIER", 322, 334], ["proliferation", "OBSERVATION", 335, 348], ["tumour cells", "OBSERVATION", 356, 368], ["invasion", "OBSERVATION", 401, 409], ["nearby tissue", "OBSERVATION", 417, 430], ["invasion", "OBSERVATION", 435, 443], ["distant", "ANATOMY_MODIFIER", 451, 458], ["organs", "ANATOMY", 459, 465], ["bloodstream", "OBSERVATION", 470, 481]]], ["The EMT proteins (Epithelial-Mesenchymal-Transitions), such as E-cadherin, vimentin, fibronectin, matrix metalloproteases (MMPs) are known to play a paramount role in the process of metastasis by trailing the cell-cell contacts (Short et al., 2016, Tulotta et al., 2016, Zhu et al., 2016).", [["Epithelial", "ANATOMY", 18, 28], ["Mesenchymal", "ANATOMY", 29, 40], ["cell-cell contacts", "ANATOMY", 209, 227], ["metastasis", "DISEASE", 182, 192], ["EMT", "GENE_OR_GENE_PRODUCT", 4, 7], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 63, 73], ["vimentin", "GENE_OR_GENE_PRODUCT", 75, 83], ["fibronectin", "GENE_OR_GENE_PRODUCT", 85, 96], ["matrix metalloproteases", "GENE_OR_GENE_PRODUCT", 98, 121], ["MMPs", "GENE_OR_GENE_PRODUCT", 123, 127], ["cell", "CELL", 209, 213], ["cell", "CELL", 214, 218], ["EMT proteins", "PROTEIN", 4, 16], ["E-cadherin", "PROTEIN", 63, 73], ["vimentin", "PROTEIN", 75, 83], ["fibronectin", "PROTEIN", 85, 96], ["matrix metalloproteases", "PROTEIN", 98, 121], ["MMPs", "PROTEIN", 123, 127], ["The EMT proteins", "TEST", 0, 16], ["E-cadherin", "TREATMENT", 63, 73], ["vimentin, fibronectin, matrix metalloproteases (MMPs", "TREATMENT", 75, 127], ["metastasis", "PROBLEM", 182, 192], ["Epithelial", "ANATOMY_MODIFIER", 18, 28], ["metastasis", "OBSERVATION", 182, 192]]], ["Therefore, EMT proteins are considered as promising targets to combat tumour metastasis.", [["tumour", "ANATOMY", 70, 76], ["tumour", "DISEASE", 70, 76], ["tumour", "CANCER", 70, 76], ["EMT proteins", "PROTEIN", 11, 23], ["EMT proteins", "TEST", 11, 23], ["combat tumour metastasis", "PROBLEM", 63, 87], ["metastasis", "OBSERVATION", 77, 87]]], ["The STAT3 is another most widely studied transcription factor associated with cancer metastasis and survival which has been found to be suppressed by KMF treatment in human prostate cancer cells (DU145) (Kwon, Kang, Kang, & Yoon, 2010).", [["cancer", "ANATOMY", 78, 84], ["prostate cancer cells", "ANATOMY", 173, 194], ["DU145", "ANATOMY", 196, 201], ["cancer", "DISEASE", 78, 84], ["KMF", "CHEMICAL", 150, 153], ["prostate cancer", "DISEASE", 173, 188], ["KMF", "CHEMICAL", 150, 153], ["STAT3", "GENE_OR_GENE_PRODUCT", 4, 9], ["cancer", "CANCER", 78, 84], ["KMF", "SIMPLE_CHEMICAL", 150, 153], ["human", "ORGANISM", 167, 172], ["prostate cancer cells", "CELL", 173, 194], ["DU145", "CELL", 196, 201], ["STAT3", "PROTEIN", 4, 9], ["transcription factor", "PROTEIN", 41, 61], ["KMF", "PROTEIN", 150, 153], ["human prostate cancer cells", "CELL_TYPE", 167, 194], ["DU145", "CELL_LINE", 196, 201], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["cancer metastasis", "PROBLEM", 78, 95], ["KMF treatment in human prostate cancer cells", "TREATMENT", 150, 194], ["most widely", "OBSERVATION_MODIFIER", 21, 32], ["metastasis", "OBSERVATION", 85, 95], ["prostate", "ANATOMY", 173, 181]]], ["In a study by Chen et al. (2013), the anti-metastatic effect of KMF in human osteosarcoma cells (OS) was investigated by inhibiting the DNA binding activity of a transcription factor called activator protein (AP-1) which resulted in reduced expression of MMP-2 & 9 (Chen et al., 2013).", [["osteosarcoma cells", "ANATOMY", 77, 95], ["KMF", "CHEMICAL", 64, 67], ["osteosarcoma", "DISEASE", 77, 89], ["KMF", "CHEMICAL", 64, 67], ["KMF", "SIMPLE_CHEMICAL", 64, 67], ["human", "ORGANISM", 71, 76], ["osteosarcoma cells", "CELL", 77, 95], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["activator protein (AP-1", "GENE_OR_GENE_PRODUCT", 190, 213], ["MMP-2", "GENE_OR_GENE_PRODUCT", 255, 260], ["KMF", "PROTEIN", 64, 67], ["human osteosarcoma cells", "CELL_TYPE", 71, 95], ["transcription factor", "PROTEIN", 162, 182], ["activator protein", "PROTEIN", 190, 207], ["AP-1", "PROTEIN", 209, 213], ["MMP", "PROTEIN", 255, 258], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["a study", "TEST", 3, 10], ["KMF in human osteosarcoma cells", "PROBLEM", 64, 95], ["activator protein", "TEST", 190, 207], ["MMP", "TEST", 255, 258], ["anti-metastatic", "OBSERVATION_MODIFIER", 38, 53], ["human", "ANATOMY", 71, 76], ["osteosarcoma cells", "OBSERVATION", 77, 95]]], ["Moreover, the other associated molecules, including ERK 1/2 and p38 were also found to be down-regulated under KMF treatment (Fig. 6).", [["KMF", "CHEMICAL", 111, 114], ["KMF", "CHEMICAL", 111, 114], ["ERK 1/2", "GENE_OR_GENE_PRODUCT", 52, 59], ["p38", "GENE_OR_GENE_PRODUCT", 64, 67], ["KMF", "SIMPLE_CHEMICAL", 111, 114], ["ERK 1/2", "PROTEIN", 52, 59], ["p38", "PROTEIN", 64, 67], ["the other associated molecules", "PROBLEM", 10, 40], ["ERK", "TEST", 52, 55], ["p38", "TEST", 64, 67], ["KMF treatment", "TREATMENT", 111, 124]]], ["Similarly, ERK 1/2-mediated down-regulation of MMPs has observed in KMF-treated human tongue squamous cancer cells (SCC4) (Lin et al., 2013).", [["tongue squamous cancer cells", "ANATOMY", 86, 114], ["SCC4", "ANATOMY", 116, 120], ["KMF", "CHEMICAL", 68, 71], ["tongue squamous cancer", "DISEASE", 86, 108], ["ERK 1/2", "GENE_OR_GENE_PRODUCT", 11, 18], ["MMPs", "GENE_OR_GENE_PRODUCT", 47, 51], ["KMF", "SIMPLE_CHEMICAL", 68, 71], ["human", "ORGANISM", 80, 85], ["tongue squamous cancer cells", "CELL", 86, 114], ["SCC4", "CELL", 116, 120], ["ERK 1/2", "PROTEIN", 11, 18], ["MMPs", "PROTEIN", 47, 51], ["KMF-treated human tongue squamous cancer cells", "CELL_LINE", 68, 114], ["SCC4", "CELL_LINE", 116, 120], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["ERK", "TEST", 11, 14], ["MMPs", "PROBLEM", 47, 51], ["KMF", "TEST", 68, 71], ["human tongue squamous cancer cells", "PROBLEM", 80, 114], ["tongue", "ANATOMY", 86, 92], ["squamous cancer", "OBSERVATION", 93, 108]]], ["In another study, KMF suppressed the transforming growth factor-\u03b21 (TGF-\u03b21) induced human non\u2013small cell lung cancer (NSCLC, A549) transition from epithelial-to-mesenchymal (EMT) and migration by abolishing Akt1-mediated Smad3 phosphorylation (Eunji, Park, Choi, Jeon, & Kim, 2015).", [["non\u2013small cell lung cancer", "ANATOMY", 90, 116], ["NSCLC", "ANATOMY", 118, 123], ["A549", "ANATOMY", 125, 129], ["epithelial-to-mesenchymal", "ANATOMY", 147, 172], ["KMF", "CHEMICAL", 18, 21], ["non\u2013small cell lung cancer", "DISEASE", 90, 116], ["NSCLC", "DISEASE", 118, 123], ["KMF", "CHEMICAL", 18, 21], ["KMF", "SIMPLE_CHEMICAL", 18, 21], ["transforming growth factor-\u03b21", "GENE_OR_GENE_PRODUCT", 37, 66], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 68, 74], ["human", "ORGANISM", 84, 89], ["non\u2013small cell lung cancer", "CANCER", 90, 116], ["NSCLC", "CANCER", 118, 123], ["A549", "CELL", 125, 129], ["epithelial", "CELL", 147, 157], ["mesenchymal", "CELL", 161, 172], ["EMT", "CELL", 174, 177], ["Akt1", "GENE_OR_GENE_PRODUCT", 207, 211], ["Smad3", "GENE_OR_GENE_PRODUCT", 221, 226], ["transforming growth factor-\u03b21", "PROTEIN", 37, 66], ["TGF-\u03b21", "PROTEIN", 68, 74], ["Akt1", "PROTEIN", 207, 211], ["Smad3", "PROTEIN", 221, 226], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["another study", "TEST", 3, 16], ["KMF", "TEST", 18, 21], ["the transforming growth factor", "TEST", 33, 63], ["TGF", "TEST", 68, 71], ["human non\u2013small cell lung cancer", "PROBLEM", 84, 116], ["NSCLC", "PROBLEM", 118, 123], ["epithelial", "TEST", 147, 157], ["Akt1", "TEST", 207, 211], ["non\u2013small cell", "OBSERVATION", 90, 104], ["lung", "ANATOMY", 105, 109], ["cancer", "OBSERVATION", 110, 116], ["NSCLC", "OBSERVATION", 118, 123], ["epithelial", "ANATOMY", 147, 157], ["mesenchymal", "ANATOMY", 161, 172]]], ["Correspondingly, Hang, Zhao, Chen, Sun, and Zhang (2015) observed the modulation of EMT-cognate proteins, including E-cadherin and vimentin in KMF-treated non-minuscule lung cancer cells (Hang et al., 2015).Anti-inflammatory effect of kaempferol ::: Therapeutic effects of kaempferolInflammation is known to be adopted by the tissues against various endogenous and exogenous pathogens.", [["non-minuscule lung cancer cells", "ANATOMY", 155, 186], ["tissues", "ANATOMY", 326, 333], ["KMF", "CHEMICAL", 143, 146], ["lung cancer", "DISEASE", 169, 180], ["kaempferol", "CHEMICAL", 235, 245], ["kaempferol", "CHEMICAL", 273, 283], ["Inflammation", "DISEASE", 283, 295], ["kaempferol", "CHEMICAL", 235, 245], ["kaempferol", "CHEMICAL", 273, 283], ["EMT", "GENE_OR_GENE_PRODUCT", 84, 87], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 116, 126], ["vimentin", "GENE_OR_GENE_PRODUCT", 131, 139], ["KMF", "SIMPLE_CHEMICAL", 143, 146], ["non-minuscule lung cancer cells", "CELL", 155, 186], ["kaempferol", "SIMPLE_CHEMICAL", 235, 245], ["kaempferol", "SIMPLE_CHEMICAL", 273, 283], ["tissues", "TISSUE", 326, 333], ["EMT", "PROTEIN", 84, 87], ["cognate proteins", "PROTEIN", 88, 104], ["E-cadherin", "PROTEIN", 116, 126], ["vimentin", "PROTEIN", 131, 139], ["KMF-treated non-minuscule lung cancer cells", "CELL_LINE", 143, 186], ["EMT-cognate proteins", "TREATMENT", 84, 104], ["E-cadherin", "TREATMENT", 116, 126], ["vimentin in KMF", "TREATMENT", 131, 146], ["non-minuscule lung cancer cells", "PROBLEM", 155, 186], ["kaempferol", "TREATMENT", 273, 283], ["Inflammation", "PROBLEM", 283, 295], ["various endogenous and exogenous pathogens", "PROBLEM", 342, 384], ["lung", "ANATOMY", 169, 173], ["cancer", "OBSERVATION", 174, 180], ["kaempferol", "OBSERVATION", 273, 283], ["known to be", "UNCERTAINTY", 299, 310], ["exogenous", "OBSERVATION_MODIFIER", 365, 374], ["pathogens", "OBSERVATION", 375, 384]]], ["However, chronic inflammation has been considered to be associated with the progression of various diseases, including cancer, arthritis, and neurodegeneration (Tuli et al., 2015, Tuli et al., 2015, Tuli et al., 2015).", [["cancer", "ANATOMY", 119, 125], ["inflammation", "DISEASE", 17, 29], ["cancer", "DISEASE", 119, 125], ["arthritis", "DISEASE", 127, 136], ["neurodegeneration", "DISEASE", 142, 159], ["cancer", "CANCER", 119, 125], ["chronic inflammation", "PROBLEM", 9, 29], ["various diseases", "PROBLEM", 91, 107], ["cancer", "PROBLEM", 119, 125], ["arthritis", "PROBLEM", 127, 136], ["neurodegeneration", "PROBLEM", 142, 159], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["inflammation", "OBSERVATION", 17, 29], ["progression", "OBSERVATION_MODIFIER", 76, 87], ["various", "OBSERVATION_MODIFIER", 91, 98], ["diseases", "OBSERVATION", 99, 107], ["cancer", "OBSERVATION", 119, 125], ["arthritis", "OBSERVATION", 127, 136]]], ["KMF has been proven to be a potent inhibitor of pro-inflammatory molecules such as inducible nitric oxide synthase (iNOS), cyclooxygenase (COX), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Kong et al., 2013a, Kong et al., 2013b, Liu et al., 2014).", [["KMF", "CHEMICAL", 0, 3], ["nitric oxide", "CHEMICAL", 93, 105], ["KMF", "CHEMICAL", 0, 3], ["nitric oxide", "CHEMICAL", 93, 105], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 83, 114], ["iNOS", "GENE_OR_GENE_PRODUCT", 116, 120], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 123, 137], ["COX", "GENE_OR_GENE_PRODUCT", 139, 142], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 145, 178], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 180, 186], ["vascular cell adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 192, 225], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 227, 233], ["KMF", "PROTEIN", 0, 3], ["pro-inflammatory molecules", "PROTEIN", 48, 74], ["nitric oxide synthase", "PROTEIN", 93, 114], ["iNOS", "PROTEIN", 116, 120], ["cyclooxygenase", "PROTEIN", 123, 137], ["COX", "PROTEIN", 139, 142], ["intercellular adhesion molecule-1 (ICAM-1", "PROTEIN", 145, 186], ["vascular cell adhesion molecule-1", "PROTEIN", 192, 225], ["VCAM", "PROTEIN", 227, 231], ["a potent inhibitor of pro-inflammatory molecules", "TREATMENT", 26, 74], ["inducible nitric oxide synthase", "TREATMENT", 83, 114], ["cyclooxygenase (COX", "TREATMENT", 123, 142], ["intercellular adhesion molecule", "TEST", 145, 176], ["ICAM", "TEST", 180, 184], ["vascular cell adhesion molecule", "TEST", 192, 223], ["VCAM", "TEST", 227, 231], ["vascular cell", "ANATOMY", 192, 205], ["adhesion molecule", "OBSERVATION", 206, 223]]], ["The anti-inflammatory mechanisms of KMF are mainly mediated (Fig. 7) by the down-regulation of several transcription factors, such as NF-\u03baB (nuclear factor kappa B) and STAT that have ability to stimulate the activation of inflammatory molecules (Hamalainen, Nieminen, Vuorela, Heinonen, & Moilanen, 2007).", [["KMF", "CHEMICAL", 36, 39], ["KMF", "CHEMICAL", 36, 39], ["KMF", "GENE_OR_GENE_PRODUCT", 36, 39], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 134, 139], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 141, 163], ["STAT", "GENE_OR_GENE_PRODUCT", 169, 173], ["Hamalainen", "SIMPLE_CHEMICAL", 247, 257], ["transcription factors", "PROTEIN", 103, 124], ["NF-\u03baB", "PROTEIN", 134, 139], ["nuclear factor kappa B", "PROTEIN", 141, 163], ["STAT", "PROTEIN", 169, 173], ["inflammatory molecules", "PROTEIN", 223, 245], ["KMF", "TEST", 36, 39], ["several transcription factors", "PROBLEM", 95, 124], ["inflammatory molecules", "PROBLEM", 223, 245], ["Hamalainen", "TREATMENT", 247, 257], ["anti-inflammatory", "OBSERVATION_MODIFIER", 4, 21], ["inflammatory", "OBSERVATION", 223, 235]]], ["Garcia-Mediavilla et al. (2007) examined the anti-inflammatory potential of KMF in the human hepatocyte-derived cell line and proved that KMF was able to reduce the expression of C-reactive protein (CRP), COX-2, and iNOS via alterations in NF-\u03baB pathway.", [["hepatocyte-derived cell line", "ANATOMY", 93, 121], ["KMF", "CHEMICAL", 76, 79], ["KMF", "CHEMICAL", 138, 141], ["KMF", "CHEMICAL", 76, 79], ["KMF", "CHEMICAL", 138, 141], ["KMF", "SIMPLE_CHEMICAL", 76, 79], ["human", "ORGANISM", 87, 92], ["hepatocyte-derived cell line", "CELL", 93, 121], ["KMF", "SIMPLE_CHEMICAL", 138, 141], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 179, 197], ["CRP", "GENE_OR_GENE_PRODUCT", 199, 202], ["COX-2", "GENE_OR_GENE_PRODUCT", 205, 210], ["iNOS", "GENE_OR_GENE_PRODUCT", 216, 220], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 240, 245], ["human hepatocyte-derived cell line", "CELL_LINE", 87, 121], ["C-reactive protein", "PROTEIN", 179, 197], ["CRP", "PROTEIN", 199, 202], ["COX-2", "PROTEIN", 205, 210], ["iNOS", "PROTEIN", 216, 220], ["NF-\u03baB", "PROTEIN", 240, 245], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["KMF", "TEST", 76, 79], ["the human hepatocyte", "TEST", 83, 103], ["KMF", "TEST", 138, 141], ["C-reactive protein", "TEST", 179, 197], ["CRP", "TEST", 199, 202], ["COX", "TEST", 205, 208], ["iNOS via alterations in NF", "PROBLEM", 216, 242], ["hepatocyte", "ANATOMY", 93, 103], ["cell line", "OBSERVATION", 112, 121]]], ["Osteopontin (OPN), a reactive oxygen species (ROS)-dependent cytokine, which engenders and activates the p38 MAPK and NF-\u03baB signaling, has been found to be down-regulated in aldosterone-induced human umbilical vein endothelial cells (HUVECs) by KMF (Liu et al., 2014).", [["human umbilical vein endothelial cells", "ANATOMY", 194, 232], ["HUVECs", "ANATOMY", 234, 240], ["oxygen", "CHEMICAL", 30, 36], ["ROS", "CHEMICAL", 46, 49], ["aldosterone", "CHEMICAL", 174, 185], ["oxygen", "CHEMICAL", 30, 36], ["aldosterone", "CHEMICAL", 174, 185], ["Osteopontin", "GENE_OR_GENE_PRODUCT", 0, 11], ["OPN", "GENE_OR_GENE_PRODUCT", 13, 16], ["reactive oxygen species", "SIMPLE_CHEMICAL", 21, 44], ["ROS", "SIMPLE_CHEMICAL", 46, 49], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 105, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 118, 123], ["aldosterone", "SIMPLE_CHEMICAL", 174, 185], ["human umbilical vein endothelial cells", "CELL", 194, 232], ["HUVECs", "CELL", 234, 240], ["Osteopontin", "PROTEIN", 0, 11], ["OPN", "PROTEIN", 13, 16], ["cytokine", "PROTEIN", 61, 69], ["p38 MAPK", "PROTEIN", 105, 113], ["NF-\u03baB", "PROTEIN", 118, 123], ["aldosterone-induced human umbilical vein endothelial cells", "CELL_LINE", 174, 232], ["HUVECs", "CELL_LINE", 234, 240], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["Osteopontin (OPN)", "PROBLEM", 0, 17], ["a reactive oxygen species", "PROBLEM", 19, 44], ["dependent cytokine", "PROBLEM", 51, 69], ["the p38 MAPK", "TEST", 101, 113], ["NF", "TEST", 118, 120], ["aldosterone", "TEST", 174, 185], ["reactive", "OBSERVATION_MODIFIER", 21, 29], ["oxygen species", "OBSERVATION", 30, 44], ["human", "ANATOMY_MODIFIER", 194, 199], ["umbilical vein", "ANATOMY", 200, 214], ["endothelial cells", "OBSERVATION", 215, 232]]], ["Comparably, KMF treatment in lipopolysaccharide (LPS)-induced macrophages revealed the consequential down-regulation of COX-2, iNOS and TNF-\u03b1 (tumour necrosis factor-\u03b1) both at transcriptional and translational levels via inhibition of NF-\u03baB and AP-1 transcription factor (Kim et al., 2015, Kim et al., 2015).", [["macrophages", "ANATOMY", 62, 73], ["KMF", "CHEMICAL", 12, 15], ["lipopolysaccharide", "CHEMICAL", 29, 47], ["LPS", "CHEMICAL", 49, 52], ["necrosis", "DISEASE", 150, 158], ["KMF", "CHEMICAL", 12, 15], ["KMF", "SIMPLE_CHEMICAL", 12, 15], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 29, 47], ["LPS", "SIMPLE_CHEMICAL", 49, 52], ["macrophages", "CELL", 62, 73], ["COX-2", "GENE_OR_GENE_PRODUCT", 120, 125], ["iNOS", "GENE_OR_GENE_PRODUCT", 127, 131], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 136, 141], ["tumour necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 143, 167], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 236, 241], ["AP-1", "GENE_OR_GENE_PRODUCT", 246, 250], ["lipopolysaccharide (LPS)-induced macrophages", "CELL_LINE", 29, 73], ["COX-2", "PROTEIN", 120, 125], ["iNOS", "PROTEIN", 127, 131], ["TNF-\u03b1", "PROTEIN", 136, 141], ["tumour necrosis factor-\u03b1", "PROTEIN", 143, 167], ["NF-\u03baB", "PROTEIN", 236, 241], ["AP-1 transcription factor", "PROTEIN", 246, 271], ["KMF treatment", "TREATMENT", 12, 25], ["lipopolysaccharide (LPS)", "TEST", 29, 53], ["macrophages", "PROBLEM", 62, 73], ["COX", "TEST", 120, 123], ["iNOS", "TEST", 127, 131], ["TNF", "TEST", 136, 139], ["tumour necrosis factor", "PROBLEM", 143, 165], ["translational levels", "TEST", 197, 217], ["NF", "TEST", 236, 238], ["AP", "TEST", 246, 248], ["TNF", "ANATOMY", 136, 139]]], ["Moreover, the protein kinase cascade mechanisms governed by Src, Syk, IRAK1, and IRAK4 that are usually involved in the activation of NF-\u03baB and AP-1 transcriptional factors can also be blocked by KMF.", [["KMF", "CHEMICAL", 196, 199], ["KMF", "CHEMICAL", 196, 199], ["Src", "GENE_OR_GENE_PRODUCT", 60, 63], ["Syk", "GENE_OR_GENE_PRODUCT", 65, 68], ["IRAK1", "GENE_OR_GENE_PRODUCT", 70, 75], ["IRAK4", "GENE_OR_GENE_PRODUCT", 81, 86], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 134, 139], ["AP-1", "GENE_OR_GENE_PRODUCT", 144, 148], ["KMF", "SIMPLE_CHEMICAL", 196, 199], ["protein kinase", "PROTEIN", 14, 28], ["Src", "PROTEIN", 60, 63], ["Syk", "PROTEIN", 65, 68], ["IRAK1", "PROTEIN", 70, 75], ["IRAK4", "PROTEIN", 81, 86], ["NF-\u03baB", "PROTEIN", 134, 139], ["AP-1 transcriptional factors", "PROTEIN", 144, 172], ["KMF", "PROTEIN", 196, 199], ["the protein kinase cascade mechanisms", "PROBLEM", 10, 47], ["IRAK4", "TREATMENT", 81, 86]]], ["The docking studies have substantiated the homogeneous binding energies of KMF as that of MG-132 which is considered to be a potent NF-\u03baB inhibitor (Kadioglu, Nass, Saeed, Schuler, & Efferth, 2015).", [["KMF", "CHEMICAL", 75, 78], ["MG-132", "CHEMICAL", 90, 96], ["KMF", "CHEMICAL", 75, 78], ["MG-132", "CHEMICAL", 90, 96], ["KMF", "SIMPLE_CHEMICAL", 75, 78], ["MG-132", "SIMPLE_CHEMICAL", 90, 96], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 132, 137], ["The docking studies", "TEST", 0, 19], ["MG", "TEST", 90, 92]]], ["Therefore, evidences are suggesting that KMF may have great potential as an anti-inflammatory drug and could be introduced for in vivo trial.Antioxidant properties of kaempferol ::: Therapeutic effects of kaempferolReactive Oxygen Species (ROS) generated by enzymatic reactions during metabolism are the major source of harmful oxidative stress (Adegoke and Forbes, 2015, Hazra et al., 2004).", [["KMF", "CHEMICAL", 41, 44], ["kaempferol", "CHEMICAL", 167, 177], ["kaempferol", "CHEMICAL", 205, 215], ["ROS", "CHEMICAL", 240, 243], ["KMF", "CHEMICAL", 41, 44], ["kaempferol", "CHEMICAL", 167, 177], ["kaempferol", "CHEMICAL", 205, 215], ["Oxygen", "CHEMICAL", 224, 230], ["KMF", "SIMPLE_CHEMICAL", 41, 44], ["kaempferol", "SIMPLE_CHEMICAL", 167, 177], ["kaempferol", "SIMPLE_CHEMICAL", 205, 215], ["Reactive Oxygen Species", "SIMPLE_CHEMICAL", 215, 238], ["ROS", "SIMPLE_CHEMICAL", 240, 243], ["an anti-inflammatory drug", "TREATMENT", 73, 98], ["kaempferol", "TREATMENT", 205, 215], ["Reactive Oxygen Species", "PROBLEM", 215, 238], ["enzymatic reactions", "PROBLEM", 258, 277], ["harmful oxidative stress", "PROBLEM", 320, 344], ["anti-inflammatory drug", "OBSERVATION", 76, 98], ["kaempferol", "OBSERVATION", 205, 215], ["Oxygen Species", "OBSERVATION", 224, 238]]], ["Although human body has antioxidant enzymes as a defenses mechanism that constantly neutralizes the ROS, the excess concentrations of ROS become fatal and cause cellular dysfunction, oxygen toxicity, senescent, stroke, autoimmune diseases, cancer, Parkinson\u2019s disease, infection and arteriosclerosis (Adegoke and Forbes, 2015, Melo et al., 2015).", [["body", "ANATOMY", 15, 19], ["cellular", "ANATOMY", 161, 169], ["cancer", "ANATOMY", 240, 246], ["ROS", "CHEMICAL", 100, 103], ["ROS", "CHEMICAL", 134, 137], ["oxygen", "CHEMICAL", 183, 189], ["toxicity", "DISEASE", 190, 198], ["stroke", "DISEASE", 211, 217], ["autoimmune diseases", "DISEASE", 219, 238], ["cancer", "DISEASE", 240, 246], ["Parkinson\u2019s disease", "DISEASE", 248, 267], ["infection", "DISEASE", 269, 278], ["arteriosclerosis", "DISEASE", 283, 299], ["oxygen", "CHEMICAL", 183, 189], ["human", "ORGANISM", 9, 14], ["body", "ORGANISM_SUBDIVISION", 15, 19], ["ROS", "SIMPLE_CHEMICAL", 100, 103], ["ROS", "SIMPLE_CHEMICAL", 134, 137], ["cellular", "CELL", 161, 169], ["oxygen", "SIMPLE_CHEMICAL", 183, 189], ["cancer", "CANCER", 240, 246], ["antioxidant enzymes", "PROTEIN", 24, 43], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["antioxidant enzymes", "TEST", 24, 43], ["the excess concentrations of ROS", "PROBLEM", 105, 137], ["cellular dysfunction", "PROBLEM", 161, 181], ["oxygen toxicity", "PROBLEM", 183, 198], ["stroke", "PROBLEM", 211, 217], ["autoimmune diseases", "PROBLEM", 219, 238], ["cancer", "PROBLEM", 240, 246], ["Parkinson\u2019s disease", "PROBLEM", 248, 267], ["infection", "PROBLEM", 269, 278], ["arteriosclerosis", "PROBLEM", 283, 299], ["cellular dysfunction", "OBSERVATION", 161, 181], ["oxygen toxicity", "OBSERVATION", 183, 198], ["autoimmune diseases", "OBSERVATION", 219, 238], ["cancer", "OBSERVATION", 240, 246], ["infection", "OBSERVATION", 269, 278], ["arteriosclerosis", "OBSERVATION", 283, 299]]], ["Studies have been performed using various funtional foods with antioxidant agents that may be availed to dispense ROS (Gao and Yang, 1999, Kim et al., 2003).", [["ROS", "CHEMICAL", 114, 117], ["ROS", "SIMPLE_CHEMICAL", 114, 117], ["Studies", "TEST", 0, 7], ["various funtional foods", "TREATMENT", 34, 57], ["antioxidant agents", "TREATMENT", 63, 81]]], ["These results showed that flavonols could be effective secondary metabolites against oxidative stress (Yoshida et al., 2008).", [["flavonols", "CHEMICAL", 26, 35], ["flavonols", "CHEMICAL", 26, 35], ["flavonols", "SIMPLE_CHEMICAL", 26, 35], ["flavonols", "TREATMENT", 26, 35], ["oxidative stress", "PROBLEM", 85, 101]]], ["KMF directly scavenges peroxynitrite (reactive nitrogen species) and hydroxyl radicals at low concentration whereas at high concentrations it enhances the expression of antioxidant enzymes (Calderon-Montano et al., 2011).", [["KMF", "CHEMICAL", 0, 3], ["peroxynitrite", "CHEMICAL", 23, 36], ["reactive nitrogen", "CHEMICAL", 38, 55], ["hydroxyl", "CHEMICAL", 69, 77], ["KMF", "CHEMICAL", 0, 3], ["peroxynitrite", "CHEMICAL", 23, 36], ["nitrogen", "CHEMICAL", 47, 55], ["hydroxyl", "CHEMICAL", 69, 77], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["peroxynitrite", "SIMPLE_CHEMICAL", 23, 36], ["reactive nitrogen species", "SIMPLE_CHEMICAL", 38, 63], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 69, 86], ["antioxidant enzymes", "PROTEIN", 169, 188], ["scavenges peroxynitrite", "TREATMENT", 13, 36], ["reactive nitrogen species", "TREATMENT", 38, 63], ["hydroxyl radicals at low concentration", "TREATMENT", 69, 107], ["antioxidant enzymes", "TEST", 169, 188], ["scavenges peroxynitrite", "OBSERVATION", 13, 36]]], ["The proposed mechanisms of action of KMF as a potent antioxidant have been reported to be associated with its up-regulatory effect on antioxidant response elements (ARE)-mediated antioxidative enzymes (Fig. 8), such as heme oxygenase, catalase and superoxide dismutases (SODs) under the control of Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathways (Saw et al., 2014).", [["KMF", "CHEMICAL", 37, 40], ["superoxide", "CHEMICAL", 248, 258], ["KMF", "CHEMICAL", 37, 40], ["heme", "CHEMICAL", 219, 223], ["superoxide", "CHEMICAL", 248, 258], ["KMF", "SIMPLE_CHEMICAL", 37, 40], ["Fig. 8", "GENE_OR_GENE_PRODUCT", 202, 208], ["heme oxygenase", "GENE_OR_GENE_PRODUCT", 219, 233], ["catalase", "SIMPLE_CHEMICAL", 235, 243], ["superoxide dismutases", "GENE_OR_GENE_PRODUCT", 248, 269], ["SODs", "GENE_OR_GENE_PRODUCT", 271, 275], ["Nuclear factor (erythroid-derived 2)-like 2", "GENE_OR_GENE_PRODUCT", 298, 341], ["Nrf2", "GENE_OR_GENE_PRODUCT", 343, 347], ["antioxidant response elements", "DNA", 134, 163], ["ARE", "DNA", 165, 168], ["antioxidative enzymes", "PROTEIN", 179, 200], ["Fig. 8", "PROTEIN", 202, 208], ["heme oxygenase", "PROTEIN", 219, 233], ["catalase", "PROTEIN", 235, 243], ["superoxide dismutases", "PROTEIN", 248, 269], ["SODs", "PROTEIN", 271, 275], ["Nrf2", "PROTEIN", 343, 347], ["KMF", "TREATMENT", 37, 40], ["antioxidant response elements", "TREATMENT", 134, 163], ["antioxidative enzymes", "TEST", 179, 200], ["heme oxygenase", "TREATMENT", 219, 233], ["catalase and superoxide dismutases", "TREATMENT", 235, 269], ["Nuclear factor", "PROBLEM", 298, 312]]], ["KMF can also be utilized in the inhibition of platelet aggregation and LDL (Low-Density Lipoprotein) oxidative susceptibility (Kowalski, Samojedny, Paul, Pietsz, & Wilczok, 2005).", [["platelet", "ANATOMY", 46, 54], ["KMF", "CHEMICAL", 0, 3], ["platelet aggregation", "DISEASE", 46, 66], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["platelet", "CELL", 46, 54], ["LDL", "SIMPLE_CHEMICAL", 71, 74], ["platelet", "CELL_TYPE", 46, 54], ["LDL", "PROTEIN", 71, 74], ["platelet aggregation", "TEST", 46, 66], ["LDL", "TEST", 71, 74], ["platelet aggregation", "OBSERVATION", 46, 66]]], ["Choe et al. (2012) extracted and purified KMF from the roots of Rhodiola sachalinensis and anticipated its antioxidant potential (Choe et al., 2012).", [["roots", "ANATOMY", 55, 60], ["KMF", "CHEMICAL", 42, 45], ["KMF", "GENE_OR_GENE_PRODUCT", 42, 45], ["roots", "ORGAN", 55, 60], ["Rhodiola sachalinensis", "ORGANISM", 64, 86], ["KMF", "PROTEIN", 42, 45], ["Rhodiola sachalinensis", "SPECIES", 64, 86], ["Rhodiola sachalinensis", "SPECIES", 64, 86], ["Rhodiola sachalinensis", "PROBLEM", 64, 86], ["Rhodiola sachalinensis", "OBSERVATION", 64, 86]]], ["Similarly, Wahab et al. (2014) extracted KMF from the beans of Cassia alata to study its antioxidant properties.", [["KMF", "CHEMICAL", 41, 44], ["KMF", "GENE_OR_GENE_PRODUCT", 41, 44], ["beans", "ORGANISM_SUBDIVISION", 54, 59], ["Cassia alata", "ORGANISM", 63, 75], ["Cassia alata", "SPECIES", 63, 75], ["Cassia alata", "SPECIES", 63, 75]]], ["KMF has additionally been found to bulwark myocardial ischemia/reperfusion (I/R) injury in rats by incrementing the calibers of SOD and decrementing the activity of P-GSK-3\u03b2 (Zhou et al., 2015).", [["myocardial", "ANATOMY", 43, 53], ["KMF", "CHEMICAL", 0, 3], ["myocardial ischemia", "DISEASE", 43, 62], ["KMF", "CHEMICAL", 0, 3], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["myocardial", "MULTI-TISSUE_STRUCTURE", 43, 53], ["rats", "ORGANISM", 91, 95], ["SOD", "GENE_OR_GENE_PRODUCT", 128, 131], ["GSK-3\u03b2", "GENE_OR_GENE_PRODUCT", 167, 173], ["SOD", "PROTEIN", 128, 131], ["rats", "SPECIES", 91, 95], ["myocardial ischemia", "PROBLEM", 43, 62], ["reperfusion (I/R) injury in rats", "PROBLEM", 63, 95], ["SOD", "PROBLEM", 128, 131], ["myocardial", "ANATOMY", 43, 53], ["ischemia", "OBSERVATION", 54, 62], ["reperfusion", "OBSERVATION", 63, 74], ["calibers", "OBSERVATION_MODIFIER", 116, 124]]], ["In a study, utilizing 1,2-dimethyl hydrazine induced male Wistar rats, Nirmala and Ramanathan (2011) investigated that KMF treatment not only lowered down the erythrocyte lysate and thiobarbituric acid reactive substances (TBARS) but additionally up-regulated the antioxidant enzymes, including catalase, SOD, and glutathione peroxidase (Gpx) levels (Nirmala & Ramanathan, 2011).", [["erythrocyte lysate", "ANATOMY", 159, 177], ["1,2-dimethyl hydrazine", "CHEMICAL", 22, 44], ["KMF", "CHEMICAL", 119, 122], ["thiobarbituric acid", "CHEMICAL", 182, 201], ["TBARS", "CHEMICAL", 223, 228], ["glutathione", "CHEMICAL", 314, 325], ["1,2-dimethyl hydrazine", "CHEMICAL", 22, 44], ["KMF", "CHEMICAL", 119, 122], ["thiobarbituric acid", "CHEMICAL", 182, 201], ["glutathione", "CHEMICAL", 314, 325], ["1,2-dimethyl hydrazine", "SIMPLE_CHEMICAL", 22, 44], ["Wistar rats", "ORGANISM", 58, 69], ["KMF", "SIMPLE_CHEMICAL", 119, 122], ["erythrocyte", "CELL", 159, 170], ["thiobarbituric acid reactive substances", "SIMPLE_CHEMICAL", 182, 221], ["TBARS", "SIMPLE_CHEMICAL", 223, 228], ["catalase", "SIMPLE_CHEMICAL", 295, 303], ["SOD", "SIMPLE_CHEMICAL", 305, 308], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 314, 336], ["Gpx", "SIMPLE_CHEMICAL", 338, 341], ["antioxidant enzymes", "PROTEIN", 264, 283], ["catalase", "PROTEIN", 295, 303], ["SOD", "PROTEIN", 305, 308], ["glutathione peroxidase", "PROTEIN", 314, 336], ["Gpx", "PROTEIN", 338, 341], ["rats", "SPECIES", 65, 69], ["a study", "TEST", 3, 10], ["1,2-dimethyl hydrazine", "TREATMENT", 22, 44], ["KMF treatment", "TREATMENT", 119, 132], ["the erythrocyte lysate", "TEST", 155, 177], ["thiobarbituric acid reactive substances", "PROBLEM", 182, 221], ["the antioxidant enzymes", "TEST", 260, 283], ["catalase", "TEST", 295, 303], ["SOD", "TEST", 305, 308], ["glutathione peroxidase", "TEST", 314, 336]]], ["Likewise, hepatoprotective effect of KMF glycosides has been investigated against carbon tetrachloride-induced liver injuries in mice by uplifting the oxidative stress scavenging potential (Wang et al., 2015, Wang et al., 2015).", [["liver", "ANATOMY", 111, 116], ["KMF glycosides", "CHEMICAL", 37, 51], ["carbon tetrachloride", "CHEMICAL", 82, 102], ["liver injuries", "DISEASE", 111, 125], ["KMF glycosides", "CHEMICAL", 37, 51], ["carbon tetrachloride", "CHEMICAL", 82, 102], ["KMF glycosides", "SIMPLE_CHEMICAL", 37, 51], ["carbon tetrachloride", "SIMPLE_CHEMICAL", 82, 102], ["liver", "ORGAN", 111, 116], ["mice", "ORGANISM", 129, 133], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["KMF glycosides", "TREATMENT", 37, 51], ["carbon tetrachloride", "TREATMENT", 82, 102], ["induced liver injuries", "PROBLEM", 103, 125], ["liver", "ANATOMY", 111, 116], ["injuries", "OBSERVATION", 117, 125]]], ["In osteoblast-like MC3T3-E1 cells, KMF inverted the antimycin A (AMA)-induced toxicity by averting the disruption of mitochondrial membrane potential and accumulation of intracellular calcium ions and ROS via P(I)3K-Akt-CREB pathway (Choi, 2011).Synergistic and other therapeutic effects of kaempferol ::: Therapeutic effects of kaempferolData about phytochemicals have proved that the synergistic properties of different flavonoids may not only be utilized to enhance the potential of chemotherapeutic drugs, but also to reduce the ineluctable side effects (Kumar et al., 2015; Tuli et al., 2015, Tuli et al., 2013).", [["osteoblast-like MC3T3-E1 cells", "ANATOMY", 3, 33], ["mitochondrial membrane", "ANATOMY", 117, 139], ["intracellular", "ANATOMY", 170, 183], ["antimycin A", "CHEMICAL", 52, 63], ["AMA", "CHEMICAL", 65, 68], ["toxicity", "DISEASE", 78, 86], ["calcium", "CHEMICAL", 184, 191], ["ROS", "CHEMICAL", 201, 204], ["kaempferol", "CHEMICAL", 291, 301], ["kaempferol", "CHEMICAL", 329, 339], ["flavonoids", "CHEMICAL", 422, 432], ["antimycin A", "CHEMICAL", 52, 63], ["AMA", "CHEMICAL", 65, 68], ["calcium", "CHEMICAL", 184, 191], ["kaempferol", "CHEMICAL", 291, 301], ["kaempferol", "CHEMICAL", 329, 339], ["flavonoids", "CHEMICAL", 422, 432], ["osteoblast-like MC3T3-E1 cells", "CELL", 3, 33], ["KMF", "SIMPLE_CHEMICAL", 35, 38], ["antimycin A", "SIMPLE_CHEMICAL", 52, 63], ["AMA", "SIMPLE_CHEMICAL", 65, 68], ["mitochondrial membrane", "CELLULAR_COMPONENT", 117, 139], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 170, 183], ["calcium", "SIMPLE_CHEMICAL", 184, 191], ["ROS", "SIMPLE_CHEMICAL", 201, 204], ["P(I)3K", "GENE_OR_GENE_PRODUCT", 209, 215], ["Akt", "GENE_OR_GENE_PRODUCT", 216, 219], ["CREB", "GENE_OR_GENE_PRODUCT", 220, 224], ["kaempferol", "SIMPLE_CHEMICAL", 291, 301], ["kaempferol", "SIMPLE_CHEMICAL", 329, 339], ["flavonoids", "SIMPLE_CHEMICAL", 422, 432], ["osteoblast-like MC3T3-E1 cells", "CELL_LINE", 3, 33], ["P(I)3K", "PROTEIN", 209, 215], ["Akt", "PROTEIN", 216, 219], ["CREB", "PROTEIN", 220, 224], ["osteoblast", "TEST", 3, 13], ["KMF", "TEST", 35, 38], ["the antimycin A (AMA)", "TREATMENT", 48, 69], ["induced toxicity", "PROBLEM", 70, 86], ["mitochondrial membrane potential", "PROBLEM", 117, 149], ["intracellular calcium ions", "TEST", 170, 196], ["kaempferol", "TREATMENT", 291, 301], ["kaempferolData", "TREATMENT", 329, 343], ["phytochemicals", "TREATMENT", 350, 364], ["different flavonoids", "TREATMENT", 412, 432], ["chemotherapeutic drugs", "TREATMENT", 486, 508], ["the ineluctable side effects", "PROBLEM", 529, 557], ["osteoblast", "ANATOMY", 3, 13], ["E1 cells", "OBSERVATION_MODIFIER", 25, 33], ["mitochondrial membrane", "OBSERVATION", 117, 139]]], ["In this scenario, KMF could act as a promising molecule to boost the therapeutic potential of the chemotherapy by refining the pharmacokinetics as well as by subsisting side effects of the therapy.", [["KMF", "CHEMICAL", 18, 21], ["KMF", "CHEMICAL", 18, 21], ["KMF", "SIMPLE_CHEMICAL", 18, 21], ["the chemotherapy", "TREATMENT", 94, 110], ["the therapy", "TREATMENT", 185, 196]]], ["A coalescence of quercetin, kaempferol and naringenin was found to be significantly more efficacious antiproliferative agent against mouse liver cancer cells Hepa-1c1c7 and human prostate cancer cells LNCaP (Campbell, King, Harmston, Lila, & Erdman, 2006).", [["liver cancer cells Hepa-1c1c7", "ANATOMY", 139, 168], ["prostate cancer cells LNCaP", "ANATOMY", 179, 206], ["quercetin", "CHEMICAL", 17, 26], ["kaempferol", "CHEMICAL", 28, 38], ["naringenin", "CHEMICAL", 43, 53], ["liver cancer", "DISEASE", 139, 151], ["prostate cancer", "DISEASE", 179, 194], ["quercetin", "CHEMICAL", 17, 26], ["kaempferol", "CHEMICAL", 28, 38], ["naringenin", "CHEMICAL", 43, 53], ["quercetin", "SIMPLE_CHEMICAL", 17, 26], ["kaempferol", "SIMPLE_CHEMICAL", 28, 38], ["naringenin", "SIMPLE_CHEMICAL", 43, 53], ["mouse", "ORGANISM", 133, 138], ["liver cancer cells Hepa-1c1c7", "CELL", 139, 168], ["human", "ORGANISM", 173, 178], ["prostate cancer cells LNCaP", "CELL", 179, 206], ["mouse liver cancer cells", "CELL_LINE", 133, 157], ["Hepa-1c1c7", "CELL_LINE", 158, 168], ["human prostate cancer cells", "CELL_TYPE", 173, 200], ["mouse", "SPECIES", 133, 138], ["human", "SPECIES", 173, 178], ["mouse", "SPECIES", 133, 138], ["human", "SPECIES", 173, 178], ["quercetin", "TREATMENT", 17, 26], ["kaempferol", "TREATMENT", 28, 38], ["naringenin", "TREATMENT", 43, 53], ["mouse liver cancer", "PROBLEM", 133, 151], ["Hepa", "TEST", 158, 162], ["human prostate cancer", "PROBLEM", 173, 194], ["LNCaP", "TEST", 201, 206], ["coalescence", "OBSERVATION_MODIFIER", 2, 13], ["liver", "ANATOMY", 139, 144], ["cancer", "OBSERVATION", 145, 151], ["prostate", "ANATOMY", 179, 187], ["cancer", "OBSERVATION", 188, 194]]], ["In a study utilizing male SD rat models, Xu, Yang, Zheng, Zhu, and Zhu (2006) observed that KMF improves the pharmacokinetics of nifedipine by reducing the drug metabolic processes (Xu et al., 2006).", [["KMF", "CHEMICAL", 92, 95], ["nifedipine", "CHEMICAL", 129, 139], ["KMF", "CHEMICAL", 92, 95], ["nifedipine", "CHEMICAL", 129, 139], ["rat", "ORGANISM", 29, 32], ["KMF", "SIMPLE_CHEMICAL", 92, 95], ["nifedipine", "SIMPLE_CHEMICAL", 129, 139], ["rat", "SPECIES", 29, 32], ["a study", "TEST", 3, 10], ["nifedipine", "TREATMENT", 129, 139]]], ["Similarly, the pharmacokinetics of tamoxifen has also been found to be altered by KMF via inhibition of drug metabolizing enzymes, including CYP3A (Piao, Shin, & Choi, 2008).", [["tamoxifen", "CHEMICAL", 35, 44], ["KMF", "CHEMICAL", 82, 85], ["tamoxifen", "CHEMICAL", 35, 44], ["KMF", "CHEMICAL", 82, 85], ["tamoxifen", "SIMPLE_CHEMICAL", 35, 44], ["KMF", "SIMPLE_CHEMICAL", 82, 85], ["CYP3A", "GENE_OR_GENE_PRODUCT", 141, 146], ["drug metabolizing enzymes", "PROTEIN", 104, 129], ["CYP3A", "PROTEIN", 141, 146], ["tamoxifen", "TREATMENT", 35, 44], ["drug metabolizing enzymes", "TEST", 104, 129], ["CYP3A", "TEST", 141, 146], ["Shin", "ANATOMY", 154, 158]]], ["Besides inhibiting the activity of phase I CYPs enzymes, KMF additionally works as an inhibitor of multidrug resistance protein 1 (MDR1) or P-glycoproteins when co-administrated with etoposide and quercetin in rats and in human leukemic cells K562/A, respectively (Li et al., 2009, Yanqiu et al., 2013).", [["leukemic cells K562/A", "ANATOMY", 228, 249], ["KMF", "CHEMICAL", 57, 60], ["etoposide", "CHEMICAL", 183, 192], ["quercetin", "CHEMICAL", 197, 206], ["KMF", "CHEMICAL", 57, 60], ["etoposide", "CHEMICAL", 183, 192], ["quercetin", "CHEMICAL", 197, 206], ["phase I CYPs", "GENE_OR_GENE_PRODUCT", 35, 47], ["KMF", "SIMPLE_CHEMICAL", 57, 60], ["multidrug resistance protein 1", "GENE_OR_GENE_PRODUCT", 99, 129], ["MDR1", "GENE_OR_GENE_PRODUCT", 131, 135], ["etoposide", "SIMPLE_CHEMICAL", 183, 192], ["quercetin", "SIMPLE_CHEMICAL", 197, 206], ["rats", "ORGANISM", 210, 214], ["human", "ORGANISM", 222, 227], ["leukemic cells K562/A", "CELL", 228, 249], ["phase I CYPs enzymes", "PROTEIN", 35, 55], ["multidrug resistance protein 1", "PROTEIN", 99, 129], ["MDR1", "PROTEIN", 131, 135], ["P-glycoproteins", "PROTEIN", 140, 155], ["human leukemic cells", "CELL_TYPE", 222, 242], ["K562/A", "CELL_LINE", 243, 249], ["rats", "SPECIES", 210, 214], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 222, 227], ["CYPs enzymes", "TEST", 43, 55], ["multidrug resistance protein", "PROBLEM", 99, 127], ["P-glycoproteins", "TREATMENT", 140, 155], ["etoposide", "TREATMENT", 183, 192], ["quercetin", "TREATMENT", 197, 206], ["leukemic cells", "OBSERVATION", 228, 242]]], ["The neuroprotective effects of quercetin, KMF and biapigenin have been investigated against kainate and N-methyl-D-aspartate-induced neuronal cell death by Silva, Oliveira, Dias, and Malva (2008).", [["neuronal cell", "ANATOMY", 133, 146], ["quercetin", "CHEMICAL", 31, 40], ["KMF", "CHEMICAL", 42, 45], ["biapigenin", "CHEMICAL", 50, 60], ["kainate", "CHEMICAL", 92, 99], ["N-methyl-D-aspartate", "CHEMICAL", 104, 124], ["neuronal cell death", "DISEASE", 133, 152], ["quercetin", "CHEMICAL", 31, 40], ["KMF", "CHEMICAL", 42, 45], ["biapigenin", "CHEMICAL", 50, 60], ["kainate", "CHEMICAL", 92, 99], ["N-methyl-D-aspartate", "CHEMICAL", 104, 124], ["quercetin", "SIMPLE_CHEMICAL", 31, 40], ["KMF", "SIMPLE_CHEMICAL", 42, 45], ["biapigenin", "SIMPLE_CHEMICAL", 50, 60], ["kainate", "SIMPLE_CHEMICAL", 92, 99], ["N-methyl-D-aspartate", "SIMPLE_CHEMICAL", 104, 124], ["neuronal cell", "CELL", 133, 146], ["quercetin", "TREATMENT", 31, 40], ["KMF", "TEST", 42, 45], ["biapigenin", "TREATMENT", 50, 60], ["kainate", "TEST", 92, 99], ["neuronal cell death", "PROBLEM", 133, 152], ["neuronal cell death", "OBSERVATION", 133, 152]]], ["Utilizing ovarian cancer cell lines, Luo et al. investigated that KMF intensified the apoptotic effect of cisplatin by significantly down-regulating c-myc gene expression (Luo, Daddysman, Rankin, Jiang, & Chen, 2010).", [["ovarian cancer cell lines", "ANATOMY", 10, 35], ["ovarian cancer", "DISEASE", 10, 24], ["KMF", "CHEMICAL", 66, 69], ["cisplatin", "CHEMICAL", 106, 115], ["KMF", "CHEMICAL", 66, 69], ["cisplatin", "CHEMICAL", 106, 115], ["ovarian cancer cell lines", "CELL", 10, 35], ["KMF", "SIMPLE_CHEMICAL", 66, 69], ["cisplatin", "SIMPLE_CHEMICAL", 106, 115], ["c-myc", "GENE_OR_GENE_PRODUCT", 149, 154], ["ovarian cancer cell lines", "CELL_LINE", 10, 35], ["c-myc gene", "DNA", 149, 159], ["ovarian cancer cell lines", "TREATMENT", 10, 35], ["cisplatin", "TREATMENT", 106, 115], ["ovarian", "ANATOMY", 10, 17], ["cancer", "OBSERVATION", 18, 24], ["cell lines", "OBSERVATION", 25, 35], ["Luo et al", "OBSERVATION", 37, 46]]], ["Thus, drug combinations could co-act and potentiate the control of intricate biological disorders.", [["drug combinations", "TREATMENT", 6, 23], ["intricate biological disorders", "PROBLEM", 67, 97]]], ["Besides governing these promising pharmacological effects, KMF has additionally been known to promote other organ protective effects as summarized in Table 2.Absorption, metabolism and bioavailability of kaempferolAlthough countless physiologically important functions of KMF have been described, poor bioavailability restricts its further clinical applications.Absorption, metabolism and bioavailability of kaempferolFlavonols are naturally dynamic polyphenolic compounds that are found in plants and plant-inferred nourishments of human diet.", [["organ", "ANATOMY", 108, 113], ["KMF", "CHEMICAL", 59, 62], ["kaempferol", "CHEMICAL", 204, 214], ["kaempferol", "CHEMICAL", 408, 418], ["Flavonols", "CHEMICAL", 418, 427], ["KMF", "CHEMICAL", 59, 62], ["kaempferol", "CHEMICAL", 204, 214], ["KMF", "CHEMICAL", 272, 275], ["kaempferol", "CHEMICAL", 408, 418], ["Flavonols", "CHEMICAL", 418, 427], ["polyphenolic", "CHEMICAL", 450, 462], ["KMF", "SIMPLE_CHEMICAL", 59, 62], ["organ", "ORGAN", 108, 113], ["kaempferol", "SIMPLE_CHEMICAL", 204, 214], ["KMF", "GENE_OR_GENE_PRODUCT", 272, 275], ["kaempferol", "SIMPLE_CHEMICAL", 408, 418], ["Flavonols", "SIMPLE_CHEMICAL", 418, 427], ["human", "ORGANISM", 533, 538], ["KMF", "PROTEIN", 272, 275], ["human", "SPECIES", 533, 538], ["human", "SPECIES", 533, 538], ["kaempferol", "TREATMENT", 204, 214], ["KMF", "TEST", 272, 275], ["kaempferol", "TREATMENT", 408, 418], ["Flavonols", "TREATMENT", 418, 427], ["naturally dynamic polyphenolic compounds", "PROBLEM", 432, 472], ["dynamic", "OBSERVATION_MODIFIER", 442, 449], ["polyphenolic compounds", "OBSERVATION", 450, 472]]], ["Their absorption as well as bioavailability in the blood is found to influence their ability to impact the cellular health.", [["blood", "ANATOMY", 51, 56], ["cellular", "ANATOMY", 107, 115], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["cellular", "CELL", 107, 115], ["the blood", "TEST", 47, 56]]], ["After intake, flavonoids undergo to metabolic processes as results of which they are enzymatically conjugated with sulphate, methyl or glycuronyl moieties.Absorption, metabolism and bioavailability of kaempferolDifferent methodologies, including estimation of dietary intake, determination of plasma or urinary level, have been used to study the absorption and bioavailability potential of flavonoids.", [["plasma", "ANATOMY", 293, 299], ["urinary", "ANATOMY", 303, 310], ["flavonoids", "CHEMICAL", 14, 24], ["sulphate", "CHEMICAL", 115, 123], ["methyl", "CHEMICAL", 125, 131], ["glycuronyl", "CHEMICAL", 135, 145], ["kaempferol", "CHEMICAL", 201, 211], ["flavonoids", "CHEMICAL", 390, 400], ["flavonoids", "CHEMICAL", 14, 24], ["sulphate", "CHEMICAL", 115, 123], ["methyl", "CHEMICAL", 125, 131], ["glycuronyl", "CHEMICAL", 135, 145], ["kaempferol", "CHEMICAL", 201, 211], ["flavonoids", "CHEMICAL", 390, 400], ["flavonoids", "SIMPLE_CHEMICAL", 14, 24], ["sulphate", "SIMPLE_CHEMICAL", 115, 123], ["methyl", "SIMPLE_CHEMICAL", 125, 131], ["glycuronyl moieties", "SIMPLE_CHEMICAL", 135, 154], ["kaempferol", "SIMPLE_CHEMICAL", 201, 211], ["plasma", "ORGANISM_SUBSTANCE", 293, 299], ["urinary", "ORGANISM_SUBSTANCE", 303, 310], ["flavonoids", "SIMPLE_CHEMICAL", 390, 400], ["flavonoids", "TREATMENT", 14, 24], ["sulphate", "TREATMENT", 115, 123], ["methyl or glycuronyl moieties", "TREATMENT", 125, 154], ["kaempferol", "TREATMENT", 201, 211], ["plasma or urinary level", "TEST", 293, 316], ["flavonoids", "PROBLEM", 390, 400], ["urinary", "ANATOMY", 303, 310], ["flavonoids", "OBSERVATION", 390, 400]]], ["In the USA and Netherlands, KMF gives an important contribution to the daily consumption of flavonoids (25\u201333%), with a mean intake of 6\u201310 mg/day (Hertog et al., 1993, Sampson et al., 2002).", [["KMF", "CHEMICAL", 28, 31], ["flavonoids", "CHEMICAL", 92, 102], ["flavonoids", "CHEMICAL", 92, 102], ["flavonoids", "SIMPLE_CHEMICAL", 92, 102], ["flavonoids", "TREATMENT", 92, 102]]], ["Though, studies have been done concerning the assimilation of other flavonoids, like quercetin, the data on the bioavailability of KMF has still remained to elucidate.", [["quercetin", "CHEMICAL", 85, 94], ["KMF", "CHEMICAL", 131, 134], ["flavonoids", "CHEMICAL", 68, 78], ["quercetin", "CHEMICAL", 85, 94], ["flavonoids", "SIMPLE_CHEMICAL", 68, 78], ["quercetin", "SIMPLE_CHEMICAL", 85, 94], ["KMF", "SIMPLE_CHEMICAL", 131, 134], ["studies", "TEST", 8, 15], ["other flavonoids", "PROBLEM", 62, 78], ["quercetin", "TREATMENT", 85, 94], ["the bioavailability of KMF", "TEST", 108, 134], ["flavonoids", "OBSERVATION", 68, 78]]], ["DeVries et al. (1998), conducted a 7-days study by utilizing tea and onions-based diet in a group of volunteers to quantify the concentrations of KMF in plasma and urine (DeVries et al., 1998).", [["tea", "ANATOMY", 61, 64], ["plasma", "ANATOMY", 153, 159], ["urine", "ANATOMY", 164, 169], ["KMF", "CHEMICAL", 146, 149], ["KMF", "CHEMICAL", 146, 149], ["tea", "ORGANISM_SUBDIVISION", 61, 64], ["volunteers", "ORGANISM", 101, 111], ["KMF", "SIMPLE_CHEMICAL", 146, 149], ["plasma", "ORGANISM_SUBSTANCE", 153, 159], ["urine", "ORGANISM_SUBSTANCE", 164, 169], ["KMF in plasma and urine", "TEST", 146, 169]]], ["Their results revealed that KMF was excreted in about 2.5% of its consumed quantity which was higher than for quercetin (0.5%) after 4 h of dose ingestion.", [["KMF", "CHEMICAL", 28, 31], ["quercetin", "CHEMICAL", 110, 119], ["KMF", "CHEMICAL", 28, 31], ["quercetin", "CHEMICAL", 110, 119], ["KMF", "SIMPLE_CHEMICAL", 28, 31], ["quercetin", "SIMPLE_CHEMICAL", 110, 119], ["KMF", "TEST", 28, 31], ["quercetin", "TREATMENT", 110, 119]]], ["Similarly, using healthy humans as subject models, DuPont, Day, Bennett, Mellon, and Kroon (2004) have also reported the similar concentration (0.05 mM) of KMF in plasma after 4 h of intake of endive-based diet, containing up to 246 mg of KMF per kg (DuPont et al., 2004).", [["plasma", "ANATOMY", 163, 169], ["KMF", "CHEMICAL", 156, 159], ["KMF", "CHEMICAL", 156, 159], ["KMF", "CHEMICAL", 239, 242], ["humans", "ORGANISM", 25, 31], ["KMF", "SIMPLE_CHEMICAL", 156, 159], ["plasma", "ORGANISM_SUBSTANCE", 163, 169], ["humans", "SPECIES", 25, 31], ["humans", "SPECIES", 25, 31], ["endive-based diet", "TREATMENT", 193, 210]]], ["In another study, researchers observed the KMF excrete about 0.9% of the total consumed flavonoids from broccoli (Nielsen, Kall, Justesen, Schou, & Dragsted, 1997).", [["KMF", "CHEMICAL", 43, 46], ["flavonoids", "CHEMICAL", 88, 98], ["flavonoids", "CHEMICAL", 88, 98], ["KMF", "SIMPLE_CHEMICAL", 43, 46], ["flavonoids", "SIMPLE_CHEMICAL", 88, 98], ["broccoli", "ORGANISM_SUBDIVISION", 104, 112], ["broccoli", "SPECIES", 104, 112], ["another study", "TEST", 3, 16]]], ["Furthermore, the absorption rate of KMF from small intestine mainly depends on the microbial hydrolysis of \u03b2-glucuronide before aglycone uptake.", [["small intestine", "ANATOMY", 45, 60], ["KMF", "CHEMICAL", 36, 39], ["\u03b2-glucuronide", "CHEMICAL", 107, 120], ["aglycone", "CHEMICAL", 128, 136], ["KMF", "CHEMICAL", 36, 39], ["\u03b2-glucuronide", "CHEMICAL", 107, 120], ["KMF", "SIMPLE_CHEMICAL", 36, 39], ["small intestine", "ORGAN", 45, 60], ["\u03b2-glucuronide", "SIMPLE_CHEMICAL", 107, 120], ["aglycone", "SIMPLE_CHEMICAL", 128, 136], ["the absorption rate", "TEST", 13, 32], ["KMF", "TEST", 36, 39], ["small intestine", "PROBLEM", 45, 60], ["\u03b2-glucuronide", "TREATMENT", 107, 120], ["small intestine", "ANATOMY", 45, 60]]], ["Rowland, Wiseman, Sanders, Adlercreutz, and Bowey (2000), reported that variation in the gut microflora population alters the absorption rate of KMF by modulating the process of hydrolysis of conjugates and alterations in aglycone ring (Rowland et al., 2000).", [["gut microflora", "ANATOMY", 89, 103], ["KMF", "CHEMICAL", 145, 148], ["aglycone", "CHEMICAL", 222, 230], ["gut", "ORGANISM_SUBDIVISION", 89, 92], ["KMF", "SIMPLE_CHEMICAL", 145, 148], ["aglycone ring", "SIMPLE_CHEMICAL", 222, 235], ["KMF", "TREATMENT", 145, 148], ["hydrolysis of conjugates", "PROBLEM", 178, 202], ["alterations in aglycone ring", "TREATMENT", 207, 235], ["gut", "ANATOMY", 89, 92]]], ["Chromatographic studies revealed the presence of early absorption peak preferentially due to the absorption of kaempferol-3-glucoside.", [["kaempferol-3-glucoside", "CHEMICAL", 111, 133], ["kaempferol-3-glucoside", "CHEMICAL", 111, 133], ["kaempferol-3-glucoside", "SIMPLE_CHEMICAL", 111, 133], ["Chromatographic studies", "TEST", 0, 23], ["early absorption peak", "PROBLEM", 49, 70], ["kaempferol", "TREATMENT", 111, 121], ["glucoside", "TREATMENT", 124, 133], ["early", "OBSERVATION_MODIFIER", 49, 54], ["absorption peak", "OBSERVATION", 55, 70]]], ["Nemeth et al. (2003), investigated that kaempferol-3-glucoside is the most preferred substrate for lactase-phlorizin hydrolase, as compared to kaempferol-3-(6-malonyl)-glucoside and kaempferol-3-glucuronide (Nemeth et al., 2003).", [["kaempferol-3-glucoside", "CHEMICAL", 40, 62], ["phlorizin", "CHEMICAL", 107, 116], ["kaempferol-3-(6-malonyl)-glucoside", "CHEMICAL", 143, 177], ["kaempferol-3-glucuronide", "CHEMICAL", 182, 206], ["kaempferol-3-glucoside", "CHEMICAL", 40, 62], ["phlorizin", "CHEMICAL", 107, 116], ["kaempferol-3-(6-malonyl)-glucoside", "CHEMICAL", 143, 177], ["kaempferol-3-glucuronide", "CHEMICAL", 182, 206], ["kaempferol-3-glucoside", "SIMPLE_CHEMICAL", 40, 62], ["lactase-phlorizin hydrolase", "GENE_OR_GENE_PRODUCT", 99, 126], ["kaempferol-3-(6-malonyl)-glucoside", "SIMPLE_CHEMICAL", 143, 177], ["kaempferol-3-glucuronide", "SIMPLE_CHEMICAL", 182, 206], ["lactase-phlorizin hydrolase", "PROTEIN", 99, 126], ["kaempferol", "TREATMENT", 40, 50], ["glucoside", "TREATMENT", 53, 62], ["lactase", "TEST", 99, 106], ["phlorizin hydrolase", "TREATMENT", 107, 126], ["kaempferol", "TEST", 143, 153], ["glucoside", "TREATMENT", 168, 177], ["kaempferol", "TREATMENT", 182, 192], ["glucuronide", "TREATMENT", 195, 206]]], ["Being hydrophilic in nature, kaempferol-3-glucuronide is found to be absorbed directly from the small intestine.", [["small intestine", "ANATOMY", 96, 111], ["kaempferol-3-glucuronide", "CHEMICAL", 29, 53], ["kaempferol-3-glucuronide", "CHEMICAL", 29, 53], ["kaempferol-3-glucuronide", "SIMPLE_CHEMICAL", 29, 53], ["small intestine", "ORGAN", 96, 111], ["kaempferol", "TREATMENT", 29, 39], ["glucuronide", "TREATMENT", 42, 53], ["hydrophilic", "OBSERVATION_MODIFIER", 6, 17], ["small intestine", "ANATOMY", 96, 111]]], ["KMF glucosides are preferentially absorbed via mechanisms of active transport and deglycosylation processes as reported for quercetin absorption (Day et al., 2003, Day et al., 2000, Gee et al., 2000, Nemeth et al., 2003).", [["KMF glucosides", "CHEMICAL", 0, 14], ["quercetin", "CHEMICAL", 124, 133], ["KMF glucosides", "CHEMICAL", 0, 14], ["quercetin", "CHEMICAL", 124, 133], ["KMF glucosides", "SIMPLE_CHEMICAL", 0, 14], ["quercetin", "SIMPLE_CHEMICAL", 124, 133], ["KMF glucosides", "TEST", 0, 14], ["deglycosylation processes", "PROBLEM", 82, 107], ["active", "OBSERVATION_MODIFIER", 61, 67]]], ["Hydroxylation is a phase I cytochrome P450 dependent enzymatic activity that is known to be involved in the metabolism of KMF.", [["KMF", "CHEMICAL", 122, 125], ["KMF", "CHEMICAL", 122, 125], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 27, 42], ["KMF", "SIMPLE_CHEMICAL", 122, 125], ["phase I cytochrome P450", "PROTEIN", 19, 42], ["KMF", "PROTEIN", 122, 125], ["Hydroxylation", "TREATMENT", 0, 13], ["a phase I cytochrome P450 dependent enzymatic activity", "TREATMENT", 17, 71], ["enzymatic activity", "OBSERVATION", 53, 71]]], ["In a study, Nielsen, Breinholt, Justesen, Cornett, and Dragsted (1998), investigated the hydroxylation capability of microsomes toward flavonols and flavones (Nielsen et al., 1998).", [["microsomes", "ANATOMY", 117, 127], ["flavonols", "CHEMICAL", 135, 144], ["flavonols", "CHEMICAL", 135, 144], ["flavones", "CHEMICAL", 149, 157], ["microsomes", "TISSUE", 117, 127], ["flavonols", "SIMPLE_CHEMICAL", 135, 144], ["flavones", "SIMPLE_CHEMICAL", 149, 157], ["a study", "TEST", 3, 10], ["the hydroxylation capability of microsomes toward flavonols", "TREATMENT", 85, 144], ["flavones", "TREATMENT", 149, 157]]], ["Like quercetin, KMF may also be subjected to basic phase II metabolic conjugation in accumulation with glucuronide or sulphate (Day et al., 2001).", [["quercetin", "CHEMICAL", 5, 14], ["KMF", "CHEMICAL", 16, 19], ["glucuronide or sulphate", "CHEMICAL", 103, 126], ["quercetin", "CHEMICAL", 5, 14], ["KMF", "CHEMICAL", 16, 19], ["glucuronide", "CHEMICAL", 103, 114], ["sulphate", "CHEMICAL", 118, 126], ["quercetin", "SIMPLE_CHEMICAL", 5, 14], ["KMF", "SIMPLE_CHEMICAL", 16, 19], ["glucuronide", "SIMPLE_CHEMICAL", 103, 114], ["sulphate", "SIMPLE_CHEMICAL", 118, 126], ["quercetin", "TREATMENT", 5, 14], ["glucuronide or sulphate", "TREATMENT", 103, 126]]], ["It is essential to identify KMF metabolites to know the various circulating forms of this moiety.", [["KMF", "CHEMICAL", 28, 31], ["KMF", "SIMPLE_CHEMICAL", 28, 31], ["KMF metabolites", "TEST", 28, 43]]], ["DuPont et al. (2004), has observed the conjugated form of KMF metabolite i.e. kaempferol-3-glucuronide (55\u201380%) in the circulating plasma (DuPont et al., 2004).", [["plasma", "ANATOMY", 131, 137], ["KMF", "CHEMICAL", 58, 61], ["kaempferol-3-glucuronide", "CHEMICAL", 78, 102], ["KMF", "CHEMICAL", 58, 61], ["kaempferol-3-glucuronide", "CHEMICAL", 78, 102], ["KMF", "SIMPLE_CHEMICAL", 58, 61], ["kaempferol-3-glucuronide", "SIMPLE_CHEMICAL", 78, 102], ["plasma", "ORGANISM_SUBSTANCE", 131, 137], ["KMF metabolite", "TEST", 58, 72], ["kaempferol", "TREATMENT", 78, 88], ["glucuronide", "TREATMENT", 91, 102]]], ["Another form of metabolite subsists as kaempferol-7-sulphate which could be due to the action of human hepatocytes (Day et al., 2001).", [["hepatocytes", "ANATOMY", 103, 114], ["kaempferol-7-sulphate", "CHEMICAL", 39, 60], ["kaempferol-7-sulphate", "CHEMICAL", 39, 60], ["kaempferol-7-sulphate", "SIMPLE_CHEMICAL", 39, 60], ["human", "ORGANISM", 97, 102], ["hepatocytes", "CELL", 103, 114], ["human hepatocytes", "CELL_TYPE", 97, 114], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["kaempferol", "TEST", 39, 49], ["sulphate", "TREATMENT", 52, 60], ["hepatocytes", "ANATOMY", 103, 114]]], ["These evidences have suggested the lesser bioavailability of KMF in the bloodstream, which needs to be improved with the aim to utilize the full therapeutic potential of KMF.", [["bloodstream", "ANATOMY", 72, 83], ["KMF", "CHEMICAL", 61, 64], ["KMF", "CHEMICAL", 170, 173], ["KMF", "CHEMICAL", 61, 64], ["KMF", "CHEMICAL", 170, 173], ["KMF", "SIMPLE_CHEMICAL", 61, 64], ["KMF", "SIMPLE_CHEMICAL", 170, 173], ["KMF in the bloodstream", "PROBLEM", 61, 83], ["KMF", "TEST", 170, 173], ["lesser", "OBSERVATION_MODIFIER", 35, 41], ["bloodstream", "ANATOMY", 72, 83]]], ["Using G. biloba extract-phospholipid complexes (GBP) of KMF, Chen et al. (2010), have shown the increase in oral bioavailability of flavonoids including quercetin and KMF in a rat model (Chen et al., 2010).", [["oral", "ANATOMY", 108, 112], ["G. biloba extract-phospholipid", "CHEMICAL", 6, 36], ["GBP", "CHEMICAL", 48, 51], ["flavonoids", "CHEMICAL", 132, 142], ["quercetin", "CHEMICAL", 153, 162], ["KMF", "CHEMICAL", 167, 170], ["flavonoids", "CHEMICAL", 132, 142], ["quercetin", "CHEMICAL", 153, 162], ["KMF", "CHEMICAL", 167, 170], ["G. biloba", "ORGANISM", 6, 15], ["extract-phospholipid complexes", "SIMPLE_CHEMICAL", 16, 46], ["GBP", "SIMPLE_CHEMICAL", 48, 51], ["oral", "ORGANISM_SUBDIVISION", 108, 112], ["flavonoids", "SIMPLE_CHEMICAL", 132, 142], ["quercetin", "SIMPLE_CHEMICAL", 153, 162], ["KMF", "SIMPLE_CHEMICAL", 167, 170], ["rat", "ORGANISM", 176, 179], ["G. biloba", "SPECIES", 6, 15], ["rat", "SPECIES", 176, 179], ["G. biloba", "SPECIES", 6, 15], ["G. biloba extract", "TEST", 6, 23], ["phospholipid complexes", "TEST", 24, 46], ["GBP", "TEST", 48, 51], ["KMF", "TEST", 56, 59], ["oral bioavailability of flavonoids", "TREATMENT", 108, 142], ["quercetin", "TREATMENT", 153, 162], ["KMF", "TREATMENT", 167, 170], ["increase", "OBSERVATION_MODIFIER", 96, 104]]], ["Similarly, Wang et al., 2015, Wang et al., 2015, investigated that phospholipid complex (TFH-PC) of KMF may not only increase the bioavailability (172%) but also increase the solubility (22.0 folds) in comparison to total intake of flavonoids (Wang et al., 2015, Wang et al., 2015).", [["TFH-PC", "CHEMICAL", 89, 95], ["KMF", "CHEMICAL", 100, 103], ["flavonoids", "CHEMICAL", 232, 242], ["flavonoids", "CHEMICAL", 232, 242], ["phospholipid complex", "SIMPLE_CHEMICAL", 67, 87], ["TFH-PC", "SIMPLE_CHEMICAL", 89, 95], ["KMF", "SIMPLE_CHEMICAL", 100, 103], ["flavonoids", "SIMPLE_CHEMICAL", 232, 242], ["phospholipid complex", "TEST", 67, 87], ["KMF", "TREATMENT", 100, 103], ["increase", "OBSERVATION_MODIFIER", 162, 170]]], ["Another approach to improve the bioavailability of the therapeutically active flavonols is to explore the effect of the supplemented food matrix ingredients.", [["flavonols", "CHEMICAL", 78, 87], ["flavonols", "CHEMICAL", 78, 87], ["flavonols", "SIMPLE_CHEMICAL", 78, 87], ["Another approach", "TREATMENT", 0, 16], ["the therapeutically active flavonols", "TREATMENT", 51, 87], ["the supplemented food matrix ingredients", "TREATMENT", 116, 156]]], ["So far, very limited data are reported about the effect of food ingredients on absorption and bioavailability of KMF.", [["KMF", "CHEMICAL", 113, 116], ["KMF", "CHEMICAL", 113, 116], ["KMF", "SIMPLE_CHEMICAL", 113, 116], ["KMF", "TEST", 113, 116]]], ["It has been found that the total absorption and bioavailability of flavonoids are associated with the composition of carbohydrate based food matrix.", [["flavonoids", "CHEMICAL", 67, 77], ["flavonoids", "CHEMICAL", 67, 77], ["carbohydrate", "CHEMICAL", 117, 129], ["flavonoids", "SIMPLE_CHEMICAL", 67, 77], ["carbohydrate", "SIMPLE_CHEMICAL", 117, 129], ["the total absorption and bioavailability of flavonoids", "PROBLEM", 23, 77], ["total", "OBSERVATION_MODIFIER", 27, 32], ["absorption", "OBSERVATION_MODIFIER", 33, 43], ["flavonoids", "OBSERVATION", 67, 77]]], ["Rodriguez-Mateos, Oruna-Concha, Kwik-Uribe, Vidal, and Spencer (2012), demonstrated that the maltitol and sucrose were found to increase and decrease the absorption of flavonoids by altering the activity of catechol-O-methyltransferase (Rodriguez-Mateos et al., 2012).", [["maltitol", "CHEMICAL", 93, 101], ["sucrose", "CHEMICAL", 106, 113], ["flavonoids", "CHEMICAL", 168, 178], ["catechol", "CHEMICAL", 207, 215], ["maltitol", "CHEMICAL", 93, 101], ["sucrose", "CHEMICAL", 106, 113], ["flavonoids", "CHEMICAL", 168, 178], ["catechol", "CHEMICAL", 207, 215], ["O", "CHEMICAL", 216, 217], ["maltitol", "SIMPLE_CHEMICAL", 93, 101], ["sucrose", "SIMPLE_CHEMICAL", 106, 113], ["flavonoids", "SIMPLE_CHEMICAL", 168, 178], ["catechol-O-methyltransferase", "GENE_OR_GENE_PRODUCT", 207, 235], ["Rodriguez", "TEST", 0, 9], ["the maltitol and sucrose", "TREATMENT", 89, 113], ["the absorption of flavonoids", "PROBLEM", 150, 178], ["Concha", "ANATOMY", 24, 30]]], ["Also, the methylation of flavonoids, such as genistein and KMF, appeared to modulate the metabolism as well as transportation of these wonderful molecules.", [["flavonoids", "CHEMICAL", 25, 35], ["genistein", "CHEMICAL", 45, 54], ["KMF", "CHEMICAL", 59, 62], ["flavonoids", "CHEMICAL", 25, 35], ["genistein", "CHEMICAL", 45, 54], ["KMF", "CHEMICAL", 59, 62], ["flavonoids", "SIMPLE_CHEMICAL", 25, 35], ["genistein", "SIMPLE_CHEMICAL", 45, 54], ["KMF", "SIMPLE_CHEMICAL", 59, 62], ["flavonoids", "TREATMENT", 25, 35], ["genistein", "TREATMENT", 45, 54], ["KMF", "TREATMENT", 59, 62], ["flavonoids", "OBSERVATION", 25, 35]]], ["Cao, Jing, Wu, and Shi (2013), indicated that the methylation of KMF not only enhances its transporting ability but also increases its hydrophobicity which further assists in the absorption, bioavailability, and binding affinity to both HSA (human serum albumin) and ovalbumin (Cao et al., 2013).", [["serum", "ANATOMY", 248, 253], ["KMF", "CHEMICAL", 65, 68], ["KMF", "CHEMICAL", 65, 68], ["KMF", "SIMPLE_CHEMICAL", 65, 68], ["HSA", "SIMPLE_CHEMICAL", 237, 240], ["human", "ORGANISM", 242, 247], ["serum", "ORGANISM_SUBSTANCE", 248, 253], ["albumin", "GENE_OR_GENE_PRODUCT", 254, 261], ["KMF", "PROTEIN", 65, 68], ["HSA", "PROTEIN", 237, 240], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 242, 247], ["its hydrophobicity", "PROBLEM", 131, 149], ["both HSA (human serum albumin)", "TREATMENT", 232, 262]]], ["Furthermore, route of administration and nanotechnology-mediated implementations in the drug delivery may also ameliorate the bioavailability of KMF.", [["KMF", "CHEMICAL", 145, 148], ["KMF", "CHEMICAL", 145, 148], ["KMF", "SIMPLE_CHEMICAL", 145, 148], ["administration", "TREATMENT", 22, 36], ["nanotechnology-mediated implementations", "TREATMENT", 41, 80], ["the drug delivery", "TREATMENT", 84, 101], ["KMF", "TEST", 145, 148]]], ["In 2009, Barve et al. reported that the half-life of KMF was 3\u20134 h and 1\u20132 h, respectively, after intravenous (10 and 25 mg/kg) and oral (100 and 250 mg/kg) dosages of KMF in male SD (Sprague-Dawley) rats (Barve et al., 2009).", [["intravenous", "ANATOMY", 98, 109], ["oral", "ANATOMY", 132, 136], ["KMF", "CHEMICAL", 168, 171], ["KMF", "CHEMICAL", 53, 56], ["KMF", "CHEMICAL", 168, 171], ["KMF", "SIMPLE_CHEMICAL", 53, 56], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 109], ["oral", "ORGANISM_SUBDIVISION", 132, 136], ["KMF", "SIMPLE_CHEMICAL", 168, 171], ["SD (Sprague-Dawley) rats", "ORGANISM", 180, 204], ["rats", "SPECIES", 200, 204]]], ["In a study, Luo et al., 2012a, Luo et al., 2012b, Luo et al., 2012, observed that encapsulated poly (ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) and poly(DL-lactic acid-co-glycolic acid) drug dosages were found to be more efficacious than KMF alone (Luo et al., 2012a, Luo et al., 2012b, Luo et al., 2012).", [["poly (ethylene oxide", "CHEMICAL", 95, 115], ["poly(propylene oxide", "CHEMICAL", 117, 137], ["poly(ethylene oxide", "CHEMICAL", 139, 158], ["PEO-PPO-PEO", "CHEMICAL", 161, 172], ["poly(DL-lactic acid-co-glycolic acid", "CHEMICAL", 178, 214], ["KMF", "CHEMICAL", 268, 271], ["poly (ethylene oxide)", "CHEMICAL", 95, 116], ["poly(propylene oxide)", "CHEMICAL", 117, 138], ["poly(ethylene oxide)", "CHEMICAL", 139, 159], ["PEO", "CHEMICAL", 161, 164], ["PEO", "CHEMICAL", 169, 172], ["poly(DL-lactic acid-co-glycolic acid", "CHEMICAL", 178, 214], ["KMF", "CHEMICAL", 268, 271], ["poly (ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)", "SIMPLE_CHEMICAL", 95, 159], ["PEO-PPO-PEO", "SIMPLE_CHEMICAL", 161, 172], ["poly(DL-lactic acid-co-glycolic acid", "SIMPLE_CHEMICAL", 178, 214], ["KMF", "SIMPLE_CHEMICAL", 268, 271], ["a study", "TEST", 3, 10], ["encapsulated poly (ethylene oxide)", "TREATMENT", 82, 116], ["poly(propylene oxide)", "TREATMENT", 117, 138], ["poly(ethylene oxide)", "TREATMENT", 139, 159], ["PEO-PPO-PEO)", "TREATMENT", 161, 173], ["poly(DL-lactic acid", "TREATMENT", 178, 197], ["co-glycolic acid", "TREATMENT", 198, 214], ["drug dosages", "TREATMENT", 216, 228]]], ["Similarly, nano-suspension of KMF was found to improve its bioavailability as well as solubility by increasing the Cmax and Area under the curve (AUC0-\u221e) value (Qian et al., 2016).", [["KMF", "CHEMICAL", 30, 33], ["KMF", "CHEMICAL", 30, 33], ["KMF", "SIMPLE_CHEMICAL", 30, 33], ["Cmax", "SIMPLE_CHEMICAL", 115, 119], ["KMF", "TEST", 30, 33], ["the curve", "TEST", 135, 144], ["AUC0", "TEST", 146, 150]]], ["Therefore, the data confirmed the significance of bioavailability and solubility of flavonoids to exert their bioactivity and indicated that improving these important pharmacokinetic parameters may probably further enhance the biological efficacy and potential physiological capacity of KMF.Epidemiological findings of studies with kaempferol-rich foodsEpidemiological studies about association between kaempferol-rich foods intake and decrease in risk of certain types of cancer have shown the variable results depending on several factors, including population type, sample size, food composition, databases used, and other concurrent lifestyle determinants.Epidemiological findings of studies with kaempferol-rich foodsNo association between consumption of KMF and total invasive cancer risk was found among middle-aged and older women in the Women\u2018s Health Study (Wang et al., 2009).", [["cancer", "ANATOMY", 473, 479], ["invasive cancer", "ANATOMY", 774, 789], ["flavonoids", "CHEMICAL", 84, 94], ["KMF", "CHEMICAL", 287, 290], ["kaempferol", "CHEMICAL", 332, 342], ["kaempferol", "CHEMICAL", 403, 413], ["cancer", "DISEASE", 473, 479], ["kaempferol", "CHEMICAL", 701, 711], ["KMF", "CHEMICAL", 760, 763], ["invasive cancer", "DISEASE", 774, 789], ["flavonoids", "CHEMICAL", 84, 94], ["KMF", "CHEMICAL", 287, 290], ["kaempferol", "CHEMICAL", 332, 342], ["kaempferol", "CHEMICAL", 403, 413], ["kaempferol", "CHEMICAL", 701, 711], ["flavonoids", "SIMPLE_CHEMICAL", 84, 94], ["KMF", "SIMPLE_CHEMICAL", 287, 290], ["kaempferol", "SIMPLE_CHEMICAL", 332, 342], ["kaempferol", "SIMPLE_CHEMICAL", 403, 413], ["cancer", "CANCER", 473, 479], ["kaempferol", "SIMPLE_CHEMICAL", 701, 711], ["cancer", "CANCER", 783, 789], ["women", "ORGANISM", 833, 838], ["women", "SPECIES", 833, 838], ["Women", "SPECIES", 846, 851], ["the data", "TEST", 11, 19], ["flavonoids", "TREATMENT", 84, 94], ["KMF", "TEST", 287, 290], ["studies", "TEST", 319, 326], ["kaempferol", "TREATMENT", 332, 342], ["Epidemiological studies", "TEST", 353, 376], ["kaempferol", "TREATMENT", 403, 413], ["cancer", "PROBLEM", 473, 479], ["studies", "TEST", 688, 695], ["kaempferol", "TREATMENT", 701, 711], ["KMF", "TREATMENT", 760, 763], ["total invasive cancer risk", "PROBLEM", 768, 794], ["cancer", "OBSERVATION", 473, 479], ["size", "OBSERVATION_MODIFIER", 576, 580], ["invasive", "OBSERVATION_MODIFIER", 774, 782], ["cancer", "OBSERVATION", 783, 789]]], ["However, among 66,940 women included in the Nurses' Health Study, Gates et al. observed a significant (40%) reduction in ovarian cancer incidence for the highest versus the lowest quintile of KMF intake (Gates et al., 2007).", [["ovarian cancer", "ANATOMY", 121, 135], ["ovarian cancer", "DISEASE", 121, 135], ["KMF", "CHEMICAL", 192, 195], ["KMF", "CHEMICAL", 192, 195], ["women", "ORGANISM", 22, 27], ["ovarian cancer", "CANCER", 121, 135], ["KMF", "SIMPLE_CHEMICAL", 192, 195], ["women", "SPECIES", 22, 27], ["a significant (40%) reduction", "PROBLEM", 88, 117], ["ovarian cancer", "PROBLEM", 121, 135], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["ovarian", "ANATOMY", 121, 128], ["cancer", "OBSERVATION", 129, 135]]], ["On the other hand, a large-scale case-control study showed non-significant (21%) reduction in the incidence of ovarian cancer among women who were at highest quintile of KMF intake (Gates et al., 2009).", [["ovarian cancer", "ANATOMY", 111, 125], ["ovarian cancer", "DISEASE", 111, 125], ["KMF", "CHEMICAL", 170, 173], ["ovarian cancer", "CANCER", 111, 125], ["women", "ORGANISM", 132, 137], ["KMF", "SIMPLE_CHEMICAL", 170, 173], ["women", "SPECIES", 132, 137], ["a large-scale case", "TEST", 19, 37], ["control study", "TEST", 38, 51], ["non-significant (21%) reduction", "PROBLEM", 59, 90], ["ovarian cancer", "PROBLEM", 111, 125], ["non-significant", "OBSERVATION_MODIFIER", 59, 74], ["ovarian", "ANATOMY", 111, 118], ["cancer", "OBSERVATION", 119, 125]]], ["Similarly, a non-significant (27%) decrease in ovarian cancer risk was noted to be associated with a high KMF intake in a rather small case-control study (124 ovarian cancer cases and 696 population-based controls) conducted in the western New York (McCann, Freudenheim, Marshall, & Graham, 2003).Epidemiological findings of studies with kaempferol-rich foodsIn addition, there was no evidence showing a relationship between KMF intake and breast cancer risk described in the Nurses Health Study II (Adebamowo et al., 2005), whereas a low consumption of KMF was significantly associated with decreased risk of estrogen receptor (ER) negative-neoplasias compared to ER-positive tumour among premenopausal women (Touillaud et al., 2005).", [["ovarian cancer", "ANATOMY", 47, 61], ["ovarian cancer", "ANATOMY", 159, 173], ["breast cancer", "ANATOMY", 440, 453], ["ER) negative-neoplasias", "ANATOMY", 629, 652], ["ER-positive tumour", "ANATOMY", 665, 683], ["ovarian cancer", "DISEASE", 47, 61], ["KMF", "CHEMICAL", 106, 109], ["ovarian cancer", "DISEASE", 159, 173], ["kaempferol", "CHEMICAL", 338, 348], ["KMF", "CHEMICAL", 425, 428], ["breast cancer", "DISEASE", 440, 453], ["KMF", "CHEMICAL", 554, 557], ["estrogen", "CHEMICAL", 610, 618], ["neoplasias", "DISEASE", 642, 652], ["tumour", "DISEASE", 677, 683], ["kaempferol", "CHEMICAL", 338, 348], ["KMF", "CHEMICAL", 425, 428], ["estrogen", "CHEMICAL", 610, 618], ["ovarian cancer", "CANCER", 47, 61], ["KMF", "SIMPLE_CHEMICAL", 106, 109], ["ovarian cancer", "CANCER", 159, 173], ["kaempferol", "SIMPLE_CHEMICAL", 338, 348], ["KMF", "SIMPLE_CHEMICAL", 425, 428], ["breast cancer", "CANCER", 440, 453], ["KMF", "SIMPLE_CHEMICAL", 554, 557], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 610, 627], ["ER", "GENE_OR_GENE_PRODUCT", 629, 631], ["ER", "GENE_OR_GENE_PRODUCT", 665, 667], ["tumour", "CANCER", 677, 683], ["women", "ORGANISM", 704, 709], ["KMF", "PROTEIN", 106, 109], ["estrogen receptor", "PROTEIN", 610, 627], ["ER", "PROTEIN", 629, 631], ["ER", "PROTEIN", 665, 667], ["women", "SPECIES", 704, 709], ["a non-significant (27%) decrease in ovarian cancer risk", "PROBLEM", 11, 66], ["a high KMF intake", "PROBLEM", 99, 116], ["control study", "TEST", 140, 153], ["ovarian cancer cases", "PROBLEM", 159, 179], ["studies", "TEST", 325, 332], ["kaempferol", "TREATMENT", 338, 348], ["breast cancer risk", "PROBLEM", 440, 458], ["a low consumption of KMF", "PROBLEM", 533, 557], ["neoplasias", "PROBLEM", 642, 652], ["positive tumour", "PROBLEM", 668, 683], ["non-significant", "OBSERVATION_MODIFIER", 13, 28], ["decrease", "OBSERVATION_MODIFIER", 35, 43], ["ovarian", "ANATOMY", 47, 54], ["cancer", "OBSERVATION", 55, 61], ["no evidence showing", "UNCERTAINTY", 382, 401], ["breast", "ANATOMY", 440, 446], ["cancer", "OBSERVATION", 447, 453], ["neoplasias", "OBSERVATION", 642, 652], ["positive", "OBSERVATION_MODIFIER", 668, 676], ["tumour", "OBSERVATION", 677, 683]]], ["An inverse association of KMF intake with advanced stage (stage III/IV or stage IV, but not non-advanced) prostate cancer in the Netherlands Cohort Study was also described (Geybels et al., 2013).", [["non-advanced) prostate cancer", "ANATOMY", 92, 121], ["KMF", "CHEMICAL", 26, 29], ["prostate cancer", "DISEASE", 106, 121], ["KMF", "SIMPLE_CHEMICAL", 26, 29], ["prostate cancer", "CANCER", 106, 121], ["KMF intake", "PROBLEM", 26, 36], ["advanced stage (stage III/IV", "PROBLEM", 42, 70], ["stage IV", "PROBLEM", 74, 82], ["prostate cancer", "PROBLEM", 106, 121], ["prostate", "ANATOMY", 106, 114], ["cancer", "OBSERVATION", 115, 121]]], ["Although there was no remarkable relationships between high KMF intake and colorectal cancer risk among women from the Nurses\u2019 Health Study and men from the Health Professionals Follow-Up Study (Lin et al., 2006), a statistically significant reduction in the risk of advanced adenoma recurrence was observed in Polyp Prevention Trial (Bobe, Sansbury, et al., 2008).", [["colorectal cancer", "ANATOMY", 75, 92], ["adenoma", "ANATOMY", 276, 283], ["KMF", "CHEMICAL", 60, 63], ["colorectal cancer", "DISEASE", 75, 92], ["adenoma", "DISEASE", 276, 283], ["KMF", "CHEMICAL", 60, 63], ["KMF", "SIMPLE_CHEMICAL", 60, 63], ["colorectal cancer", "CANCER", 75, 92], ["women", "ORGANISM", 104, 109], ["men", "ORGANISM", 144, 147], ["adenoma", "CANCER", 276, 283], ["KMF", "PROTEIN", 60, 63], ["women", "SPECIES", 104, 109], ["men", "SPECIES", 144, 147], ["colorectal cancer", "PROBLEM", 75, 92], ["a statistically significant reduction", "PROBLEM", 214, 251], ["advanced adenoma recurrence", "PROBLEM", 267, 294], ["no", "UNCERTAINTY", 19, 21], ["remarkable", "OBSERVATION_MODIFIER", 22, 32], ["colorectal", "ANATOMY", 75, 85], ["cancer", "OBSERVATION", 86, 92], ["significant", "OBSERVATION_MODIFIER", 230, 241], ["reduction", "OBSERVATION_MODIFIER", 242, 251], ["advanced", "OBSERVATION_MODIFIER", 267, 275], ["adenoma", "OBSERVATION", 276, 283], ["Polyp", "OBSERVATION", 311, 316]]], ["Furthermore, consumption of higher dose of KMF was found to be protective against gastric cancer in a case-control study conducted in the Spain (Garcia-Closas, Gonzalez, Agudo, & Riboli, 1999).", [["gastric cancer", "ANATOMY", 82, 96], ["KMF", "CHEMICAL", 43, 46], ["gastric cancer", "DISEASE", 82, 96], ["KMF", "CHEMICAL", 43, 46], ["KMF", "SIMPLE_CHEMICAL", 43, 46], ["gastric cancer", "CANCER", 82, 96], ["KMF", "TREATMENT", 43, 46], ["gastric cancer", "PROBLEM", 82, 96], ["control study", "TEST", 107, 120], ["gastric", "ANATOMY", 82, 89], ["cancer", "OBSERVATION", 90, 96]]], ["KMF intake was also significantly associated with decreased risk of pancreatic cancer among current smokers (but not among never or former smokers) in the large Multiethnic Cohort Study with participants from Hawaii and California (Nothlings, Murphy, Wilkens, Henderson, & Kolonel, 2007) and among male smokers who were not consuming supplements of vitamin E or \u03b2-carotene in the \u03b1-Tocopherol, \u03b2-Carotene Cancer Prevention Study (Bobe, Weinstein, et al., 2008).", [["pancreatic cancer", "ANATOMY", 68, 85], ["KMF", "CHEMICAL", 0, 3], ["pancreatic cancer", "DISEASE", 68, 85], ["vitamin E", "CHEMICAL", 349, 358], ["\u03b2-carotene", "CHEMICAL", 362, 372], ["\u03b1-Tocopherol", "CHEMICAL", 380, 392], ["\u03b2-Carotene", "CHEMICAL", 394, 404], ["Cancer", "DISEASE", 405, 411], ["KMF", "CHEMICAL", 0, 3], ["vitamin E", "CHEMICAL", 349, 358], ["\u03b2-carotene", "CHEMICAL", 362, 372], ["\u03b1-Tocopherol", "CHEMICAL", 380, 392], ["KMF", "SIMPLE_CHEMICAL", 0, 3], ["pancreatic cancer", "CANCER", 68, 85], ["vitamin E", "SIMPLE_CHEMICAL", 349, 358], ["\u03b2-carotene", "SIMPLE_CHEMICAL", 362, 372], ["\u03b1-Tocopherol", "SIMPLE_CHEMICAL", 380, 392], ["\u03b2-Carotene", "SIMPLE_CHEMICAL", 394, 404], ["participants", "SPECIES", 191, 203], ["pancreatic cancer", "PROBLEM", 68, 85], ["vitamin E", "TREATMENT", 349, 358], ["\u03b2-carotene", "TREATMENT", 362, 372], ["Carotene Cancer", "TREATMENT", 396, 411], ["pancreatic", "ANATOMY", 68, 78], ["cancer", "OBSERVATION", 79, 85], ["Cancer", "OBSERVATION", 405, 411]]], ["Moreover, high intakes of KMF were inversely associated with the development of lung tumour in a case-control study carried out in Los Angeles County, manifesting still only among tobacco smokers and not among non-smokers (Cui et al., 2008).", [["lung tumour", "ANATOMY", 80, 91], ["KMF", "CHEMICAL", 26, 29], ["lung tumour", "DISEASE", 80, 91], ["KMF", "CHEMICAL", 26, 29], ["KMF", "GENE_OR_GENE_PRODUCT", 26, 29], ["lung tumour", "CANCER", 80, 91], ["tobacco", "ORGANISM", 180, 187], ["KMF", "PROTEIN", 26, 29], ["tobacco", "SPECIES", 180, 187], ["high intakes of KMF", "PROBLEM", 10, 29], ["lung tumour", "PROBLEM", 80, 91], ["control study", "TEST", 102, 115], ["lung", "ANATOMY", 80, 84], ["tumour", "OBSERVATION", 85, 91]]], ["The data of a case-control study of lung cancer in women in Spain exhibited a non-significant association for the highest vs. lowest tertile intake of KMF (Garcia-Closas, Agudo, Gonzalez, & Riboli, 1998).Epidemiological findings of studies with kaempferol-rich foodsConsequently, in the above-presented findings, consuming KMF rich diet may be related to lower cancer risk which could be feasible in specific tumour types and in certain populations.", [["lung cancer", "ANATOMY", 36, 47], ["cancer", "ANATOMY", 361, 367], ["tumour", "ANATOMY", 409, 415], ["lung cancer", "DISEASE", 36, 47], ["KMF", "CHEMICAL", 151, 154], ["kaempferol", "CHEMICAL", 245, 255], ["KMF", "CHEMICAL", 323, 326], ["cancer", "DISEASE", 361, 367], ["tumour", "DISEASE", 409, 415], ["KMF", "CHEMICAL", 151, 154], ["kaempferol", "CHEMICAL", 245, 255], ["KMF", "CHEMICAL", 323, 326], ["lung cancer", "CANCER", 36, 47], ["women", "ORGANISM", 51, 56], ["kaempferol", "SIMPLE_CHEMICAL", 245, 255], ["KMF", "SIMPLE_CHEMICAL", 323, 326], ["cancer", "CANCER", 361, 367], ["tumour", "CANCER", 409, 415], ["women", "SPECIES", 51, 56], ["a case-control study", "TEST", 12, 32], ["lung cancer", "PROBLEM", 36, 47], ["KMF", "TEST", 151, 154], ["studies", "TEST", 232, 239], ["kaempferol", "TREATMENT", 245, 255], ["lower cancer risk", "PROBLEM", 355, 372], ["lung", "ANATOMY", 36, 40], ["cancer", "OBSERVATION", 41, 47], ["cancer", "OBSERVATION", 361, 367], ["tumour", "OBSERVATION", 409, 415]]], ["More epidemiological studies with larger cohorts are required to further investigate the potential role of kaempferol-rich foodstuffs in prevention of chronic diseases, such as cancer.Conclusion and future perspectivesFunctional foods have always been known to upgrade health benefits due to their broad spectrum of biological functions and interactions.", [["cancer", "ANATOMY", 177, 183], ["kaempferol", "CHEMICAL", 107, 117], ["chronic diseases", "DISEASE", 151, 167], ["cancer", "DISEASE", 177, 183], ["kaempferol", "CHEMICAL", 107, 117], ["kaempferol", "SIMPLE_CHEMICAL", 107, 117], ["cancer", "CANCER", 177, 183], ["epidemiological studies", "TEST", 5, 28], ["larger cohorts", "PROBLEM", 34, 48], ["kaempferol", "TREATMENT", 107, 117], ["chronic diseases", "PROBLEM", 151, 167], ["cancer", "PROBLEM", 177, 183], ["chronic", "OBSERVATION_MODIFIER", 151, 158], ["diseases", "OBSERVATION", 159, 167], ["cancer", "OBSERVATION", 177, 183]]], ["Evidences have suggested the salutary effects of dietary KMF in plummeting the peril of lethal diseases, such as cancer.", [["cancer", "ANATOMY", 113, 119], ["KMF", "CHEMICAL", 57, 60], ["lethal diseases", "DISEASE", 88, 103], ["cancer", "DISEASE", 113, 119], ["KMF", "CHEMICAL", 57, 60], ["KMF", "SIMPLE_CHEMICAL", 57, 60], ["cancer", "CANCER", 113, 119], ["dietary KMF", "TREATMENT", 49, 60], ["lethal diseases", "PROBLEM", 88, 103], ["cancer", "PROBLEM", 113, 119], ["lethal diseases", "OBSERVATION", 88, 103], ["cancer", "OBSERVATION", 113, 119]]], ["Current chemotherapeutic agents are known to pose serious health risks which could be solved by utilizing natural bioactive metabolites like KMF.", [["KMF", "CHEMICAL", 141, 144], ["KMF", "CHEMICAL", 141, 144], ["KMF", "SIMPLE_CHEMICAL", 141, 144], ["Current chemotherapeutic agents", "TREATMENT", 0, 31]]], ["However, the scientific community should always endeavour to ameliorate the potency of such wondrous molecules.", [["wondrous molecules", "PROTEIN", 92, 110], ["such wondrous molecules", "PROBLEM", 87, 110]]], ["As the structure of KMF revealed the availability of electron donor atoms, such as oxygen which can make the co-ordinate bond with metal atoms and resulting metal complexes of KMF may further boost its biological activity (Kashyap et al., 2016, Kashyap et al., 2016, Tuli et al., 2014).", [["KMF", "CHEMICAL", 20, 23], ["oxygen", "CHEMICAL", 83, 89], ["KMF", "CHEMICAL", 176, 179], ["oxygen", "CHEMICAL", 83, 89], ["KMF", "CHEMICAL", 176, 179], ["electron donor atoms", "SIMPLE_CHEMICAL", 53, 73], ["oxygen", "SIMPLE_CHEMICAL", 83, 89], ["metal atoms", "SIMPLE_CHEMICAL", 131, 142], ["KMF", "SIMPLE_CHEMICAL", 176, 179], ["KMF", "PROTEIN", 20, 23], ["KMF", "PROTEIN", 176, 179], ["electron donor atoms", "TREATMENT", 53, 73], ["oxygen", "TREATMENT", 83, 89]]], ["Computational implements like QSAR models can be acclimated to explore the unknown molecular interactions of KMF with recognized cellular receptors (Bose, Michael, Prashanth, & Chitraa, 2015).", [["cellular", "ANATOMY", 129, 137], ["KMF", "GENE_OR_GENE_PRODUCT", 109, 112], ["cellular", "CELL", 129, 137], ["KMF", "PROTEIN", 109, 112], ["cellular receptors", "PROTEIN", 129, 147]]], ["Synergistic amalgamations with other promising natural bioactive molecules could also be visually perceived as another prospective of future study to enhance the therapeutic potential of KMF (Tuli, Kashyap, & Sharma, 2015).", [["KMF", "CHEMICAL", 187, 190], ["KMF", "CHEMICAL", 187, 190], ["KMF", "SIMPLE_CHEMICAL", 187, 190], ["Synergistic amalgamations", "TREATMENT", 0, 25], ["future study", "TEST", 134, 146], ["KMF", "TEST", 187, 190], ["bioactive molecules", "OBSERVATION", 55, 74]]], ["Moreover, the role of KMF in modulating the expression and activity of drug metabolizing enzymes, such as CYPs could also avail the scientific communities to come forward to design novel strategies with subsisting chemotherapeutic agents (Bibi, 2008, Huang et al., 2014, Zhang et al., 2006a, Zhang et al., 2006b).", [["KMF", "CHEMICAL", 22, 25], ["KMF", "GENE_OR_GENE_PRODUCT", 22, 25], ["CYPs", "GENE_OR_GENE_PRODUCT", 106, 110], ["KMF", "PROTEIN", 22, 25], ["drug metabolizing enzymes", "PROTEIN", 71, 96], ["CYPs", "PROTEIN", 106, 110], ["drug metabolizing enzymes", "TEST", 71, 96], ["subsisting chemotherapeutic agents", "TREATMENT", 203, 237]]], ["Such approaches might be auxiliary in reducing the KMF-associated toxic (Canada et al., 1989, Silva et al., 1997) effects by lowering the requisite of active dosages.", [["KMF", "CHEMICAL", 51, 54], ["active dosages", "TREATMENT", 151, 165], ["toxic", "OBSERVATION_MODIFIER", 66, 71]]], ["Furthermore, novel derivatives of KMF could additionally be an option to ameliorate the potency as well as dose-associated toxicity of this molecule.", [["KMF", "CHEMICAL", 34, 37], ["toxicity", "DISEASE", 123, 131], ["KMF", "CHEMICAL", 34, 37], ["KMF", "SIMPLE_CHEMICAL", 34, 37], ["KMF", "TREATMENT", 34, 37], ["associated toxicity of this molecule", "PROBLEM", 112, 148]]], ["Rho and his colleagues have designed KMF predicated rhamnosides and purposed them as a paramount moiety in the obviation of inflammatory disorders (Rho et al., 2011).", [["inflammatory disorders", "DISEASE", 124, 146], ["rhamnosides", "CHEMICAL", 52, 63], ["Rho", "GENE_OR_GENE_PRODUCT", 0, 3], ["rhamnosides", "SIMPLE_CHEMICAL", 52, 63], ["Rho", "PROTEIN", 0, 3], ["inflammatory disorders", "PROBLEM", 124, 146], ["inflammatory", "OBSERVATION_MODIFIER", 124, 136]]], ["Lower potency of a drug has also been found to be associated with its poor solubility and low bioavailability that can further be amended by utilizing the modern nanotechnology implements (Kuldeep and Ganju, 2014, Pinho et al., 2014).", [["its poor solubility", "PROBLEM", 66, 85], ["potency", "OBSERVATION_MODIFIER", 6, 13]]], ["Luo et al., 2012a, Luo et al., 2012b, Luo et al., 2012, have designed a novel nano-formulation for KMF utilizing Poly DL-lactic acid-co-glycolic acid, nanoparticles with amended bioavailability and cytotoxic effect against ovarian cancer (Luo et al., 2012a, Luo et al., 2012b, Luo et al., 2012).", [["ovarian cancer", "ANATOMY", 223, 237], ["KMF", "CHEMICAL", 99, 102], ["Poly DL-lactic acid-co-glycolic acid", "CHEMICAL", 113, 149], ["ovarian cancer", "DISEASE", 223, 237], ["KMF", "CHEMICAL", 99, 102], ["Poly DL-lactic acid-co-glycolic acid", "CHEMICAL", 113, 149], ["KMF", "SIMPLE_CHEMICAL", 99, 102], ["Poly DL-lactic acid-co-glycolic acid", "SIMPLE_CHEMICAL", 113, 149], ["nanoparticles", "SIMPLE_CHEMICAL", 151, 164], ["ovarian cancer", "CANCER", 223, 237], ["KMF", "TEST", 99, 102], ["Poly DL", "TEST", 113, 120], ["lactic acid", "TEST", 121, 132], ["co", "TEST", 133, 135], ["glycolic acid, nanoparticles", "TREATMENT", 136, 164], ["cytotoxic effect", "PROBLEM", 198, 214], ["ovarian cancer", "PROBLEM", 223, 237], ["ovarian", "ANATOMY", 223, 230], ["cancer", "OBSERVATION", 231, 237]]], ["Moreover, the acerbic and astringent taste of most of the flavonoids could additionally be overcome by utilizing the nanotechnology mediated encapsulation processes which may further enhance their applicability on the more astronomically immense scale in aliment items (Munin and Edwards-Levy, 2011).", [["flavonoids", "CHEMICAL", 58, 68], ["flavonoids", "SIMPLE_CHEMICAL", 58, 68], ["the acerbic and astringent taste", "TREATMENT", 10, 42], ["the nanotechnology mediated encapsulation processes", "TREATMENT", 113, 164]]], ["Thus, KMF could prove to be a promising therapeutic agent and is certainly worth of further molecular studies.Conflict of interestNone.", [["KMF", "CHEMICAL", 6, 9], ["KMF", "SIMPLE_CHEMICAL", 6, 9], ["further molecular studies", "TEST", 84, 109]]]], "PMC7185877": [["IntroductionThe concept of autoimmunity was first predicted by Nobel Laureate Paul Ehrlich at the start of the twentieth century: he described it as \u201chorror autotoxicus\u201d (Janewa et al., 2004).", [["autoimmunity", "DISEASE", 27, 39]]], ["His experiments led him to conclude that the immune system is normally focused on responding to foreign materials; it has an inherent tendency to avoid attacking self tissues.", [["immune system", "ANATOMY", 45, 58], ["tissues", "ANATOMY", 167, 174], ["self tissues", "TISSUE", 162, 174], ["attacking self tissues", "PROBLEM", 152, 174]]], ["Nevertheless, when this process goes wrong, the immune system can attack self tissues, resulting in autoimmune disease (Bell and Bird, 2005).", [["immune system", "ANATOMY", 48, 61], ["tissues", "ANATOMY", 78, 85], ["autoimmune disease", "DISEASE", 100, 118], ["self tissues", "TISSUE", 73, 85], ["autoimmune disease", "PROBLEM", 100, 118], ["autoimmune", "OBSERVATION", 100, 110]]], ["Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis (MS), can create life-long disability and increased mortality.IntroductionEven in 2008, we do not completely understand the primary initiators or causes of many of these autoimmune diseases.", [["Autoimmune diseases", "DISEASE", 0, 19], ["rheumatoid arthritis", "DISEASE", 29, 49], ["multiple sclerosis", "DISEASE", 54, 72], ["MS", "DISEASE", 74, 76], ["disability", "DISEASE", 100, 110], ["autoimmune diseases", "DISEASE", 243, 262], ["Autoimmune diseases", "PROBLEM", 0, 19], ["rheumatoid arthritis", "PROBLEM", 29, 49], ["multiple sclerosis (MS)", "PROBLEM", 54, 77], ["increased mortality", "PROBLEM", 115, 134], ["these autoimmune diseases", "PROBLEM", 237, 262], ["rheumatoid", "OBSERVATION_MODIFIER", 29, 39], ["arthritis", "OBSERVATION", 40, 49], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["sclerosis", "OBSERVATION", 63, 72], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["mortality", "OBSERVATION", 125, 134], ["autoimmune", "OBSERVATION", 243, 253]]], ["No single theory or mechanism can adequately explain all features or pathogeneses of autoimmune diseases.", [["autoimmune diseases", "DISEASE", 85, 104], ["autoimmune diseases", "PROBLEM", 85, 104], ["autoimmune", "OBSERVATION", 85, 95]]], ["The clinically wide spectrum of autoimmune diseases is best considered as the mosaic of autoimmunity.", [["autoimmune diseases", "DISEASE", 32, 51], ["autoimmunity", "DISEASE", 88, 100], ["autoimmune diseases", "PROBLEM", 32, 51], ["autoimmunity", "PROBLEM", 88, 100], ["autoimmune diseases", "OBSERVATION", 32, 51]]], ["In particular, virus infections have long been associated with autoimmune diseases, whether MS, diabetes, or myocarditis (Fujinami, 2004, Fujinami et al., 2006, Horwitz and Sarvetnick, 1999, von Herrath and Oldstone, 1996).", [["infections", "DISEASE", 21, 31], ["autoimmune diseases", "DISEASE", 63, 82], ["MS", "DISEASE", 92, 94], ["diabetes", "DISEASE", 96, 104], ["myocarditis", "DISEASE", 109, 120], ["virus infections", "PROBLEM", 15, 31], ["autoimmune diseases", "PROBLEM", 63, 82], ["MS", "PROBLEM", 92, 94], ["diabetes", "PROBLEM", 96, 104], ["myocarditis", "PROBLEM", 109, 120], ["virus infections", "OBSERVATION", 15, 31], ["associated with", "UNCERTAINTY", 47, 62], ["autoimmune diseases", "OBSERVATION", 63, 82], ["myocarditis", "OBSERVATION", 109, 120]]], ["Several mechanisms have been proposed to explain virus triggers of autoimmune diseases.", [["autoimmune diseases", "DISEASE", 67, 86], ["autoimmune diseases", "PROBLEM", 67, 86], ["autoimmune", "OBSERVATION", 67, 77]]], ["For example, molecular mimicry has been assigned a presumptive role in the pathogenesis of several human diseases, including insulin-dependent diabetes mellitus type-1 (IDDM), ankylosing spondylitis, Guillain-Barre syndrome, primary biliary cirrhosis, and MS (Fujinami, 2001, Horwitz and Sarvetnick, 1999, Janewa et al., 2004).", [["primary biliary cirrhosis", "ANATOMY", 225, 250], ["diabetes mellitus", "DISEASE", 143, 160], ["IDDM", "DISEASE", 169, 173], ["ankylosing spondylitis", "DISEASE", 176, 198], ["Guillain-Barre syndrome", "DISEASE", 200, 223], ["primary biliary cirrhosis", "DISEASE", 225, 250], ["MS", "DISEASE", 256, 258], ["human", "ORGANISM", 99, 104], ["insulin", "GENE_OR_GENE_PRODUCT", 125, 132], ["biliary", "ORGAN", 233, 240], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["several human diseases", "PROBLEM", 91, 113], ["insulin-dependent diabetes mellitus type", "PROBLEM", 125, 165], ["IDDM", "PROBLEM", 169, 173], ["ankylosing spondylitis", "PROBLEM", 176, 198], ["Guillain", "PROBLEM", 200, 208], ["Barre syndrome", "PROBLEM", 209, 223], ["primary biliary cirrhosis", "PROBLEM", 225, 250], ["MS", "PROBLEM", 256, 258], ["several", "OBSERVATION_MODIFIER", 91, 98], ["human diseases", "OBSERVATION", 99, 113], ["insulin-dependent", "OBSERVATION_MODIFIER", 125, 142], ["ankylosing spondylitis", "OBSERVATION", 176, 198], ["Barre syndrome", "OBSERVATION", 209, 223], ["biliary", "ANATOMY", 233, 240], ["cirrhosis", "OBSERVATION", 241, 250]]], ["The immune response to the virus cross-reacts with self because of molecular mimicry, which engenders autoimmunity as follows (Fujinami et al., 2006); virus-infected-antigen presenting cells (APCs) present viral peptides in the contexts of MHC class I and II, respectively, to naive CD8+ T cells and CD4+ T cells.", [["antigen presenting cells", "ANATOMY", 166, 190], ["APCs", "ANATOMY", 192, 196], ["CD8+ T cells", "ANATOMY", 283, 295], ["CD4+ T cells", "ANATOMY", 300, 312], ["autoimmunity", "DISEASE", 102, 114], ["antigen presenting cells", "CELL", 166, 190], ["APCs", "CELL", 192, 196], ["MHC class I", "GENE_OR_GENE_PRODUCT", 240, 251], ["CD8", "GENE_OR_GENE_PRODUCT", 283, 286], ["CD4", "GENE_OR_GENE_PRODUCT", 300, 303], ["antigen presenting cells", "CELL_TYPE", 166, 190], ["APCs", "CELL_TYPE", 192, 196], ["MHC class I and II", "PROTEIN", 240, 258], ["naive CD8+ T cells", "CELL_TYPE", 277, 295], ["CD4+ T cells", "CELL_TYPE", 300, 312], ["the virus cross", "TEST", 23, 38], ["molecular mimicry", "PROBLEM", 67, 84], ["virus", "PROBLEM", 151, 156], ["APCs", "TEST", 192, 196], ["viral peptides", "PROBLEM", 206, 220], ["CD4+ T cells", "PROBLEM", 300, 312], ["viral peptides", "OBSERVATION", 206, 220]]], ["Activation of T cells engenders IFN-\u03b3 production, which further activates APCs, leading to production of IL-12, a potent T-cell-differentiating cytokine.", [["T cells", "ANATOMY", 14, 21], ["APCs", "ANATOMY", 74, 78], ["T-cell", "ANATOMY", 121, 127], ["T cells", "CELL", 14, 21], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 32, 37], ["APCs", "CELL", 74, 78], ["IL-12", "GENE_OR_GENE_PRODUCT", 105, 110], ["T-cell", "CELL", 121, 127], ["T cells", "CELL_TYPE", 14, 21], ["IFN", "PROTEIN", 32, 35], ["\u03b3", "PROTEIN", 36, 37], ["APCs", "CELL_TYPE", 74, 78], ["IL-12", "PROTEIN", 105, 110], ["T-cell-differentiating cytokine", "PROTEIN", 121, 152], ["T cells", "PROBLEM", 14, 21], ["IFN", "PROBLEM", 32, 35], ["\u03b3 production", "PROBLEM", 36, 48], ["IL", "TEST", 105, 107]]], ["Effector CD4+ T cells release proinflammatory cytokines such as IFN-\u03b3 and IL-2, thereby stimulating T cells to differentiate into effector T cells.", [["CD4+ T cells", "ANATOMY", 9, 21], ["T cells", "ANATOMY", 100, 107], ["effector T cells", "ANATOMY", 130, 146], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-2", "GENE_OR_GENE_PRODUCT", 74, 78], ["T cells", "CELL", 100, 107], ["T cells", "CELL", 139, 146], ["Effector CD4+ T cells", "CELL_TYPE", 0, 21], ["proinflammatory cytokines", "PROTEIN", 30, 55], ["IFN-\u03b3 and IL-2", "PROTEIN", 64, 78], ["T cells", "CELL_TYPE", 100, 107], ["effector T cells", "CELL_TYPE", 130, 146], ["Effector CD4", "TEST", 0, 12], ["T cells", "PROBLEM", 14, 21], ["proinflammatory cytokines", "TEST", 30, 55], ["IFN", "TEST", 64, 67], ["IL", "TEST", 74, 76], ["effector T cells", "OBSERVATION", 130, 146]]], ["Activated T cells can also secrete IFN-\u03b3 and TNF, which can engender macrophage activation.", [["T cells", "ANATOMY", 10, 17], ["macrophage", "ANATOMY", 69, 79], ["T cells", "CELL", 10, 17], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 35, 40], ["TNF", "GENE_OR_GENE_PRODUCT", 45, 48], ["macrophage", "CELL", 69, 79], ["Activated T cells", "CELL_TYPE", 0, 17], ["IFN", "PROTEIN", 35, 38], ["\u03b3", "PROTEIN", 39, 40], ["TNF", "PROTEIN", 45, 48], ["Activated T cells", "PROBLEM", 0, 17], ["secrete IFN", "TEST", 27, 38], ["TNF", "PROBLEM", 45, 48]]], ["The activated macrophages in turn release TNF, nitric oxide, and reactive oxygen intermediates, which can kill infected cells and uninfected cells.", [["macrophages", "ANATOMY", 14, 25], ["cells", "ANATOMY", 120, 125], ["cells", "ANATOMY", 141, 146], ["nitric oxide", "CHEMICAL", 47, 59], ["oxygen", "CHEMICAL", 74, 80], ["nitric oxide", "CHEMICAL", 47, 59], ["oxygen", "CHEMICAL", 74, 80], ["macrophages", "CELL", 14, 25], ["TNF", "GENE_OR_GENE_PRODUCT", 42, 45], ["nitric oxide", "SIMPLE_CHEMICAL", 47, 59], ["reactive oxygen intermediates", "SIMPLE_CHEMICAL", 65, 94], ["cells", "CELL", 120, 125], ["cells", "CELL", 141, 146], ["activated macrophages", "CELL_TYPE", 4, 25], ["TNF", "PROTEIN", 42, 45], ["infected cells", "CELL_TYPE", 111, 125], ["uninfected cells", "CELL_TYPE", 130, 146], ["The activated macrophages in turn release TNF", "TREATMENT", 0, 45], ["nitric oxide", "TREATMENT", 47, 59], ["reactive oxygen intermediates", "TREATMENT", 65, 94], ["uninfected cells", "PROBLEM", 130, 146], ["macrophages", "OBSERVATION", 14, 25], ["reactive", "OBSERVATION_MODIFIER", 65, 73], ["oxygen intermediates", "OBSERVATION", 74, 94], ["uninfected cells", "OBSERVATION", 130, 146]]], ["Dead and dying cells are then phagocytosed by macrophages and dendritic cells (DCs), which can present self antigens to autoreactive CD4+ T cells.", [["cells", "ANATOMY", 15, 20], ["macrophages", "ANATOMY", 46, 57], ["dendritic cells", "ANATOMY", 62, 77], ["DCs", "ANATOMY", 79, 82], ["CD4+ T cells", "ANATOMY", 133, 145], ["cells", "CELL", 15, 20], ["macrophages", "CELL", 46, 57], ["dendritic cells", "CELL", 62, 77], ["DCs", "CELL", 79, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 133, 136], ["dying cells", "CELL_TYPE", 9, 20], ["macrophages", "CELL_TYPE", 46, 57], ["dendritic cells", "CELL_TYPE", 62, 77], ["DCs", "CELL_TYPE", 79, 82], ["autoreactive CD4+ T cells", "CELL_TYPE", 120, 145], ["Dead and dying cells", "PROBLEM", 0, 20], ["dendritic cells", "PROBLEM", 62, 77], ["dendritic cells", "OBSERVATION", 62, 77]]], ["Similarly, effector CD8+ T cells can kill infected cells via perforin and granzyme granules.", [["effector CD8+ T cells", "ANATOMY", 11, 32], ["cells", "ANATOMY", 51, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 20, 23], ["cells", "CELL", 51, 56], ["perforin", "GENE_OR_GENE_PRODUCT", 61, 69], ["granzyme", "GENE_OR_GENE_PRODUCT", 74, 82], ["granules", "CELLULAR_COMPONENT", 83, 91], ["effector CD8+ T cells", "CELL_TYPE", 11, 32], ["infected cells", "CELL_TYPE", 42, 56], ["perforin", "PROTEIN", 61, 69], ["T cells", "PROBLEM", 25, 32], ["infected cells", "PROBLEM", 42, 56], ["perforin and granzyme granules", "PROBLEM", 61, 91], ["granzyme granules", "OBSERVATION", 74, 91]]], ["Cell debris is taken up by APCs, which can present self antigens to autoreactive CD8+ T cells.", [["Cell", "ANATOMY", 0, 4], ["APCs", "ANATOMY", 27, 31], ["CD8+ T cells", "ANATOMY", 81, 93], ["Cell", "CELL", 0, 4], ["APCs", "CELL", 27, 31], ["CD8", "GENE_OR_GENE_PRODUCT", 81, 84], ["APCs", "CELL_TYPE", 27, 31], ["autoreactive CD8+ T cells", "CELL_TYPE", 68, 93], ["Cell debris", "PROBLEM", 0, 11], ["debris", "OBSERVATION", 5, 11]]], ["The generation of such cells can engender autoimmune responses with enhanced inflammation if not modulated by regulatory T cells releasing IL-10 and/or TGF-\u03b3.", [["cells", "ANATOMY", 23, 28], ["T cells", "ANATOMY", 121, 128], ["inflammation", "DISEASE", 77, 89], ["cells", "CELL", 23, 28], ["T cells", "CELL", 121, 128], ["IL-10", "GENE_OR_GENE_PRODUCT", 139, 144], ["TGF-\u03b3.", "GENE_OR_GENE_PRODUCT", 152, 158], ["regulatory T cells", "CELL_TYPE", 110, 128], ["TGF", "PROTEIN", 152, 155], ["such cells", "PROBLEM", 18, 28], ["autoimmune responses", "PROBLEM", 42, 62], ["enhanced inflammation", "PROBLEM", 68, 89], ["IL", "TEST", 139, 141], ["TGF", "TEST", 152, 155]]], ["Consequently, patients can develop autoimmune disease through virus-induced autoimmunity.IntroductionAlthough some viruses can modulate the development of autoimmune disease as discussed above, interestingly, some experimental evidence exists for experimental allergic encephalomyelitis (EAE) (Barnett et al., 1996, Fujinami et al., 2006), which is an experimental model of MS, that viruses can protect against autoimmune disease.", [["autoimmune disease", "DISEASE", 35, 53], ["autoimmunity", "DISEASE", 76, 88], ["autoimmune disease", "DISEASE", 155, 173], ["allergic encephalomyelitis", "DISEASE", 260, 286], ["EAE", "DISEASE", 288, 291], ["MS", "DISEASE", 374, 376], ["autoimmune disease", "DISEASE", 411, 429], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["autoimmune disease through virus", "PROBLEM", 35, 67], ["induced autoimmunity", "PROBLEM", 68, 88], ["some viruses", "PROBLEM", 110, 122], ["autoimmune disease", "PROBLEM", 155, 173], ["experimental allergic encephalomyelitis", "PROBLEM", 247, 286], ["autoimmune disease", "PROBLEM", 411, 429], ["autoimmune", "OBSERVATION", 35, 45], ["viruses", "OBSERVATION", 115, 122], ["autoimmune", "OBSERVATION", 155, 165], ["exists for", "UNCERTAINTY", 236, 246], ["allergic encephalomyelitis", "OBSERVATION", 260, 286]]], ["Possible mechanisms of protecting against autoimmune disease are considered as \u201caltered peptide ligand\u201d, which activates regulatory cells that modulate the disease (Barnett et al., 1996, Fujinami et al., 2006), and \u201cactivation-induced cell death\u201d (AICD) which engenders anergy or unresponsiveness of T cells (Fujinami, 2001).", [["cells", "ANATOMY", 132, 137], ["cell", "ANATOMY", 235, 239], ["T cells", "ANATOMY", 300, 307], ["autoimmune disease", "DISEASE", 42, 60], ["death", "DISEASE", 240, 245], ["cells", "CELL", 132, 137], ["cell", "CELL", 235, 239], ["T cells", "CELL", 300, 307], ["regulatory cells", "CELL_TYPE", 121, 137], ["T cells", "CELL_TYPE", 300, 307], ["autoimmune disease", "PROBLEM", 42, 60], ["altered peptide ligand\u201d", "PROBLEM", 80, 103], ["the disease", "PROBLEM", 152, 163], ["cell death", "PROBLEM", 235, 245], ["AICD", "TREATMENT", 248, 252], ["anergy", "PROBLEM", 270, 276], ["unresponsiveness of T cells", "PROBLEM", 280, 307], ["cell death", "OBSERVATION", 235, 245]]], ["These imply that viruses having molecular mimicry with self proteins are useful to vaccinate against autoimmune disease.", [["autoimmune disease", "DISEASE", 101, 119], ["self proteins", "PROTEIN", 55, 68], ["self proteins", "PROBLEM", 55, 68], ["autoimmune disease", "PROBLEM", 101, 119], ["viruses", "OBSERVATION", 17, 24]]], ["Using molecular biology and DNA manipulation methods, it has also been possible to express mimic proteins in adequate live vectors (Arnon and Ben-Yedidia, 2003) and thereby design transgenic vector vaccines (Janewa et al., 2004, Roitt et al., 1998) against autoimmune disease.", [["autoimmune disease", "DISEASE", 257, 275], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["DNA manipulation methods", "TREATMENT", 28, 52], ["design transgenic vector vaccines", "TREATMENT", 173, 206], ["autoimmune disease", "PROBLEM", 257, 275]]], ["The development of vaccines has been an important contribution of autoimmune disease therapy and public health.IntroductionHerein, we construct a simple mathematical model based on the autoimmune disease model proposed in Iwami et al. (2007a) and Iwami (2007).", [["autoimmune disease", "DISEASE", 66, 84], ["autoimmune disease", "DISEASE", 185, 203], ["vaccines", "TREATMENT", 19, 27], ["autoimmune disease therapy", "TREATMENT", 66, 92], ["a simple mathematical model", "TREATMENT", 144, 171], ["the autoimmune disease model", "PROBLEM", 181, 209], ["important contribution of", "UNCERTAINTY", 40, 65], ["autoimmune disease", "OBSERVATION", 66, 84]]], ["We consider a viral infection that can induce cross-reactive immune responses with self antigen caused by molecular mimicry.", [["viral infection", "DISEASE", 14, 29], ["a viral infection", "PROBLEM", 12, 29], ["self antigen", "PROBLEM", 83, 95], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29], ["molecular mimicry", "OBSERVATION", 106, 123]]], ["Our model suggests that the viral infection can induce various symptoms of autoimmune disease such as relapse.", [["viral infection", "DISEASE", 28, 43], ["autoimmune disease", "DISEASE", 75, 93], ["the viral infection", "PROBLEM", 24, 43], ["various symptoms", "PROBLEM", 55, 71], ["autoimmune disease", "PROBLEM", 75, 93], ["relapse", "PROBLEM", 102, 109], ["viral", "OBSERVATION_MODIFIER", 28, 33], ["infection", "OBSERVATION", 34, 43], ["autoimmune", "OBSERVATION", 75, 85]]], ["Furthermore, we propose that a form of immune response function determines whether a viral infection can be beneficial or detrimental.", [["viral infection", "DISEASE", 85, 100], ["immune response function", "PROBLEM", 39, 63], ["a viral infection", "PROBLEM", 83, 100], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["infection", "OBSERVATION", 91, 100]]], ["Using the model, we consider the possibility of development of a vector vaccine that can relieve autoimmune disease symptoms.Mathematical modelThe breaking of tolerance or unresponsiveness to self antigens, involving the activation of autoreactive lymphocytes, is a critical event in the pathogenesis of autoimmune disease (von Herrath and Oldstone, 1996).", [["autoreactive lymphocytes", "ANATOMY", 235, 259], ["autoimmune disease", "DISEASE", 97, 115], ["autoimmune disease", "DISEASE", 304, 322], ["autoreactive lymphocytes", "CELL", 235, 259], ["autoreactive lymphocytes", "CELL_TYPE", 235, 259], ["a vector vaccine", "TREATMENT", 63, 79], ["autoimmune disease symptoms", "PROBLEM", 97, 124], ["unresponsiveness", "PROBLEM", 172, 188], ["self antigens", "PROBLEM", 192, 205], ["autoreactive lymphocytes", "PROBLEM", 235, 259], ["autoimmune disease", "PROBLEM", 304, 322], ["autoreactive lymphocytes", "OBSERVATION", 235, 259], ["autoimmune", "OBSERVATION", 304, 314]]], ["The molecular mimicry theory has become an important paradigm to explain the triggering of autoaggressive T lymphocytes (Anderton, 2006).", [["autoaggressive T lymphocytes", "ANATOMY", 91, 119], ["autoaggressive T lymphocytes", "CELL", 91, 119], ["autoaggressive T lymphocytes", "CELL_TYPE", 91, 119], ["autoaggressive T lymphocytes", "PROBLEM", 91, 119]]], ["Viruses and microbial agents might possess protein structures or shapes that mimic normal host self proteins.", [["normal host self proteins", "PROTEIN", 83, 108], ["Viruses", "PROBLEM", 0, 7], ["microbial agents", "TREATMENT", 12, 28], ["protein structures", "PROBLEM", 43, 61], ["normal host self proteins", "OBSERVATION", 83, 108]]], ["An immune response elicited against the pathogen will eliminate it and will cross-react with one or more self antigens that share determinants with the agent (von Herrath and Oldstone, 1996).", [["the pathogen", "PROBLEM", 36, 48]]], ["The cross-reactive immune response can break a tolerance for self antigens and might engender autoimmune disease.", [["autoimmune disease", "DISEASE", 94, 112], ["self antigens", "PROBLEM", 61, 74], ["autoimmune disease", "PROBLEM", 94, 112], ["cross-reactive immune response", "OBSERVATION", 4, 34], ["autoimmune", "OBSERVATION", 94, 104]]], ["We consider a viral infection that can induce cross-reactive immune responses with a self antigen caused by molecular mimicry (see Fig. 1).", [["viral infection", "DISEASE", 14, 29], ["a viral infection", "PROBLEM", 12, 29], ["a self antigen", "TEST", 83, 97], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29]]], ["To explore effects of the viral infection and dynamical behavior of the vicious cycle of autoimmunity, we propose the following mathematical model based on the autoimmune disease model proposed in Iwami et al. (2007a) and Iwami (2007);T\u2032=g(T)-\u03b21TI-\u03b1D,I\u2032=f(D,V)-\u03b3I,V\u2032=(k-u-\u03b22I)V.Variables T, D, I, and V, respectively, signify the number of target (uninfected) cells, damaged cells (which implies a concentration of self antigen), cross-reactive immune cells, and viral agents with molecular mimicry.", [["cells", "ANATOMY", 360, 365], ["cells", "ANATOMY", 375, 380], ["immune cells", "ANATOMY", 445, 457], ["viral infection", "DISEASE", 26, 41], ["autoimmunity", "DISEASE", 89, 101], ["autoimmune disease", "DISEASE", 160, 178], ["T\u2032=g(T)-\u03b21TI-\u03b1D,I\u2032=f(D,V)-\u03b3", "CHEMICAL", 235, 262], ["cells", "CELL", 360, 365], ["cells", "CELL", 375, 380], ["immune cells", "CELL", 445, 457], ["target (uninfected) cells", "CELL_TYPE", 340, 365], ["damaged cells", "CELL_TYPE", 367, 380], ["cross-reactive immune cells", "CELL_TYPE", 430, 457], ["V.", "SPECIES", 276, 278], ["the viral infection", "PROBLEM", 22, 41], ["autoimmunity", "PROBLEM", 89, 101], ["the autoimmune disease model", "PROBLEM", 156, 184], ["Iwami", "TEST", 222, 227], ["T\u2032=g(", "TEST", 235, 240], ["damaged cells", "PROBLEM", 367, 380], ["self antigen", "TEST", 415, 427], ["cross-reactive immune cells", "PROBLEM", 430, 457], ["viral agents", "TREATMENT", 463, 475], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["infection", "OBSERVATION", 32, 41], ["autoimmune disease", "OBSERVATION", 160, 178], ["damaged cells", "OBSERVATION", 367, 380], ["reactive immune cells", "OBSERVATION", 436, 457], ["viral agents", "OBSERVATION", 463, 475]]], ["The immune responses eliminate target cells and viral agents at a rate of \u03b2^1 and \u03b22, respectively.", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["\u03b2^1", "GENE_OR_GENE_PRODUCT", 74, 77], ["\u03b22", "GENE_OR_GENE_PRODUCT", 82, 84], ["target cells", "CELL_TYPE", 31, 43], ["\u03b22", "PROTEIN", 82, 84], ["target cells", "PROBLEM", 31, 43], ["viral agents", "TREATMENT", 48, 60], ["a rate", "TEST", 64, 70]]], ["We assume a \u201cMalthusian growth rate\u201d k in viral agents, which decay at a rate u as considered in Nowak et al. (1991).", [["a \u201cMalthusian growth rate", "TEST", 10, 35], ["viral agents", "TREATMENT", 42, 54]]], ["The parameters \u03b1 and \u03b3 represent the decay rate of damaged and cross-reactive immune cells, respectively.", [["immune cells", "ANATOMY", 78, 90], ["\u03b1", "GENE_OR_GENE_PRODUCT", 15, 16], ["\u03b3", "GENE_OR_GENE_PRODUCT", 21, 22], ["immune cells", "CELL", 78, 90], ["\u03b1", "PROTEIN", 15, 16], ["\u03b3", "PROTEIN", 21, 22], ["damaged and cross-reactive immune cells", "CELL_TYPE", 51, 90], ["cross-reactive immune cells", "OBSERVATION", 63, 90]]], ["The function g(T) is the \u201ctarget cell growth function\u201d.", [["cell", "ANATOMY", 33, 37], ["cell", "CELL", 33, 37], ["target cell", "OBSERVATION", 26, 37], ["growth function", "OBSERVATION", 38, 53]]], ["In Iwami et al. (2007a), we consider two target cell growth functions g1(T)=\u03bb-\u03bcT, which means a constant growth and g2(T)=\u03bb-\u03bcT+pT(1-T/L) which means a logistic growth.", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["\u03bb", "TEST", 76, 77], ["T+pT", "TEST", 125, 129], ["a logistic growth", "PROBLEM", 149, 166]]], ["A form of this function considerably affects the dynamics of autoimmune disease (Iwami et al., 2007a, Iwami, 2007).", [["autoimmune disease", "DISEASE", 61, 79], ["autoimmune disease", "PROBLEM", 61, 79], ["autoimmune disease", "OBSERVATION", 61, 79]]], ["However, to examine the effect of viral infection with molecular mimicry specifically, we consider that target cells are always constant T=T* (we omit target cell dynamics).", [["cells", "ANATOMY", 111, 116], ["cell", "ANATOMY", 158, 162], ["viral infection", "DISEASE", 34, 49], ["cells", "CELL", 111, 116], ["cell", "CELL", 158, 162], ["target cells", "CELL_TYPE", 104, 116], ["viral infection", "PROBLEM", 34, 49], ["target cells", "PROBLEM", 104, 116], ["infection", "OBSERVATION", 40, 49]]], ["This assumption is justified by some homeostatic ability of organs, which exactly balances the growth of target cells with the damage.", [["organs", "ANATOMY", 60, 66], ["cells", "ANATOMY", 112, 117], ["organs", "ORGAN", 60, 66], ["cells", "CELL", 112, 117], ["target cells", "CELL_TYPE", 105, 117], ["the damage", "PROBLEM", 123, 133]]], ["On the other hand, the assumption is not biologically unnatural if the target cells are abundant in the organ.", [["cells", "ANATOMY", 78, 83], ["organ", "ANATOMY", 104, 109], ["cells", "CELL", 78, 83], ["organ", "ORGAN", 104, 109], ["target cells", "CELL_TYPE", 71, 83], ["organ", "ANATOMY", 104, 109]]], ["We leave the inclusion of target cell dynamics as a subject for future work.", [["cell", "ANATOMY", 33, 37], ["cell", "CELL", 33, 37]]], ["We can model the vicious cycle in the following form:(1)D\u2032=\u03b21I-\u03b1D,I\u2032=f(D,V)-\u03b3I,V\u2032=(k-u-\u03b22I)V,where \u03b21=\u03b2^1T, represents a level of autoimmune disease progression.", [["autoimmune disease", "DISEASE", 130, 148], ["D\u2032=\u03b21I-\u03b1D,I\u2032=f(D,V)-\u03b3I,V\u2032=(k-u-\u03b22I)V", "CHEMICAL", 56, 92], ["D\u2032=\u03b21I-\u03b1D,I\u2032=f(D,V)-\u03b3I", "SIMPLE_CHEMICAL", 56, 78], ["k-u-\u03b22I)V", "SIMPLE_CHEMICAL", 83, 92], ["\u03b21", "GENE_OR_GENE_PRODUCT", 99, 101], ["\u03b2^1T", "SIMPLE_CHEMICAL", 102, 106], ["\u03b21", "PROTEIN", 99, 101], ["\u03b2^1T", "CELL_LINE", 102, 106], ["I\u2032", "TEST", 66, 68], ["V)-", "TEST", 73, 76], ["V\u2032", "TEST", 79, 81], ["V", "TEST", 91, 92], ["autoimmune disease progression", "PROBLEM", 130, 160], ["autoimmune", "OBSERVATION", 130, 140]]], ["A strong immune affinity with self antigen (\u03b21) tends to develop into autoimmune disease Ea+ according to initial values (see Fig. 3(c)) when the virus cannot establish persistent infection (k-u<0).", [["autoimmune disease", "DISEASE", 70, 88], ["infection", "DISEASE", 180, 189], ["self antigen", "GENE_OR_GENE_PRODUCT", 30, 42], ["\u03b21", "GENE_OR_GENE_PRODUCT", 44, 46], ["self antigen", "PROTEIN", 30, 42], ["\u03b21", "PROTEIN", 44, 46], ["A strong immune affinity", "PROBLEM", 0, 24], ["self antigen", "TEST", 30, 42], ["autoimmune disease Ea", "PROBLEM", 70, 91], ["the virus", "PROBLEM", 142, 151], ["persistent infection", "PROBLEM", 169, 189], ["k", "TEST", 191, 192], ["persistent", "OBSERVATION_MODIFIER", 169, 179], ["infection", "OBSERVATION", 180, 189]]], ["The healthy state Eh is always stable, which implies that the immune tolerance can occur after development of autoimmune disease if we can remove the damaged cells and the immune responses (simulations not shown).", [["cells", "ANATOMY", 158, 163], ["autoimmune disease", "DISEASE", 110, 128], ["Eh", "GENE_OR_GENE_PRODUCT", 18, 20], ["cells", "CELL", 158, 163], ["damaged cells", "CELL_TYPE", 150, 163], ["the immune tolerance", "PROBLEM", 58, 78], ["autoimmune disease", "PROBLEM", 110, 128], ["the damaged cells", "PROBLEM", 146, 163], ["stable", "OBSERVATION_MODIFIER", 31, 37], ["autoimmune", "OBSERVATION", 110, 120]]], ["Furthermore, because dDa+/d\u03b21>0, an appropriate decrease of the immune affinity with self antigen can delay autoimmune disease progression (a considerable decrease of the affinity with self antigen (\u03b21<2\u03b1h\u03b3/m) can engender the immune tolerance Eh).Symptoms of autoimmune disease in model (3) ::: Sigmoid immune response function ::: ResultsOn the other hand, when the virus can maintain its replications (k-u>0), strong immune affinities with self and viral antigen (large \u03b21 and \u03b22) also engender the development of autoimmune disease without viral infection (Fig. 4(I)).", [["autoimmune disease", "DISEASE", 108, 126], ["autoimmune disease", "DISEASE", 260, 278], ["autoimmune disease", "DISEASE", 517, 535], ["viral infection", "DISEASE", 544, 559], ["self antigen", "GENE_OR_GENE_PRODUCT", 85, 97], ["large \u03b21", "GENE_OR_GENE_PRODUCT", 467, 475], ["\u03b22", "GENE_OR_GENE_PRODUCT", 480, 482], ["self antigen", "PROTEIN", 185, 197], ["viral antigen", "PROTEIN", 452, 465], ["\u03b21", "PROTEIN", 473, 475], ["\u03b22", "PROTEIN", 480, 482], ["dDa+/d\u03b2", "TEST", 21, 28], ["the immune affinity", "PROBLEM", 60, 79], ["self antigen", "PROBLEM", 85, 97], ["autoimmune disease progression", "PROBLEM", 108, 138], ["self antigen", "TEST", 185, 197], ["autoimmune disease", "PROBLEM", 260, 278], ["the virus", "PROBLEM", 364, 373], ["k-u", "TEST", 405, 408], ["strong immune affinities", "PROBLEM", 413, 437], ["self and viral antigen", "TEST", 443, 465], ["autoimmune disease", "PROBLEM", 517, 535], ["viral infection", "PROBLEM", 544, 559], ["considerable", "OBSERVATION_MODIFIER", 142, 154], ["decrease", "OBSERVATION_MODIFIER", 155, 163], ["autoimmune disease", "OBSERVATION", 260, 278], ["autoimmune", "OBSERVATION", 517, 527], ["without", "UNCERTAINTY", 536, 543], ["viral", "OBSERVATION_MODIFIER", 544, 549], ["infection", "OBSERVATION", 550, 559]]], ["However, if the immune affinity with self antigen is weak, the patient develops autoimmune disease with a viral infection (Fig. 4(V)).", [["autoimmune disease", "DISEASE", 80, 98], ["viral infection", "DISEASE", 106, 121], ["self antigen", "GENE_OR_GENE_PRODUCT", 37, 49], ["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["the immune affinity", "PROBLEM", 12, 31], ["self antigen", "PROBLEM", 37, 49], ["autoimmune disease", "PROBLEM", 80, 98], ["a viral infection", "PROBLEM", 104, 121], ["autoimmune disease", "OBSERVATION", 80, 98], ["viral", "OBSERVATION_MODIFIER", 106, 111], ["infection", "OBSERVATION", 112, 121]]], ["Because dDa+/d\u03b21>0 and dDc/d\u03b22<0 in region (V) (a marked decrease of affinity with viral antigen engenders unlimited viral replications).", [["dDc", "PROTEIN", 23, 26], ["d\u03b22", "PROTEIN", 27, 30], ["viral antigen", "PROTEIN", 83, 96], ["dDa+", "TEST", 8, 12], ["d\u03b2", "TEST", 13, 15], ["dDc/d\u03b22", "TEST", 23, 30], ["a marked decrease of affinity", "PROBLEM", 48, 77], ["viral antigen engenders", "TREATMENT", 83, 106], ["viral replications", "TREATMENT", 117, 135]]], ["Interestingly, because Ea+ and Ec* are stable simultaneously in region (III), the symptoms of autoimmune disease depend on the patients\u2019 states.", [["autoimmune disease", "DISEASE", 94, 112], ["Ea+", "GENE_OR_GENE_PRODUCT", 23, 26], ["Ec*", "GENE_OR_GENE_PRODUCT", 31, 34], ["patients", "ORGANISM", 127, 135], ["Ea", "PROTEIN", 23, 25], ["Ec*", "PROTEIN", 31, 34], ["patients", "SPECIES", 127, 135], ["Ea", "TEST", 23, 25], ["the symptoms", "PROBLEM", 78, 90], ["autoimmune disease", "PROBLEM", 94, 112], ["stable", "OBSERVATION_MODIFIER", 39, 45], ["autoimmune disease", "OBSERVATION", 94, 112]]], ["Furthermore, in regions (II) and (IV), the relapse of autoimmune disease, which is a common symptom of autoimmune disease, can occur.", [["autoimmune disease", "DISEASE", 54, 72], ["autoimmune disease", "DISEASE", 103, 121], ["autoimmune disease", "PROBLEM", 54, 72], ["autoimmune disease", "PROBLEM", 103, 121], ["autoimmune disease", "OBSERVATION", 54, 72], ["autoimmune disease", "OBSERVATION", 103, 121]]], ["Actually, the symptoms of autoimmune disease also depend on the patients\u2019 states in (II) (patients with affinities near G(\u03b22) in (II) tend not to represent relapse symptoms, as discussed above).", [["autoimmune disease", "DISEASE", 26, 44], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 90, 98], ["the symptoms", "PROBLEM", 10, 22], ["autoimmune disease", "PROBLEM", 26, 44], ["relapse symptoms", "PROBLEM", 156, 172], ["autoimmune disease", "OBSERVATION", 26, 44]]], ["Consequently, the viral infection prevents immune tolerance and engenders the relapse pattern of autoimmune disease.Detrimental or beneficial viral infection ::: Vector vaccine against autoimmune diseaseWe consider whether infection by a virus having molecular mimicry with a self antigen that can replicate itself (k-u>0) is beneficial or detrimental for autoimmune disease.", [["viral infection", "DISEASE", 18, 33], ["autoimmune disease", "DISEASE", 97, 115], ["viral infection", "DISEASE", 142, 157], ["autoimmune diseaseWe", "DISEASE", 185, 205], ["infection", "DISEASE", 223, 232], ["autoimmune disease", "DISEASE", 356, 374], ["the viral infection", "PROBLEM", 14, 33], ["immune tolerance", "PROBLEM", 43, 59], ["autoimmune disease", "PROBLEM", 97, 115], ["beneficial viral infection", "PROBLEM", 131, 157], ["Vector vaccine", "TREATMENT", 162, 176], ["autoimmune diseaseWe", "PROBLEM", 185, 205], ["infection", "PROBLEM", 223, 232], ["a virus", "PROBLEM", 236, 243], ["a self antigen", "TEST", 274, 288], ["autoimmune disease", "PROBLEM", 356, 374], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33], ["immune tolerance", "OBSERVATION", 43, 59], ["autoimmune disease", "OBSERVATION", 97, 115], ["beneficial", "OBSERVATION_MODIFIER", 131, 141], ["viral", "OBSERVATION_MODIFIER", 142, 147], ["infection", "OBSERVATION", 148, 157], ["infection", "OBSERVATION", 223, 232]]], ["First we assume that autoimmune disease has already developed before the patient is infected with the virus having molecular mimicry with self proteins (V(0)=0).", [["autoimmune disease", "DISEASE", 21, 39], ["patient", "ORGANISM", 73, 80], ["self proteins", "PROTEIN", 138, 151], ["patient", "SPECIES", 73, 80], ["autoimmune disease", "PROBLEM", 21, 39], ["the virus", "PROBLEM", 98, 107], ["self proteins", "TEST", 138, 151], ["autoimmune", "OBSERVATION", 21, 31], ["infected", "OBSERVATION", 84, 92]]], ["In model (2), we assume that Ea is stable (\u03b21>\u03b1\u03b3h/m) with V(0)=0, which corresponds to Fig. 2(c), irrespective of the sign of k-u (we remark that the infection with k-u>0 persists and initiates autoimmune disease even if \u03b21\u03b3(k-u)/m).", [["infection", "DISEASE", 150, 159], ["autoimmune disease", "DISEASE", 194, 212], ["Ea", "PROTEIN", 29, 31], ["k-u", "TEST", 126, 129], ["the infection", "PROBLEM", 146, 159], ["k-u", "TEST", 165, 168], ["autoimmune disease", "PROBLEM", 194, 212], ["stable", "OBSERVATION_MODIFIER", 35, 41], ["infection", "OBSERVATION", 150, 159], ["autoimmune disease", "OBSERVATION", 194, 212]]], ["Actually, if the affinity with viral antigen is low (\u03b22H(\u03b22)) because the viral infection cannot affect the disease progression.", [["viral infection", "DISEASE", 74, 89], ["\u03b22)", "GENE_OR_GENE_PRODUCT", 57, 60], ["viral antigen", "PROTEIN", 31, 44], ["the affinity", "TEST", 13, 25], ["viral antigen", "TEST", 31, 44], ["the viral infection", "PROBLEM", 70, 89], ["the disease progression", "PROBLEM", 104, 127], ["viral", "OBSERVATION_MODIFIER", 74, 79], ["infection", "OBSERVATION", 80, 89], ["disease", "OBSERVATION", 108, 115]]], ["Consequently, we assume the following conditions: k-u>0,\u03b1\u03b3hm\u03b3(k-u)m.We evaluate the effect of viral infection as follows.", [["viral infection", "DISEASE", 94, 109], ["\u03b1\u03b3hm\u03b3(k-u)m", "GENE_OR_GENE_PRODUCT", 56, 67], ["u>0", "PROTEIN", 52, 55], ["\u03b1\u03b3hm\u03b3", "PROTEIN", 56, 61], ["viral infection", "PROBLEM", 94, 109], ["viral", "OBSERVATION_MODIFIER", 94, 99], ["infection", "OBSERVATION", 100, 109]]], ["Let V(0)>0; then the stable equilibrium changes from Ea to Ec (the patients get the viral infection).", [["viral infection", "DISEASE", 84, 99], ["Ea to Ec", "GENE_OR_GENE_PRODUCT", 53, 61], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Let V", "TEST", 0, 5], ["the stable equilibrium changes", "PROBLEM", 17, 47], ["the viral infection", "PROBLEM", 80, 99], ["stable", "OBSERVATION_MODIFIER", 21, 27], ["equilibrium", "OBSERVATION", 28, 39], ["infection", "OBSERVATION", 90, 99]]], ["We then have the following relations: \u03b21<H(\u03b22)\u21d2Da<Dc,Ia<Ic.They imply that the viral infection always imparts a detrimental effect on patients and accelerates autoimmune disease on the region because the viral infection increases damaged cells (Da2\u03b1\u03b3h/m) with V(0)=0, which fundamentally corresponds to Fig. 3(c), irrespective of a sign of k-u.", [["cells", "ANATOMY", 238, 243], ["viral infection", "DISEASE", 79, 94], ["autoimmune disease", "DISEASE", 159, 177], ["infection", "DISEASE", 210, 219], ["Da<Dc", "GENE_OR_GENE_PRODUCT", 47, 52], ["Ia<Ic", "GENE_OR_GENE_PRODUCT", 53, 58], ["patients", "ORGANISM", 134, 142], ["cells", "CELL", 238, 243], ["Ia<Ic", "PROTEIN", 53, 58], ["damaged cells", "CELL_TYPE", 230, 243], ["Da2\u03b1\u03b3h", "PROTEIN", 245, 251], ["patients", "SPECIES", 134, 142], ["Da<Dc", "TEST", 47, 52], ["the viral infection", "PROBLEM", 75, 94], ["autoimmune disease", "PROBLEM", 159, 177], ["the viral infection increases damaged cells", "PROBLEM", 200, 243], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["infection", "OBSERVATION", 85, 94], ["autoimmune disease", "OBSERVATION", 159, 177], ["viral", "OBSERVATION_MODIFIER", 204, 209], ["infection", "OBSERVATION", 210, 219]]], ["Furthermore, let the immune affinity with viral antigen be high (\u03b22>\u03b3(k-u)/m).", [["viral antigen", "PROTEIN", 42, 55], ["the immune affinity", "TEST", 17, 36], ["viral antigen", "TEST", 42, 55]]], ["We also exclude high affinity with self antigen (\u03b21>G(\u03b22)) because of a neutral effect of the infection.", [["infection", "DISEASE", 94, 103], ["G(\u03b22)", "GENE_OR_GENE_PRODUCT", 52, 57], ["self antigen", "PROTEIN", 35, 47], ["\u03b21", "PROTEIN", 49, 51], ["high affinity", "PROBLEM", 16, 29], ["self antigen", "TEST", 35, 47], ["the infection", "PROBLEM", 90, 103], ["high affinity", "OBSERVATION_MODIFIER", 16, 29], ["neutral effect", "OBSERVATION", 72, 86], ["infection", "OBSERVATION", 94, 103]]], ["To avoid a bad prognosis such as a relapse of autoimmune disease, we also exclude the possibility of the relapse caused by viral infection (\u03b22>2\u03b3(k-u)/m and F(\u03b22)0,2\u03b1\u03b3hm\u03b3(k-u)m.Let V(0)>0 and then the convergence equilibrium changes from Ea+ to Ec* (the patients get the viral infection) or it does not change because the region (III) in Fig. 4 represents bistability of Ea+ and Ec,Ia+>IcIa+<Ic) and relieve symptoms of autoimmune disease (Da+>Dc.", [["autoimmune disease", "DISEASE", 46, 64], ["viral infection", "DISEASE", 123, 138], ["viral infection", "DISEASE", 271, 286], ["autoimmune disease", "DISEASE", 420, 438], ["k-u)m", "GENE_OR_GENE_PRODUCT", 171, 176], ["Let V(0)", "GENE_OR_GENE_PRODUCT", 177, 185], ["Ea+", "SIMPLE_CHEMICAL", 238, 241], ["patients", "ORGANISM", 254, 262], ["Ea+", "SIMPLE_CHEMICAL", 371, 374], ["Ea", "PROTEIN", 238, 240], ["Ea", "PROTEIN", 371, 373], ["Ec", "PROTEIN", 379, 381], ["Ia", "PROTEIN", 382, 384], ["IcIa", "PROTEIN", 386, 390], ["patients", "SPECIES", 254, 262], ["a bad prognosis", "PROBLEM", 9, 24], ["autoimmune disease", "PROBLEM", 46, 64], ["the relapse", "PROBLEM", 101, 112], ["viral infection", "PROBLEM", 123, 138], ["Let V", "TEST", 177, 182], ["the convergence equilibrium changes", "PROBLEM", 197, 232], ["Ec*", "TREATMENT", 245, 248], ["the viral infection", "PROBLEM", 267, 286], ["Ea", "TEST", 371, 373], ["Ec", "TEST", 379, 381], ["Ia", "TEST", 382, 384], ["symptoms", "PROBLEM", 408, 416], ["autoimmune disease", "PROBLEM", 420, 438], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["infection", "OBSERVATION", 129, 138], ["infection", "OBSERVATION", 277, 286], ["autoimmune", "OBSERVATION", 420, 430]]], ["We remark that the vaccine might be unable to replicate (the orbit converges to Ea+) according to patients\u2019 states because of bistability.", [["orbit", "ANATOMY", 61, 66], ["orbit", "ORGAN", 61, 66], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["the vaccine", "TREATMENT", 15, 26], ["bistability", "PROBLEM", 126, 137]]], ["Therefore, the vector vaccine might have to be used with other immunosuppressive drugs to switch the patient state from Ea+ to Ec*.", [["patient", "ORGANISM", 101, 108], ["Ea+", "SIMPLE_CHEMICAL", 120, 123], ["Ea", "PROTEIN", 120, 122], ["Ec*", "PROTEIN", 127, 130], ["patient", "SPECIES", 101, 108], ["the vector vaccine", "TREATMENT", 11, 29], ["other immunosuppressive drugs", "TREATMENT", 57, 86]]], ["Although many restrictions discussed above exist for the success of therapeutic vaccine, we can theoretically design the transgenic vector vaccine (because of these stringent restrictions, it is also true that the transgenic vector vaccine might only be effective to certain specific patient states).", [["patient", "ORGANISM", 284, 291], ["patient", "SPECIES", 284, 291], ["therapeutic vaccine", "TREATMENT", 68, 87], ["the transgenic vector vaccine", "TREATMENT", 117, 146], ["these stringent restrictions", "TREATMENT", 159, 187], ["the transgenic vector vaccine", "TREATMENT", 210, 239]]], ["Moreover, if we consider the additional effects for suppression of autoreactive immune cells, these restrictions can be relaxed.", [["immune cells", "ANATOMY", 80, 92], ["autoreactive immune cells", "CELL", 67, 92], ["autoreactive immune cells", "CELL_TYPE", 67, 92], ["autoreactive immune cells", "PROBLEM", 67, 92], ["autoreactive immune cells", "OBSERVATION", 67, 92]]], ["However, we leave the inclusion of additional effects as a subject for future work.DiscussionIncreasing evidence exists that infectious agents play an important role in autoimmune disease (Janewa et al., 2004, Roitt et al., 1998).", [["autoimmune disease", "DISEASE", 169, 187], ["infectious agents", "TREATMENT", 125, 142], ["autoimmune disease", "PROBLEM", 169, 187], ["infectious", "OBSERVATION", 125, 135]]], ["Viruses are an important factor that can precipitate autoimmune disease by various mechanisms (Fujinami, 2004, Pender, 2004, von Herrath et al., 2003).", [["autoimmune disease", "DISEASE", 53, 71], ["Viruses", "PROBLEM", 0, 7], ["autoimmune disease", "PROBLEM", 53, 71]]], ["For example, viruses that stimulate the production of IL-12, such as herpes simplex virus, human herpesvirus, influenza virus, and coronavirus, have been isolated from or have been associated with exacerbation of MS (Fujinami, 2001, Libbey and Fujinami, 2002, Monteiro et al., 1998, Whitton and Fujinami, 1999).", [["herpes simplex virus", "DISEASE", 69, 89], ["influenza virus", "DISEASE", 110, 125], ["MS", "DISEASE", 213, 215], ["IL-12", "GENE_OR_GENE_PRODUCT", 54, 59], ["herpes simplex virus", "ORGANISM", 69, 89], ["human herpesvirus", "ORGANISM", 91, 108], ["influenza virus", "ORGANISM", 110, 125], ["coronavirus", "ORGANISM", 131, 142], ["IL-12", "PROTEIN", 54, 59], ["herpes simplex virus", "SPECIES", 69, 89], ["human", "SPECIES", 91, 96], ["herpesvirus", "SPECIES", 97, 108], ["influenza virus", "SPECIES", 110, 125], ["coronavirus", "SPECIES", 131, 142], ["herpes simplex virus", "SPECIES", 69, 89], ["human herpesvirus", "SPECIES", 91, 108], ["influenza virus", "SPECIES", 110, 125], ["viruses", "PROBLEM", 13, 20], ["IL", "TEST", 54, 56], ["herpes simplex virus", "PROBLEM", 69, 89], ["human herpesvirus", "PROBLEM", 91, 108], ["influenza virus", "PROBLEM", 110, 125], ["coronavirus", "PROBLEM", 131, 142], ["exacerbation of MS", "PROBLEM", 197, 215], ["viruses", "OBSERVATION", 13, 20], ["herpes simplex virus", "OBSERVATION", 69, 89], ["influenza virus", "OBSERVATION", 110, 125]]], ["On the other hand, viruses can abrogate an ongoing autoimmune reaction by inducing apoptosis of autoreactive cells, by secreting various cytokines, or by immune suppression (Fujinami, 2001).", [["autoreactive cells", "ANATOMY", 96, 114], ["autoimmune reaction", "DISEASE", 51, 70], ["autoreactive cells", "CELL", 96, 114], ["autoreactive cells", "CELL_TYPE", 96, 114], ["cytokines", "PROTEIN", 137, 146], ["viruses", "PROBLEM", 19, 26], ["an ongoing autoimmune reaction", "PROBLEM", 40, 70], ["autoreactive cells", "PROBLEM", 96, 114], ["secreting various cytokines", "PROBLEM", 119, 146], ["viruses", "OBSERVATION", 19, 26], ["autoimmune", "OBSERVATION", 51, 61], ["autoreactive cells", "OBSERVATION", 96, 114]]], ["Nevertheless, it is difficult to obtain direct evidence for virus-induced initiation of autoimmune disease or protection from autoimmune disease because we are all infected by multiple viruses (Fujinami et al., 2006).DiscussionUsing the simple mathematical model, we analyzed whether and how a viral infection having molecular mimicry with self proteins can impart a detrimental or beneficial effect to autoimmune disease patients (see Fig. 6).", [["autoimmune disease", "DISEASE", 88, 106], ["autoimmune disease", "DISEASE", 126, 144], ["viral infection", "DISEASE", 294, 309], ["autoimmune disease", "DISEASE", 403, 421], ["patients", "ORGANISM", 422, 430], ["self proteins", "PROTEIN", 340, 353], ["patients", "SPECIES", 422, 430], ["virus", "PROBLEM", 60, 65], ["autoimmune disease", "PROBLEM", 88, 106], ["autoimmune disease", "PROBLEM", 126, 144], ["a viral infection", "PROBLEM", 292, 309], ["self proteins", "PROBLEM", 340, 353], ["autoimmune disease patients", "PROBLEM", 403, 430], ["autoimmune disease", "OBSERVATION", 88, 106], ["autoimmune disease", "OBSERVATION", 126, 144], ["multiple", "OBSERVATION_MODIFIER", 176, 184], ["viruses", "OBSERVATION", 185, 192]]], ["Furthermore, we consider the possibility of development of a therapeutic vaccine against autoimmune disease.", [["autoimmune disease", "DISEASE", 89, 107], ["a therapeutic vaccine", "TREATMENT", 59, 80], ["autoimmune disease", "PROBLEM", 89, 107]]], ["Our findings suggest that the success of therapeutic vaccine necessitates the following: (i) patients have an appropriate immune response function, such as f2; (ii) affinities with self and non-self antigen are in the beneficial region shown in Fig. 6; (iii) the vector vaccine replicates in vivo.", [["patients", "ORGANISM", 93, 101], ["non-self antigen", "GENE_OR_GENE_PRODUCT", 190, 206], ["f2", "PROTEIN", 156, 158], ["patients", "SPECIES", 93, 101], ["therapeutic vaccine", "TREATMENT", 41, 60], ["self and non-self antigen", "PROBLEM", 181, 206], ["the vector vaccine", "TREATMENT", 259, 277]]], ["Although these restrictions can be relaxed if we consider additional immunological effects such as immune suppression, memory response, and exhaustion of effector cells, we found the distinct possibility of designing a therapeutic vaccine.DiscussionIn Iwami et al. (2007a) and Iwami (2007), we investigated the influence of functional form of immune proliferation on autoimmune disease symptoms.", [["effector cells", "ANATOMY", 154, 168], ["autoimmune disease", "DISEASE", 367, 385], ["effector cells", "CELL", 154, 168], ["effector cells", "CELL_TYPE", 154, 168], ["additional immunological effects", "TREATMENT", 58, 90], ["immune suppression", "TREATMENT", 99, 117], ["exhaustion of effector cells", "PROBLEM", 140, 168], ["a therapeutic vaccine", "TREATMENT", 217, 238], ["immune proliferation", "PROBLEM", 343, 363], ["autoimmune disease symptoms", "PROBLEM", 367, 394], ["immune proliferation", "OBSERVATION", 343, 363]]], ["We demonstrated that sigmoid function such as f2 can induce a bistable structure and periodic behavior.", [["f2", "DNA", 46, 48], ["sigmoid function", "PROBLEM", 21, 37], ["a bistable structure", "PROBLEM", 60, 80], ["periodic behavior", "PROBLEM", 85, 102], ["sigmoid", "ANATOMY", 21, 28]]], ["As described in this paper, we omit the target cell dynamics and add the viral replication cycle compared with the model considered in Iwami et al. (2007a).", [["cell", "ANATOMY", 47, 51], ["cell", "CELL", 47, 51], ["the viral replication cycle", "TREATMENT", 69, 96]]], ["The difference of immune response functions also strongly affects the autoimmune disease symptoms.", [["autoimmune disease", "DISEASE", 70, 88], ["immune response functions", "PROBLEM", 18, 43], ["the autoimmune disease symptoms", "PROBLEM", 66, 97], ["immune response", "OBSERVATION", 18, 33]]], ["If the virus cannot establish a persistent infection (k-u<0), then f2 induces bistability (Fig. 3(c)) but f1 does not, then (Fig. 2(c)).", [["infection", "DISEASE", 43, 52], ["f2", "DNA", 67, 69], ["f1", "PROTEIN", 106, 108], ["the virus", "PROBLEM", 3, 12], ["a persistent infection", "PROBLEM", 30, 52], ["persistent", "OBSERVATION_MODIFIER", 32, 42], ["infection", "OBSERVATION", 43, 52]]], ["On the other hand, if the virus can replicate itself (k-u>0), then f2 induces bistability and a periodic orbit (Fig. 3(d)), but f1 does not, then (Fig. 2(d)).", [["f2", "DNA", 67, 69], ["f1", "PROTEIN", 128, 130], ["the virus", "PROBLEM", 22, 31], ["bistability", "PROBLEM", 78, 89], ["a periodic orbit (Fig.", "TREATMENT", 94, 116], ["orbit", "ANATOMY", 105, 110]]], ["Consequently, the sigmoid function f2, which is biologically more reasonable (because APCs only slightly induce immune cells when only a few antigens exist, Iwami et al., 2007a) than the convex function f1 represents various symptoms such as relapse in autoimmune disease.", [["APCs", "ANATOMY", 86, 90], ["immune cells", "ANATOMY", 112, 124], ["autoimmune disease", "DISEASE", 253, 271], ["APCs", "CELL", 86, 90], ["immune cells", "CELL", 112, 124], ["f2", "DNA", 35, 37], ["APCs", "CELL_TYPE", 86, 90], ["immune cells", "CELL_TYPE", 112, 124], ["f1", "PROTEIN", 203, 205], ["the sigmoid function f2", "TEST", 14, 37], ["APCs", "TEST", 86, 90], ["immune cells", "PROBLEM", 112, 124], ["various symptoms", "PROBLEM", 217, 233], ["autoimmune disease", "PROBLEM", 253, 271], ["sigmoid", "ANATOMY", 18, 25], ["autoimmune disease", "OBSERVATION", 253, 271]]], ["That slight inducement implies that the various symptoms of autoimmune disease might be related with the function.", [["autoimmune disease", "DISEASE", 60, 78], ["the various symptoms", "PROBLEM", 36, 56], ["autoimmune disease", "PROBLEM", 60, 78], ["slight", "OBSERVATION_MODIFIER", 5, 11], ["autoimmune", "OBSERVATION", 60, 70]]], ["However, the results might not be sufficiently robust to the form of immune proliferation function.", [["immune proliferation function", "PROBLEM", 69, 98], ["immune proliferation", "OBSERVATION", 69, 89]]], ["For example, APCs are known to induce immune cells only slightly when many antigens exist (high zone tolerance) (Janewa et al., 2004).", [["APCs", "ANATOMY", 13, 17], ["immune cells", "ANATOMY", 38, 50], ["APCs", "CELL", 13, 17], ["immune cells", "CELL", 38, 50], ["APCs", "CELL_TYPE", 13, 17], ["immune cells", "CELL_TYPE", 38, 50], ["antigens", "PROTEIN", 75, 83], ["APCs", "TEST", 13, 17], ["immune cells", "PROBLEM", 38, 50], ["immune cells", "OBSERVATION", 38, 50]]], ["For that reason, we might have to use a bell-shaped proliferation function to consider high zone tolerance instead of the proliferation as an increasing function of antigen load (De Boer et al., 1993, De Boer et al., 1996).", [["antigen", "GENE_OR_GENE_PRODUCT", 165, 172], ["a bell-shaped proliferation function", "TREATMENT", 38, 74], ["high zone tolerance", "PROBLEM", 87, 106], ["the proliferation", "PROBLEM", 118, 135], ["antigen load", "PROBLEM", 165, 177]]], ["Consequently, a more complete understanding of immune proliferation must be the foundation for the development of a therapeutic vaccine.DiscussionViruses trigger autoimmune disease, but they are also likely to be important for reactivation of autoimmunity (viruses can behave as reactivators of autoimmune disease) (Horwitz and Sarvetnick, 1999).", [["autoimmune disease", "DISEASE", 162, 180], ["autoimmunity", "DISEASE", 243, 255], ["autoimmune disease", "DISEASE", 295, 313], ["immune proliferation", "PROBLEM", 47, 67], ["a therapeutic vaccine", "TREATMENT", 114, 135], ["autoimmune disease", "PROBLEM", 162, 180], ["autoimmunity (viruses", "PROBLEM", 243, 264], ["autoimmune disease", "PROBLEM", 295, 313], ["immune proliferation", "OBSERVATION", 47, 67]]], ["Some clinical data show that viral infections trigger MS relapse (Andersen et al., 1993).", [["viral infections", "DISEASE", 29, 45], ["MS", "DISEASE", 54, 56], ["Some clinical data", "TEST", 0, 18], ["viral infections", "PROBLEM", 29, 45], ["viral", "OBSERVATION_MODIFIER", 29, 34], ["infections", "OBSERVATION", 35, 45]]], ["It has been suggested that a determinant spreading (self-antigen diversification) is a relapse mechanism (Lehmann et al., 1993).", [["a determinant spreading", "PROBLEM", 27, 50], ["self-antigen diversification", "TREATMENT", 52, 80]]], ["Furthermore, in Borghans et al. (1998), they showed that T cell regulatory circuitry induces autoimmune relapse using a simple mathematical model.", [["T cell", "ANATOMY", 57, 63], ["T cell", "CELL", 57, 63], ["T cell regulatory circuitry", "PROBLEM", 57, 84], ["autoimmune relapse", "PROBLEM", 93, 111], ["a simple mathematical model", "TREATMENT", 118, 145], ["autoimmune relapse", "OBSERVATION", 93, 111]]], ["Another possible mechanism of the relapse is considered as cross-reactive immune responses through a process of molecular mimicry.", [["the relapse", "PROBLEM", 30, 41], ["possible", "UNCERTAINTY", 8, 16], ["relapse", "OBSERVATION", 34, 41], ["molecular mimicry", "OBSERVATION", 112, 129]]], ["In our model, relapses can also occur under the viral infection with molecular mimicry (in the absence of determinant spreading).", [["viral infection", "DISEASE", 48, 63], ["relapses", "PROBLEM", 14, 22], ["the viral infection", "PROBLEM", 44, 63], ["relapses", "OBSERVATION", 14, 22], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["infection", "OBSERVATION", 54, 63]]], ["The immune response function f2 can induce a limit cycle that corresponds to relapse of autoimmune disease only when the virus can replicate itself (see Fig. 4).", [["autoimmune disease", "DISEASE", 88, 106], ["f2", "DNA", 29, 31], ["autoimmune disease", "PROBLEM", 88, 106], ["the virus", "PROBLEM", 117, 126], ["autoimmune disease", "OBSERVATION", 88, 106]]], ["This implies that the viral infection engenders the relapse.", [["viral infection", "DISEASE", 22, 37], ["the viral infection", "PROBLEM", 18, 37], ["viral", "OBSERVATION_MODIFIER", 22, 27], ["infection", "OBSERVATION", 28, 37], ["relapse", "OBSERVATION_MODIFIER", 52, 59]]], ["Therefore, our model supports that the cross-reactive immune response is also a relapse mechanism.DiscussionThis study highlights the immune response functions and molecular mimicry with the self antigen to investigate the possibility of vector vaccine development.", [["the cross-reactive immune response", "PROBLEM", 35, 69], ["This study", "TEST", 108, 118], ["the self antigen", "TEST", 187, 203], ["vector vaccine development", "TREATMENT", 238, 264], ["cross-reactive immune response", "OBSERVATION", 39, 69]]], ["Although our model might over-simplify complex interactions in autoimmune disease, its simplicity illustrates the general and qualitative properties of viral infection with molecular mimicry.", [["autoimmune disease", "DISEASE", 63, 81], ["viral infection", "DISEASE", 152, 167], ["autoimmune disease", "PROBLEM", 63, 81], ["viral infection", "PROBLEM", 152, 167], ["autoimmune disease", "OBSERVATION", 63, 81], ["viral infection", "OBSERVATION", 152, 167], ["molecular mimicry", "OBSERVATION", 173, 190]]], ["Our model is a starting point, but must include more immunological factors such as immunosuppression and apoptosis to merit further theoretical and mathematical investigation.", [["immunosuppression", "TREATMENT", 83, 100], ["apoptosis", "PROBLEM", 105, 114], ["mathematical investigation", "TEST", 148, 174]]]]}